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Abstract
The purpose of this thesis is to explore the methodological and empirical issues
relating to the economic evaluation of minimal access surgery (MAS). Given the
likely increase in the utilisation of economic analysis in this area, it is crucial to
explore whether the methods of economic evaluation have limitations in the face of
the particular characteristics of MAS. The comparison of abdominal hysterectomy
(AH) and transcervical endometrial resection (TCRE), for the treatment of
menorrhagia, is used as a vehicle to develop methods in relation to MAS. Having
reviewed the literature and issues relating to the economic analysis of this group of
technologies, the empirical starting point of the thesis is the assessment of the
limitations of economic evaluations alongside clinical trials, using a trial comparing
AH and TCRE. Three major areas of weakness are identified, and alternative ways
of addressing these weaknesses are explored in the remainder of the thesis. The
first area of methodological development relates to the measure of benefit used in
economic evaluation of MAS. In this clinical context, it is argued that the trade-offs
that exist between MAS and conventional surgery, in terms of process
characteristics and outcomes, should result in an important role for patients'
preferences in the construction of a benefit measure. A cost-utility analysis using
the standard quality-adjusted life year (GALY) is undertaken, using trial data
augmented with valuation data from a further study. The lack of consistency
between individual preferences and standard QALYs suggests a major weakness
with this measure of benefit. The strengths and weaknesses of an alternative
measure of benefit in cost-utility analysis - the ex ante healthy years equivalent
(HYE) - are assessed based on a further valuation study. It is shown that it is
feasible to elicit ex ante HYEs from patients and that this measure of benefit
exhibits some consistency with other expressions of patients' preferences.
However, the HYE is likely to impose a greater measurement burden than the
standard QALY. The second area of methodological development in the thesis is the
analysis of the generalisability of trial-based economic evaluation, given the
limitations that often exist with the external validity of trials. A framework is
developed within which trial and observational data can be synthesised. This
facilitates the use of sensitivity analysis to explore the robustness of base-case
(trial-generated) results to alternative sources of data, which may be more
representative of routine practice. The third area of methodological development
stems from the importance of patients' preferences in relation to MAS. This
element relates to the use of methods to model and to evaluate management
strategies which use patients' preferences to determine treatment allocation. It is
concluded that preference-based decision making has the potential to be cost-
effective in relation to TCRE and AH, and MAS applications more generally. The
thesis demonstrates the importance of continued development in the detailed
methods of economic evaluation.
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Chapter 1
Introduction
1.1 The role of economic evaluation in health care
This thesis considers the methodological issues relating to the economic
evaluation of minimal access surgery (MAS). It is now widely recognised that, in
order to ensure that the health service maximises patient benefits from the
limited resources available for health care, a systematic and formal assessment
of the costs and consequences of health care interventions is necessary. The
tools of economic evaluation have, therefore, become widely used to inform
resource allocation in health care systems across the world. There is now an
extensive literature on the basic methods of economic evaluation in health care
[Drummond et al, 1987; Detsky and Naglie, 1990; Luce and Elixhauser, 1990;
Petitti, 1994] and a growing literature relating to applied economic evaluation of
health care interventions [Backhouse et al, 1992].
1
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The increased demand for economic evaluation is clear in the UK. The largest
component of the National Health Service (NHS) Research and Development
strategy is a programme of health technology assessment where economic
evaluation is a prominent research priority [Department of Health, 1993A and
1995]. The Health Services Research Board of the Medical Research Council
now presumes that economic evaluation will normally be required as part of the
clinical trials it funds. In addition to publicly funded economic evaluation, the
pharmaceutical industry has increased its funding of economic evaluation of its
products, both for regulatory purposes in some countries and for commercial
reasons [Evans, 1995].
Despite the development of guidelines for economic evaluation in health care in
several countries and for various purposes [Henry, 1992; Association of the
British Pharmaceutical Industry, 1994; Ministry of Health, 1994; Canadian
Coordinating Office for Health Technology Assessment, 1994; Drummond and
Jefferson, 1996; Panel on Cost-Effectiveness in Health and Medicine, 1996],
uncertainty still remains regarding the most appropriate detailed methods for
economic analysis, necessitating further methodological development in this area
[Drummond et al, 1993A].
1.2 Economic evaluation of MAS
The current limitations of the tools of economic evaluation are highlighted when
they are applied to health care technologies with particular characteristics. One
group of technologies which poses some particular problems for economic
analysis is minimal access surgery. The need for a detailed assessment of the
methods of economic evaluation in relation to MAS is emphasised by the
growing importance of MAS procedures within the health service. In 1993, a
committee formed to advise the UK government predicted that, by the year
2000, 70% to 80% of surgical practice will be based on MAS techniques
[Cuschieri, 1993]. Given the large amount of health service resources that are,
therefore, likely to be devoted to MAS during the next few years, formal
2
Chapter 1	 Introduction
assessment of their costs and consequences relative to conventional treatment is
essential.
Significant research resources are being devoted to the clinical evaluation of
MAS procedures in the UK; for example, the MRC has recently funded a large
multi-centre trial of laparoscopic surgery for colorectal cancer [MRC, personal
communication]; and the NHS Executive Research and Development Programme
has recently agreed to fund a multi-centre trial involving 1800 women to
evaluate laparoscopic hysterectomy [Mr Ray Garry, personal communication].
Expenditure on the evaluation of MAS procedures may increase further in the UK
if recent calls for the mandatory evaluation of surgical technologies prior to
routine use are heeded [Advisory Council on Science and Technology (ACOST),
1993]. Although the Department of Health has so far rejected these calls
[Department of Health, 1993B], it has agreed to fund a voluntary system for
registering surgical procedures the effectiveness and safety of which have yet to
be established, with procedures on this register feeding into the priority setting
process for the NHS Health Technology Assessment Programme [Sheldon and
Faulkner, 1996]. Although the register does not focus on the need for economic
assessment, the likely increase in funding for clinical evaluation of surgical
procedures will stimulate a demand for formal economic analysis, given that
economic evaluation is a key part of the NHS Research and Development
Programme. However, prior to increased funding of applied economic
evaluations of MAS procedures, it is necessary to develop further the tools of
analysis based on a careful consideration of the characteristics of this group of
technologies.
1.3 Contribution of the thesis
The methodological problems related to the economic evaluation of MAS, and
alternative approaches to overcoming them, are the focus of this thesis.
3
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In part, the thesis reviews and applies some recent methodological
developments, in particular relating to economic analysis alongside clinical trials,
the role of the standard QALY in cost-utility analysis and the systematic
presentation of uncertainty in economic evaluation. Although this does not
represent new methodological work, these methods are being applied in detail to
the area of MAS for the first time, providing new insight into their strengths and
limitations in an important area of applied economic evaluation.
Much of the thesis, however, is devoted to the development of novel evaluative
methods. MAS procedures tend to develop quickly, often with new versions of
an application in a given clinical area diffusing prior to full evaluation of earlier
versions. Related to this is the variation that often exists in how applications of
MAS are actually used in routine clinical practice. These characteristics of MAS
limit the external validity of many economic evaluations in this area, particularly
those undertaken as part of, or alongside, a clinical trial. An important
contribution of this thesis is the development of a framework to analyse the
generalisability of an economic evaluation. Starting out with a core model based
on trial data to provide high levels of internal validity, the framework involves
the incorporation of experimental and observational data from a range of
alternative sources within a series of sensitivity analyses. The aim is to assess
the robustness of the base-case results to these alternative parameter estimates.
A second contribution relates to the multi-dimensionality of outcomes often
associated with MAS and the limitations this imposes on cost-effectiveness
analysis and cost-utility analysis based on the standard QALY. These problems
stimulate a consideration of alternative benefit measures for economic analysis;
in particular the role of healthy-years equivalents (HYEs) based on the time trade-
off (TTO) valuation instrument. The thesis considers the differences in results of
cost-utility analysis based on the standard GALY compared to those using the
TTO-based HYE; the consistency of this measure of benefit with more
descriptive measures of preference; and the practical issues related to the use of
HYEs.
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A third area in which this thesis contributes to the methods of economic
evaluation relates to the role of patients' preferences in determining treatment
allocation. The standard approach to economic evaluation in health care is to
compare two or more interventions relating to a particular group of patients and
to identify the (single) economically superior option, with the presumption that
this will be provided to each patient in that group. If heterogeneity exists in the
clinical characteristics of individuals, and these differences affect the extent of
patient benefit, then it may represent good value for money to provide an
intervention to a sub-group of patients which is not cost-effective for the whole
group. Benefits will also depend on patients' preferences for particular treatment
processes and prognoses and health states, and there seems to be a marked
variation in patients' preferences relating to the range of different consequences
of MAS procedures. There would seem to be a case, therefore, for allowing
patients' preferences to play a formal part in determining treatment allocation,
but this itself requires full economic evaluation and this approach to patient
management has rarely been factored into the methods of economic evaluation.
The thesis explores three alternative models of preference-based treatment
allocation, considering for each the design of an economic analysis, data
requirements and practicalities.
1.4 A case-study: surgical treatment for menorrhagia
As a way of highlighting the importance of these various areas of method, and
as a vehicle for exploring the feasibility and implications of alternative
approaches to the economic evaluation of MAS, the surgical treatment of
menorrhagia is used as a case-study throughout the thesis. It is not the purpose
of this section to provide a systematic and comprehensive review of existing
evidence on the effectiveness and costs of alternative approaches to the
management of menorrhagia. Rather, the purpose is briefly to summarise the
key issues in the literature that impact on the economics of alternative
treatments for menorrhagia, as well as to highlight the important areas of
uncertainty relating to the use of surgical technologies in this clinical area.
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1.4.1 The burden of menorrhagia
Menorrhagia, or 'excessive' menstrual bleeding, represents a major health care
burden in the UK. This fact is illustrated by a range of statistics.
• The condition affects approximately 22% of otherwise healthy women
[Gath eta!, 1987].
• Some 822,000 prescriptions are issued for menorrhagia each year,
costing £7 million [Effective Health Care, 1995].
• Menstrual problems account for some 12% of gynaecology referrals
[Bradlow et al, 1992].
• Approximately 10,000 MAS procedures are undertaken each year for
menorrhagia [RCOG Audit Unit, personal communication].
• The chance of a woman having undergone a hysterectomy by the age of
55 for menstrual problems is between 7% and 13% [Grant and Hussein,
1984; Vessey et al, 1992].
• Rates of surgical treatment for menorrhagia appear to be increasing in the
UK [Vessey et al, 1992; Coulter et al, 1993; Bridgman, 1994; Coulter
1994].
Although the majority of women with menorrhagia exhibit no abnormal pathology
(in these circumstances this condition is sometimes referred to as dysfunctional
uterine bleeding), the condition clearly has a detrimental impact on women's
health-related quality of life [Garratt et al, 1993; Jenkinson et al, 1994].
Furthermore, the burden in terms of the health care resources devoted to the
care of women with menorrhagia is significant. Figure 1.1 breaks down the
resource impact of menorrhagia in terms of the cost of visits to the GP, drugs,
conservative surgery and hysterectomy. It can be seen that surgery represents
77% of the cost of menorrhagia.
1.4.2 Treatment options
The first-line therapy for most women with menorrhagia is medical treatment.
However, there has been a widespread opinion that such drug treatment for this
6
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Drugs (Um) (11.74%
Conservative surgery (£5m) (8.38°/
GPs (6.9m) (11.64%
ysterectomy (£40.7) (68.24%)
Figure 1.1 Resource costs of menorrhagia to the health service in England and
Wales (1994 prices). Costs have been estimated as follows. GP costs
are based on 868,000 consultations per year (31 per 1000 women
[Coulter et al, 1991] applied to a female population of 28 million) at a
unit cost of £8 per visit [Netten, 19941. Drug costs are taken from
Effective Health Care [1995]. The cost of hysterectomy assumes that
74,000 are undertaken each year [Effective Health Care, 19951, with
50% for menorrhagia, at a unit cost of £1,100 (see Chapter 3). The
cost of conservative surgery is based on 10,000 procedures [RCOG
Audit Unit, personal communication], with a unit cost of £500 (see
Chapter 3).
condition is ineffective [Consumers' Association Ltd, 1990], with recent research
demonstrating a mismatch between the prescribing policies of GPs and the most
effective drug treatments [Coulter et al, 199513].
The perceived ineffectiveness of medical therapies has resulted in a large
proportion of women being referred to hospital for possible surgical intervention.
Traditionally, the only widespread surgical intervention was hysterectomy: a
survey undertaken in 1988-89 found that 60% of women underwent
hysterectomy within five years of being referred to hospital with menorrhagia
[Coulter eta!, 1991]. In the UK, the abdominal form of the operation has
traditionally represented about 90% of hysterectomies [Vessey et al, 19921.
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Recently, there has been a major change in surgical treatment in this area. In
particular, the advent of therapeutic endoscopy in a range of specialties has
stimulated hysteroscopic therapies for menorrhagia. Typically, these treatments
involve the endometrium being resected using electro-diathermy with either a
loop or rollerball device (transcervical resection of the endometrium (TCRE))
[Magos eta!, 1989], or ablated using a Nd:YAG laser [Goldrath, 19811. In
principle, the attraction of these various forms of MAS alternatives to
hysterectomy, from a clinical point of view, is their association with a shorter
stay in hospital and a shorter period of convalescence for the patient. The
former also explains the expectation of lower health service costs with these
treatments, in comparison with hysterectomy.
The endoscopic revolution has also had important implications for hysterectomy.
Some centres are now using laparoscopic hysterectomy or laparoscopic-assisted
vaginal hysterectomy [Hunter and McCarthey, 1993]. In essence, these
developments represent an attempt to retain the conventional therapeutic effects
of hysterectomy (ie. amenorrhoea), whilst reducing the severity and length of
convalescence, and duration of hospital stay.
To date, three randomised controlled trials (RCTs) have been published
comparing non-hysterectomy forms of MAS (TCRE or laser ablation) with
abdominal hysterectomy (AH), based in Reading [Gannon eta!, 1991]; Bristol
[Dwyer et al, 1993] and Aberdeen [Pinion et al, 1994]. Overall, they show a
clear trade-off between the effects of the two forms of surgery: TCRE and laser
ablation result in fewer complications, a shorter convalescence and less peri-
operative pain, but these treatments often fail to ameliorate women's symptoms
adequately; whereas AH provides a once-and-for-all solution to heavy menstrual
bleeding. The cohort of women in the Bristol trial forms the basis of much of the
detailed analysis described in this report. On the basis of the results published
so far, however, the long-term effects of TCRE and laser ablation remain unclear.
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The cost-effectiveness of alternative surgical treatments for menorrhagia, relative
both to each other and to medical therapy, has been subject to little detailed
analysis. There have been several cost analyses of alternative forms of surgery
[Manyonda and Varma, 1991; East et al, 1994; Nezhat eta!, 1994; Messina et
al, 1995; Brumsted et al, 1996], but these have generally been incomplete in
their coverage of costs and based on small sample sizes without appropriate
controls. Some of the generated data for cost analyses [Gannon eta!, 1991;
Summitt et al, 1992; Raju and Auld, 1994], but their methods have been
unclear. To date, no data on the cost-effectiveness of surgical procedures have
been published.
1.5 Structure of the thesis
The thesis is made up of eight further chapters, the details of which are
summarised below.
Chapter 2 is a review of the issues and literature relating to the
economics of MAS. The chapter considers the economic characteristics of MAS
in terms of resource and non-resource consequences of these interventions
relative to therapeutic baselines. A systematic review of published economic
evaluations of MAS applications is presented, focusing on the particular
evaluative methods employed in studies. Based on the economic characteristics
of MAS and the review of published studies, the chapter identifies the
methodological problems likely to be faced in economic evaluation in this clinical
area.
Chapter 3 is the starting point of the empirical analysis, and takes the
form of a cost-effectiveness analysis of AH versus TCRE alongside the RCT
undertaken in Bristol. Taking a health service perspective, the costs of the two
forms of management until two years follow-up are reported, and these are
related to differential effectiveness in terms of women's satisfaction rates with
treatment. Although the analysis in the chapter provides the firm evidential basis
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for further development in subsequent chapters, it raises some specific areas of
uncertainty about the relative cost-effectiveness of the two treatments. In
particular, the need for a generic measure of benefit, the importance of reflecting
women's preferences within the evaluative analysis and the limited external
validity of trial-based evaluations are emphasised.
Chapter 4 details an analysis of women's descriptive preferences
concerning the treatment of menorrhagia. Using a survey of 221 women
referred to hospital for possible surgery for menorrhagia, the chapter explores
women's attitudes to, and preferences for, the characteristics of treatment and
the trade-offs between them. It is concluded that women are heterogenous in
their treatment-related preferences in this area, and that their preferences for the
characteristics of treatment often conflict with each other when a specific
therapy has to be identified.
Chapter 5 details a cost-utility analysis of AH versus TORE, which has the
aim of assisting in resource allocation between specialties and disease areas by
expressing cost-effectiveness in terms of a generic measure of benefit which
partly reflects patients' preferences - the quality-adjusted life year (QALY). The
analysis is based on resource and non-resource consequence data taken from the
Bristol trial, augmented by health state valuation data elicited from a sample of
60 women with menorrhagia. The chapter indicates that, even with core data
taken from a RCT, a range of uncertainties remains when conclusions are being
sought about relative cost-effectiveness. Methods for the systematic handling of
this uncertainty are considered which identify some robust conclusions, but
areas of analytical uncertainty are highlighted, in particular in relation to the
extent to which the QALY truly reflects patients' preferences.
Chapter 6 considers the issues related to the generalisability of economic
evaluation of MAS. A framework for the analysis of the generalisability of
economic analysis is offered. This takes the form of a series of sensitivity
analyses of base-case models, which are based on trial evidence, by the
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incorporation of alternative parameter estimates from data sources more closely
related to routine clinical practice. Five specific analyses of generalisability are
presented, focusing on specific alternative data sources: alternative RCTs; a
survey of national clinical practice; the extremes of clinical practice in terms of
resource use; hospital-specific unit costs; and developments in the technologies
under evaluation. The chapter concludes that incorporating the results of routine
practice into evaluations based initially on RCTs can generate major variations in
cost and benefit estimates.
Chapter 7 explores the shortcomings of GALYs as a generic measure oi
benefit in the economic analysis of MAS. The feasibility of using an alternative
measure - the ex ante HYE based on the TTO valuation instrument - is
considered, and estimates of this benefit measure are elicited from a sample of
63 women referred to hospital with menorrhagia. The chapter concludes that
there is a trade-off between the use of QALYs and ex ante HYEs, with the
former likely to be easier to elicit but with a weak relationship to individuals'
preferences, and the latter more likely to reflect preferences but imposing a
considerable measurement burden.
Chapter 8 considers the novel concept of preference-driven treatment
allocation in the area of minimal access surgery. Three models of preference-
based management are evaluated in relation to abdominal hysterectomy and
transcervical endometrial resection. It is concluded that these approaches have
scope to be cost-effective forms of management, but may prove difficult to
incorporate into routine practice.
Chapter 9 draws together the conclusions of the thesis, focusing on the
contribution of the thesis to the methods of economic evaluation, with particular
reference to minimal access surgery, and considering the implications for the
relative cost-effectiveness of AH and TCRE.
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Minimal Access Surgery: Economic
Characteristics and Implications for
Evaluative Methods
2.1	 Introduction
This chapter reviews the actual and potential economic characteristics of MAS
and issues of method associated with the economic evaluation of this
technology. Firstly, it considers the types of technology which can usefully be
grouped under the headings of 'minimally invasive therapy' and 'minimal access
surgery'; secondly, it reviews the characteristics of the technologies as they
impact on the health benefits patients are likely to experience; thirdly, it
considers the implications of MAS for health service and societal resource use;
fourthly, it reviews a sample of economic assessments of MAS interventions;
and finally, it explores the methodological difficulties involved with the evaluation
of these technologies.
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Medical science continues to generate a wide variety of new technologies. In
the broadest sense, health care technologies include "the drugs, devices, and
medical and surgical procedures used in medical care, and the organisational and
supportive systems within which such care is provided" [Office of Technology
Assessment, 1982, p200-1]. New technologies can impose a cost on health
services [Neumann and Weinstein, 1991]. This cost includes not only any
capital costs but also the costs of such things as staff, in-patient care, the
operating cost of any hardware, any building space, consumables, drugs, training
and any complications experienced by patients. Two crucial issues need,
therefore, to be considered: how does the cost of new technologies compare
with that of existing technologies and what additional benefits are being
generated by these new technologies. It is becoming increasingly recognised
that these two issues need to be formally addressed before new technologies
diffuse widely within the health service [Advisory Group on Health Technology
Assessment, 1992].
One set of therapeutic technologies which is beginning to diffuse within the UK
National Health Service (NHS) is characterised, clinically, by a reduction in the
physical trauma imposed upon patients, as a result either of avoiding penetration
of the body or of using an endoscope or catheter to facilitate a therapeutic
procedure. To date, the terminology associated with these technologies has
been variable, but they have been generically referred to as 'minimally invasive
therapy' or 'minimal access surgery'. Perhaps the most important example of
this form of technology is endoscopic therapy, where treatment is undertaken at
the end of a telescope which permits internal areas of the body to be viewed
without the need for large openings to facilitate access. Laparoscopic therapy is
one type of endoscopic treatment which has quite recently found a role in a
number of high volume surgical procedures. Often referred to as 'keyhole
surgery', laparoscopic therapy is centred around a number of small incisions
through which instruments are inserted to facilitate the viewing and treatment of
a given body cavity. The absence of the large incisions associated with
conventional open surgery usually results in less post-operative trauma to the
patient and a shorter period of convalescence.
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It is clear that these new forms of treatment have important implications for the
NHS, largely because of the likely extent of their use. Clinicians have predicted
their rapid diffusion, to the extent that they will replace virtually all open surgery
[Wickham, 1987]. A working party convened by the Department of Health and
the Scottish Home and Health Department forecast that, by the year 2000, 70%
to 80% of surgical practice will be based on MAS techniques [Cuschieri, 1993];
MAS is currently used in about 20% to 30% of surgical interventions in NHS
hospitals [Welsh Health Planning Forum, 1994]. It remains true, however, that
few applications of MAS have been subject to thorough clinical and economic
evaluation, despite their enormous potential scope [Banta, 1993A; Lancet, 1993;
Pearson, 1994]. By radically altering the process by which much surgery is
delivered, there is likely to be an important impact on the costs and benefits of
the relevant therapeutic procedures. Whether this results in an overall
improvement or deterioration in the efficiency of health service delivery is, as
yet, unclear.
2.2 Defining the relevant set of technologies
2.2.1 Minimally invasive therapies
Over many years, health care has become progressively less physically traumatic
to the patient. Technological developments have continued to reduce the
disbenef its associated with the process and short-term outcomes of health care
interventions. For example, hysterectomy is now only rarely used to manage
cervical intra-epithelial neoplasia, which can be treated at a woman's first visit to
hospital following an abnormal smear, using loop diathermy resection [Giles and
Gafar, 19911; and developments in pharmaceuticals have resulted in many
patients with peptic ulcer avoiding surgery [Paimela eta!, 1991].
The term 'minimally invasive therapy' (MIT) can, in principle, refer to any
treatment which has replaced a more invasive alternative. As such, the
membership of this group of therapies is enormous, encompassing a significant
proportion of modern therapeutic clinical practice. It would include non-invasive
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Minimally Invasive Therapies
Those therapies which seek to replace a more invasive alternative. For example, pharmacotherapy and
endoscopic therapy.
Minimal Access Surgery (MAS)
Those minimally invasive therapies which are invasive.
For example, endoscopic and percutaneous therapy.
Non-Invasive Therapy
Those therapies which do not require penetration of
the body. For example, pharmacotherapy and
external radiotherapy.
New Clinicians
New procedures
undertaken by new clinical
professional groupings.
For example, PTCA by
cardiologists
New therapies
MAS which represents
a new way of treating a
condition. For example
TCRE.
New Processes
MAS which represents a
different way of doing a
standard procedure. for
example laparoscopic
hysterectomy.
Existing Clinicans
New procedures
undertaken by same
clinical professionals as
conventional surgery.
For example, TCRE by
gynaecologists
Figure2.1
	
Sub-categorisation of minimal invasive therapies. TCRE = transcervical
resection of the endometruim; PTCA = percutaneous transluminal
coronary angioplasty.
treatments such as pharmacotherapy, radiotherapy and shockwave lithotripsy, as
well as invasive therapies which have replaced more radical procedures, such as
percutaneous and endoscopic therapies. If the purpose of organising
technologies into categories is to discuss the nature and implications of their
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shared characteristics, it can be argued that the interventions which logically fall
within the group labelled MIT are too heterogenous to facilitate useful analysis.
2.2.2 Minimal access surgery
A possible movement from this broad grouping of technologies to a more
selective one is illustrated in Figure 2.1. The term 'minimal access surgery'
(MAS), which excludes non-invasive procedures, has been defined to include five
minimal access surgical approaches: laparoscopy (eg. laparoscopic
cholecystectomy), endoluminal endoscopy (eg. endometrial ablation), perivisceral
endoscopy (eg. nephrectomy), thoracoscopy (eg. pleurectomy) and intra-articular
(eg. menisectomy) [Cuschieri, 1991]. Treatments within this more limited group
share some key characteristics in that they are all endoscopic therapies and,
therefore, all invasive and they use similar equipment. There would seem to be
good reason also to include percutaneous therapies (eg. percutaneous
transluminal coronary angioplasty (PTCA)) amongst the MAS group: although the
catheter and the x-ray replace the endoscope, these treatments too are invasive
but have replaced forms of open surgery.
A further level of categorisation is shown in Figure 2.1. MAS can be divided into
those therapies which represent not only a less invasive means of treating a
given condition than was previously the case, but also treat in a quite different
way; and those therapies which are just a less invasive way of doing an
established procedure. Examples of the first category include TCRE which,
unlike established surgical treatment for menorrhagia using hysterectomy, leaves
the uterus in place [Dwyer et al, 1993]; and PTCA, where arterial stenoses and
occlusions are re-vascularised using a catheter, guidewire and balloon rather than
by coronary artery bypass graft (CABG) [Goodman, 1992]. Examples of the
second category of MAS include laparoscopic cholecystectomy, which removes
the diseased gallbladder without the need for a large surgical opening [Wolfe et
al, 1991A], and laparoscopic-assisted vaginal hysterectomy, where the removal
of the uterus is made easier by the use of endoscopic methods [Olsson et al,
1996].
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A further way of categorising entirely new forms of treatment is to distinguish
between those that are undertaken by the same professional clinical group as the
conventional form of surgery and those that are undertaken by a new clinical
group. An example of the first type of procedure is TCRE which is undertaken
by the same gynaecologists who undertake hysterectomy. Examples of the
second include gastroenterologists who now treat a range of gastrointestinal
tract conditions using endoscopy, where treatment would previously have been
the preserve largely of the general surgeon; another example is the use of PTCA
by cardiologists as a form of coronary artery revascularisation which would
previously have been undertaken by cardiac surgeons using CABG.
MAS is a set of therapeutic procedures rather than a homogeneous technology.
It is clear, however, that these therapies share some important characteristics
which have implications for economic efficiency and for evaluative methods.
The remainder of this chapter, therefore, concentrates on MAS, although many
of the points made also apply to the broader category of NT.
2.3 Implications of MAS: patients' benefits
2.3.1 Short-term benefits, long-term uncertainties
Conventional open surgery has some very clear implications for patients'
experiences of therapy. These arise not only from the fact that a large opening
is required through which the surgeon gains access to the operating field, but
also from the fact that retraction, handling and instrument-related trauma will
cause tissue damage and the exposure, cooling and drying of internal structures
[Hirsch and Hailey, 1992]. Inevitably this will result in patients' health status
deteriorating following open surgery: post-operative pain and limitations in
physical functioning often require patients to remain in hospital for several days
following their operation and limit their ability to return to usual activities for
some weeks.
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These 'short-term disbenefits' of conventional surgery will cause more distress
to some groups of patients than to others. Those particularly affected will be
individuals with dependent children and with friends and relatives requiring long-
term care; patients who live on their own with nobody to help them during their
convalescence; patients for whom a prolonged period away from work has a high
personal opportunity cost; and individuals who have jobs requiring strenuous
physical activity who may be unable to return to work for particularly long
periods.
The process of conventional surgery may represent more than a short-term
disbenefit to some. Individuals who are frail due to old age or concomitant
illness will be at risk of serious post-operative morbidity or of mortality, to the
extent that open surgery is often avoided altogether. Moreover, open surgery
has some clear cosmetic disbenefits; for many, the existence of a large scar -
which will fade over time but which may not altogether disappear - will be
considered more than just a short-term disadvantage.
The disbenef its associated with the process and short-term outcomes of
conventional surgery have contributed to the clinical development and diffusion
of MAS. In the case of those forms of MAS which are simply less invasive
means of undertaking a standard therapy, the advantages seem obvious.
However, a randomised trial comparing laparoscopic and open appendicectomy
found that there were no statistically significant differences between patients
undergoing the two treatments in terms of postoperative pain, analgesic
requirements and the proportions having returned to normal activity after three
weeks [Tate et al, 1993].
The rapid diffusion of laparoscopic cholecystectomy is likely to reflect the
perception that it reduces pain and disability, relative to the open form of the
procedure, without an apparent increased mortality or overall morbidity [NIH
Consensus Development Panel on Gallstones and Laparoscopic
Cholecystectomy, 1993]. There has, however, been little thorough evaluation of
the technique and there have been reports of complications in some patients
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[Smith, 1991; Wolfe et al, 1991B; Shanahan and Knight, 1992; Messahel, 1995]
and suggestions that minilaparotomy cholecystectomy may be a preferable
technique [Baxter and O'Dwyer, 1992].
As regards those types of MAS which are not only less invasive than open
surgery but also characterised by a new therapeutic approach, it would appear
that the perception of improvement in process and short-term outcomes is again
the key to their development. For example, TCRE was being used by almost
50% of gynaecologists to treat menorrhagia by as early as 1991 [Royal College
of Obstetricians and Gynaecologists Medical Audit Unit, 1991], prior to data
from randomised controlled trials (RCTs). Subsequent trial data indicated that,
despite a clear reduction in post-operative pain and time until return to usual
activities, it is not as effective as hysterectomy in relieving menstrual symptoms
[Gannon et al, 1991; Dwyer eta!, 1993; Pinion eta!, 19941. Similarly, PICA is
associated with increased post-operative incidence of angina and of repeat
hospitalisations relative to CABG [Pocock et al, 1995], but is an established
means of treating some forms of ischaemic heart disease.
The ability of MAS procedures to allow patients to return to their usual activities
faster than would conventional surgery has been a particularly strong 'selling
point' of the technology. Most of the clinical papers on laparoscopic
cholecystectomy have focused much greater attention on patients' duration of
convalescence than is the norm in clinical journals [Reddick and Olsen, 1989;
Barkun et al, 1992; Stoker et al, 1992; McMahon et al, 1994; Stoker et al,
1994]. There has, however, been a concentration on the time patients take until
they actually return to work rather than are able to resume usual activities. The
American Journal of Surgery published a paper devoted to the consideration of
the extent of interruption of professional and home activity in a sample of
patients in the US and France following laparoscopic cholecystectomy [Vitale et
al 1991]. The authors reported that 63% of Americans in their sample,
compared with 25% of French, returned to work within two weeks of their
operation, emphasising that there is an important distinction between returning
to work and being able to go to work.
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A key characteristic of MAS is the extent to which particular examples of the
technology have diffused widely as a result of these types of perceived short-
term benefit without a great deal of consideration of longer term outcomes. An
illustration of the potential dangers that may result from this is the treatment of
benign prostatic hypertrophy using transurethral resection of the prostrate
(TURP) - a minimal access alternative to open prostatectomy introduced in the
1970s and used in 95% of prostatectomies undertaken in non-federal, short-stay
hospitals in the US by 1986 [Concato et al, 1992]. This rapid diffusion occurred
without formal evaluation, but reflects the perceived advantages of TURP in
terms of it being less invasive relative to open prostatectomy [Wennberg, 1990].
Several retrospective studies using large administrative databases in several
countries have, however, claimed that patients undergoing TURP have a higher
incidence of stricture and of re-operation, and an elevated risk of death, relative
to open prostatectomy [Wennberg et al, 1987; Wennberg et al, 1988; Roos et al,
1989; Malenka et al, 1990; Andersen et al, 1990; Sidney et al, 1992]. Although
it is possible to question the ability of these studies fully to control for
differences in case-mix [Concato et al, 1992], the case of TURP emphasises that
beneficial changes in the process of care, resulting in less immediate post-
operative pain and a shorter convalescence, may not automatically result in an
overall improvement in effectiveness.
It is possible to identify a trade-off facing patients when deciding whether to
choose some forms of MAS rather than conventional surgery. The short-term
benefits for MAS, which are largely related to the process of treatment, may be
accompanied by longer term disbenefits. These disbenef its can sometimes be
defined (ie. risks): for instance, a significant proportion of women undergoing
TCRE require repeat treatment to alleviate their menstrual symptoms; there may
be an excess risk of mortality in men undergoing TURP. Occasionally, there is
widespread ignorance amongst clinicians about longer-term outcomes because
patients either have not been followed up for a sufficiently long period, or follow-
up has not been undertaken systematically (ie. disbenefits cannot be defined;
there is uncertainty). It is by no means clear whether patients are fully aware of
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the risks and uncertainties associated with longer term outcomes when they
agree to undergo these types of MAS.
2.3.2 The dynamic impact of MA S: changing thresholds for surgical
treatment
As well as facing trade-offs when deciding whether or not to choose MAS rather
than conventional surgery, there are trade-offs associated with the choice of
MAS rather than non-surgical treatment, and the advent of MAS may alter the
thresholds relating to decisions about whether or not to treat patients surgically.
Such a change may fundamentally alter the mix of patients undergoing surgical
intervention. The pressures that alter surgical thresholds can originate from the
patient and/or from the clinician, depending upon the nature of the decision
making process.
Adopting the 'patient as consumer' perspective, it is possible to see how MAS
may influence surgical thresholds. Prior to the advent of MAS, some types of
patient, whose symptoms were not sufficiently serious to justify what they
perceived as the short-term disbenef its of surgery, postponed such treatment
indefinitely. These patients, therefore, considered that the private costs of
surgery (the private opportunity cost of the time spent in hospital and
convalescing rather than at work, at leisure or fulfilling family commitments; and
any direct costs such as those associated with child minding) were greater than
the expected net benefits in terms of relief of symptoms. These benefits might
be modest as a result of the underlying disease and symptoms not being
particularly serious or because of the risks and short-run disbenef its of surgery
being high. Unlike some forms of MAS, open surgery is usually undertaken
under general anaesthetic, and the perceived mortality risk associated with this
may reduce expected net benefits further. The availability of MAS is likely to
influence that private trade-off, with the expectation of equivalent (or greater)
net benefits at reduced (or equivalent) private cost.
The 'doctor as agent' perspective would suggest a similar weighing up of the
costs and benefits of conventional surgery, but from the viewpoint of the health
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service or the individual clinician: the net benefits anticipated for the patient
would not justify the health service inputs required or the clinician's own time
commitment. The availability of MAS may again alter this cost-benefit trade-off
if it requires fewer health service resources.
It would appear that the first of these perspectives might have more relevance in
relation to some forms of MAS than other areas of health care. The availability
of minimal access alternatives to hysterectomy, for example, has been widely
publicised in the lay press, and gynaecologists have claimed that patient demand
has been an important factor behind the rapid diffusion of these procedures
[Sutton, 1993]. Moody [1992] has argued that the public became aware of
laparoscopic cholecystectomy, through the media, before most surgeons; and
Banta et al [1993B] suggested that patient demand influenced the diffusion of
PTCA and laparoscopic cholecystectomy.
Some evidence does exist to support the hypothesis that the availability of MAS
alters surgical thresholds. Using health maintenance organisation (HMO) claims
data, Legorreta et al [1993] found that cholecystectomy rates had increased
since the introduction of the laparoscopic form of the procedure. Although the
rate of open procedures declined between 1988 and 1992, the total
cholecystectomy rate increased from 1.37 per 1000 enrollees to 2.15 per 1000.
Furthermore, as a direct result of this increased cholecystectomy rate, total HMO
medical expenditures for cholecystectomy increased over this period by 17.8%.
This occurred despite a reduction of 25.1% in the unit cost of a
cholecystectomy. In an attempt to exclude the possibility that a change in the
patient or clinician population was influencing the findings, the authors compared
these results with those for appendectomy and inguinal herniorrhaphy, where the
diffusion of MAS methods had hitherto been limited. They found no significant
increases in operation rates or medical expenditures for these comparator
procedures. The findings of the study contrast with the generally stable rates of
cholecystectomy in the US during most of the 1980s prior to the introduction of
MAS [Diehl, 1993]. Similar evidence on a change in surgical thresholds for
cholecystectomy has been generated in other US studies [Steiner et al, 1994;
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Fendrick et al, 1994], as well as studies in Canada and Australia [Marshall et al,
1994] and the UK [Lam et al, 1996].
A second possible example of a changing surgical threshold is in the area of the
management of peripheral vascular disease. Studies have shown that, since the
late 1970s, the use of percutaneous transluminal angioplasty (PTA) has
increased significantly, but without a reduction - often with an increase - in the
use of bypass surgery [Anderson et al, 1986; Jeans et al, 1986; Veith et al,
1990; Tunis eta!, 1991]. The situation relating to peripheral vascular disease
appears to be mirrored in coronary vascular disease where the utilisation of
bypass surgery has failed to decrease despite the rapid expansion of PTCA
[Anderson and Lomas, 1988; Feinleib et al, 1989; Weintraub et al, 1990].
Evidence also exists to indicate that the diffusion of MAS techniques to treat
menorrhagia has shifted the referral threshold for surgery in that area. Bridgman
[1994] found that, for the Mersey region of the NHS, the standardised operation
ratio for dysfunctional uterine bleeding rose to 135 [95% confidence intervals
129-141], compared to a 1990-91 baseline. Similar results have been found for
the Oxford region of the NHS [Coulter, 1994].
It has been argued that surgical thresholds have been shifted so significantly in
some areas that MAS procedures are being used inappropriately. Spiro
suggested that "diagnostic laparoscopic cholecystectomy" is being carried out in
some centres where, because the procedure is straightforward relative to open
surgery, it is undertaken on patients with abdominal pain who have gallstones
incidentally uncovered by ultrasound but who do not have symptoms of biliary
colic [Spiro 1992]. Spiro characterises the surgeons perspective as "Well you've
got gallstones, and we can't do very much about your indigestion. Let's take
out your gallbladder, since this is now so easy to do, and see if you get better.
Those stones aren't doing you any good, and they could be the cause of your
trouble" [p.1671. It has been suggested that there is evidence of similar
developments outside general surgery. On the basis of a series of 171 patients
referred for a second opinion regarding the need for PTCA, it has been estimated
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that 50% of PTCAs undertaken in the US are unnecessary, or at least could be
postponed [Graboys et al, 1992].
2.4 Implications of MAS: resource use
It is likely that the development and diffusion of MAS will have important
implications for health service resource use. It is useful, however, to draw a
distinction between short- and long-term implications.
2.4.1 Short-term impact on health service resource use
In the short-term, MAS will continue to be adopted across most surgical
specialities, and this will impact on two key categories of resource use.
Hospital stay. Commentators have frequently indicated the significant
effect of MAS on duration of hospital in-patient stay [Hoare, 1992; Banta, 1992;
Wickham, 1993]. Although some applications of MAS appear to provide little
reduction in hospital length of stay [Tate et al, 1993; Stoker et al, 1994], this
claim has evidence to support it for many forms of MAS. For example, studies
have shown a significantly shorter initial hospital stay, relative to conventional
surgery, in laparoscopic colectomy [Falk et al, 1993], PTCA [Sculpher et al,
1994], TCRE [Dwyer et al, 1993] and laparoscopic cholecystectomy [Kesteloot
and Penninckx, 1993]. Although this implication of MAS will probably have a
positive impact on both patient benefits and health service costs, it is worth
noting the following caveats.
The first caveat is that a reduction in the demand for hospital beds may not
automatically result in a realisation of cash savings. In the short-term, it is
unlikely that MAS will facilitate the closure of surgical wards or redeployment of
ward nursing staff, which are necessary to reduce cost markedly, because MAS
procedures currently represent only a proportion of total surgical procedures, and
there remains a need for conventional surgical backup facilities for those MAS
procedures that can result in complications [Wilson et al, 1986]. Moreover, it is
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unlikely that reduced demand for hospital beds will permit a significant number of
patients waiting for elective surgical procedures (MAS or conventional) to
undergo their treatment earlier than otherwise would be the case, because MAS
rarely frees up significant amounts of other resources used for surgical patients,
such as theatre time. Another way of viewing this is that MAS has a different
production function to conventional surgery, requiring fewer inputs of in-patient
bed days. Ideally, the health service needs to alter the mix of inputs it has
available for the production process (by reducing bed days) to free-up cash for
other inputs. In the short-run at least, however, the health service faces
constraints when trying to change this mix.
A second factor that may limit the cost impact of a reduced demand for hospital
beds is the importance of the baseline therapy. Some MAS procedures are
replacing non-invasive therapies rather than open surgery. Occasionally this type
of therapeutic shift has the potential to happen for the bulk of patients with a
given condition. For example, trials in the US have indicated that argon laser
trabeculoplasty may be more effective than medical management for primary
open angle glaucoma [Glaucoma Laser Trial Research Group, 1990]; having
largely replaced intra-ocular surgery for the condition in patients for whom
medical therapy is ineffective [Glaucoma Laser Trial Research Group, 1989]. The
possible increase in the utilisation of primary PTCA, instead of the conventional
use of intravenous administration of thrombolytic agents, to achieve coronary
artery recanalisation after acute myocardial infarction, is another example [Grech
and Ramsdale, 1993]. A further example is the use of laser laparoscopy rather
than expectant management to treat pelvic pain associated with endometriosis
[Sutton et al, 1994]. More frequently, MAS is replacing a non-invasive therapy
for a sub-group of patients because of the shift in surgical thresholds discussed
above. It may be the case, therefore, that the use of some types of MAS
increases demands on hospital-resources, including in-patient beds, because they
replace medical management (or no intervention at all) rather than the
conventional surgical intervention usually assumed.
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A third caveat with regard to the impact of MAS on in-patient days is that a
general reduction in post operative lengths of hospital stay had begun, in most
developed countries including the UK, prior to the significant diffusion of MAS
[Department of Health, 1990]. A long term trend can be identified in specialties
where MAS has only recently began to diffuse: in one English region, the
average length of stay per episode in gynaecology fell from 5.1 days in 1975 to
3.0 days in 1985 [Ferguson et al, 1991]. Some of this general trend is doubtless
associated with the growth of day-case surgery which can be used for some
non-MAS surgical procedures, reflecting a change of attitude in the health
service [Audit Commission, 1992; Royal College of Surgeons of England, 1992].
For example, the length of stay for hernia repair fell from 10 days to 24 hours
without a pronounced change in surgical technique [Johnson, 1994];
laparoscopic hernia repair has no advantage over open repair in terms of length
of stay [Stoker et al, 1994]. It may be argued, therefore, that the more
widespread use of MAS is being superimposed onto a system already displaying
a reduced need for hospital beds and that the additional savings resulting from
MAS may not be as significant as is frequently claimed.
A final caveat regarding the link between MAS and reduced lengths of hospital
stay is that most commentators who emphasise this link concentrate on initial
hospitalisations. Some forms of MAS require patients to return for subsequent
treatment more frequently than they would have had they undergone
conventional surgery. For example, the Bypass Angioplasty Revascularization
Investigation (BARI) trial comparing PTCA with CABG in patients with multi-
vessel coronary artery disease found that, after a mean follow-up of 5.4 years,
20.5% of the 915 patients randomised to PTCA required at least one subsequent
CABG, 23.2% required at least one further PICA and, in addition, 10.8% needed
at repeat PTCA and a CABG; of the 914 patients randomised to CABG, the
respective rates were 0.7%, 6.9% and 0.4% [BARI Investigators, 1996].
Therapeutic resources. The advent of MAS may influence the demand for
resources such as theatre/treatment room time, staff number and mix,
anaesthetic and therapeutic equipment, consumables, gases and drugs. There is,
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however, no clear link between the use of MAS procedures and a reduced
demand for these types of therapeutic resource. Some forms of MAS offer
savings in some categories but place additional demands on others. For
example, the use of the neodymium yttrium aluminum garnet (Nd:YAG) laser to
palliate advanced colorectal cancer, rather then palliative surgical resection,
substitutes less expensive endoscopy suite time for theatre time, and requires
less anaesthetic and staff support, but needs investment in expensive laser
equipment [Vondeling, Mathus-Vliegen and Banta 1991; Sculpher, 1993].
Furthermore, laparoscopic procedures are undertaken in theatre, and it has been
suggested that they require up to 75% additional time to be completed compared
to open surgery [McCloy, 1992]. For example, laparoscopic cholecystectomy
has been shown to take longer than the open procedure in a number of countries
[Hirsch and Hailey, 1992; Kesteloot and Pennickx, 1993]. TCRE, on the other
hand, requires less time in theatre, fewer staff and puts less demand upon
anaesthetic resources; even allowing for additional equipment costs, overall
operation costs are less than those associated with abdominal hysterectomy (see
Chapter 2).
The use of MAS procedures can, therefore, either increase or decrease the
demands on therapeutic resources. Indeed, generalisation about therapeutic
resource use is difficult even in relation to a specific form of MAS due to
differences in how they are applied in clinical practice and the speed of
development over time. For example, there is considerable variation between
clinicians undertaking laparoscopic surgery in whether they use disposable
consumables or re-usable equipment, with significant cost implications (see
Chapter 6). Therapeutic resource use is also influenced by the different versions
of operations which exist. For example, the use of laparoscopic techniques in
hysterectomy has resulted in a number of specific procedures developing
including laparoscopic-assisted vaginal hysterectomy, total laparoscopic
hysterectomy and laparoscopic-assisted doderlein hysterectomy [Garry et al,
1994].
27
Chapter 2	 Minimal access surgery
Furthermore, the caveats outlined above regarding the reduced demand for in-
patient beds associated with MAS need to be born in mind here too. In short,
the effect of MAS on short-run hospital costs depends very much on the MAS
application and the baseline against which it is compared. Although a number of
studies indicate advantages in these sorts for costs for MAS technologies
[Kesteloot and Pennickx, 1993], others suggest that some applications of MAS
may be more costly than their comparators [Cuckow, 1994; McMahon et al,
1994].
2.4.2 The costs to the health service of transition
McKinlay [1981] identifies seven stages in the career of a medical innovation,
running from "promising report" to "erosion and discreditation". The process of
shifting MAS procedures from the "promising report" to the "standard
procedure" is not costless [Gelijns and Fendrick, 1993]. For many MAS
procedures, there is a need to invest in new capital equipment: endoscopes,
videos, monitors, lasers. The 'learning curve' related to new ways of
undertaking therapy also imposes costs. The development of a new MAS
procedure from use in a limited number of clinical centres and by enthusiasts into
routine clinical practice and widespread use requires organisation and training. In
the NHS there is no systematic process to achieve this. The initial diffusion of
skills often comes through workshops and seminars facilitated by the funding of
companies manufacturing or marketing the equipment used as part of MAS
procedures. Sometimes enterprising clinical enthusiasts take the initiative by
running courses, 'selling' new procedures in terms of the financial advantages to
the health service and perceived patient and professional benefits [Bryan, 1993].
Either way, resources are expended in this process: both the time participating
clinicians spend away from their practice and the time that goes into organising
and providing the seminars, workshops and courses.
Costs are also associated with the transition of clinicians to being accomplished
practitioners of new MAS procedures; that is, with the movement up the learning
curve. Inexperienced practitioners are likely to require more resources to
complete a procedure than experienced ones. For example, one study reported a
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mean operating time for laparoscopic cholecystectomy of 2.4 hours for the first
50 patients receiving treatment, against a mean of 1.8 hours for the next 65
patients [Hirsch and Hailey, 1992]. Moreover, it is likely that a clinician at the
foot of the learning curve will not be so effective as a more experienced clinician
in undertaking a new form of MAS [Still and Walsh, 1992]. This may result in
additional health service costs due to an increased likelihood of complications or
technical failure [See et al, 1993]. There have been some well-published
examples of complications with MAS procedures which have apparently been
due to a lack of experience on the part of the clinician [eg. Times, 1992].
Indeed, some clinicians may never fully climb the learning curve associated with
a new MAS procedure. Evidence exists to support the view that clinicians need
to undertake a procedure frequently to become accomplished practitioners
[Showstack et al, 1987; Luft et al, 1987; Cromwell et al, 1990; Luft et al, 1990;
Hannan eta!, 1991; Woods eta!, 1992; Farley and Ozminkowski, 1992],
although the quality of these observational studies has been questioned [NHS
Centre for Reviews and Dissemination, 1995]. If volumes are insufficient for this
purpose, costs are likely to be imposed on the health service and patients.
It is important to emphasise, however, that the costs associated with clinicians
moving up learning curves are in no way unique to MAS procedures. Any new
therapeutic practice will impose transition costs; indeed fully established surgical
procedures may impose 'learning curve costs' if clinicians undertake too few to
become proficient. Furthermore, the cost of a new MAS procedure undertaken
by an inexperienced clinician may still be lower than that of a conventional
surgical procedure carried out by an experienced surgeon. The overall benefits
for patients too may be higher; hence patients may be prepared to accept the
additional risk of complications or technical failure related to a 'sub-optimal' MAS
procedure, relative to conventional surgery undertaken by an experienced
practitioner.
2.4.3 Long-term impact on health service resource use
The foregoing discussion would suggest that the assumption that the
development and use of MAS procedures automatically reduces the cost of
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health service resource use in the short-run is possibly unfounded. Uncertainty
surrounds this issue, however, because of the absence of good quality economic
evaluations of new MAS procedures compared to conventional therapy.
Knowledge about the effects of the greater use of MAS on resource use in the
longer term is even more sketchy, although various commentators have made
predictions [Wickham, 1993; Wickham, 1994; Banta et al, 1993A; Banta,
1993B]. For instance, Wickham [1993] predicted that, in the longer term, the
diffusion of MAS will have the following sorts of organisational effect.
(a) The large general hospital of over 350 beds will be replaced by "single
storey 'stand alone production units" [p12] because there will be fewer
in-patients at any given time.
(b) There will be a greater need for well trained nursing staff, experienced in
the various types of MAS.
(c) Greater cooperation will be required between providers of care in the
hospital, clinic and community.
(d) There will be a radical change in the nature of therapeutic facilities, with a
movement away from the traditional operating theatre towards purpose-
built therapy suites containing radiological, ultrasonic and endoscopic
facilities, and multiple-monitor displays.
(e) There will be less need for the type of methods traditionally required to
achieve asepsis during an operation such as 'gowning up'; there will also
be a reduced demand for sterile operating clothing. More sophisticated
ways of sterilising modern equipment such as endoscopes may be
required, however.
(f) Changes will continue in the type of doctor who undertakes interventional
therapy; for example, recent changes have resulted in an increased role
for interventional radiologists and physician gastroenterologists in areas
previously the preserve of vascular and general surgeons, respectively.
Wickham sees a declining role for the surgeon: "it would seem that
surgeons are going to have to accept the changing status of being only
one member of a group of interventionalists and not the present 'leader of
the pack" [p13].
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(g)
	
The changing type of doctor will alter specialty boundaries. Wickham
predicts further specialisation but with a declining role for the surgeon.
"It may well be that organ specific physicians will after diagnosis direct
the patient to the most efficient 'sub-contractor interventionalist" [p131.
Similarly the surgeon's role in pre- and post-operative care may well give
way to more involvement by anaesthetists and intensive care physicians.
However, in general, these longer-term implications of MAS are extrapolations
from developments which have been taking place in medicine for some years.
For various reasons, hospitals are less pre-occupied with open surgery than
previously was the case and there has been an increased role for non-invasive
therapies such as drugs, more sophisticated forms (and hence often greater
utilisation) of diagnostic technologies and the development of hospital-based
screening and assessment programmes. Although probably a key explanatory
factor, innovations in surgical techniques are only partly responsible for the
changing face of medicine, and of the hospital and its staff; the specific
development of MAS has an even more limited explanatory role in these
developments.
It is reasonable to suggest that the diffusion of new forms of MAS may
accelerate the sorts of changes Wickham outlined, but it is important to
remember that MAS techniques are unlikely totally to replace conventional
surgery. Hirsch and Hailey referred to studies which report between 1.8% and
10% of laparoscopic cholecystectomies being converted to open procedures
[Hirsch and Hailey, 1992]; Tate et al [1993] report that 20% of laparoscopic
appendicectomies require conversion to open surgery. Although these types of
result may well be a reflection of the process of climbing the learning curve
referred to above, the need to convert from MAS to open techniques at short
notice may limit the speed and extent of hospital change.
It is unlikely that the sorts of long-term change in health care in general and the
hospital in particular identified by Wickham will reduce the total amount (and
value) of resources society allocates to health care. Although there may be
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some release of resources following the possible closure of traditional in-patient
wards and surgical theatres, new forms of infrastructural investment in such
things as interventional suites and therapeutic and diagnostic equipment may
well at least absorb these savings. Furthermore, the perceived advantages of
greater throughput achieved by hospitals as a result of declining patient lengths
of stay may be cancelled out by a re-discovery of the post-war hidden-iceberg of
illness: the changing thresholds to surgical intervention discussed above is a
specific example of the more general phenomenon that new breakthroughs in
medicine generate new 'needs' which eventually lead to increased utilisation of
health care resources. As such, MAS may represent in the 1990s what renal
dialysis was in the 1960s and plastic hip replacement surgery was in the 1970s
[Klein, 1989].
2.4.4 The impact on resource use outside the hospital
In addition to the effects that MAS may have on hospital-based resource use,
there is likely to be an impact on the resource use consequences of health care
outside the hospital.
Community-based health services. It is possible that any cost reductions
related to the shorter lengths of in-patient hospital stay associated with MAS,
relative to conventional surgery, will be offset by a greater burden on
community-based health services. The post-operative care which was previously
provided by hospitals is now more frequently the responsibility of primary health
care teams and district nurses. However, as noted above, shorter lengths of
stay and the growth of day-case surgery have been generally evident over recent
years, and are not solely related to increased use of MAS. To the extent,
therefore, that it results in less post-operative morbidity for the patient, some
forms of MAS may reduce the burden on community-based health services.
A study from the Welsh Health Planning Forum has attempted to quantify the
organisational changes that are likely to take place as a result of developments in
MAS in the area of gastroenterology [Warner et al, 1993]. Using a Delphi panel
of clinical and technological experts and site visits to a number of clinical centres
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in the US, Sweden, the Netherlands and Canada, the study explored the
following hypothesis: "that as a result of emerging technology in the fields of
diagnostics, treatment and communications, the role and function of the acute
hospital, and its relationship with community services and general practice, could
by the year 2002 alter considerably" [p.5]. The authors report that "in general
the results of the Delphi meeting strongly support this hypothesis" [p.291.
On the basis of the Delphi meeting, the study reached some additional
conclusions regarding gastroenterology:
(a) there will be an increased use of day-case surgery in gastroenterology
because of greater use of endoscopic and other activities;
(b) there will be a greater use of community-based minimally invasive
techniques where GPs initiate (and sometime directly undertake)
endoscopic and other forms of diagnosis (which will be open-access) and
initiate and monitor therapy;
(c) there may, therefore, be an increased role for GP decision making but,
due to the growth of specialist radiologists and endoscopists, this may be
more apparent than real; and
(d) the community-based approach would be more "clinically efficient"
[p.29].
Patients' private cost. Increased use of MAS procedures may also affect
patients' private costs. As noted above, it is likely that patients who undergo
MAS rather than conventional surgery will incur fewer direct costs such as those
associated with child minding. Perhaps more importantly, the shorter lengths of
stay associated with the shift from conventional surgery to MAS will reduce the
time patients are required to allocate to the process of health care and the period
of convalescence. This time is of value to individuals, in terms of either work-
related income which for some individuals is reduced or removed as a result of
illness, or the enjoyment of leisure time. The link between MAS procedures and
reduced private costs may not, however, be automatic for the reasons discussed
above in relation to reduced lengths of hospital stay.
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Production losses. It has been argued that, even if MAS procedures are
more expensive than conventional surgery in terms of direct health service costs,
these costs may be offset by the production gains resulting from patients' earlier
return to normal activities [McCloy, 1992]. As noted above, the impact of MAS
on the period until return to usual activities has been of considerable interest in
clinical evaluations. Patients' length of convalescence will undoubtedly have an
important effect on their health-related quality of life (HRQL), which is a key
outcome of these interventions, although part of this impact will be a reflection
of improvements in other key domains of HRQL such as post-operative pain.
Whether patients' early return to normal activities should also be valued in
monetary terms is an area of methodological controversy considered in more
detail in Section 2.6.2.
One of the important conclusions of the foregoing discussion is that MAS is not
synonymous with improved benefits to patients, or with reduced costs to the
health service or to society more widely. Although it may well be true that many
MAS procedures reduce the level of trauma patients experience with surgery,
some major assumptions are required to conclude, without empirical support,
that these procedures improve health. Furthermore, even if a net benefit to
patients is proven, it is not necessarily the case that these benefits will be
considered of sufficient value to justify any additional cost.
2.5 A review of published economic evaluations of MAS
2.5.1 Introduction
There is now a general acceptance amongst clinicians and health service
managers of two 'health care truisms': the amount of resources available for
society to devote to maintaining and improving health is, and always will be,
finite; and the opportunities available to the health service to attempt to
influence health are continuing to grow rapidly. It is, therefore, incumbent upon
society to assess the extent to which particular health care technologies
generate the sorts of benefits that justify the resources devoted to them.
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There now exists an established set of general methods to evaluate the value for
money offered by health care technologies [Drummond et al, 1987; Eisenberg,
1989; Luce and Elixhauser, 1990; Pettiti, 1994; Sloan, 1995], although some of
the specific analytical techniques required to undertake an economic evaluation
remain controversial [Drummond et al, 1993A]. Most groups of health care
technology raise particular problems and issues as regards their economic
evaluation, where this may be related to the clinical area to which they are
relevant or to the nature of the technologies themselves. This section of the
chapter considers the methodological issues related to the economic evaluation
of MAS in more detail.
Much can be learnt about the methods of economic evaluation from reviewing
published studies in the area. A systematic review of published economic
analyses has been undertaken with he following objectives:
(a) to describe the economic evaluation methods which tend to be adopted
for the economic evaluation of MAS procedures;
(b) to assess whether the methods that generally prevail are adequate given
the characteristics of the technologies under evaluation and, if not, where
methodological developments are most urgently required; and
(c) to identify any novel methods which have been developed in this area.
2.5.2 Review methods
The focus of the review is economic evaluations of MAS undertaken since 1985.
The choice of year in which to begin the review is based on the fact that the
majority of developments of MAS have taken place over the last decade.
Economic evaluation is taken to mean a full analysis, as defined by Drummond et
al [1987], which includes cost-effectiveness analysis, cost-utility analysis, cost-
minimisation analysis and cost-benefit analysis. This definition excludes studies
which have looked in detail at costs and outcomes within a cost-consequence
framework because they do not incorporate decision rules to assess technical or
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allocative efficiency. MAS is defined as in Section 2.2.2 above; namely, an
application of endoscopic or percutaneous therapy.
The sample of studies in the review has been identified using the following
strategy.
(a) A search of publications on the Medline and Health Planning and
Administration on-line databases (US National Library of Medicine) as at
July 1996. The search employed a mixture of index terms and free text
searches, details of which are provided in Appendix 2.1. The abstracts of
each article retrieved were read and the full articles of apparently
appropriate studies acquired.
(b) Several comprehensive reviews of MAS have been published [Hirsch and
Hailey, 1992; Banta, 1991; Banta, 1993A; Hirsch, 1994; Pearson, 19941.
The references cited in each were manually searched and full copies of
articles apparently fulfilling the inclusion criteria for the review acquired.
(c) Each article was read carefully and a decision taken as to whether or not
it fulfilled the inclusion criteria for the review.
2.5.3 Results of the review
The search of the on-line databases generated 181 possible full economic
evaluations of MAS applications. On the basis of the abstracts, 155 articles
were excluded for the following reasons: 23 were cost or cost-consequence
analyses; 2 looked at benefits only and not at costs; 40 were reviews rather
than evaluation studies; and 90 did not relate to MAS. The manual search of the
references of the MAS reviews identified a further three likely full economic
evaluations. Hence, full articles were acquired for 29 studies.
After studying the full articles, a further 13 studies were excluded because they
were only cost or cost-consequence analyses (9), were not evaluation studies (2)
or because they were not evaluations of MAS (2). This left a total of 16 studies
for detailed review, the results of which are described in Table 2.1.
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One observation from the review is the paucity of rigorous economic evaluations
of MAS applications. If predictions that up to 80% of surgery will be undertaken
on a minimal access basis by 2000 are accurate, it should be seen as a major
research priority to increase the number of economic assessments in this area.
Contrasting with the dearth of full economic evaluations is the large number of
cost analyses and cost-consequence analyses. By systematically describing the
various clinical benefits and disbenefits, as well as the costs, of MAS alongside
an appropriate comparator, some cost-consequence analyses would have
provided useful information to health service decision makers. However, the
majority of these partial economic evaluations fail to provide any clear indication
of the value for money offered by MAS: they are either clinical evaluations which
include a modest amount of cost (or charge) data almost as an after-thought, or
they are detailed costings without data on outcomes.
2.6 Issues of method in the economic evaluation of MAS
A range of methodological issues exist in relation to the economic evaluation of
MAS, many of which are brought out by assessment of the economic
characteristics of MAS and by the review of published studies. The key issues
are discussed below, some of which provide the focus of subsequent chapters.
2.6.1 Sources of data
Good quality data on the resource and non-resources consequences of
interventions are a requirement whatever the technology being evaluated.
However, there are some particular issues of method associated with measuring
the effects of surgical procedures in general, and MAS in particular, that deserve
specific attention.
The randomised controlled trial. Amongst the hierarchy of methods of
clinical evaluation, it is widely accepted that the properly designed RCT, with an
adequate sample size, is the preferred method for assessing the health effects of
therapeutic interventions [Pocock, 1983]. In addition, the RCT is increasingly
seen as a vehicle for the collection of resource use data [Drummond and
Stoddart, 1984; Eisenberg eta!, 1989; Drummond and Davies, 1991; Drummond
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Chapter 2
	 Minimal access surgery
1995]. Of the 16 economic evaluations of MAS procedures reviewed here, 3
were based largely on data collected in a RCT (Table 2.1). Chapter 3 of this
thesis uses RCT data as a starting point for the economic evaluation of AH
versus TCRE.
The primacy of RCTs follows from the link between random allocation - usually
of patients to alternative therapeutic interventions - and internal validity
[Jaeschke and Sackett, 1989]. That is, randomisation facilitates control over
potential but unknown confounding variables, which may influence the outcome
of interest, because they should be symmetrically allocated across the arms of
the trial, thus allowing differences in effectiveness and resource use to be safely
attributed to the only factor known to vary systematically between treatments -
the intervention itself.
The RCT is accepted as being the gold standard for the evaluation of drug
therapies and such methods are required in many countries to establish the
clinical efficacy and safety of new compounds prior to licensing [Dukes, 1986].
The process of 'blinding both clinicians and patients to the exact details of the
intervention to which patients have been randomised - thus minimising the
chance of measurement bias - ensures that the advantages of the true
experiment are maximised.
Although RCTs have successfully been carried out to evaluate surgery [Miller et
al, 1989], their use in this area remains rare compared to trials employing
historical controls [Sacks at al, 1982]. As an example of a set of new surgical
procedures, some forms of MAS have entered into widespread clinical use with
very little evaluation by ROT. For example, despite a survey indicating that 58%
of British surgeons thought a trial was required and 45% were willing to be
involved [McMahon at al, 1992], only six RCTs have been located in the
published literature focusing on the clinical or patient-based outcomes of
laparoscopic cholecystectomy [Barkun et al, 1992; Trondsen et al, 1993;
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McMahon et al, 1994; Berggren et al, 1994; Makinen and Nordback, 1995;
Dauleh et al, 1995]. Furthermore, five of these were small, randomising
between 24 and 78 patients. It should be noted, however, that evaluation of
MAS by RCT is more common in some specialties other than in general surgery.
In gynaecology, for example, a range of MAS procedures has now been subject
to trial-based evaluation [Berget eta!, 1987; Tulandi, 1986; Lundorff eta!, 1991;
Summitt et al, 1992; Dwyer et al, '1993; Pinion et al, 1994].
A number of potential difficulties in using RCTs to assess the effects of surgical
technologies have been identified in the literature, many of which are particularly
relevant to new MAS procedures. The first problem relates to that fact that is it
usually felt to be virtually impossible to incorporate a placebo control and double
blinding into a RCT of a surgical procedure and that this represents a movement
away from the "gold standard for proper evaluation" [Stirrat et al, 1992, p.81].
However, there has been successful use of placebo controls and double blinding
in evaluations of MAS procedures; for example, a recent RCT compared
transurethral microwave treatment for benign prostatic hypertrophy with sham
treatment using double blinding [Bdesha et al, 1993]. It may also be possible to
blind the evaluator of the technology if they are independent of the clinical team.
Moreover, even if placebo control and blinding are not feasible, this might only
preclude the successful completion of an explanatory trial in surgery which
would seek to test a biological hypothesis under optimal conditions to establish
the relative efficacy of procedures [Schwartz and Lellouch, 1967]. If an RCT is
to be undertaken to inform clinical policy, however, it is more likely to exhibit a
pragmatic rather than an explanatory design, whereby alternative procedures are
compared under conditions which would normally apply in routine practice, in
order to identify the apparently more effective therapy [MacRae, 19891.
The second problem relates to the 'learning curve' in MAS, which has some
important implications for the use of RCTs [van der Linden, 1980; MacRae,
1989; Stirrat et al, 1992]. One implication is that it is likely that RCTs will be
undertaken by clinical enthusiasts: clinicians with high levels of skill, often based
in medical schools. Indeed, some of the few RCTs evaluating MAS techniques
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specify a minimum level of experience for the clinicians carrying out treatment.
Given that the surgeon (or endoscopist) is a fundamental part in the therapeutic
technology of MAS (which is less the case with drug therapy), their
characteristics directly influence resource and non-resource consequences. As
has been noted above, studies have now highlighted the link between the
experience of the therapist and clinical results. Hence it may be doubted that
RCTs of MAS can ever be truly pragmatic if the trial therapists have
characteristics which are dissimilar to those of the practitioners who will
undertake the procedure following widespread diffusion. The generalisability or
external validity of RCTs in this area may, therefore, be limited.
It is possible, however, to design RCTs of MAS which attempt to maximise
external validity. One approach would be to undertake the trial in a number of
centres which more fully represent the heterogeneity of clinical practice. The
use of a multicentre design may bring additional advantages, moreover, by
avoiding the tendency to under-power trials which frequently prevents the
detection of relatively effective therapies [Frieman et al, 1978]. As either an
addition or an alternative to increasing the number of centres, the generalisability
of a RCT may be increased by ensuring that therapists within the trial occupy the
full spectrum of clinical experience likely to be observed in routine practice:
senior registrars as well as consultants, for example. If it is not feasible for each
clinician taking part in the trial to undertake each of the therapies being
evaluated, there should be an effort to ensure that the skill/experience mix of the
clinicians is equivalent in the two arms of the trial. If this is not feasible -
clinicians are often further up a learning curve for an established procedure than
they are for a new one - statistical methods can be used to adjust results for
asymmetry in clinicians' experience between the arms of the trial NRC Health
Services and Public Health Research Board, 1993].
A third problem likely to be encountered when designing trials of MAS
procedures is the variability that exists between centres in certain elements of
the procedure. For example, some centres use a laser as an integral part of
laparoscopic cholecystectomy, while others use diathermy (Voyles et al, 1990;
45
Chapter 2	 Minimal access surgery
Hunter, 1991]. The problem can be overcome, as long as the variability in
methods is known when the trial is being designed. In which case, if the
alternative methods are considered important enough and sufficient patient
numbers and resources are available, patients can be randomised to two or more
forms of MAS as well as to conventional surgery. A similar problem exists
concerning the potential speed of change of MAS technologies. If a trial is
designed to evaluate a new MAS procedure and, midway through the study, the
clinicians in the study feel that the procedure should alter in some way, the value
of the results may be limited. The extent to which this is a significant problem
will inevitably depend on the importance of the technological change and
whether the trial can recruit sufficient additional patients to assess the new form
of the technology within the same study.
A fourth and related problem is that trial protocols may impose atypical patterns
of care upon unrepresentative samples of patients, which makes the resource
use and outcomes observed difficult to generalise to routine clinical practice.
This problem can be minimised by a making the RCT as pragmatic as possible:
undertaking it in as many centres as is feasible; including the vast majority of
patients to encompass the heterogeneity of the presenting condition; and
developing a protocol which does not impose new or additional forms of clinical
practice to the norm in a given centre [Simon et al, 1995].
A fifth difficulty likely to be encountered when RCTs are used to evaluate MAS
procedures concerns patient recruitment. In view of the most apparent
characteristics of MAS relating to the reduction in trauma and length of
convalescence, potential study patients may not be attracted to the idea of
entering a clinical trial which involves a chance of being randomised to an
alternative form of therapy: the patient quite simply may not be indifferent
between the options under evaluation. It has been argued that patient
recruitment to RCTs designed to evaluate laparoscopic cholecystectomy has
suffered in this way: "Well intentioned and well-designed protocols have
drowned in the tidal wave of optimism among patients and physicians about the
benefits of the laparoscopic approach" [Cotton, 1992, p1626]. Clinicians, too,
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may be reluctant to randomise patients into trials; it has been shown that a
common reason for this reluctance is the clinician's fear of admitting ignorance
to patients [Taylor, Margolese and Soskolne, 19841.
Various suggestions have been made as to how recruitment problems related to
RCTs could be overcome within RCTs. These include the education of the public
regarding the social and moral arguments in favour of "doing their bit" for
improving health [Baum, 1993], the provision of incentives to doctors to recruit
patients such as emphasising the 'training' effect of trials [Macintyre, 1991], the
concept of randomised consent designs for clinical trials where patients'
preferences about treatment options are taken into account at randomisation
[Brewin and Bradley, 1989; Zelen, 1990] and the use of pre-randomisation
[Chang et al, 1990]. Despite calls for more RCTs in health care technology
assessment [Advisory Group on Health Technology Assessment, 1992], it is
likely that the use of trials to evaluate MAS procedures will be hampered by
patient recruitment problems.
It is likely that an important focus for future evaluation of MAS procedures will
be on the long-term implications of these technologies, and a sixth problem with
RCTs lies here. In order to have detected the alleged shortcomings of TURP (see
Section 2.3.1) as part of a RCT, such a study would have to have been both
large in terms of patient numbers - to identify the suggested higher incidence
amongst TURP patients of stricture, re-operation and death, which are rare
events - and based on a very long-term period of follow up. The cost of running
a RCT and the possible difficulties in recruiting patients and clinicians, however,
may limit the scope for designing sufficiently large trials. Although trial patients
can be 'flagged' for some key clinical events such as death or the development
of cancer, the cost and logistical difficulties of organising trial-specific data
collection over many years usually results in RCTs having a relatively short-term
focus. For this reason, it has been argued that "case-control studies . . .
constitute, at least for now, the only feasible method for studying rare and late
adverse effects of drugs and other technologies. Randomised trials are simply
47
Chapter 2	 Minimal access surgery
neither big enough nor long enough to detect important but rare adverse events"
[Jaeschke and Sackett, 1989, p.509].
A seventh problem concerns the sample size of RCTs used to collect resource
use data. Most trials are powered to detect differences in clinical end-points
such as survival rates. If data from RCTs are to be used to determine the cost-
effectiveness of MAS procedures, sample sizes will need to be sufficient to get
reasonably tight estimates of levels of resource use. This will require more
general evidence on the variability in these types of data amongst patients
[Drummond and O'Brien, 1993].
A final problem with RCTs relates to concerns that have been raised about the
ethics of RCTs in general [Passamani, 1991]. When they are used as a vehicle
for the collection of resource use data, additional concerns may be identified.
Perhaps the most intractable of these occurs when the clinical uncertainty
concerning two technologies has been resolved by a RCT, but it would be
necessary to continue randomising patients to achieve a sample size sufficient
for good estimates of resource use. Should randomisation continue despite the
fact that clinical uncertainty may have been removed [Buxton and Sculpher,
19941? As such, this is a specific example of the general conflict between
ethics at an individual level and those at a societal level that frequently arises
within discussions of rationing and economic evaluation [Mooney and McGuire,
1988].
It is probably true that the relative rarity of the RCT in health care evaluation
[Fletcher and Fletcher, 1979] is more the result of the difficulties and cost of
undertaking them, and of a failure of clinicians to accept genuine clinical
uncertainty, than of a widespread concern about their potential limitations
regarding evaluative methods; this applies in particular to surgery. Although it is
widely accepted that, even with the sort of drawbacks described above, the
appropriately undertaken RCT offers the most rigorous source of evaluative data,
in many contexts such trials simply are not possible due to such factors as poor
patient recruitment, ethical concerns, the nature of the technology and the
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urgency of getting results. Inevitably, therefore, the surgical evaluation literature
is full of non-experimental evaluative designs and these have contributed to
clinical policy decisions in the area. When assessing how to evaluate emerging
MAS procedures, these methods need to be considered.
Observational studies. The non-experimental study can serve a useful
purpose in establishing the potential effectiveness of new technologies and the
cost-effectiveness of undertaking a ROT. In clinical areas where the prognosis is
poor and no effective intervention has previously existed, positive evidence from
such analyses may be sufficiently credible to prompt the diffusion of a new
technology [Advisory Group on Health Technology Assessment, 1992]. Indeed,
it is possible to identify by this route technologies which are self-evidently
effective, such as dialysis in terminal renal failure [Guyatt et al, 1986].
Furthermore, the non-experimental study can serve a purpose in selecting those
new technologies with a likelihood of improving outcomes, and these can then
be subject to more rigorous evaluation [Sculpher eta!, forthcoming]. Such
studies can also provide data to plan certain aspects of RCTs, such the
calculation of sample sizes, and inclusion and exclusion criteria [Roos, 1989].
Further advantages of non-experimental designs have been identified [Sechrest
and Hannah, 1990]:
(a) data are often readily available, and analyses can be undertaken quickly
and at limited cost;
(b) the results of non-experimental studies may have high levels of external
validity because the unrealistic conditions of the experimental design are
avoided; and
(c) quasi-experiments (ie. when two or more groups are compared
retrospectively or prospectively but are not generated by random
allocation) may be inherent in administrative arrangements which routinely
generate data.
Sechrest and Hannah argue that, faced with these possible advantages but also
with the clear problems of non-experimental data, the researcher can either
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ignore the information provided or seek to improve the weaknesses in design and
to strengthen interpretations of the findings of non-experimental studies. Some
researchers have accepted the latter approach and have sought ways to
strengthen causal interpretations of non-experimental data. These include a
consideration of a greater role for meta-analysis [Cordray, 1990] and ex post
adjustment of the results of non-experimental studies based on the expected
direction and size of their biases [Miller et al, 1989]. There have also been calls
for greater use of Bayesianism in evaluative research, whereby the value of
analysis can be independent of study design [Berry, 1993].
With a focus on determining the cost-effectiveness of a technology, Sculpher et
al [forthcoming] suggest an iterative approach to economic evaluation, where
early-stage assessment would involve the synthesis of available data to clarify
the key uncertainties in resource use and outcomes to plug into subsequent
designs. In certain circumstances, early-stage modelling is sufficient to identify
the cost-effectiveness of a technology (eg. screening for diabetic retinopathy
[Dasbach et al, 1990]).
2.6.2 Indirect costs
A methodological controversy which impinges on cost analyses involving MAS
procedures is whether or not to include indirect costs. Of the 16 studies in the
review of published economic evaluations in Section 2.5 , only one considered
indirect costs. However, the fact that patients return to their normal activities
more speedily with many types of MAS than with conventional surgery is fairly
clear and, as discussed above, this has become a clear clinical 'selling point' for
these sorts of technology [Stoker et al, 1994]. Whether these consequences
should also be valued in monetary terms is less clear. Amongst health
economists, certainly in the UK, there is little consensus about the incorporation
of indirect cost savings into the calculus of economic evaluation [Drummond et
al, 1993A]. Koopmanschap and Rutten [1994] found that decisions about
whether or not to include indirect costs in an economic evaluation can have a
major impact on results. This has also been concluded in the specific area of the
economic evaluation of MAS: Cook et al's [1994] comparison of alternative
50
Chapter 2	 Minimal access surgery
treatments for gallstone disease, found that the inclusion of indirect costs altered
the results of the analysis markedly.
A number of concerns exist as regards the validity of valuing these effects as a
form of cost. Firstly, invariably those studies which do value these
consequences concentrate on earlier return to work and value this time using
gross pay rates, although the time of patients not actively engaged in the labour
market is also of value and a focus solely on the value of forgone working time
may bias service provision against individuals not in employment [Ratcliffe,
1995].
A second concern relates to the implications of an effectively permanent pool of
unemployed on such costs: if an individual is required to take time off work due
to illness, the employer can, in principle, dip into this pool for temporary labour
with little effect on total production. Models have, however, recently been
developed to address this problem [Koopmanschap and van lneveld, 1992].
A further concern about the appropriateness of incorporating indirect costs into
economic evaluation is the risk of double-counting. If the outcomes of treatment
have been valued in non-monetary terms on the benefit side of a CUA and if
those outcomes include increased mobility and quicker return to usual activities,
it would surely not be appropriate to value these particular outcomes again in
monetary terms to incorporate on the cost side of the analysis.
2.6.3 Assessing generalisability
Section 2.6.1 argues that trial data on the resource and non-resource
consequences of MAS may have limited external validity. Indeed, even if the
economic analysis is based on observational, rather than experimental, data,
there may be limits to external validity if the data are taken from only a small
number of centres at a particular point in time. It is, therefore, important for an
economic assessment of this form of technology to explore the generalisability of
its results to data from other sources. The review of published economic
evaluations of MAS in Section 2.5 above indicated that four studies considered
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the generalisability of their results at a descriptive level within their discussions.
For example, Carlsson et al [1989] discussed the development of anaesthesia-
free extracorporeal shock wave lithotripsy in out-patients, indicating that this
would probably reduce costs below that of the base-case analysis, but
suggesting that the effect of the approach on effectiveness was as yet
unknown.
Seven studies in the review provided some assessment of generalisability in the
form of their sensitivity analyses. However, this typically involved some
plausible one-way variation in parameters that were considered likely to vary by
location or context. Using this approach, it is possible to state under which
conditions the base-case conclusions remain robust. For example, Laffel et al
[1987] looked at how variation in the time until presentation to the health care
system influences the relative cost-effectiveness of alternative forms of
thrombolysis and primary PTCA, and found that this was a crucial parameter. A
more sophisticated approach was followed by Mays [1991] who assessed the
impact on the relative cost-effectiveness of ESWL and percutaneous
nephrolithotomy of alternative scenarios about such variables as the utilisation of
capital equipment.
Most studies using this approach, however, simply varied assumptions within the
analysis over a plausible range. Only one study undertook a rigorous assessment
of generalisability by incorporating alternative sources on data into the analysis
and assessing the extent to which the base-case conclusions were robust to the
results of clinical practice in other centres. England et al [1987] generated base-
case conclusions from a simulation model based on data taken from one centre,
and then undertook a sensitivity analysis by incorporating data from several
other sites.
If the resource and non-resource consequences of MAS procedures are likely to
vary considerably by treatment location and over time, it is important for the
conclusions of economic evaluations which are based on data (whether
observational or experimental) taken from one or a small number of centres, to
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be established as robust to other sources of data. Chapter 6 of this thesis
explores these methods further in the context of the economic comparison of AH
and TCRE.
2.6.4 Benefit measurement
In recent years, there has been a move to complement conventional clinical
outcome measures, such as survival rates and technical success rates, with
measures of patients' own assessment of their health status [McDowell and
Newell, 1987; Streiner and Norman, 1989]; and some specific work has been
undertaken in the area of surgery [Cleary eta!, 1991A]. The terminology related
to this broad group of outcome measures is variable; but the terms 'quality of
life' and 'health-related quality of life [HRQU' appear frequently in the literature
[Mosteller and Falotico-Taylor, 1989; Spilker, 1990; Patrick and Erickson, 1993].
Furthermore, various types of measure exist under these sorts of general
heading, including specific and generic instruments, profiles and indices [Guyatt
and Jaeschke, 1990]. The increased use of these instruments is evident in
evaluations of MAS procedures. The Nottingham Health Profile (NHP), a generic
measure of perceived health [Hunt et al, 1986], has been used to evaluate PTCA
[Henderson, 1989], TURP [Doll et al, 1993], percutaneous nephrolithotomy
[Mays, 1991] and laparoscopic cholecystectomy [Barkun eta!, 1992]. Another
generic measure, the SF-36 [Ware, 1993], has been used in evaluations of
laparoscopic cholecystectomy [McMahon eta!, 19941.
Specific instruments have also been used, such as the General Health
Questionnaire to assess psychological well-being in the evaluation of TCRE
[Dwyer et al, 1993], and the McGill Pain Questionnaire and Hospital Anxiety and
Depression Scale (HADS) in the assessment of laparoscopic cholecystectomy
[Barkun et al, 1992; McMahon et al, 1994]. The use of HRQL measures
provides a broader assessment of the outcomes of MAS than do clinical
measures in isolation.
In order to assess the cost-effectiveness of MAS procedures, however, it is
usually necessary to acquire outcome data which exhibit certain characteristics
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[Cairns, 1996]. Unless the MAS procedure dominates its conventional
comparator(s) - that is, it is at least as effective on all measures of outcome and
is less costly - an assessment of cost-effectiveness will require the incremental
cost of the more expensive technology to be related to its improved outcomes.
The conventional way of doing this in economic evaluation is through the use of
some form of incremental cost to effect ratio. In cost-effectiveness analysis
(CEA), effectiveness is measured on a uni-dimensional scale in natural units
which should embrace the key differences in outcomes between the technologies
under comparison. In the review of published economic evaluations in Section
2.5, the majority of studies ( 10/16) were CEAs, with cost-effectiveness
expressed using measures such as life-years gained [England et al, 1987],
disability days averted [Labelle et al, 1987] and additional survivors [Laffel et al,
1987].
A shortcoming of CEA is that it limits the assessment of relative cost-
effectiveness to a specific clinical area or programme. For example, in the
review, Carlsson et al's [1989] comparison of ESWL and percutaneous
nephrolithtomy for the removal of renal stones expressed cost-effectiveness by
relating cost to treatment success rates, where the latter was defined as being
stone at follow-up. Whilst this information may be useful to decision makers
looking to allocate resources in this particular clinical area, it is unlikely that
condition-specific outcome measures of this type would assist in cross-
programme resource allocation because, outside the area of renal stones, this
measure of outcome would have little meaning.
There has, therefore, been an increasing use of cost-utility analysis (CUA) to
facilitate, in principle, a system-wide assessment of relative cost-effectiveness.
With this type of evaluation, technologies are compared using generic measures
of effectiveness or benefit which, although uni-dimensional, can more fully
embrace the various outcomes of programmes. The most frequently used
measure of benefit in CUA is the quality-adjusted life-year (QALY), which is a
measure of the additional life-years generated by technologies, weighted by the
perceived quality of those years [Loomes and McKenzie 1989; Mooney and
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Olsen, 19911. In principle, the relative cost-effectiveness of all uses of health
care resources can be compared using the QALY.
Of the 16 published economic evaluations of MAS procedures reviewed in
Section 2.5, six were CUAs. This proportion compares with 10/93 identified in a
review of all economic evaluations published in 1992 [Briggs and Sculpher,
1994). One factor explaining the greater use of CUA in the economic evaluation
of MAS is the multi-dimensionality of outcomes of these technologies when they
are compared to standard interventions. As discussed above, the comparison of
MAS and open surgery frequently highlights a trade-off in outcomes: open
surgery often has a higher chance of a good longer-term outcome, but the
process of treatment and the shorter-term outcomes (eg. duration of
convalescence) tend to be superior with MAS. It is not easy to express this
trade-off using standard CEA, but CUA can encompass differences in the various
dimensions of HRQL as well as in mortality. Chapter 5 of this thesis considers
the methods and practice of CUA in detail, in relation to the surgical treatment of
menorrhagia.
It is not clear, however, that the standard QALY fully reflects individuals'
preferences about the trade-offs inherent in MAS compared to standard therapy.
These individuals could be members of the public, as their values would be used
to inform the process of allocating society's scarce resources. It could be
argued, however, that patients' preferences over combinations of outcomes
should have an important role in the decision making process. Chapter 4
considers the treatment-related preferences of a sample of 221 women with
menorrhagia and their implications for economic evaluation.
It has recently been argued that, even when patients' values are used to
measure QALYs, the assumptions underling the standard approach to QALY
estimation will not generate a benefit measure which is necessarily consistent
with their preferences [Gafni, 1989; Richardson et al, 1996]. Benefit measures
have been suggested for use in CUA which seek to avoid some of these
assumptions. These include the risk-adjusted QALY [Riskin et al, 1 9801 and
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various forms of healthy-years equivalent (HYE) [Mehrez and Gafni, 1989; Cook
et al, 1994; Gafni et al, 1995], but there are issues about their practicality in
applied evaluations. Chapter 7 focuses on alternative benefit measures to the
standard QALY in CUA and the implications of one - the ex ante HYE - for the
economic analysis of AH versus TCRE.
2.6.5 Preference-based treatment allocation
Patients' preferences about MAS and conventional therapy can be incorporated
into economic evaluation in a more direct manner than through conventional
CUA. It is usually the logic of economic evaluation that a single preferred
intervention is identified from the two or more being compared and that this will
be used in future clinical practice. Occasionally, however, this 'all or nothing'
policy approach is abandoned when clinical heterogeneity exists and a treatment
that is found to be cost-effective for a particular sub-group of patients is not
considered to represent good value for money for all patients.
However, patients differ in ways other than their clinical characteristics, in
particular in terms of their preferences. Given that the benefits patients derive
from many therapies are often tied to their preferences about likely outcomes
[Henshaw et al, 1993], it can be argued that the question that an economic
evaluation should explicitly ask is what are the incremental costs and benefits of
having all the comparators under evaluation available from which patients can
choose. This approach seems particularly appropriate to the evaluation of MAS
procedures, where patients may exhibit particularly strong preferences about the
trade-offs in outcomes between interventions.
Although looking at the valuation of the outcomes provided by the average (or
the median) patient or member of public might result in the MAS procedure being
considered relatively cost-effective, many patients will have quite different
preferences. An economic evaluation could then assess whether the incremental
cost of retaining the conventional therapy, as well as having the MAS procedure
available, could be justified by the additional benefits enjoyed by this 'atypical'
group of patients. Chapter 8 considers preference-based treatment allocation in
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detail and explores whether this form of management is potentially cost-effective
in the area of surgical treatment of menorrhagia.
2.7 Conclusions
If the recent Cushieri Report on MAS is accurate, 70% to 80% of surgical
procedures will be undertaken using endoscopic and percutaneous methods
within 10 years [Cuschieri, 1993]. Although a large number of specific
technologies falls into the MAS category, it is valuable to consider their common
actual and potential characteristics, and the methodological issues that surround
their evaluation.
It is argued in this chapter that there is no automatic link between the advent
and diffusion of new MAS techniques and an increase in the cost-effectiveness
of health care provision. It is, therefore, crucial to undertake appropriate
economic evaluation of MAS procedures, and it is likely that this clinical area will
absorb an increasing proportion of research and development resources in
coming years. For this reason it is important to develop further the methods of
economic evaluation and, in particular, to understand the methodological issues
and difficulties which arise in assessing the cost-effectiveness of this type of
technology.
A range of methodological issues relating to the economic analysis of MAS have
been discussed in this chapter. Some of these have been discussed widely in
the methods literature as they arise in relation to the economic evaluation of a
range of health care technologies; others have not been fully considered in the
literature. The key issues are:
(a) the RCT has a number of limitations as a source of resource and non-
resource consequence data for economic analysis;
(b) generalisability needs to be assessed carefully in economic analysis of
MAS;
57
Chapter 2
	 Minimal access surgery
(c) the multi-dimensionality of the outcomes of MAS may mean that
conventional CEA is not suitable for the evaluation of these technologies;
(d) CUA will provide a means of handling multi-dimensional outcome and
generate information to assist in cross-programme resource allocation, but
the standard QALY may not reflect individuals' preferences about trade-
offs between outcomes; and
(e) if there is heterogeneity in patients' treatment-related preferences
regarding MAS, it may be appropriate to assess the potential cost-
effectiveness of preference-driven treatment allocation.
The remaining chapters of this thesis look in detail at particular approaches to
the economic evaluation of MAS and, in particular, these key methodological
issues.
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Appendix 2.1	 Details of the strategy used to search Medline and
Health Planning and Administration databases
Strategy to identify full economic evaluations
The following index terms were used:
• cost-benefit analysis.
The following free text searches were made on titles:
• economic evaluation;
• cost effectiveness;
• cost utility;
• cost minimisation/minimization;
• cost-benefit.
Strategy to identify applications of minimal access surgery.
The following generic term was used:
• minimal invasive surgery.
The following index terms were used related to types of technology:
• endoscopy;
• laparoscopy;
• angioplasty;
• hysteroscopy;
• gastroscopy;
• sigmoidoscopy;
• thoracoscopy;
• angioscopy.
The following free text searches were done on titles:
• minimal(ly) invasive;
• minimal access.
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Documents were not considered if they were not English language; were animal
studies; or were classified as the following document types: review, comment,
letter or editorial.
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AH versus TCRE: A Cost-Effectiveness
Analysis Alongside a Randomised Controlled
Trial
3.1	 Introduction
Using the case-study of abdominal hysterectomy (AH) versus transcervical
resection of the endometrium (TORE), this chapter details an economic
evaluation of MAS versus conventional surgery alongside a RCT. The analysis
provides an opportunity to explore the methodological implications of running an
economic evaluation alongside a trial which has been designed largely from the
perspective of clinical evaluation. The chapter provides a starting point for the
methodological developments introduced in subsequent chapters, by highlighting
the areas of uncertainty likely to exist in trial-based analysis.
The economic evaluation is undertaken alongside a ROT which was set up largely
in response to the perceived need for applications of MAS to be subjected to
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experimental evaluation [Stirrat et al, 1990]. The trial took place in Bristol and
included 200 women and, based on an initial follow-up of four months, the
clinical evaluation showed that TCRE reduces post-operative morbidity,
permitting patients to return more quickly to their usual activities, but is not so
effective as AH at relieving menstrual symptoms [Dwyer et al, 1993].
Furthermore, a sub-group of resection patients requires additional surgical
treatment.
The trial provided an ideal opportunity to begin the economic assessment of the
two treatments. Other studies have considered the relative costs of AH and
TCRE [Rutherford and Glass, 1990; Manyonda and Varma, 1991; Gannon eta!,
1991; Vilos et al, 19961, but none of these incorporated the cost of
complications or of re-treatment of resection failures. Furthermore, no study
attempted to relate the differential cost of the procedures to differential
effectiveness to assess their relative cost-effectiveness.
Based on data collected in the Bristol RCT, this chapter reports the resource
costs of the two procedures from a health service perspective. In addition,
alternative measures of outcome are presented including menstrual symptoms,
patient satisfaction and descriptive health-related quality of life (HRQL). Relative
cost-effectiveness is expressed using patient satisfaction to define treatment
success. Two points of follow-up were used in the analysis: four months post-
operation and an average of 2.2 years post-operation.
3.2 Methods
3.2.1 Design of the trial
The clinical trial was a parallel group, randomised controlled trial based at the
gynaecology department of a teaching hospital. A total of 200 women were
recruited to the trial between January 1990 and June 1991. Required sample
size was estimated with reference to the anticipated rate of patient satisfaction
with the two treatments. After withdrawals, 97 patients underwent AH and 99
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TCRE. A detailed description of the design of the clinical trial has been reported
elsewhere [Dwyer et al, 19931.
3.2.2 Short-term analysis: four months post-operation
Resource use. Data were collected prospectively on the health service
resources used in the treatment of each woman in the trial during the period
from randomisation to four months after her operation. These resource use data
can be described under seven general headings: pre-operative, operative, post-
operative, in-patient hotel, complications, re-treatment and general practice. Pre-
operative resources included pathology tests, drugs and blood transfusions.
Operative resources were the staff present, equipment, consumables, drugs,
theatre time and histology tests. Anaesthetic resource use was estimated from
a separate study based at the hospital in 1990 which looked in detail at a sample
of five TCREs and 13 AHs [Dr D. Wilkins, personal communication]. Operative
resource use data also included those resources consumed as a result of related
procedures undertaken, as part of the theatre episode, in addition to the main
procedure of AH or TCRE. In-patient hotel resource use was represented by the
number of in-patient nights each woman spent in hospital. If patients spent any
time in the intensive therapy unit (ITU), the number of hours was recorded.
Immediate post-operative resource use included tests, drugs and blood
transfusions.
Data were collected on the additional resource use resulting from all operative
and post-operative complications, together with late complications requiring
readmission to hospital: additional operative procedures, drugs, tests, and in-
patient stay. Re-treatment resource use was that resulting from repeat TCRE or
AH on women for whom initial TCRE was considered a failure at four months
follow-up. Data were also collected on general practice resources: four months
after their operation, each woman was asked how many visits they had made to
their GP since their operation.
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Valuing resource use. Health service resources used by the patients in
the two arms of the trial until four months follow-up are valued in 1994 prices.
Where available, the unit costs used are those generated routinely for Bristol
General Hospital, where the patients were treated. Where such unit costs are
not available, a variety of published sources is used.
All consumables used during the treatment episode have been costed using
market prices including value added tax (VAT). The unit cost of tests
undertaken during the treatment episode are those estimated routinely by the
hospital. Drugs have been costed based on British National Formulary prices plus
VAT; to represent Pharmacy Department overhead costs an uprate of 20% is
added, which was the department's administrative costs as a percentage of its
total drug budget in 1990-1. AH patients who had both ovaries removed during
their operation were advised to use hormone replacement therapy (HRT): an
estimate of the present value of the cost of using HRT for four months is
calculated. The cost of blood transfusions is estimated using the contract price
of the red cell (operative additive solution) product for the South Western
Regional Health Authority plus an allowance for hospital handling costs, based on
the estimate of each patient receiving four units of blood.
Operative staff time is costed using the mid-range salary for each relevant
member of staff, uprated by 11% to allow for employers' costs. Although
surgical procedures were largely undertaken by a clinical research fellow, the
time of surgeons, as well as that of anaesthetists, is costed using the consultant
pay scale.
The cost of surgical equipment which is not considered usually available in a
gynaecological theatre (non-routine) is estimated separately. For this equipment,
per patient costs are based on the estimation of an annual equivalent cost using
a discount rate of 6% and assuming the equipment has a useful life of five years.
Annual rates of utilisation have been estimated assuming that all surgically-
treated menorrhagia would be treated using the modality for which the
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equipment is relevant. For all other routine theatre equipment, costs are taken
from the Bevan Report [Bevan, 1989], in the form of a cost per minute of theatre
time, adjusted to a 1994 price base.
An anaesthetic cost per minute is used based on the separate study at the
hospital, with the costs adjusted to a 1994 price base. Theatre overhead costs
have been taken from the Bevan Report [Bevan, 1989], in the form of a cost per
minute of theatre time, also adjusted to a 1994 price base, and these are taken
to represent the cost of all resources not directly allocated to a given patient.
Total operative costs per patient are, therefore, made up of a fixed cost per
patient (non-routine equipment, some staff, drugs and consumables) and a
variable cost per minute of time in theatre (routine equipment, most staff,
anaesthetic and overheads).
The ward cost of a patient's hospital stay is estimated by multiplying the number
of nights each patient was in hospital by the daily ward unit cost, where the
latter is the sum of the average hospital ward and general service cost per in-
patient day estimated for the hospital's 1991-2 cost returns. The cost of any
patient stay in ITU is estimated by multiplying the relevant length of stay by the
average daily cost of ITU for a spontaneously breathing patient estimated by
Ridley eta! [1991] and adjusted to a 1994 price base.
The cost of re-treatment of patients for whom TCRE was considered a failure at
four months follow-up, with either repeat resection or AH, is estimated using
mean pre-operative resource use for the relevant procedure together with the
actual length of hospital stay for each re-treated patient.
The cost of a visit to a general practitioner is estimated assuming a 8.25 minute
consultation [DHSS, 1987]. The cost of a GP's time is based on average net
remuneration, allowing for superannuation and national insurance and assuming a
38 hour week and a 46 week year [DHSS, 19871. An uprate of 66% on the cost
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of GP time is used to represent direct and indirect practice expenses [Special
Medical Development Project Team, 1990].
Outcome measures. The RCT collected a range of outcome measures at
or before four months follow-up. These included pain during the week following
surgery; improvement in menstrual symptoms; time away from usual activities;
and rates of satisfaction with treatment where women indicated whether they
were 'very satisfied', 'quite satisfied', 'not very satisfied' or 'very dissatisfied'.
3.2.3 Longer-term analysis: two years post-operation
The clinical and economic characteristics of these two surgical treatments are
time dependent: resource use and effects are not confined to the pen-operative
period and convalescence but extend, in principle, throughout a woman's life.
The costs and consequences of TCRE, in particular, are likely to vary markedly
with time because the treatment has been shown to fail in a proportion of
women, who often require further surgery. Both treatments may have longer-
term consequences that impact on patient benefits and health service resource
use. It is crucial, therefore, to follow-up those women in the Bristol RCT for as
long a period as is feasible.
Postal questionnaire. For the longer-term follow-up, all women in the trial
were sent a questionnaire in the post which sought information on menstrual
symptoms, HRQL, satisfaction with treatment for their menstrual problems and
health service resource consumption. The questionnaires were sent out in two
batches: the first 100 patients receiving surgery were sent a questionnaire in
February 1993; the remaining patients received one in October 1993. Women
were asked to complete the questionnaire and to return it to the study team in a
pre-paid envelope.
Menstrual symptoms. The first section of the questionnaire sought
information on women's menstrual symptoms. Women randomised to TCRE
were asked about continued menstrual bleeding. All women were asked about
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pain, either associated with their period (for TCRE patients) or similar to that they
previously experienced before a period (for AH patients). For those women
experiencing pain, they were asked to rate its severity compared to the pain they
experienced before surgery. Similar information was also requested on
premenstrual symptoms described as bloating, breast tenderness or headache.
Women were also asked whether they had taken time off work during the last
year as a result of menstrual problems.
Health-related quality of life. In the second part of the questionnaire,
women were asked to complete the Short Form 36 (SF36), a generic measure of
subjective health in the form of a profile with 36 items [Ware et .341993]. The
instrument has eight multi-item dimensions covering physical functioning, social
functioning, role limitations due to physical problems, role limitations due to
emotional problems, mental health, vitality, pain and general health perception.
Based on responses, a scoring algorithm produces a scale from 0 (for poor
health) to 100 (good health) for each dimension. Although the SF36 was
developed in the USA, it has been shown to be internally consistent, valid and
acceptable to individuals in the UK [Brazier et a/,1992; Jenkinson et a/,1993;
Garratt et a1,1993]; it has also been used with women with menorrhagia, and
been found to be acceptable and sensitive to change [Jenkinson et al, 1994;
Coulter et al, 1994A; Ruta et al, 1995]. In the analysis reported here, if a
woman failed to respond to one or more items on a particular dimension, her
overall score for that dimension is taken as missing data.
Resource use and costs. The final section of the questionnaire asked
women whether they had received any hospital treatment since their original
surgery. The purpose of this section was twofold. Firstly, to establish which
women, having originally been randomised to TCRE, had received additional
surgical treatment for their menstrual problems since the initial four month
follow-up. Information on the re-treatment of some women not responding to
the postal questionnaire was available from other sources, such as hospital
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records. Life table methods are used to estimate the cumulative probability of
re-treatment by two years after initial surgery [Kahn and Sempos 1989].
The second purpose of the section of the questionnaire on resource use was to
assess what other hospital resources women had used as a result of their
menstrual problems. Women were asked to detail any visits to hospital they had
made since their four-month follow-up. Based on the judgement of a clinical
collaborator (Dr Nuala Dwyer), resource use likely to be related to menstrual
problems was identified. A separate question in this section of the questionnaire
asked women whether they were using HRT.
The total treatment costs estimated on the basis of 4 months follow-up are
revised using the resource use data collected within the questionnaire. For
resource use related to re-treatment, the unit cost of a repeat procedure is based
on the average cost estimated in the earlier analysis and includes pre-operative,
operative, post-operative and ward costs, and costs related to average
complications. The cost of one out-patient visit per additional surgical procedure
is added to this. Re-treatment costs relating to women who did not respond to
the postal questionnaire and whose re-treatment details were not known from
other sources are counted as missing data.
The unit costs associated with other related resource use, together with that of
hormone replacement therapy, are based on those used in the short-term
analysis and those routinely estimated by United Bristol Health Trust. Unit costs
additional to those in the four-month analysis are the cost of an ultrasound
(£50), the cost of a urinary dynamics test (£200) and the cost of an out-patient
visit (£80). It is established practice in economic evaluation to discount resource
costs that occur in future years [Drummond et al, 1987]. Therefore, all re-
treatment and other related costs are discounted according to the time that
elapsed since randomisation using a 6% annual discount rate [HM Treasury
1991]. All costs are expressed at a 1994 price level.
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3.2.4 Cost-effectiveness analysis
Based on the two episodes of data collection, the Bristol RCT provided data, four
months and 2.2 years after surgery, on the health service resource costs of the
two procedures and a range of outcome measures consisting of symptoms,
satisfaction rates and descriptive measures of HRQL. Given the aim to use these
data to inform resource allocation decisions in this area, costs are related to
outcomes to assess the relative value for money of the two surgical therapies.
Cost-effectiveness analysis (CEA) relates the differential cost of two or more
treatments to their differential effectiveness. In order to achieve this, however,
it is necessary for effectiveness to be measured on a uni-dimensional scale which
adequately reflects the overall impact of the treatment options on patient
benefits [Drummond et al, 1987]. As surgical treatments for menorrhagia, AH
and TCRE have a range of different effects. A woman's satisfaction with
treatment, however, can be considered a relevant uni-dimensional measure of
outcome in this context. Although the measurement of patient satisfaction is
relatively under-developed [Fitzpatrick, 1993], a woman's reaction to this sort of
question is likely to be influenced by her overall experience with the treatment.
In rating her satisfaction, she needs to trade-off any elements of the process and
short- and longer-term outcomes of treatment which she did not like against
those she did, and hence arrive at a global assessment of the intervention from
her perspective. The fact that satisfaction rates reflect patients' perceptions,
and also that they have more intuitive meaning than some other measures of
effectiveness used in CEA, are the main reasons for their use here.
For the CEA, it is necessary to dichotomise the four-level satisfaction response
offered to women. If a women indicated in the questionnaire that she was 'very
satisfied' or 'quite satisfied', her treatment has been defined as successful. In
contrast, if she answered that she was 'not very satisfied' or 'very dissatisfied',
her treatment is taken as being unsuccessful. Using this measure of treatment
success, the differential cost of AH and TCRE are related to their differential
success rates using cost and outcome data up to four months and 2.2 years.
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Table 3.1
	 Short-term analysis: resource use from randomisation until 4 months
follow-up. Figures are numbers of patients (%) or means (95% Cl)
Resource Use
	 TCRE (n=99)	 AH (n=97)
Pre-operative
Full blood count (FBC) (n(%))	 99 (100)
Blood grouped and saved (n(%))
	
99 (100)
Blood transfusion and additional FBC (n(%)) 4 (4)
97 (100)
97 (100)
4 (4)
Antibiotics (n(%)) 99 (100) 97 (100)
Operative
Theatre time mins (mean 95% CI) 51.2 (49.2 to 53.2) 2.9 (60.6 to 65.2)
Histology test (n(%)) 99 (100) 97 (100)
Post-operative
FBC (n(%)) 0(0) 97(100)
Blood transfusion and additional FBC (n(%)) 2 (2) 2(2)
Urea and electrolytes (n(%)) 3 (3) 0 (0)
Analgesia (n(%)) 49 (49) 97 (100)
HRT as a result of removal of both
ovaries (n(%)) 0(0) 5(5)
In-patient nights (mean (95% Cl)) 2.1 (1.9 to 2.2) 6.4 (6.16 to 6.58)
GP visits (mean (95% Cl)) 0.7 (0.5 to 0.9) 2.2 (1.8 to 2.6)
3.2.5 Statistical analysis
All analyses are undertaken on an intention-to-treat basis. That is, despite the
fact that a proportion of the group which was initially randomised to TCRE
subsequently underwent a hysterectomy, all comparisons leave women in the
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group to which they were originally randomised. Variation in differential costs is
shown using 95% confidence intervals. Unless otherwise stated, all statistical
hypothesis tests are Wilcoxon Rank Sum tests and a 5% significance level is
used [Armitage and Berry 1989].
3.3 Results
3.3.1 Short-term analysis: four months post-operation
Resource use. Table 3.1 details the main elements of resource use until
four months follow-up under the headings introduced in Section 3.2.1 above.
The staff present in theatre for TORE were a trolley nurse (it has been assumed
they were present for the first 10 minutes only), a surgeon, an anaesthetist, an
anaesthetic nurse and a circulating nurse; for AH a senior house officer and an
instrument nurse were also present. Non-routine operative equipment included a
camera, colour monitor, xenon light source, resectoscope and telescope. The
consumables used during TORE were a loop (which was changed, on average,
once every seven patients), irrigation tubing, catheter and gloves; a mean of 7.4
litres (95% CI 6.84 to 7.96) of glycine irrigation fluid was also used.
Due to the fact that TORE does not ensure infertility, 10 patients (10%) in this
group requested laparoscopic sterilisation at the time of their resection.
Additional operating time is reflected in the average times detailed in Table 3.1;
Filshie clips were also required. For AH, the list of consumables used included
suturing materials, blades, dressings, catheter and gloves. Anaesthetic resource
use, for both patient groups, included a range of drugs and gases.
Table 3.2 provides details of the operative, post operative and late complications
occurring in study patients where additional resource use resulted. The Table
also describes those additional resources. A total of 12 patients in the TORE arm
of the trial required re-treatment after their initial operation, due either to
dissatisfaction with results at four months follow-up (11 patients) or to abnormal
histology (one patient).
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Table 3.2
	 Short-term analysis: operative, post-operative and late complications
resulting from procedures and details of additional resource use*
Complication	 TCRE	 AH	 Additional resource use
Operative complicationst
Uterine perforation 4 0 Antibiotics 3-9 days
Fluid overload 1 0 3 hours in ITU; urea and electrolytes
x 4; diuretics 1 day
Haemorrhage (>500m1) 1 3 Transfusion
Bladder perforation 0 1 Supra-pubic catheter; antibiotics
8 days
Inadvertent removal of ovaries o 1 HRT until menopause
Post-operative complicationst
Urinary retention 0 4 'Foley catheter and bag
Urinary infection 0 12 Antibiotics 5 days
Pelvic haematoma 1 8 Antibiotics 5 days; pelvic ultrasound
Pelvic infection 2 1 Antibiotics 5 days
Haemoglobin < 10 0 10 Ferrous sulphate 3 months
Wound haematoma 0 1 Return to theatre for 20 minutes
Suspected haemorrhage 0 1 Return to theatre for laparotomy
for 40 minutes; transfusion
Late complicationst t
Intractible diarrhoea 0 1 Readmitted for 10 nights; antibiotics
10 days
Pelvic haematoma 0 1 Readmitted for 3 nights; antibiotics
5 days
Bleeding plus pelvic haematoma 0 1 Readmitted for 1 night
Suspected deep vein thrombosis 0 1 Readmitted for 2 nights
Vaginal bleeding 1 0 Readmitted for 2 nights
Retreatment**
Using endometrial resection 7 0 Additional procedure; 2 nights in
hospital
Using hysterectomy 5 0 Additional procedure: 5 or 6 nights
in hospital
.
	 Only complications resulting in additional resource use detailed
t	 Any extra stay in hospital included in results for overall stay
t t Complications occurring up to four months after operation
** As a result of assessment at four months
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Table 3.4
	 Short-term analysis: outcome measures collected until four months after
surgery*
Outcome measure AH
(n=97)
TCRE
(n=99)
Post-operative pain
Number (%) experiencing no pain at':
Day 1 5 (5) 6 (6)
Day 2 4 (4) 19(19)
Day 3 5 (5) 48 (48)
Day 4 6 (6) 61 (62)
Day 5 9 (9) 74 (75)
Day 6 13(13) 78 (79)
Day 7 14(14) 81(82)
Pre-menstrual symptoms
Number of women whose pre-menstrual
symptoms improved after surgery*:
Dysmenorrhoea 81/86 53/85
Bloating 35/77 14/78
Breast tenderness 21/50 13/60
Mood 16/41 11/36
Post-operative recovery
Median (range) time off work (weeks) 11(1-24) 2 (<1-8)
Median (range) time until return to daily
activities (weeks)
4(1-10) 1 (<1-8)
Satisfaction with treatment
Number (%):
Very satisfied 77 (80) 66 (67)
Quite satisfied 13(13) 17 (17)
Not very satisfied 6 (6) 13(13)
Very dissatisfied 0 (0) 2 (2)
*	 See Dwyer et al [1993] for further details
t	 Women judged subjectively
#	 Denominator is the number of women complaining on symptom before surgery
Resource costs per patient. Appendix 3.1 details the unit costs used to
value the resource use of patients in the trial. Table 3.3 shows the resource
costs per patient, for each major cost component and in total, up to four months
follow-up. The total mean cost of surgically treating menorrhagia using TCRE is
74
Chapter 3	 RCT-based economic evaluation
statistically significantly lower than that using AH: the mean difference is -
£529.66 (95% Cl £458 to £601).
Outcome measures. The range of outcome measures collected over the
period between surgery and four months follow-up is detailed in Table 3.4. The
table shows a clear trade-off in these outcomes: the proportion of women
experiencing pain during the week following surgery is higher in the AH arm and
women undergoing TCRE return to work and to their usual activities earlier;
however, the improvement in pre-menstrual symptoms is more pronounced in
the AH group as is women's satisfaction with treatment. If satisfaction rates are
used to define a treatment success as defined in Section 3.2.4, 90% of women
randomised to AH were treated successfully compared to 83% randomised to
TCRE (Chi squared, p =0.04.).
3.3.2 Longer-term analysis: two years post-operation
As part of the longer-term assessment, questionnaires were posted to all 196
women who underwent surgery in the trial. Three questionnaires were returned
incomplete, these women having moved and provided no forwarding address. A
total of 155 women returned a completed questionnaire - a response rate of
79%. Of these, 82 and 73 had been randomised to TORE and to AH,
respectively. The mean period of time that had elapsed since surgery for those
women responding to the questionnaire was 2.8 years (range 1.8 to 3.8). The
mean follow-up period overall, including that for women not responding, was 2.2
years (range 0.3 years to 3.8 years).
Menstrual symptoms. Table 3.5 presents details of women's responses
to questions on menstrual symptoms. Of women randomised to resection, and
including those women who eventually had an AH in the denominator, 70% were
still experiencing some bleeding. If the denominator is adjusted to remove those
women who had a AH (ie. departing from the intention-to-treat analysis), this
rate increases to 87% (54/62). More women who had been randomised to TORE
still experienced pain, but fewer of these women considered their pre-menstrual
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Longer-term analysis: menstrual symptoms reported in the postal
questionnaire. Unless stated, details are the number of women reporting
the symptom over the number of women answering the question, with
percentages in parentheses
Symptom TCRE	 AH
Women experiencing bleeding 54/77 (70).
Of those experiencing bleeding;
Mean (SD) days bleeding per month 4.5 (3.1)
Women reporting clots 11/54 (20)
Women reporting flooding episodes 6/54 (11)
Women experiencing pain 46/72 (64) 13/70 (19)
Compared to before operation for those
Not as bad 29/46 (63) 10/13 (77)
About the same 7/46 (15) 2/13 (15)
Worse 10/46 (22) 1/13 (8)
Pre-menstrual symptoms compared to before
surgery
Not as bad 30/71 (42) 52/68 (76)
About the same 28/71 (39) 13/68 (19)
Worse 13/71 (18) 3/68 (4)
Women taking time off work due to menstrual
problems
18/80 (23) 3/71 (4)
*	 Denominator includes 15 women who responded to the questionnaire and who had
undergone AH after their initial TCRE
symptoms to have improved since surgery. More women who had been
randomised to TCRE had taken time off work during the previous year as a result
of menstrual problems.
Health-related quality of life. Table 3.6 provides details of the SF36 scores
which have been calculated on the basis of women's responses to the
questionnaire. The scores are calculated on a scale from 0 (poor health) to 100
(good health), and results are presented for each of the eight dimensions, by
treatment group. Details of means with standard deviations and medians with
ranges are provided, as well as mean differences with 95% confidence intervals.
The mean score on seven of the eight dimensions favours women randomised to
AH. With a mean difference of nearly 10 points, the most marked difference
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Table 3.6
	
Longer-term analysis: SF-36 scores from postal questionnaire responses.
Mean differences relate to AH scores minus TCRE scores.
SF-36 dimension
TCRE AH
differences
Cl)
Mean (SD) Median (Range) Mean (SD) Median (Range) Mean
(95%
Physical function 89.6 (17.8) 95 (5-100) 92.1 (14.3) 100 (10-100) 2.5 (-2.82 to 7.82)
Role limitations
(physical) 82.7 (33.1) 100 (0-100) 82.0 (33.6) 100 (0-100) -0.7 (-11.5 to 10.1)
Role limitations
(emotion) 80.0 (31.6) 100 (0-100) 86.2 (29.8) 100 (0-100) 6.2 (-3.8 to 16.2)
Social function 84.4 (22.5) 100 (0-100) 90.4 (16.1) 100 (22-100) 6.0 (-0.5 to 12.5)
Mental health 74.1 (15.7) 76 (36-100) 76.4 (17.1) 82 (28-100) 2.3 (-3.1 to 7.7)
Energy 60.8 (20.6) 60 (5-100) 62.3 (21.7) 70 (10-95) 1.5 (-5.4 to 8.4)
Pain 73.2 (26.2) 77.8 (11-100) 83.1 (22.9) 100 (22-100) 9.9 (1.9 to 17.9)
Health
perceptions 74.4 (21.7) 77(10-100) 79.7 (20.2) 87 (15-100) 5.3 (-1.5 to 12.1)
between the groups in favour of AH patients is in bodily pain (p =0.01). Quite
large differences in mean scores are evident in role limitations due to emotional
problems (6 points; p = 0.12), social functioning (6 points; p = 0.12) and
general health perceptions (5 points; p = 0.09), but none of these reflects an
overall statistically significant difference.
Satisfaction. There are clear differences in women's levels of satisfaction
with treatment between the two treatment groups. Amongst women
randomised to TCRE, 46 (57%) were 'very satisfied' with treatment, 18 (22%)
were 'quite satisfied', 12 (15%) were 'not very satisfied' and 5 (6%) were 'very
dissatisfied'. The relevant numbers for women randomised to AH were 61
(85%), 8 (11%), 2 (3%) and 1 (1%), respectively. If these rates are used to
define a treatment success, 79% of the women randomised to TCRE and 96% of
women randomised to AH were treated successfully (Chi squared, p =0.002) at
longer-term follow-up.
In response to the question about whether they would have the same operation
if they had the choice again, 19 (24%) of women randomised to TCRE said they
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The cumulative probability of treatment failure for women randomised to
TCRE based on longer-term follow-up.
would not, compared to 4 (6%) of patients randomised to AH (Chi squared,
p =0.002).
Resource use and costs. A number of women originally randomised to
TCRE underwent a repeat resection and/or a hysterectomy due to failure of the
initial procedure to ameliorate symptoms. A total of three women were known
to have received re-treatment between four months follow-up and the current
period of follow-up, despite not responding to the postal questionnaire. Including
re-treatments by four months follow-up, a total of 10 patients received a repeat
TCRE and 18 underwent a hysterectomy. Four women received both a repeat
TCRE and a hysterectomy.
Figure 3.1 shows 'failure curves for women randomised to TCRE. Three curves
are shown relating to the cumulative probability of a repeat TCRE, of a
hysterectomy and of any form of re-treatment, respectively. These estimates
are based on life table analysis and the assumption that, if a woman did not
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respond to the postal questionnaire and re-treatment details were not available
through some other source, her data are censored at four months (the point of
the last follow-up). On this basis, by two years after initial surgery, the
cumulative probability of a repeat TCRE was 12%, that of a hysterectomy was
16% and that of any form of re-treatment was 23%. If it is assumed that details
of any re-treatment would have been available through other sources for all
women regardless of whether or not they had completed the questionnaire, these
probabilities fall slightly to 11%, 14% and 20%, respectively.
Of the women responding to the questionnaire, 9 (11%) who had been
randomised to TCRE were judged to have used hospital resources which were
related to their menstrual problems after four months follow-up. This resource
use is in addition to the re-treatment detailed above and mostly took the form of
between one and four out-patient visits, but two women underwent an
ultrasound scan and one women had a hysteroscopy. Five (6%) of the women
randomised to AH who responded to the questionnaire reported other hospital
resource use which was judged to be related to the treatment of their menstrual
problems, which consisted of 1 or 2 out-patient visits, 2 ultrasound scans for
one woman and a urinary dynamics test for another. Of the women randomised
to TCRE and responding to the item in the questionnaire, 9 (11%) had been
taking hormone replacement therapy for a mean duration of 11 months (SD =8);
12 (17%) of the AH group had been using such therapy for a mean duration of
13 months (SD =10).
Table 3.7 presents the results of the revised cost analysis which adds the cost
of re-treatment and of other related resource use between four months and an
average of 2.2 years follow-up to the short-term analysis. The table treats data
relating to women not responding to the postal questionnaire, and whose re-
treatment and other related resource use details were not available to the study
through other routes, as missing. Compared to the results of the cost analysis at
four months, the 'cost gap' between TCRE and AH has closed: as a percentage
of the mean total cost of AH, the mean total cost of TCRE was 53% at four
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Table 3.7
	
Revised analysis of the health service costs per patient in the trial based
on a mean overall follow-up of 2.2 years.
TCRE AH
Mean (SD) Median (Range) Mean (SD) Median (Range)
Initial surgery 513 (102) 483 (446-1256) 1123 (210) 1053 (876-2414)
Re-treatment costs to 85 (248) 0 (0-1029) o o
4 months
Re-treatment costs
after 4 months
185 (396) 0 (0-1157) 0 0
Other related resource
use after 4 months:
- hospital costs 11(40) 0 (0-284) 10 (43) 0 (0-238)
- HRT 3 (8) 0 (0-26) 5 (12) 0 (0-31)
Total costs* 790 (493) 523 (446-2148) 1110 (168) 1053 (876-2036)
Only relates to those patients for whom there is full follow-up (78 patients in the TCRE
group and 70 in the AH group), so the summations of the mean and median columns do
not equate exactly with the stated totals.
months; it has increased to 71% at a mean overall follow-up of 2.2 years.
However, total cost differences between the two groups remain statistically
significant (difference £320, 95% CI 198-442). Table 3.7 shows that the mean
total cost of AH at 2.2 years is actually slightly lower than that at four months.
This is due to the fact that there is full follow-up on only 70 of the 97 women
randomised to AH, so the two estimates of total cost are based on somewhat
different samples. As a result, there may be a risk of bias in the estimate of
longer-term cost, but the extent of this is likely to be small given the limited
resource use in the AH group between four months and 2 years.
Figure 3.2 shows the distribution of total costs by randomised group. The figure
emphasises the greater spread in total costs amongst women randomised to
TCRE, although, as Table 3.7 shows, the mean and median of the distribution
are lower for women in that group.
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Distribution of mean total costs over 2.2 years. Includes only those
women for whom there is full follow-up data.
3.3.3 Cost-effectiveness analysis
Based on both four months and 2.2 years follow-up within the trial, AH appears
to be more expensive in terms of health service costs. The outcomes of the two
treatments during these two periods of follow-up, however, are equivocal: the
shorter-term outcomes tend to favour TCRE, but the longer-term impact on
menstrual symptoms and HRQL generally favours AH. If success is defined as a
woman indicating that she is 'very satisfied' or 'quite satisfied' with treatment,
AH can be considered statistically significantly more effective than TCRE, both
at four months (p =0.04) and 2.2 years (0.002). Table 3.8 relates the additional
cost of AH to its additional effectiveness using CEA. At 4 months after surgery,
the difference in treatment success on the basis of women's satisfaction was
only 7% which results in an incremental cost of AH per additional success of
£7,557. After 2.2 years, the difference in success rates increased to 17% as
satisfaction with AH increased and that with TCRE declined. Therefore, as the
difference in costs falls as more women who were randomised to TCRE
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Table 3.8
	
	
Cost-effectiveness relating costs to treatment success defined in terms of
patient satisfaction
Period of follow-up
4 months
	 4 months	 2.2 years
(All patients)	 (Full follow-up)
Total mean cost
AH £1123 £1095 £1110
TCRE £594 £519 £790
Difference £529 £576 £320
Success rates*
AH 90% 96% 96%
TCRE 83% 84% 79%
Difference 7% 12% 17%
Incremental cost per additional success £7557 £4800 £1882
*	 Defined as women reporting that she is 'very satisfied' or 'quite satisfied' with the results of her
treatment
required additional treatment, the incremental cost of AH per additional
treatment success declines to £1,882.
The apparent reduction in the total cost of AH at 2.2 years compared to four
months is a result of the fact that 24 (25%) women randomised to AH were lost
to longer-term follow-up, and most of these women consumed no resources
between four months and 2.2 years. Given the skewed nature of the cost
distribution shown in Figure 3.2, it only requires a small number of the higher
cost women at four months to be lost to follow-up for the mean cost to decline
at 2.2 years. To allow for the effect of loss to follow-up, Table 3.8 also reports
the costs and effectiveness of treatment at four months solely for those patients
followed up for the full 2.2 years. On this basis, the incremental cost of AH per
additional treatment success is £4,800.
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3.4 Discussion
3.4.1 Resource costs
This study has found that, over a mean period of 2.2 years, the total mean cost
of surgically treating menorrhagia using TCRE is statistically significantly lower
than that using AH. At four months follow-up, the mean total cost of TCRE is
53% that of AH. This cost difference is largely explained by two components of
health service resource use which are higher amongst AH patients: operative
resources and hotel resources. As regards operative resources, the fixed cost
(£24.89 versus £17.25), the variable cost per minute (£3.09 versus £2.63) and
the mean operating time (62.9 minutes versus 51.2 minutes) are all higher for
AH patients.
The most important difference in health service resource use between the two
groups, however, is length of in-patient stay. The statistically significantly
longer mean length of stay of AH patients in the trial (a mean of 6.37 nights
versus 2.09) leads to the mean difference in ward costs accounting for 96% of
the mean difference in total cost at four months.
The short-term cost analysis incorporates the cost implications of the finding in
the randomised trial that, at four months follow-up, 11 (12%) patients who
initially received TCRE were defined as having had treatment failure and required
further surgery. For one additional patient AH was required because of an
abnormal histological finding. Of these 12 patients, seven received repeat TCRE
and five underwent hysterectomy.
The key longer-term issue in relation to resource costs is whether this re-
treatment rate increases as follow-up continues. By 2.2 years after surgery, and
adjusting for differential periods of follow-up, the cumulative probability of a
woman undergoing a repeat TCRE was 12% and that of her having a
hysterectomy was 16%. In terms of costs, this has the effect of closing the gap
between TCRE and AH. Whereas the mean total cost of TCRE was 53% that of
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AH at four months follow-up, that percentage had increased to 71% at a mean
overall follow-up of 2.2 years.
A crucial issue as regards cost is whether this cost gap will narrow further -
perhaps to the point that it closes entirely - as more time elapses. It is probably
the case that re-treatment rates for women randomised to TCRE will not increase
markedly over the next few years, as most women, for whom initial TCRE failed,
have probably re-presented for further assessment and treatment. In the longer
term, some other items of health service resource use may have an influence on
the differential cost of the two treatments. Most women who undergo AH will
not require cervical cytology every five years until the age of 64 years; and the
resource cost of treating cervical and uterine cancer will also be avoided in a
sub-group of these patients. However, hysterectomy has been associated with
increased risk of premature ovarian failure [Siddle et al, 1987] and cardiovascular
disease [Centerwall, 1981], which will have a cost impact. A large long-term
follow-up study has been funded by the UK Department of Health to assess
these risks. It is unlikely, however, that these serious clinical events will occur
in a sufficient number of women to close the cost gap significantly.
3.4.2 Health outcomes
A range of outcome data was collected in the trial. Shortly after surgery, TCRE
avoids much of the morbidity associated with AH, resulting in women returning
to their normal activities more quickly. By four months follow-up, results are
more equivocal. Although, overall, the majority of women in both treatment
groups are treated successfully on the basis of satisfaction rates at four months
(83% TCRE; 90% AH), this success rate is statistically significantly higher
amongst AH patients, probably reflecting their greater improvement in menstrual
symptoms and treatment failure in a proportion of women in the TCRE group.
As the period of follow-up lengthens in a trial comparing surgical treatments for
menorrhagia, strictly clinical measures of health outcome become less relevant to
an evaluation, and patients' perceived health status take on more importance.
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Hence, the longer-term follow-up reported here concentrates on patients'
symptoms, their perceptions of their HRQL and satisfaction levels. On the basis
of the postal questionnaire, patients initially randomised to AH were doing as
well or better on each of these measures of outcome than patients randomised
to TCRE.
The longer-term follow-up study reported here has two weaknesses. The first is
the fact that a proportion of women has been lost to follow-up (17 (17%) and 24
(25%) of TCRE patients and AH patients, respectively), and no longer-term
symptom and HRQL data were available for these women. It is crucial to assess
the longer term outcomes of surgery for menorrhagia, and the only feasible way
of doing this is through postal questionnaires. However, this form of data
collection inevitably results in some patients being lost to follow-up. Indeed, the
79% overall response rate in this study might be considered quite high. The
possibility exists that non-responders differ from responders. However, for a
major bias to be introduced into the results, these differences would have to
apply asymmetrically between the two randomised groups. Although it might be
considered unlikely that, for example, non-responders randomised to AH are
largely dissatisfied with the results of surgery and non-responders randomised to
TCRE are generally satisfied, it is not possible unequivocally to exclude the
possibility of bias. A degree of caution is, therefore, necessary in interpreting
these results.
The second weakness of the long-term assessment of outcomes is the lack of
baseline data for the SF36. As the SF36 has been shown to be sensitive to
changes in the health of women who have undergone surgery for menorrhagia
[Jenkinson et al, 1994], it would have been useful for women in this trial to have
completed the instrument at randomisation and at various subsequent intervals.
However, when the trial was being planned, the SF36 had not been fully
developed, nor had it been validated in the UK. Furthermore, it was felt that
there was no sufficiently sensitive alternative general measure of HRQL available
at the time. Although the availability of the SF36 data at baseline would have
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strengthened the study, the use of the instrument at a single point of follow-up,
given that the trial is randomised, provides a valuable picture of HRQL, which no
previously published trial in this area has given.
3.4.3 Cost-effectiveness
,
It is likely that the cost advantage of TCRE over AH will remain, whatever the
period of follow-up. However, for purchasers and providers of health care in this
area, the crucial issue to consider is the relative cost-effectiveness of the two
procedures, which requires an assessment of both costs and outcomes. On
current evidence, there is a clear trade-off between the two treatments. On the
one hand, AH will resolve menstrual problems and is more likely to provide high
levels of satisfaction with treatment. On the other hand, despite leaving a
proportion of women dissatisfied, TCRE does seem to provide satisfactory
treatment for most women and involves a much shorter period of convalescence
than AH.
A CEA relates the differential cost of two interventions to a uni-dimensional
measure of effectiveness. If women's satisfaction with treatment is seen as an
adequate 'all-embracing' measure of effectiveness, then its use in CEA seems
appropriate. On this basis, and assuming that the results presented here are
typical of those that would prevail in routine clinical practice, the use of AH
rather than TCRE to treat menorrhagia would, on average, have an incremental
cost of f1882 for each extra treatment success on the basis of data collected at
longer-term follow-up. The ultimate decision about whether this is a reasonable
cost to pay, given the benefits effects generated, has to be left to health care
purchasers.
3.4.4 Methodological issues
The trial-based economic analysis of AH versus TCRE reported in this chapter
represents a starting point for the exploration of the methodological issues
related to the economic evaluation of MAS in general and AH versus TCRE in
particular. In economic analysis alongside clinical trials, uncertainty associated
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with the results is usually expressed in terms of the variability in stochastic data,
and the results presented here reflect this in the use of hypothesis tests and
confidence intervals around mean cost differences. However, several other
sources of uncertainty exist in economic evaluation [Briggs et al, 1994]. Two
areas of uncertainty in particular are highlighted by this chapter, and these relate
to the measurement of benefits and to generalisability.
It is clear from the results presented in this chapter that, whilst AH is apparently
more costly than TCRE, at least on the basis of 2.2 years follow-up, it is unclear
which treatment is the more effective given the trade-off discussed above in
terms of short-term versus longer-term outcomes; a trade-off which is typical of
many forms of MAS when compared with conventional surgery and which lies at
the heart of the economic issues considered in this thesis. The CEA presented
here is based on the premise that reported rates of satisfaction with treatment
are an adequate all-embracing measure of effectiveness, reflecting how women
trade-off the various characteristics of the two treatments. However, it is
unlikely that this fairly crude way of defining a treatment success fully reflects
women's attitudes to the alternative treatments. In order to develop a measure
of benefit which more accurately reflects the preferences of women with
menorrhagia, it is necessary to understand more about the nature of these
preferences, and this is the focus of Chapter 4 of this thesis.
A further limitation of the use of satisfaction rates as a primary outcome
measure within CEA is that such an outcome lacks the generic qualities required
as a basis of informed resource allocation across disease areas and health care
programmes. The SF36 data collected within the Bristol trial 2.2 years after
surgery represents a means of expressing the outcomes of the two treatments
on a generic scale. However, although work is being undertaken to translate
SF36 data into a single index [Brazier et al, 1994], no way yet exists of
expressing its results on the uni-dimensional scale necessary to assess cost-
effectiveness. The use of cost-utility analysis, where benefits are measured in
terms quality-adjusted life years (QALYs), offers a way of expressing the
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outcomes of AH and TCRE in the form of a generic measure of benefit.
Furthermore, in that patients' values can be used to construct QALYs, this form
of benefit measure may have the further advantage of more adequately reflecting
patients' treatment-related preferences than success rates based on patient
satisfaction. Chapters 5 and 7 consider the use of cost-utility analysis in the
evaluation of AH versus TCRE, focusing on its empirical implications and its
methodological strengths and weaknesses.
The second methodological issue highlighted by the trial-based economic analysis
reported in this chapter relates to generalisability. Although an increasing
number of economic evaluations are being undertaken alongside RCTs [Adams et
al, 1992], it has been recognised that the possible limits on the external validity
of clinical trials discussed in Chapter 1 may have a significant impact on the
economic variables collected within trials [Drummond and Stoddart, 1984;
Eisenberg eta!, 1989; Drummond and Davies, 1991; Drummond, 1995].
Firstly, clinical trials of MAS - and indeed other surgical procedures - tend to be
undertaken in specialist units. The Bristol trial of AH versus TCRE was
undertaken in a medical school by clinical enthusiasts and clinical practice,
especially in relation to TCRE, may not be typical of routine clinical practice
elsewhere in the NHS.
Secondly, MAS techniques tend to develop quickly and, no sooner has a trial
been completed focusing on one version of an application, than another is
beginning to diffuse. Women were recruited into the Bristol trial during 1990-1,
and it is likely that clinical practice, in relation to both TCRE and AH will have
changed since then. In particular, although these two surgical techniques are the
most frequently used for the treatment of menorrhagia [RCOG Audit Unit,
personal communication], other forms of MAS such as laser ablation are used in
some centres. Furthermore, new approaches to TCRE and hysterectomy, such
as the use of rollerball resection rather than the loop in TCRE and laparoscopic
assistance in hysterectomy, are becoming more widely used.
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The third impact that trial-based data might have upon the generalisability of an
economic evaluation relates to the atypical clinical practice that tends to be
generated by a clinical trial, wherever it is undertaken. In the Bristol trial, for
example, the clinical investigators decided not to use drugs to prepare the
endometrium prior to TCRE because this was not possible with AH and might
bias the results. This decision was taken despite that fact that most centres use
such drugs with TCRE FICOG Audit Unit, personal communication].
The limitations that the use of data from RCTs impose upon the generalisability
of an economic evaluation, together with the development of methods to
address this problem, are the focus of Chapter 6 of this thesis.
3.5 Conclusions
The first route into the economic analysis of MAS is often the use of
effectiveness and key resource use data from a clinical trial set up primarily to
inform clinical policy. Given the high internal validity of data from these trials,
this approach can begin to answer some of the questions that need to be
addressed to inform resource allocation. However, trial-based analysis is rarely
the final word in the economic evaluation of health care technologies and,
typically, key uncertainties remain.
This is clearly the situation as regards the economic assessment of AH versus
TCRE. The Bristol trial provides a useful way into the analysis of the two
treatments, but several areas of uncertainty are highlighted, and these require
additional data collection and analysis to be illuminated, which is the focus of
subsequent chapters.
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Appendix 3.1	 Unit costs used to value resource use
Resource	 Unit
	 Cost (£)
Tests
Full blood count
'Group and save'
Urea and electrolytes
Pelvic ultrasound
Histology test
Blood transfusion
Blood and regional handling cost
Hospital handling cost
Drugs
Antibiotics
Co-amoxiclav
Amoxycillin
Metronidazole
Amoxycillin (IV)
Metronidazole (IV)
Gentamicin (IV)
Frusemide
Ferrous suphate
Analgesics
Papaveretum
Paracetamol
Per test
Per test
Per test
Per test
Per test
One unit of red cell
(OAS) product
One unit of red cell
(OAS) product
Per 375mg tablet
Per 250mg capsule
Per 400mg tablet
Per 500mg vial
Per 100mg bottle
Per 2m1 vial
Per 40mg tablet
Per 170mg tablet
Per 1m1 amp
Per 10 500mg tablets
1.59
9.54
4.51
14.58
71.44
Oestrogen	 Per 625ug tablet
	
0.07
Theatre staff
Surgeon (consultant)
Anaesthetist (consultant)
Anaesthetic nurse (Grade H)
Instrument nurse (Grade G)
Trolley nurse (Grade G)
Circulating nurse (Grade G)
Senior house officer
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Resource Unit	 Cost (£)
GP visit Per visit	 5.51
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Theatre equipment
'Non-routine'
Camera	 Per patient	 2.36
Light source	 Per patient	 1.07
Telescope	 Per patient	 1.87
Resectoscope	 Per patient	 1.07
Theatre consumables
Loops	 Per patient	 3.46
Irrigation tubing: in	 Per patient	 3.69
Catheter	 Per patient	 0.21
Gloves	 Per patient	 0.74
Glycine	 Per 2 litre bag	 2.48
Suturing materials	 Per patient	 8.43
Blades	 Per patient	 0.21
Dressings	 Per patient	 0.32
Supra pubic catheter	 Per patient	 5.83
'Foley' catheter	 Per patient	 2.64
'Filshie' clips	 Per patient	 17.69
Theatre anaesthesia
TCRE	 Per minute	 0.27
AH	 Per minute	 0.35
Theatre overheads	 Per minute	 1.08
Hospital "hotel" services
Ward	 Per in-patient day	 120.00
ITU	 Per in-patient day	 494.00
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Women's Views on Menorrhagia: Health-
Related Quality of Life and Preferences
4.1	 Introduction
The purpose of this chapter is to explore women's attitudes to menorrhagia and
their preferences. Often in economic evaluations decisions are taken about
methods for benefit measurement without a full understanding of patients'
attitudes and preferences in the clinical area in question. The work reported in
this chapter was undertaken to answer a range of research questions, not all of
which were related to economic analysis. However, by assessing the
characteristics of women's attitudes to heavy bleeding and alternative forms of
management, the study serves as a bridge between the cost-effectiveness
analysis in Chapter 3, which links costs to a measure of effect collected on
patients within the context of a trial, and a more complete measurement of
benefit which is consistent with women's health- and treatment-related
preferences.
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It is clear from Chapter 3 that the process and outcomes of surgical treatment
for menorrhagia are inherently multi-dimensional. The choice of treatment
involves trade-offs in terms of such things as complications and side effects,
duration of convalescence, prophylaxis against specific cancers, probability of
success, contraceptive effect and achievement of amenorrhoea and
hypomenorrhoea. The advent of MAS procedures for menorrhagia has
accentuated these trade-offs, presenting a stark choice to women who fail with
drugs and require further treatment: undergo MAS and experience a swift return
to usual activities but risk an unsuccessful treatment; or accept a hysterectomy
which has a much longer convalescence, has various risks associated with it but
which provides a once-and-for-all solution to menorrhagia and offers a
prophylaxis against some gynaecological cancers.
These characteristics are typical of many applications of MAS in a range of
clinical areas, and they pose some specific problems for economic evaluation. In
particular, as emphasised by the trial-based analysis detailed in Chapter 3, it is
unlikely that any single clinical or patient-based measure of outcome will
adequately represent the net benefit of treatment from a patient's perspective.
If the measurement of benefit is to be a central element of economic analysis of
AH and TCRE, it is important to have a greater understanding of women's
attitudes to the condition and of their treatment-related preferences.
Furthermore, although clinicians will have a crucial role in identifying the feasible
treatments for a given women with menorrhagia - that is, in excluding treatments
that are not medically advisable or not available within the centre - the existence
of trade-offs in the process and outcomes of interventions would suggest an
important role for women in identifying a preferred therapy. The concept of
shared decision making has some important implications for economic analysis.
Little research has been undertaken on women's preferences in the area of
menorrhagia. Warner [1994] identified 257 women with a range of menstrual
problems and invited them, together with a control group of 105 women without
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similar problems, to complete a lengthy questionnaire, part of which focused on
preferences for particular treatments and for the effects of therapy. Of the 257
women, 39% had menorrhagia. It was found that women would prefer therapy
that normalised, rather than eliminated, their periods (89%) and that also offered
a reversible contraceptive effect (74%). Preferences regarding a 'one-off'
operation compared to tablets were very similar in the group (47% versus 44%).
Preferences were most strongly related to a woman's reproductive status:
women without children or who had not been sterilised were less likely to prefer
a treatment that affected their periods or fertility. The study concluded that
'treatment for menstrual complaints should be decided with reference to the full
scope of the individual's menstrual problems and treatment aspirations' [Warner
eta!, 1994; p.109].
As part of a large study looking at the treatment of menorrhagia in general
practice, Coulter et al [199413] asked women about their preferences for
treatment, and considered the extent to which these preferences influenced GPs'
management decisions. Of the 488 women who completed a questionnaire,
36.5% indicated that they had a strong preference regarding treatment, and
these patients were more likely to be older, to have received higher education, to
be in social class I or ll and to have previously consulted a GP with menstrual
problems. Of these women, 14.8% indicated a preference for surgery, a
preference which was more likely in women with severe menorrhagia and who
had not received higher education. As a part of a separate questionnaire, GPs
were asked to indicate their understanding of each woman's preferences, and
this was correct in only 34.4% of those cases where a strong treatment
preference was expressed.
With the exception of these two studies, very little has been published on
women's preferences for, and for the characteristics of, treatment of
nnenorrhagia. No studies have been identified that look specifically at women's
attitudes to the trade-offs that present themselves in choosing between MAS
and hysterectomy. Within economic evaluation, there is a strong tradition of
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considering the value patients attach to the outcomes of care, and this is the
focus of Chapters 5, 7 and 8 of this thesis. The aim of this chapter is to report
on survey work which has elicited details of women's attitudes to menorrhagia
and its treatment. The survey offers a descriptive overview of women's health-
related quality of life (HRQL), attitudes to menorrhagia and alternative
treatments, as well as their preferences and aspirations.
4.2 Methods
4.2.1 Survey sample
The survey was undertaken using a postal questionnaire. The population of
interest was women who had recently been referred for the first time to hospital
by their GP due to menorrhagia. The survey was undertaken in two centres: at
St Michael's Hospital in Bristol and at the Princess Margaret Hospital in Swindon;
and women were recruited during two overlapping time periods. To identify a
sample, all new referral letters sent to the hospitals' gynaecology departments
by GPs were scrutinised by a medical secretary to see if sufficient information
existed to include the women in the study. The inclusion criterion was that a
woman was to be a new and non-urgent referral for heavy bleeding. Each
woman identified in this manner over a specific period was sent a questionnaire.
On the basis of the information provided in the questionnaire, women were
excluded from the analysis if they had serious concomitant illness; if they had
previously undergone gynaecological surgery; if, by the time they completed the
questionnaire, they had already had their out-patient appointment; or if their
symptoms suggested that they did not have uncomplicated menorrhagia leg.
inter-menstrual bleeding).
4.2.2 Components of the questionnaire
The questionnaire was designed to elicit information in a number of areas. Prior
to the main survey beginning in Bristol, a pilot study was undertaken with the
purpose of testing how women comprehended the exercise and to identify any
element that was easily misunderstood. In the pilot study, questionnaires were
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sent to 10 women who had been referred to St Michael's hospital, eight of
whom replied. Small changes were made to the questionnaire on the basis of
their responses.
In Section 1 of the questionnaire, women were asked to provide their date of
birth and their post code. In Section 2, they were asked a series of questions
about their menstrual symptoms, including the duration of the problem and the
presence of blood clots. In Section 3, the respondent was asked to complete the
EuroQol instrument, a non-disease specific means of describing and valuing
HRQL [EuroQol Group, 1990; Brooks, 19961. The first part of the EuroQol asks
respondents to categorise their health state on five dimensions (mobility, self
care, usual activities, pain and anxiety/depression), where each dimension has
three possible levels of response. In the second part of the instrument,
respondents are asked to value their health status using a vertical rating scale
presented like a thermometer, which is labelled with 'best imaginable health
state' at the top and 'worst imaginable health state' at the bottom. Women in
the survey were asked to complete both parts of the EuroQol from two
perspectives: their health today and their health on the day during which their
menstrual bleeding is heaviest.
Section 4 was made up of two parts. In the first part, a series of 10
characteristics of treatment was listed and framed in the first person from the
woman's perspective. Examples of these were 'I want to stay in hospital for as
short a period as possible', 'I want treatment that will put a stop to my periods
for good', and 'I don't want to have to worry about contraception after
treatment'. Women were asked to rate each characteristic of treatment on a
four point categorical scale defined as 'very important', 'of some importance', 'of
little importance' and 'not important'. They were then asked to list, and to rank,
the three most important characteristics from their point of view.
In the second part of Section 4 women were presented with two unnamed
scenarios describing the process and outcomes of TCRE and AH, respectively.
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The scenarios were based on a review of the relevant clinical literature and on
clinical opinion. They used a mixture of condition- and treatment-specific items,
as well as more general ones, and they covered the whole period between the
operation and one year follow-up. In the case of TCRE, the description included
details of the risk of treatment failure. Women were asked to indicate, on the
basis of the scenarios, which treatment option they would choose to have, and
they were given the opportunity to respond that they did not know or that they
would not like either, preferring to put up with their symptoms. They were then
asked to value the two scenarios on the EuroQol rating scale.
In Section 5 women were asked to indicate which information sources they had
been exposed to in relation to treatments for menorrhagia, and they were asked
whether they felt well-informed by these sources. Women were then asked
whether they had any strong positive or negative preferences about treatments.
4.2.3 Analysis
The samples from the two centres are analysed separately and together for
Sections 2 and 3 of the questionnaire, which focus on descriptive data for the
samples. The analyses of Section 4 and part of Section 5 are also undertaken
centre-by-centre and pooled. Due to the fact that it concentrates on only a sub-
group of women (ie. those with strong positive or negative treatment
preferences), the analysis of the remainder of Section 5 is based only on pooled
data.
4.3 Results
4.3. 1 Survey population
In Bristol women were sent questionnaires between January 1994 and October
1995; in Swindon recruitment took place between August 1994 and March
1995. In Bristol, a total of 175 women were identified from GP referral letters
and were sent a questionnaire. Of these, 115 (66%) women returned a
completed questionnaire. Two of these women were excluded: one because her
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questionnaire responses indicated that she did not actually have menorrhagia;
the other was because she had already undergone a TCRE. Therefore, a total of
113 women were included in the Bristol sample.
In the Swindon survey, 202 questionnaires were sent out and 119 (59%) were
returned completed. Of these, 11 women were excluded because they had
already had an out-patient appointment (3), they had a concomitant illness (6),
they had undergone previous gynaecological surgery (1) and they had inter-
menstrual bleeding (1). Hence 108 women were entered into the study in
Swindon.
4.3.2 Characteristics of women in the survey
Table 4.1 details the characteristics of women in the survey. In addition to
women's ages, the table shows the severity of their menorrhagia in terms of a
range of questions including duration, days with heavy flow and the passing of
blood clots. In both centres, 50% of the median number of days of a woman's
period consisted of heavy flow. Overall, 88% and 91% of women passed blood
clots and experienced flooding episodes, respectively.
An important point as regards the analysis of the questionnaire is the comparison
between the two centres of the women in the survey Table 4.1 shows that
there are no statistically, significant differences in most of the characteristics of
the two groups. The only exception to this is the duration of women's menstrual
problems, which was significantly shorter in the Swindon sample (p =0.02). For
this reason, the bulk of the remainder of the analysis presents the results of the
two centres separately as well as pooled.
4.3.3 General health status
The severity of women's menorrhagia evident in Table 4.1 is mirrored in their
responses to the EuroQol questionnaire, which are shown in Table 4.2. The
table emphasises the major impact of women's 'heaviest' days on their health
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Table 4.1
	 Characteristics of the samples of women included in the survey in
Bristol and Swindon
Characteristic Bristol
(n=113)
Swindon
(n=108)
P Value Pooled
(n=221)
Mean (SE) age (years) 41.38 (0.73) 40.47 0.41* 40.94
(0.82) (0.55)
Median (range) duration of
menorrhagia (months)
24(3-360) 12 (1-420) 0.02 18 (1-420)
Median (range) days per month
bleeding
8 (2-31) 8 (3-31) 0.93t 8 (2-31)
Median (range) days per month with
heavy flow
4 (1-21) 4 (1-25) 0.67t 4 (1-25)
Number (%) of women passing
blood clots
94(86) 93 (90) 0.40° 187 (88)
Number (%) of women experiencing
flooding
105 (95) 89 (87) 0.09° 194 (91)
Number (%) of pads on heaviest 0.54s
day: 1(1) 1(1) 2 (1)
1-4 36 (33) 38 (37) 74 (35)
5-9 51(47) 45 (44) 96 (46)
10-14 21(19) 18 (18) 39(18)
15 or more
Median (range) days of work lost
during previous year due to
menstrual problems
0 (0-50) 0 (0-36) 0.62' 0 (0-50)
T test
t	 Wilcoxon rank-sum test
e	 Fisher's exact test
#	 Mann Whitney U test
status, by showing the large number of women who moved from having no
impairment (ie. level 1 on a given dimension of the instrument) on the day the
questionnaire was completed to having an impairment (le. levels 2 or 3) on their
'heaviest day'.
Figure 4.1 brings this point out further using pooled data from the two centres.
The figure shows, for each dimension of the EuroQol, the percentage of women
with an impairment on the day the questionnaire was completed and on their
heaviest day, respectively. Overall, 43% of women had an impairment to their
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Table 4.2	 EuroQol classifications and valuations of women in the survey in Bristol and
Swindon
Bristol (n=113) Swindon (n=108) Pooled (n=221)
Today 'Heaviest' Today 'Heaviest Today 'Heaviest'
EuroQol groups (n(%))
Group 1: Mobility
No problems in
walking about
86 (86) 23 (23) 94 (93) 29 (29) 180 (90) 52 (26)
Some problems in
walking about
14 (14) 73 (72) 5 (5) 67 (68) 19 (9) 140 (70)
Confined to bed 0 (0) 5 (5) 2 (2) 3 (3) 2 (1) 8 (4)
Group 2: Self care
No problems with self
care
97 (96) 77 (84) 97 (98) 84 (88) 194 (97) 161 (86)
Some problems with
self care
4(4) 15(16) 2(2) 11(12) 6(3) 26(14)
Unable to wash or
dress
0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
Group 3: Usual
activities
No problems with
usual activities
83 (82) 14(14) 92 (92) 15 (15) 175 (87) 29 (15)
Some problems with
usual activities
14(14) 66(65) 6(6) 70(71) 20(10) 136(68)
Unable to perform
usual activities
4(4) 22(22) 2(2) 13(13) 6(3) 35(18)
Group 4: Pain
No pain or discomfort 72 (71) 4 (4) 72 (73) 6 (6) 144 (72) 10 (5)
Some pain or
discomfort
28 (27) 48 (45) 25 (26) 54 (53) 53 (27) 102 (49)
Extreme pain or
discomfort
2 (2) 54(51) 1(1) 42 (41) 3(2) 96 (46)
Group 5: Emotional
Not anxious or
depressed
73 (72) 12 (12) 68 (71) 13 (13) 141 (71) 25 (12)
Moderately anxious or
depressed
28(27) 56 (54) 27(28) 54(53) 55 (28) 110 (53)
Extremely anxious or
depressed
1	 (1) 36 (35) 1	 (1) 35 (34) 2 (1) 71(34)
EuroQol visual 78.59 40.79 82.79 41.91 80.59 41.32
analogue scores
(mean (SE))
(1.91) (2.19) (1.46) (2.46) (1.22) (1.63)
'Heaviest' means the day during which menstrual bleeding is heaviest
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Figure 4.1 Proportion of women with an impairment on EuroClol dimensions on the day they
completed the questionnaire and on their heaviest day. Data are pooled from the
two centres.
health status, on one or more dimensions, on the day they completed the questionnaire,
compared to 99% on the heaviest day of their period.
The major down-turn in women's health status during the day when their blood loss is
heaviest is also emphasised in the EuroQol rating scale results, which are also shown in
Table 4.2. The mean value women attached to their health state on their heaviest day is
only 51% that of the value they associated with their health state on the day the
questionnaire was completed (52% in Bristol, 51% in Swindon).
4.3.4 Treatment characteristics
Table 4.3 shows how women rated the various characteristics of surgical treatment on a
scale running from 'very important' to 'not important'. On the basis of pooled data, the
three characteristics most frequently rated as 'very important' were getting back to usual
activities as soon as possible, experiencing the least pain and discomfort and spending as
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short a time as possible in hospital. A large proportion of women in Bristol
(45%) also rated the stopping of periods for good as 'very important'.
Figure 4.2 shows the mean ranking on the importance scale, where 'very
important' counts as the highest rank (1) and 'not important' counts as the
lowest rank (4). The figure shows that, with the exception of the characteristic
of reducing periods which women in Swindon ranked much higher than those in
Bristol due perhaps to the fact that women in Swindon are referred earlier, the
mean ranks were very similar between the centres. Reflecting the large number
of women rating them as 'very important', the highest mean ranks were for
getting back to usual activities as soon as possible, experiencing the least pain
and discomfort and having a short hospital stay.
Women were also asked to indicate which three characteristics listed in the
questionnaire were most important to them, and to rank these. Table 4.4 details
their responses. The characteristic most frequently rated as the most important
by women in both centres was the stopping of periods for good (27% and 29%
in Bristol and Swindon, respectively). In contrast, the characteristic with the
next highest overall proportion of women rating it as the most important was not
removing the womb (18% overall; 20% and 17% in Bristol and Swindon,
respectively). Getting back to usual activities quickly was considered the most
important characteristic of treatment by 23% of women in Swindon, but by only
9% in Bristol.
If a woman's top three characteristics are scored 3 (most important), 2 (second
most important), 1 (third most important) or 0 if it is not rated in the top three,
the mean score per characteristic can be calculated, and these are also detailed
in Table 4.4. Overall, the highest mean scores were for stopping periods for
good, an early return to usual activities and the least pain and discomfort.
However, the characteristic of not removing the womb also scored quite highly
in both centres.
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1
	
2
	
3
	
4
Very important	 Some imponance	 Little importance	 Not important
Bristol 1111 Swindon M Pooled
Figure 4.2
	
Mean ranks women attached to the characteristics of surgical treatment
for menorrhagia.
In order to encourage women to think about the trade-offs existing between
treatments in terms of these characteristics, they were asked to choose
between, and to value, two treatment scenarios, one describing AH and the
other TCRE. Table 4.5 shows that very similar proportions of women in the two
centres preferred each of the two treatments; overall 43% preferred AH and
41% preferred TCRE. A total of 13% and 19% in Bristol and Swindon,
respectively, either would accept neither treatment or felt unable to choose. The
approximately equal division of women in the survey in terms of preferences for
AH and TCRE was also reflected in the values they attached to the two
scenarios using the EuroQol rating scale. Table 4.5 shows the very similar mean
scores for AH and for TCRE in both centres.
4.3.5 Information and treatment preferences
Figure 4.3 shows the proportions of women in the two samples receiving
information from various sources about treatments for menorrhagia. The main
source is women's GPs, but a large proportion of women had received
information from friends (37% overall) and from magazines (30%). Despite the
fact that 70% of women overall had received information from their GPs, only
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Table 4.5	 Women's preferences concerning the two treatment options
described in unlabelled scenarios in the questionnaire
Bristol
(n=113)
Swindon
(n=108)
Pooled
(n=221)
Number (%) preferring:
AH 50 (46) 40 (39) 90 (43)
TCRE 44 (41) 42 (42) 86 (41)
Would accept neither 4 (4) 5 (5) 9 (4)
Unable to choose 10(9) 14(14) 24(11)
Mean (SE) rating scale value for
AH 61.77 (3.41) 56.50 (3.56) 59.34 (2.46)
TCRE 57.25 (2.96) 56.31 (3.02) 56.82 (2.11)
.	 EuroQol rating scale - 0 ('worst imaginable health state') to 100 ('best imaginable health
state')
44% of women considered themselves well-informed about menorrhagia and its
treatment (51% in Bristol and 37% in Swindon).
When asked to think about specific treatments for their menorrhagia, 46% of
women in Bristol and 39% in Swindon (43% overall) indicated that they had a
strong positive preference for a particular treatment. Very similar proportions -
47% and 37% in Bristol and Swindon, respectively - reported strong negative
preferences for treatments. Table 4.6 shows where these preferences lay, for
the group overall, by listing the actual treatments women noted on the
questionnaire. The first part of the table shows the specific treatments listed by
women. In the second part, treatments have been grouped into broad classes;
for example, the various medical treatments have been grouped into drug
therapy.
Table 4.6 clearly shows that women are heterogenous in their treatment
preferences, with roughly equal proportions having a strong positive and negative
preferences, respectively, for hysterectomy. A similar case is true with drug
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Figure 4.3
	
Sources of information on menorrhagia to which women had access.
therapy, although the proportion with negative preferences is much larger than
that with positive ones: 11% have a strong preference for a particular drug or for
medical treatment in general, whilst 22% have a strong negative preference.
Although the major issue in surgical treatment for menorrhagia is the choice
between MAS and hysterectomy, relatively few women have strong (positive or
negative) preferences about the former.
4.4 Discussion
A broad choice exists between MAS and open surgery in many clinical areas,
and these treatments invariably have different risks, types of process and
outcomes over which patients are likely to have preferences which will influence
how they benefit from treatment. This has important implications for the
measure of benefit used in the economic comparison of MAS and open surgery.
In addition, if patients' preferences are to be given a greater role in determining
their optimal treatment, ways of incorporating this form of management into
economic analysis are required.
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Table 4.6
	
Treatment cited by women for which they had a strong positive or
negative preference. Data only relate to those women who indicated a
strong preference and are pooled across centres
Treatment Number (%)*
Treatments cited by women for which they have a positive preference
Hysterectomy 31(54)
Option 1 in questionnaire (AH) 8 (14)
HRT 4(7)
Option 2 in questionnaire (TCRE) 3 (5)
Laser treatment 3 (5)
D&C 2 (4)
Other 6(11)
Treatments cited by women for which they had a negative preference
Hysterectomy 32 (49)
Tablets 6 (9)
Laser treatment 4 (6)
Option 1 in questionnaire (AH) 3 (5)
Option 2 in questionnaire (TCRE) 3 (5)
D&C 3 (5)
HRT 3 (5)
The pill 3 (5)
Surgery 2 (3)
Other 6 (9)
Treatment groups for which women had a positive preference
Hysterectomy 39 (68)
Minimal access surgery 17 (12)
Drug therapy 6(11)
D&C 2 (4)
Other 3 (5)
Treatment groups for which women had a negative preference
Hysterectomy 35 (55)
Drug therapy 14 (22)
Minimal access surgery 6 (9)
D&C 3 (5)
Other 6 (9)
Percentages based on total number of treatments detailed (ie. some women detailed more
than one)
Despite the importance of preferences in the management of menorrhagia, little
is known about the strength and direction of women's preferences, particularly in
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relation to surgical treatments. This chapter describes a survey of women who
had recently been referred to hospital with heavy periods, providing valuable
information on their HRQL and their preferences for the characteristics of
treatment, and for the treatments themselves.
It is clear from the survey that heavy periods have a serious impact on women's
HRQL, and this confirms the results of other studies [Coulter et al, 1994A]. On
the basis of women's responses to the EuroQol instrument, the most frequent
health state into which women classified themselves in relation to the heaviest
day of their period was 21222. That is, the typical woman on her heaviest day
had moderate impairment on all dimensions of health status except self-care. A
recent study by the University of York, funded by the Department of Health,
asked 3395 members of the public to value a number of the EuroQol health
states using the time-trade-off valuation technique [Williams, 1995] 1 . Using the
data from these interviews and further modelling techniques, the study was able
to allocate values - on a zero (death) to 1 (perfect health) scale - to all Euroaol
states. The mean value for the health state 21 222 on the basis of the public's
values was 0.62, which means that, on average, the public would be willing to
trade-off nearly 40% of their remaining life-years to avoid a permanent
impairment to health status to the extent that this survey indicates is associated
with menorrhagia on the heaviest day of a woman's period.
In choosing between AH and TCRE, a number of risks and benefits need to be
considered. The questionnaire asked women to consider a range of treatment
characteristics, and their responses indicate that some were considered
particularly important, including a speedy return to usual activities, the least
possible pain and discomfort following surgery and stopping periods for good.
However, neither treatment has all the characteristics that women feel are
important. When women were asked to consider the three most important
characteristics of surgical treatment to them, the highest scores in the groups
overall were associated with stopping periods for good (best achieved with
1 The time-trade-off valuation technique is discussed in more detail in Chapter 5
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hysterectomy) and with a speedy return to usual activities (best achieved with
minimal access surgery). This conflict of objectives was evident in some women
at the individual level also: 11% of women indicated that both being in hospital
for as short a period as possible and having a treatment that ended their periods
for good were 'very important' to them; 11% of women rated a treatment that
removed their womb and one that caused the least pain and discomfort during
convalescence as 'very important'. This emphasises the point that the benefit
measure used in the economic evaluation of AH and TORE should reflect how
women trade-off the characteristics of these two treatments.
If women are to play a greater role in identifying their optimal treatment, trade-
offs are again all important. When women were asked to think about these
trade-offs in the questionnaire, by way of two unlabelled scenarios describing AH
and TORE, 15% of women overall either felt unable to choose or indicated that
they would rather put up with their symptoms than have either. It is likely that
this rate would alter if women were provided with additional information, but it
shows that a large proportion were unprepared to accept the trade-offs inherent
in the choice between AH and TORE. Of those who were able to state a
preference for one of the treatments described, very similar proportions preferred
hysterectomy and TORE, suggesting that women have quite different attitudes to
the trade-offs.
Clearly the issue of information is crucial to the preferences women express
about therapy. Although 77% of women said that they had received information
about treatments from their GP, only 44% felt they were well-informed. If
women are to make a greater contribution to decisions about treatment in this
area, the sources of information they currently have access to need to be
supplemented by up-to-date, balanced, accurate and accessible sources.
Given the apparent inadequacy of existing information sources, it is perhaps not
surprising that less than half the women in the survey had strong positive (43%
overall) or negative (42%) preferences for specific treatments. These results are
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similar to Coulter et al's [1994B] study which found that 46% of women with
menorrhagia consulting GPs had no positive treatment preference. Of those
women in the current survey who did express preferences, it was clear that
views were most often formed about hysterectomy, with similarly large
proportions of women expressing strong positive preferences for the removal of
their uterus as negative ones. In contrast to hysterectomy, preferences
concerning MAS were not well formed, which again is likely to reflect inadequate
information. In comparison with Coulter et al's [1994B] survey in general
practice which found that 17% of women would prefer drug therapy, very few
women in this survey reported positive preferences about drug treatment,
probably reflecting the fact that, as hospital referrals, many of them would have
tried drugs already which had failed to ameliorate their symptoms adequately.
4.5 Conclusions
This chapter emphasises the importance of some descriptive assessment of
patients' treatment-related attitudes and preferences regarding MAS prior to
detailed benefit measurement for economic evaluation. The chapter has shown
several important things about women's attitudes to menorrhagia: that it has a
major detrimental impact on HRQL; that women have clear preferences about the
characteristics of TORE and AH in terms of process and outcomes; that there is
heterogeneity between women in these preferences; and that many women are
able to make trade-offs between the characteristics of treatments. These
findings have important implications for the benefit measure used in the
economic evaluation of AH and TORE. The first of these is the need to develop a
measure of benefit which reflects the impact of the two treatments on the
characteristics which women think important. The second implication is that, if
patients' values are considered important for resource allocation in this area, the
benefit measure used in the economic evaluation should also reflect how women
trade-off the various characteristics of treatment. Chapter 5 considers the
extent to which cost-utility analysis based on the standard QALY meets these
requirements.
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A Cost-Utility Analysis of AH Versus TCRE
Using the Standard QALY Model
5.1	 Introduction
The purpose of this chapter is to explore the role of cost-utility analysis (CUA) in
the economic evaluation of MAS procedures. Chapter 3 assessed the relative
cost-effectiveness of AH and TCRE using the methods of cost-effectiveness
analysis (CEA) and treatment success, defined in terms of women's satisfaction
with the results of surgery, as the measure of effectiveness. In the Bristol trial,
AH was found to be significantly more costly than TCRE, but more effective, at
2.2 years. Therefore, to assess the relative cost-effectiveness of the two
interventions, it is necessary for commissioners to judge whether the greater
chance of a treatment success with AH is worth paying for in terms of its
incremental cost.
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The use of CEA has a number of limitations, both in general and specifically in
the economic evaluation of MAS. This chapter uses CUA, and the standard
QALY as a measure of benefit, in an attempt to overcome some of these
limitations and, therefore, to provide some firmer evidence on the relative cost-
effectiveness of the two procedures. A secondary aspect of the chapter is to
develop a decision analytical model to provide a framework for the CUA, to
facilitate the movement away from the comparison of two groups within a RCT.
The model also provides a link to Chapter 6 which explores the generalisability of
the estimates of cost and benefit presented here. Given the uncertainty that is
associated with estimates of cost and benefit in all economic evaluations, a
further element of the chapter deals with how to deal systematically with
uncertainty.
Section 5.2 of the chapter discusses the limitations of simple CEA and Section
5.3 reviews the methods of CUA. Section 5.4 details the methods used in the
CUA of AH versus TCRE, and Section 5.5 presents the results. Section 5.6
provides a discussion of the results and their implications for clinical and
purchasing policy, and of the methodological issues associated with CUA in this
area; and Section 5.7 offers some conclusions.
5.2 The limitations of cost-effectiveness analysis
As a form of economic evaluation, CEA has some important limitations. The first
of these is that the measure of effectiveness incorporated into the analysis must
be uni-dimensional. Drummond et al [1987] state that two conditions must hold
for a CEA to be appropriate:
'(a) that there is one, unambiguous, objective of the intervention(s) and
therefore a clear dimension along which effectiveness can be assessed; or
(b) that there are many objectives, but that the alternative interventions
are thought to achieve those to the same extent. (p.74-)
113
Chapter 5	 The standard QALY model
In the case of MAS, it is not clear that these conditions exist, and particularly in
the case of the surgical treatment for menorrhagia where there is no single
objective of treatment. Clearly the amelioration of excessive blood loss is
important; but the diffusion of TCRE has taken place with the clear
understanding that AH is 100% effective in this regard. As highlighted in
Chapter 3, the comparison between TCRE and AH is characterised by clear
trade-offs: TCRE results in less post-operative morbidity but is less effective at
improving symptoms, and frequently requires women to have further surgery.
The CEA reported in Chapter 3 uses satisfaction rates as its key measure of
effectiveness. In principle, it is possible that a patient's satisfaction with surgery
reflects their perception of its effectiveness in terms of improving symptoms,
whilst allowing for the 'process disbenefits' of treatment. In practice, it is
important to question whether dichotomizing this measure into 'satisfied with
treatment' (successful treatment) and 'not satisfied with treatment'
(unsuccessful treatment) adequately embraces women's preferences regarding
the trade-offs between the technologies. Furthermore, the measurement of
patient satisfaction in health services research in general has been criticised on
various grounds including patients' ability to make technical judgements, the
factors that influence their responses to questions, the reliability and validity of
instruments to measure satisfaction and the practical use of satisfaction results
[Fitzpatrick, 1993].
A second limitation of CEA relates to its usefulness in health care resource
allocation. For within-programme resource allocation, CEA has a clear role to
play. For example, for a decision maker whose objective is to maximise benefits
from a fixed budget in the area of asthma care, information on the incremental
cost per additional episode-free day of new treatments may be of value as
episode free days may be considered a good composite measure of effectiveness
[Sculpher and Buxton, 1993]. For between-programme resource allocation,
however, condition-specific measures of effectiveness have limited usefulness.
For example, the episode-free day does not represent useful information for a
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decision maker considering whether to allocate additional funding to asthma care
or to surgical oncology, as the measure has little relevance to the latter area.
Satisfaction rates do have generic characteristics, in that it is possible to ask
patients or service users across various programmes whether or not they are
satisfied with care. However, satisfaction will mean quite different things to
different people in different clinical contexts: for example, satisfaction with
gynaecological surgery for a benign condition cannot be assumed to be of equal
value to satisfaction with treatment for a life-threatening illness.
The cost-effectiveness ratio relating to the economic comparison of AH and
TCRE, estimated in Chapter 3, therefore has limitations. Firstly, it is not clear
whether, as a simple measure of effectiveness, satisfaction can fully represent
women's preferences regarding the inherent trade-offs between the technologies.
Secondly, the relevance of the cost per successful treatment for health service
resource allocation is likely to be limited to narrow questions concerning funding
treatments for menorrhagia, rather than broader between-programme and
between-specialty issues.
5.3	 Cost-utility analysis
The limitations of CEA in many contexts have encouraged the development of
fuller forms of economic evaluation. Cost-benefit analysis (CBA) is grounded
firmly in the principles of welfare economics [Mishan, 1971A], and has been
used widely in economic appraisals relating to transport and the environment
[Jones-Lee, 1976; Pearce et al, 1989]. In the field of health care, however, the
use of CBA has been hampered by the need to value health benefits in monetary
terms [Pauly, 1995]. In the 1960s and 1970s, controversial benefit valuation
methods were adopted in health, based on the human capital method [Becker,
1964], but the limitations of this approach [Mishan, 1971B] resulted in few
genuine CBAs being published [Backhouse et al, 1992]. In recent years, CBA
has experienced something of a renaissance, with the use of stated preference
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(willingness to pay) methods to value health benefits [O'Brien and Viramontes,
1994; O'Brien et al, 1995; Donaldson et al, 1995; Chestnut eta!, 1996].
However, these methods have not been used widely in full economic evaluations
and, although promising, require further research [Johannesson, 1993; Arrow et
al, 1993].
Given the difficulties in applying CBA in the field of health care, CUA has
developed as a means of more fully reflecting the outcomes of health care in the
evaluation calculus. Although described in general texts as a separate form of
economic evaluation [Drummond et al, 1987; Luce and Elixhauser, 1990;
Robinson, 1993], CUA was originally conceived as a particular example of CEA
[Weinstein and Stason, 1977].
CUA is characterised by the use of a generic measure of benefit which embodies
the impact of a technology on both health-related quality of life (HRQL) and life
expectancy, and the trade-offs between the various dimensions of HRQL and
between HRQL and life expectancy [Williams, 1985]. This dual impact and
trade-off characteristic has traditionally been expressed in terms of the quality-
adjusted life year (QALY) [Loomes and McKenzie, 1989]. As a generic measure
of benefit, the QALY can, in principle, be used to compare the cost-effectiveness
of technologies across health care programmes, in terms of their incremental
cost per additional QALY [Maynard, 1991]. This form of economic evaluation
has been used to assess a range of health care technologies [Gerard, 1992].
The standard approach to CUA is illustrated in Figure 5.1 in the form of a QALY
profile. The curves show the impact of an intervention on duration of life along
the horizontal axis. Over time, patients move between health states which are
associated with varying levels of HRQL, and a patient's duration in a given health
state is quality-weighted according to the relevant level of HRQL. The multi-
dimensional nature of HRQL [Patrick and Erickson, 1993] is dealt with by the
various dimensions being valued on a single utility, preference or valuation scale,
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Figure 5.1 The QALY profile showing prognosis with a hypothetical treatment
versus no treatment. The effect of treatment on patients' duration of life
is shown on the horizontal axis, and the vertical axis shows the quality
weightings based on a 0 to 1 valuation scale. The areas between the
two profiles show the difference in 0ALYs as a result of treatment. The
area marked B shows the initial reduction in QALYs as a result of
treatment, perhaps due to adverse events. The area marked A shows the
larger increase in QALYs as a result of treatment.
between 0 (equivalent to death) and 1 (equivalent to good health), and has been
taken as having cardinal measurement properties. Not only does valuation
overcome the problem of comparing alternative dimensions of HRQL, in principle
it also provides a means by which the preferences of key groups, such as
patients or the general public, can be incorporated into the measure of the
benefit of health care interventions. In Figure 5.1, the areas under the QALY
profiles represent the QALYs associated with the interventions; the difference in
areas between the profiles is the additional QALYs generated by the more
effective technology.
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One of the earliest examples of a CUA of alternative health care interventions
was Stason and Weinstein's evaluation of therapy for hypertension [Stason and
Weinstein, 1977]. Seen as a simple extension to CEA, their evaluation used
assumptions for the health state valuations (quality weights). Since then, a
range of techniques has been used to attach values to health states [Torrance,
1986]. Although there has recently been a consideration of the assumptions
underlying the QALY [Loomes and McKenzie, 19891, and a debate, at a
theoretical level, about alternative ways of measuring the benefits of health care
to reflect society's (or some other group's) preferences [Gafni, 1989; Gafni et al,
1993; Johannesson et al, 1993; Culyer and Wagstaff, 1993], the measure of
benefit invariably used in CUA is the standard QALY. [Chapter 7 reviews this
literature more fully.]
The standard QALY model shown in Figure 5.1 can also be expressed as in
Equation 5.1 below:
GALYs = H(Q).T	 (5.1)
where H(Q) is the value function and T is life years [Johannesson et al, 1993].
The economic evaluation of TORE in comparison with AH can be usefully
extended by undertaking a CUA of the interventions. The two weaknesses of
CEA in this clinical context can, in principle, be addressed by expressing the
benefits of the treatments in terms of GALYs. The multi-dimensionality of, and
the inherent trade-offs between, the outcomes of the two forms of surgery, can
be overcome with CUA, by the valuation of HRQL on a single scale and the
synthesis of these data with those relating to patients' duration in relevant health
states. Moreover, by evaluating the technologies in terms of QALYs, their
relative value for money can be compared with that of other technologies within
and outside gynaecology.
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Figure 5.2
	
The first part of the decision tree model representing the initial surgical
intervention and convalescence (Decision Tree A). Abbreviations: pre-op = pre-
operative; comps= complications; h.stay = hospital stay; con y = convalescence.
5.4 Methods
The CUA described here is made up of six elements: the decision analytical
model; health state description; health state valuation; QALY estimation;
resource costs; and dealing with uncertainty. Each element of the analysis is
described in detail below.
5.4.1 The decision analytical model
Model structure. The main source of data for the CUA is the Bristol RCT
comparing AH and TCRE described in Chapter 3. However, to move to the more
detailed level of analysis that CUA represents, some additional data are required.
To provide a framework within which to synthesise data from all sources, a
decision tree model has been developed, which is illustrated in two parts in
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Figure 5.3
	
The second part of the decision tree model representing the subsequent
prognosis after initial surgical intervention (Decision Tree B).
Abbreviations: men=menorrhagia; conv=convalescence.
Figures 5.2 and 5.3. Figure 5.2 shows Decision Tree A, which represents the
period of the initial surgical intervention and subsequent convalescence; and
Decision Tree B in Figure 5.3 shows the period after initial surgery for women
initially undergoing TCRE.
Following the usual convention, decision nodes and chance nodes are shown as
boxes and circles, respectively. In addition, rectangles within branches signify
resource use and diamonds represent health states. In Decision Tree A, for
example, a patient initially undergoing TCRE will consume pre-operative
resources and theatre resources; there is a risk of operative mortality and of
complications which will result in resource use; all patients consume ward-
related resources during their hospital stay and experience a convalescence; once
they have recovered from the operation, women will move into the Post-AH or
Post-TCRE health state, depending on which operation they have undergone;
over time, women may consume other related resources such as hormone
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replacement therapy. In the base-case analysis, the model considers the two-
year period after surgery, which is broadly equivalent to the average period of
follow-up of women in the Bristol Rd.
Decision Tree B relates solely to women initially undergoing TCRE. This shows
that women can 'fail' on treatment (ie. their menorrhagia returns). Treatment
failure may result in re-treatment, a repeat TORE or an AH. A repeat TORE could
be followed by further failure and an AH. The risk of operative mortality and of
complications with subsequent re-treatments for women initially undergoing
TCRE is allowed for in the model although this is not shown explicitly in Decision
Tree B.
Taken together, the two sub-trees provide a number of possible pathways
through which a woman can pass over two years. These pathways differ
according to the risk and number of treatment failures, and, consequently, health
status, and the number of additional treatments. For each pathway, estimates of
cost and benefit are generated.
Model probabilities. The probability data used in the CUA are shown in
Figures 5.2 and 5.3 and relate to the branches coming out of each chance node.
These data are taken largely from the Bristol RCT. Although no procedure-
related deaths occurred in the Bristol trial, this may have been because the trial
sample was too small to detect such a rare event. Other studies have indicated
that the mortality risk associated with AH is approximately 0.1% [Dicker et al,
1982]. As yet, insufficient data have been collected on TCREs to estimate its
mortality risk adequately. Therefore, in the base-case analysis, it is assumed
that the mortality risk per procedure is 0.1% for both TORE and AH. The
implications of this assumption are tested using sensitivity analysis.
The probability of complication is based on the proportion of women in the
Bristol RCT who experienced any of the operative or post-operative
complications detailed in Table 3.2 in Chapter 3. The longer-term follow-up data
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from the Bristol trial have permitted the calculation of treatment failure
probabilities allowing for differential follow-up using life table methods (see
Chapter 3). The failure probabilities used here are based on failure rates until
two years. The decision tree allows for the possibility of a woman failing initial
TCRE but not receiving additional surgery, because a woman may rather put up
with her symptoms than experience the disbenef its of further surgery. It was
not possible, prospectively, to ascertain which women firmly fell into this group
in the Bristol trial. Therefore, in the base-case analysis, it is assumed that 0% of
women experience this sort of failure. The implications of this assumption are
tested using sensitivity analysis.
5.4.2 Health state descriptions
In order to estimate the relative benefits of TCRE and AH in terms of QALYs, it is
necessary to value the outcomes of the two technologies on the standard 0 to 1
valuation scale; that is, to estimate quality weights. To achieve this, those
health states relevant to menorrhagia and its treatment need to be described and
then valued by a sample of individuals from an appropriate population.
Identifying the relevant health states. The standard QALY model splits
the outcomes of treatment into discrete health states. As regards the
comparison of TCRE and AH, this involves identifying the key health states that
constitute the possible prognoses of these two types of surgery. For those
health states that may recur, in a broadly similar form, over time (eg.
menorrhagia and convalescence after TCRE), the standard QALY model has a
single description and value, however the state is sequenced - whatever the
duration of the state.
As a result of the inevitable variation between patients in the process and
outcome of surgery, there are numerous possible health states associated with
the treatment of menorrhagia, and it is unlikely to be feasible to describe and to
value each of them within a CUA. One means of simplification is to use a
clinical trial to ask patients, in effect, to describe their own health at various
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points in time using a standardised descriptive classification of health status like
the EuroQol instrument [Brooks, 1996] which is linked to a tariff of externally-
generated values. This has the potential advantage of capturing information on
patients at a number of time points which may coincide with key clinical events.
Although this CUA of AH versus TCRE is based largely on data from a RCT, the
latest and validated version of the EuroQol was not available at the outset of the
trial, and no other valuation system was considered appropriate. So the use of a
standard descriptive and valuation system was not feasible in this analysis.
Furthermore, there are factors which might lead to an alternative approach to
identifying health states for a CUA. For example, in certain clinical contexts, the
descriptive system offered by generic valuation systems may lack sensitivity to
differences between, and changes within, patients in underlying health status
[Cook and Richardson, 1993]. A number of CUAs have, therefore, selected
study-specific health states as a way of representing the outcomes of
interventions [Mohide eta!, 1988; De Haes eta!, 1991; Hall eta!, 1992;
Sculpher et al, 1996B], and this was the approach adopted here.
In the context of the comparison of AH and TCRE, it has been necessary to
identify key health states related to the surgical management of menorrhagia
that can be described and subsequently valued. These health states should
relate to the key phases of the typical patient's prognosis following surgery, but
should be manageable in number: the more health states, the greater the burden
of the valuation task and the more complex the modelling.
For the purposes of this CUA, five health states have been identified, as detailed
below.
(a)	 Menorrhagia ('Men' in Figures 5.2 and 5.3). For CUA of acute conditions,
patients' health status prior to treatment would not need to be
established as a distinct health state because it represents a common
baseline for each comparator. However, for women receiving any
treatment other than hysterectomy, menorrhagia can be viewed as a
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chronic condition with the potential to represent a burden on the HRQL
for some years. In particular, because there is a risk of treatment failure
following TCRE, women may again experience the condition some months
or years after initial surgery. Hence, it is necessary for menorrhagia to
represent a distinct health state within this CUA. It has been assumed
that, if women fail on TCRE, the health state they return to is identical to
the one they experienced prior to surgery.
(b) Convalescence following TCRE ('Con y TCRE' in Figures 5.2 and 5.3). A
major difference between TORE and AH is in convalescence following
surgery. This difference is manifested not only in the duration of
convalescence, but also in the HRQL associated with the phase. It is,
therefore, necessary for convalescence following TORE to be a separate
health state within the CUA. Given the possible need for re-treatment
following a TCRE, this period of convalescence might be experienced
twice or more by women.
(c) Convalescence following AH ('Con y AH' in Figures 5.2 and 5.3). The
rationale for including convalescence following TCRE as a distinct health
state also applies to convalescence following AH. Of course, a woman
can experience this health state only once in her prognosis.
(d) Pre-menopausal following recovery from successful TCRE ('Post-TCRE' in
Figures 5.2 and 5.3). Once a woman has recovered from the
convalescence following a TORE, she may enter one of many health
states. These will differ according to the amount of bleeding and
menstrual pain she experiences and the impact on her functional status.
Within a CUA, it is necessary to simplify these health states and here it is
assumed that a woman's prognosis after TCRE can either be unsuccessful
(in which case she reverts to the state of menorrhagia (see (a) above)), or
successful. This health state, therefore, describes the typical woman's
124
Chapter 5	 The standard QAL Y model
HRQL after TCRE, when there has been an improvement in symptoms.
The health state focuses only on the period prior to the menopause.
(e)	 Pre-menopausal following recovery from AH ('Post-AH' in Figures 5.2 and
5.3). As for TCRE, there is a large number of health states a woman can
experience. To keep the valuation exercise and CUA as manageable as
possible, this health state describes the typical HRQL of a pre-menopausal
woman after undergoing AH, and having passed through the
convalescence phase.
Describing health states. Various approaches have been adopted for
describing health states within CUA [Llewellyn-Thomas et al, 1984; Froberg and
Kane, 1989A; Furlong et al, 1990; Gerard et al, 1993]. Decisions have to be
taken about whether the health states are described in point form phrases or
narrative paragraphs; whether they will be covered in the first, second or third
person, or in summary form; how much information will be provided; whether to
adopt a holistic design, where a descriptive scenario represents a combination of
many attributes, or a decomposed design, which allows specific attributes within
health states to be analysed separately; how to frame the descriptive scenario
(eg. whether to detail the probability of dying or the probability of surviving); and
whether to use disease labels within the scenario.
Some empirical work has shown that these decisions influence how individuals
value health state scenarios. Llewellyn-Thomas et al [1984] found values varied
considerably according to whether scenarios were written in the first person
singular and were full in detail, or in point-form with only the most severe health
problems detailed. McNeil et al [1982] found that values associated with
different treatments for lung cancer were influenced by whether the treatments
were mentioned, and by whether probabilities were couched in terms of living or
dying.
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Other studies have found that values are not sensitive to how the health state
scenarios are described. O'Connor et al [1987] found that the way information
was presented to cancer patients on the side effects of a hypothetical drug did
not influence their values. Gerard et al [1993] found that the labelling and
framing methods of scenarios relating to breast cancer had no significant effect
on the values provided by a convenience sample of women.
Although there is uncertainty in the literature both about the effects of
alternative ways of describing health states on subsequent valuations, and about
the implications of any such effects for the appropriateness of different
descriptive methods, some authors have produced guidance for developing
scenarios based on empirical work. Furlong et al [1990] suggest the following
guidelines, which are discussed below in relation to the valuation exercise
undertaken in the CUA of AH versus TCRE.
(a) The descriptions should be comprehensible for the intended respondents.
The choice of women with menorrhagia as the sample of valuers is likely
to satisfy this point (see below).
(b) All important aspects of the health state should be explicitly included.
The process of selecting the information for descriptive scenarios in this
study was made up of the following elements.
(i)	 A set of basic general attributes of HRQL relevant to menorrhagia
and its treatment was selected including pain, social function,
vitality, emotion and sexual function. In addition, some condition-
specific information was included. These attributes and condition-
specific details were identified from a review of the published
literature on the HRQL implications of menorrhagia, and from
access to databases relating to its treatment from three major
prospective studies: the Bristol RCT comparing AH and TCRE
[Dwyer et al, 1993] (see Chapter 3); the Oxford Treatment for
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Menorrhagia Study [Peto et al, 1993; Coulter et al, 1994A and
1994B; Jenkinson et al, 1994]; and the North West Thames
Hysterectomy Study [Clarke et al, 1995]. In addition, information
was identified from videos of two focus groups organised by the
King's Fund Centre for Health Services Development, which
provided a valuable source of data on the implications of
menorrhagia and its treatment for women's HRQL. A set of draft
descriptive scenarios was developed using these sources of
information.
(ii) The draft scenarios were presented to a group of gynaecologists
and health service researchers with extensive experience in the
area of menorrhagia. One individual had, in the course of her
research, interviewed 80 women with menorrhagia, or whom had
been treated for menorrhagia, to assess their perceptions of the
condition and its treatment. On the basis of the comments of this
group, a set of revised scenarios was developed.
(iii) A pilot study was undertaken on a convenience sample of 20
women. One objective of the pilot study was to assess women's
reactions to the revised scenarios: whether they understood them
and found the language appropriate. On the whole, the women in
the pilot study commented favourably on the scenarios, but some
small changes were made, resulting in the descriptive scenarios
used in the valuation exercise.
5.4.3 Health state valuation
A key characteristic of CUA is that the health states through which a typical
patient passes before, during and after some form of health care intervention, are
valued. In this context, valuation means that each health state is 'quality- or
preference-weighted' on a 0 to 1 scale. In order for values to be used to quality-
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adjust information on life expectancy to arrive at QALYs, the 0 on the scale
accords with death and the 1 with good health.
Valuation instrument. A range of alternative valuation instruments has
been used in CUA [Torrance et al, 1986; Patrick and Erickson, 1993]. The four
most frequently used, however, are category rating, magnitude estimation,
standard gamble and time trade-off [Gerard, 1992]. The choice between these
methods is far from straightforward. In principle, magnitude estimation, where
respondents compare a health state with some standard and report the extent to
which it is 'better' or 'worse', produces a ratio scale, but this has not been
adequately tested [MuIley, 1989]. Category rating, which involves asking
respondents to complete a visual analogue scale where each step is taken as
being an equal interval, has the advantage of being easy to understand on the
part of the respondent. However, there are doubts about its ability to generate
the genuine interval scale required for CUA [Nord, 19911, and concerns about
respondents distributing their values across the full scale [Mulley, 1989].
Some economists argue that the standard gamble valuation technique should be
used in CUA, as it has the soundest theoretical basis [Gafni, 1994]. With its
origins in von Neumann and Morgenstern's [1944] work on utility theory,
underlying the standard gamble is a set of axioms based on a normative theory
of decision making under uncertainty. As well as a strong theoretical
underpinning, it is argued that values generated by the standard gamble embody
respondents' attitude to risk because the values are elicited in a risky context
[Gafni, 1994]. Although the standard gamble is considered by many to be the
gold standard for eliciting health state values for CUA, it has disadvantages.
These include the fact that the normative theory of behaviour which underlies it
has been shown to be an inadequate explanation of how individuals actually
make decisions under uncertainty [Schoemaker, 1982]. Furthermore,
respondents often find it difficult to use. The limitations of the standard gamble
are discussed further in Chapter 7.
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The time trade-off (TTO) valuation technique was developed by Torrance [1972]
as a means of avoiding some of the difficulties respondents have with the
standard gamble, while retaining its forced choice element. Although it can be
criticised because of the absence of a strong theoretical underpinning, the TTO
has been used widely in studies in Canada [Torrance, 1976; Mohide et al, 1988]
and the UK [Buxton eta!, 1987; Daly eta!, 1993; Sculpher et al, 1996B].
Evidence exists to suggest that the TTO produces very similar values to the
standard gamble [Krabbe et al, 1996].
Although the two forced choice-based instruments, the standard gamble and
TTO, have been shown to have acceptable intra rater reliability and
reproducibility [Froberg and Kane, 1989B], it is very difficult to validate these
techniques, as no true gold standard means of valuation exists. The criterion
validity of some techniques has been explored. Torrance [1987] showed that
the criterion validity of the TTO against the standard gamble was adequate; most
valuation methods have been shown to generate values consistent with expected
direction in types and severity of illness [Patrick and Erickson, 1993].
On the practical level, there seems to be some evidence pointing towards the
superiority of the TTO. Torrance [1976] concluded:
'... this study points to the time trade-off method as the best of the three
(standard gamble, TTO and category rating) tested for use on the general
public in the measurement of social preferences for health states.'
(p.135).
As a preliminary to the largest health state valuation exercise undertaken in the
UK, the standard gamble and TTO were compared within-respondent on the
basis of 335 interviews with a sample of the general public [Williams et al, 1995;
Dolan et al, 1996]. Five criteria were used to compare the two forms of
valuation: completeness, logical consistency, concurrent validity, discriminant
validity and test-retest reliability. Against these criteria, the study found that the
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standard gamble and the TTO had little to choose between them, but the TTO
was selected for the large-scale survey because it resulted in more complete data
and more consistent valuations at the individual level.
These considerations, both theoretical and practical, have prompted the use of
the TTO in the current study.
Sample of respondents. Values were elicited from a sub-sample of the
women ref erred to St Michael's l-lospital in Bristol wit'n uncomplicateO
menorrhagia who took part in the survey detailed in Chapter 4. Of the women
referred to the hospital and who completed the questionnaire, a target sample of
60 women for interview was established. Chapter 4 provides full details of the
sample from which the women interviewed was drawn. In brief, potentially
eligible women were identified from GP referral letters received by the hospital
between January and October 1994. These women were sent a letter explaining
the study and a questionnaire to complete. The letter also asked if they were
willing to be interviewed by a trained female interviewer prior to their visit to the
out-patient clinic.
If women responded positively to the invitation to be interviewed, they were
contacted by telephone to arrange a convenient time and day. Women were told
they would be interviewed in their homes unless they preferred to come to St
Michael's Hospital. They were excluded from valuation exercise if, on the basis
of available data including the information provided in the questionnaire, they had
significant concomitant illness; they lived too great a distance from St Michael's
Hospital to make an interview practicable; or interview prior to their hospital
appointment was not feasible.
Interviews were undertaken by two trained female researchers. The interview
schedule consisted of three elements.
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Figure 5.4 The time trade-off instrument used to value chronic health states
considered better than death. The intermediate health state i, which is
likely to be considered better than death, is valued relative to good
health and death. Respondents are asked to consider a chronic health
state i and to imagine spending the rest of their life (Time TI in that state
(Alternative 2). They are asked to compare that situation with one
where they spend a shorter period (X) in good health (Alternative 1).
The time period X is varied until the respondent is indifferent between
Alternative 1 and Alternative 2. The value of health state i is then
calculated as x/t. [Source: Torrance, 1986].
(a) Introduction. During this section of the interview the researcher
introduced herself and the nature of the exercise. She also asked the
respondent for permission to tape the interview. Finally, a short
additional questionnaire was given to the woman to complete, asking a
series of socio-demographic questions.
(b) Valuation of chronic health states. The next stage of the interview
consisted of respondents ranking and valuing the chronic health states.
Written scenarios were presented to respondents on cards describing
states (a), (d) and (e) detailed in Section 5.4.2 above: menorrhagia; pre-
menopausal following recovery from successful TCRE; and pre-
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Figure 5.5 The time trade-off instrument used to value temporary health states.
The valuation of temporary health states is made up of two stages. In
the first stage, an intermediate temporary health state i is valued relative
to the best state (good health) and the worst temporary health state j.
The respondent is offered a choice between health state i lasting for the
duration of the temporary states (T) followed by good health (Alternative
1), and health state j for a shorter duration (X) followed by good health
(Alternative 2). The time period X is varied until the respondent is
indifferent between the two alternatives, and the value of the temporary
state i is calculated as 1-x/t, if the value of state j is assumed to be 0.
The second stage of the process involves re-scaling the value of health
state i onto the standard 0 to 1 scale. This involves valuing the worse
temporary health state j as a short duration chronic state, where the
duration is the same as the temporary states, as shown in Figure 5.4,
and calculating the value of state i using the following formula: Hi = 1-
(1-Hj)(X/T). [Source: Torrance, 1986].
menopausal following recovery from AH. In addition to these three
descriptive scenarios, a fourth card reading 'your health state today' was
shown to women. The respondents were then asked to rank the health
states described in the scenarios.
Following ranking, the TTO technique was carefully explained to
respondents. The three health states described in the scenarios were
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considered sufficiently long-term in duration (about 10 years, on average)
to value using the standard TTO technique for chronic states illustrated in
Figure 5.4. To avoid anchoring bias, the 'converging ping-pong' approach
to the TTO was adopted, whereby the period in the particular state being
valued is systematically altered over the interval of the respondent's life
expectancy on a high-low basis, converging inwards, until indifference is
established [Mohide et al, 19891.
(c)	 Valuation of temporary health states. The two other health states listed
in Section 5.4.2 above - convalescence following TCRE (b) and
convalescence following AH (c) - were valued as temporary health states,
using Torrance's [1986] two-stage technique, as illustrated in Figure 5.5.
Respondents were asked to rank the two temporary states. The preferred
health state was then valued, relative to the worst, for the duration of the
temporary health states, which was assumed to be 10 weeks.
The second stage of the valuation technique for temporary health states
is required to translate the value of the temporary state onto the standard
0 to 1 scale. To achieve this, the least preferred of the two temporary
states is valued as a short duration chronic state, where the duration is
not the respondent's life expectancy as for the chronic states, but the
duration of the temporary health states (10 weeks). It was felt that,
faced with the choice between the worst temporary health state for 10
weeks followed by death and a shorter period in good health, the short
life expectancy would dominate the details of HRQL in a woman's
response. Hence, following Cook et al [1994], the worst temporary
health state was valued as a short duration chronic state twice with two
different durations: 10 weeks (Approach I) and 10 years (Approach II).
Therefore, two alternative sets of values have been calculated for the two
temporary health states. It was planned that, if there were no clear
differences between the two approaches, Approach I would be used
because of its theoretical advantages.
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Table 5.1
	
Duration of convalescence by type of surgery, and times until treatment for
women failing on initial TCRE. Figures are means (standard errors)"
Duration	 TCRE	 AH
Duration of convalescence (weeks)
With surgical complications 4.71 (0.68) 10.65
(0.64)
Without surgical complications 2.32 (0.15) 11.63
(0.70)
Time until re-treatment (months)t
First repeat TCRE 7.4 (1.54)
Hysterectomy following one repeat TCRE 14.9 (5.81)
Hysterectomy without prior repeat TCRE 10.4 (2.83)
*	 All data taken from Bristol RCT (see Chapter 3). Mean estimates are used in the base-case
analysis, information on standard errors is used in the sensitivity analysis.
t	 Months after first TCRE.
5.4.4 QALY estimation
As illustrated in Figure 5.1, within the standard model, GALYs are estimated by
multiplying the health state value by the length of time a patient spends in that state,
and summing across health states over the time span of the evaluation. Therefore, for
the possible pathways through which a woman can pass over two years shown in
Figures 5.2 and 5.3, assumptions are made about which health states a woman
experiences and for how long.
The duration of time in a given health state is, as far as possible, taken from the
Bristol RCT. The period of convalescence is assumed to be the mean time
women in the Bristol trial, who were in employment, reported that it took them
to return to work following surgery, allowing for whether they experienced any
complication. For women initially undergoing TCRE, there is a risk of treatment
failure and the need for additional surgery. The trial provides data on the risk of
failure and the time period until re-treatment(s), but it was not feasible to collect
data on when a woman's health status deteriorated to the extent that she
sought further surgery. In the base-case analysis of the model, it is assumed
that, if a woman undergoes re-treatment, she experienced half the period
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between recovery from initial surgery and re-treatment in the 'pre-menopausal
following recovery from successful TCRE' state, and half that period in the
'menorrhagia' state.
For all women undergoing a hysterectomy (whether initially or as a re-treatment
following initial TCRE), they are assumed to remain in the health state 'pre-
menopausal following recovery from AH' until two years. In the base-case
analysis, it is assumed that, as in the Bristol trial, women's average age is 41
years. Table 5.1 details the duration of convalescence for the two groups
according to whether there were complications with initial surgery, and times
until re-treatment for women failing initial TCRE.
It is standard practice in economic evaluation to discount future costs from
health care interventions to reflect individuals' and society's time preference
[Drummond et al, 1987; Weinstein and Stason, 1977]. Until recent years, it was
widely accepted that the benefits generated by health care programmes in future
years should also be discounted, usually at the same rate as costs [Keeler and
Cretin, 1983]. Recently, however, there has been a debate about whether it is
appropriate to use a positive discount rate for benefits [Parsonage and
Neuberger, 1992; Cairns, 1992]. Although Chapter 7 includes some
consideration of the validity of the standard approach to discounting benefits in
economic evaluation, this thesis does not consider the methods of discounting in
detail. Department of Health guidelines on discounting health benefits expressed
in natural units show some inconsistency: joint guidelines with the Association of
the British Pharmaceutical Industry recommend that two approaches be adopted:
a 6% discount rate and a 0% rate [Association of the British Pharmaceutical
Industry/Department of Health, 1994]; but guidelines for public policy appraisal
in the field of health suggest a rate of 1.5% to 2% for these benefits
[Department of Health, 19951. Given the uncertainty that currently exists in this
area of method, the following approach is taken here. In the base-case analysis,
future QALYs are discounted at 6% per annum. However, the sensitivity
analysis considers alternative values for the discount rate including a 0% rate.
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5.4.5 Resource costs
The health service resource use and unit costs relating to the surgical procedures
and used in the model are at a June 1994 price base, and are based on those
estimated from the Bristol RCT and described in Chapter 3. Procedure costs are
divided into those which, on average, are incurred when a patient has surgical
complications and those which, on average, are incurred when surgery is
straightforward. This distinction in procedure costs reflects the difference in
length of hospital stay and time in theatre following complicated procedures, as
well as the cost of complications in terms of such things as additional
disposables, diagnostic tests and drugs. Table 5.2 details the lengths of hospital
stay and times in theatre for TCRE and AH, according to whether there were
complications associated with the procedure or not. Table 5.3 presents the
procedure costs used in the model, again distinguishing between procedures with
and without complications. It is assumed that, for the very small proportion of
women who die during surgery, the only costs incurred are the pre-operative and
theatre costs.
For women initially undergoing TCRE, there is a risk of additional subsequent
surgery for their menorrhagia. For re-treatments, the expected cost of a
procedure includes the cost of complications weighted by the probability that
complications will occur.
The Bristol RCT did not collect data on the proportion of women undergoing
cervical screening, so the cost of this area of resource use was not included in
the trial-based economic evaluation described in Chapter 3. However, cervical
screening generates a NHS resource cost that will differ between women having
a TCRE and those undergoing AH. It has been assumed, therefore, that women
who retain their uterus are offered screening every five years, and that 74% of
women undergo screening [Brown and Sculpher, 1993]. The unit cost of
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Table 5.2	 Length of hospital stay and time in theatre according to whether women had
complications. Figures means (standard errors)*
Resource use	 TCRE	 AH
Length of hospital stay (days)
With surgical complications 3.25 (0.70) 6.64 (0.19)
Without surgical complications 1.99 (0.02) 6.19 (0.12)
Time in theatre (minutes)
With surgical complications 63.75 (3.09) 63.16 (2.23)
Without surgical complications 50.12 (0.97) 62.75 (1.24)
All data are taken from the Bristol RCT (see Chapter 3).
cytology, including laboratory costs, is taken as £8 (Dr Flanally, personal
communication).
The model also incorporates the cost of women using hormone replacement
therapy (HRT). Based on data collected in the Bristol trial at 2.2 years after
initial surgery, 10% of women who undergo TCRE and who do not have a
hysterectomy are taken as using HRT compared to 17% of women who have a
hysterectomy. Whether a woman initially undergoes TCRE or AH, there is a
chance she will use other health service resources because of menstrual
problems, as shown by the Bristol RCT. Hence an 'other' cost category is added
to the two-year costs of therapy based on the Bristol results. All costs occurring
after initial surgery are discounted at an annual rate of 6% NM Treasury, 1991].
Due to the fact that building a model as a framework for economic evaluation
requires simplifying assumptions that a RCT-based analysis may not, it would be
expected that the model detailed here would generate cost estimates that are
slightly different to those presented in Chapter 3, which were taken directly from
the Bristol trial. The reasons for this include the fact that the model is using two
year treatment failure probabilities for the cost of TCRE, whereas the RCT-based
analysis estimated costs based on all failures. Furthermore, HRT rates in the trial
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Table 5.3
	
Procedure costs used in the model (£)
Cost element	 TCRE	 AH
With complications
Pre-operative 17 17
Theatre 267 292
Ward 389 795
Complications 68 84
Post-operative 3 7
General practice 4 12
Other 11 10
Total 759 1217
Without complications
Pre-operative 17 17
Theatre 231 291
Ward 238 741
Post-operative 3 7
General practice 4 12
Other 11 10
Total 504 1078
were analysed on an intention to treat basis; the rate of HRT use incorporated
into the model is calculated separately for women who had a hysterectomy,
regardless of their randomised group.
5.4.6 Data synthesis and decision rules
The purpose of CUA is to assist purchasers in the decision as to whether a
particular intervention or programme is more cost-effective than its comparator,
and hence whether it represents a good use of health service resources. The
RCT-based economic evaluation of AH and TCRE detailed in Chapter 3 showed
that AH is statistically significantly more costly than TCRE, and the model-based
analysis presented here will be consistent with this. The main focus of this
CUA, therefore, is to assess whether AH is worth purchasing: is its incremental
cost justified in terms of any additional benefits?
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In order to address this question, CUA synthesises cost and benefit estimates
into a ratio which represents the incremental cost per additional QALY of the
more costly, but more effective, intervention under comparison. In principle,
purchasers can then use this information in comparison with similar ratios
generated by economic evaluations of other interventions. This comparison can
help to decide whether the additional resources required can be taken from other
treatments which have higher incremental cost per QALY ratios, or from an
expanding overall budget. The concept of the 'DALY league table' has
developed as a possible means of assisting in this decision making process,
ranking a range of interventions in ascending order of their incremental cost per
QALY [Williams, 1985; Maynard, 1991]. Some authors have criticised a
formalised use of league tables on the grounds of the current weakness and
variability of the methods used in CUA [Drummond et al, 1993B; Mason et al,
1993]; others have doubted the value to specific decision makers of league
tables which consist of studies from various locations and contexts [Gerard and
Mooney, 1993]. However, if CUA is to be of use to health care purchasers,
decision rules need to be established involving incremental cost per QALY
thresholds below which an intervention would be considered cost-effective.
No such thresholds have emerged in the UK, either by central diktat or
consensus. Laupacis et al [1992] made tentative suggestions about such
thresholds for the Canadian health care system. They argued that various grades
of recommendation exist. For example, a Grade B recommendation would
suggest that there is 'strong evidence for adoption and appropriate utilisation' if
a new technology is more effective and costly than an existing comparator and
each additional QALY costs less than (Can) $20,000; a Grade C recommendation
would suggest that 'moderate evidence for adoption and appropriate utilisation'
exists if a new technology is more costly and more effective that an established
one with each additional QALY generated costing no more than (Can) $100,000.
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Even if these thresholds are broadly appropriate to Canada, they are unlikely to
be sufficiently conservative for the UK, which spends, per head, about between
60% and 70% the amount spent in Canada [OECD, 1996]. Using an exchange
rate of £1 to (Can)$2 and adjusting for the lower health care expenditure in the
UK by weighting the Canadian values by 65% would imply a lower threshold of
£6,500 and an upper threshold of £33,000. These two values have no
grounding in policy or empiricism. However, within any economic evaluation
presenting results in the form of an incremental cost to effect ratio, it is essential
to use some form of threshold in order to handle adequately the uncertainty in
the analysis. To assist in the presentation of results and the formulation of
broad policy conclusions from the CUA presented here, it is assumed that these
two illustrative incremental cost per DALY thresholds are broadly acceptable
lower and upper bounds to define cost-effectiveness.
5.4.7 Dealing with uncertainty
Inherent in all economic evaluations is uncertainty about its results and
conclusions. Briggs et al [1 994] identified four types of uncertainty in economic
evaluation which relate to data inputs, extrapolation, generalisability and
analytical methods.
Data inputs. The trial-based economic evaluation in Chapter 3 considered
the implications of variation in stochastic data using standard statistical
methods. This form of uncertainty also exists in the modelling undertaken here,
in relation to estimates of resource use, probabilities of clinical events and health
state valuations. In most economic evaluations, the unit costs of items of
resource use are deterministic; that is, they come in the form of point estimates,
usually from particular health care facilities, with no sampling variation around
them. The major source of uncertainty with unit costs is measurement error as a
result of the differences in costing methods between different health care
facilities and between different countries. The key uncertain unit cost estimate
in relation to the differential cost of AH and TCRE is that of a hospital in-patient
day.
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Using a series of sensitivity analyses, the implications of variation in data inputs
in the model is the particular area of uncertainty considered in this chapter. The
objective is to consider how robust the conclusions of the base-case analysis are
to variations in the values of particular parameters. To present the results of the
sensitivity analyses, a cost-effectiveness (CE) plane is used as shown in Figure
5.6. For a given comparison of two health care interventions, the CE plane plots
their cost difference against the difference in their effects (in this case QALYs).
Hence the economic comparison can be summarised in terms of four quadrants.
If the plane were used to illustrate the economic comparison of AH and TCRE,
the expected location for the comparison would be Quadrant I (AH more costly
and more effective) or Quadrant IV (AH more costly and less effective).
Although the RCT-data do not support it, at least until two years follow-up, the
economic comparison of AH and TCRE could be located in Quadrant III (AH less
costly and less effective) or Quadrant ll (AH less costly and more effective). If
the comparison were located in Quadrant II, the policy conclusion would be clear:
AH would be more cost-effective because it dominates TCRE, being less costly
and more effective. A similar policy conclusion in favour of TCRE would be valid
if the comparison were located in Quadrant IV.
In Quadrants I and III, the concept of a threshold incremental cost per QALY ratio
becomes crucial for a policy decision, as purchasers have to decide whether
incremental costs are worth incurring in order to generate the additional benefits.
The dotted line in Figure 5.6 illustrates a maximum threshold ratio. If the AH-
TCRE comparison is located in Quadrant I and the incremental ratio is less than
the threshold (ie. in the area marked b), AH would be considered more cost-
effective than TCRE. Conversely, if the ratio is greater than the threshold (ie. in
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Figure 5.6	 The cost-effectiveness plane used to present the results of a cost-utility
analysis. (Source: Briggs, 1995).
the area marked a), TCRE would be considered more cost-effective.
Using base-case data, a policy conclusion from the CUA is suggested using the
illustrative lower and upper bound threshold ratios described above. The aim of
the sensitivity analysis is to assess how robust that conclusion is to alternative
values of parameters. In other words, if the values of particular data inputs
change, will the economic comparison of AH and TCRE switch quadrant, or alter
from (to) area a to (from) area b in Quadrants I or III?
Extrapolation. Uncertainty associated with extrapolation is concerned
with the process of trying to make the results of the analysis more
comprehensive by moving away from the primary data source. In the context of
this analysis, a major limitation imposed by the Bristol RCT as the main source of
data, is its short period of follow-up. Ideally, a detailed CUA of these two
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interventions would be based on a time horizon of women's entire lifetimes.
Such long-term data will not be available for many years. However, given that
purchasers require some indication of the likely longer term cost-effectiveness of
the two procedures, two simple extrapolations are added to the analysis
presented here.
(a) Until the menopause. The first extrapolation models the costs and
benefits of treatment until the menopause based on the following
assumptions: that women will continue until the menopause in the health
state in which they are located at two years; that there are no differences
between the treatments in terms of consumption of health service
resources over that period; and that the average age at the menopause is
51 years [Luoto eta!, 19941.
(b) Until death. The second extrapolation models costs and benefits until
death using the following assumptions: after the menopause women
move into a good health state for the remainder of their life valued at 1.0;
that there are no differences between the treatments in terms of
consumption of health service resources over that period; and that the
average age at death is 80 years.
These simple extrapolations allow a consideration of the potential cost-
effectiveness of the two therapies over the longer term.
Generalisability. Uncertainty relating to generalisability is concerned with
the extent to which the results of an evaluation when applied to a particular
context (eg. to a specific population, hospital, set of clinicians) hold true when
the focus of the evaluation is altered to another context. In relation to the
current analysis, uncertainty of this type is generated by the fact that only one
ROT is used to provide parameter estimates; that a ROT is the main source of
data, and trials may generate estimates of resource use and benefits that are
unrepresentative of routine practice; that the focus is on one type of MAS
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treatment and hysterectomy, when several others are also used in practice; and
that unit costs are related largely to one centre. Chapter 6 focuses specifically
on an analysis of the generalisability of the CUA presented here.
Analytical method. Uncertainty relating to analytical method springs from
the fact that many of the methods used in economic analysis are subject to
controversy about their appropriateness. The sensitivity analysis in this chapter
considers the implications of using a 0% discount rate on benefits. However,
perhaps the main source of analytical uncertainty in the current study is the
methods used to estimate benefits. These are explored, and alternatives are
presented, as a particular focus of Chapter 7.
5.5 Results
5.5.1 Health State valuation
The final health state scenarios, related to menorrhagia and its treatment, used in
the valuation exercise are shown in Box 5.1.
As part of the valuation exercise, 175 women were identified from referral
letters, to whom letters were sent explaining the study, as well as a
questionnaire and an interview consent form to complete. A total of 115 women
returned completed forms, of whom 89 agreed to be interviewed. Out of these
89 women, the target sample of 60 was achieved. In reaching this number, 29
exclusions were made, details of which are provided in Table 5.4.
Table 5.5 presents the socio-demographic and clinical characteristics of the
sample of women interviewed, and details of the severity of their menorrhagia.
In order to value the health states, assumptions about women's life expectancy
were required. One (2%) woman was in the 20 to 29 years age group (assumed
life expectancy 60 years); 26 (43%) women were in the 30 to 39 years age
group (assumed life expectancy 50 years); 29 (48%) women were in the 40 to
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Box 5.1	 Health state scenarios used in valuation exercise. All scenarios were
presented unlabelled to women.
Health State A (Menorrhagia - chronic state)
• She experiences heavy periods requiring 10 or more pads during the worst day of her period.
• She experiences painful periods.
• She worries about flooding in public. She avoids wearing light-coloured clothing and makes sure she is
never far from a lavatory.
• Because of these worries, she is limited in her social activities such as meeting friends and sporting
activities.
• She often has difficulties in performing her usual daily activities, especially her work.
• She generally feels tired and lacking in vitality.
• She often feels moody, irritable and depressed.
• Her menstrual problems prevent her from enjoying her sex life.
Health State B (Convalescence following TCRE - temporary state)
Recently, she had surgery for her heavy menstrual bleeding and painful periods,
•
	 It is likely that her heavy bleeding will have disappeared.
• She is aware that there is a risk that the operation may not solve her menstrual problems.
•	 She has returned home from hospital and is feeling some discomfort.
•	 She feels tired for some of the day.
Her discomfort and tiredness mean she is not prepared to go back to work, although she has resumed her
activities around the house and most of her social activities.
She occasionally feels moody, irritable or depressed.
She is currently not able to have a sex life.
Health State C (Convalescence following AH - temporary state)
Recently, she had surgery for her heavy menstrual bleeding and painful periods.
•
	 Her menstrual problems have disappeared and she will no longer have periods.
•	 She has returned home from hospital but sometimes needs to take pain killers.
•	 She is limited physically as she cannot drive, lift objects or walk very far. She finds it difficult to bend.
•	 She feels tired for much of the day.
Because of these problems, she is not prepared to go back to work or to resume her usual activities fully
around the house or her social activities.
She occasionally feels moody, irritable or depressed.
She is currently not able to have a sex life.
Health State D (Premenopausal following recovery from successful TCRE - chronic state)
• She had surgery for her menstrual bleeding and painful periods three months ago.
• Her operation has not left her with a scar.
• She still has periods but they are much lighter since her operation.
• She still has some pain with her periods.
• She still has her womb, although it is very unlikely that she would become pregnant.
• She is not limited in her social activities.
• She is able to perform her usual daily activities such as work.
• She occasionally feels moody, irritable or depressed.
• Because of the improvement in her menstrual symptoms, she is more able to enjoy her sex life.
Health state E (Premenopausal following recovery from AH - chronic state)
• She had surgery for her menstrual bleeding and painful periods three months ago.
• Her operation has left her with a faint scar on her abdomen.
• She no longer has periods or pain.
• She no longer has a womb so she is unable to bear children.
• She is not limited in her social activities.
• She is able to perform her usual daily activities, such as work.
• She occasionally feels moody, irritable or depressed.
• Because of the improvement in her menstrual symptoms, she is more able to enjoy her sex life.
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Table 5.4	 Details of reasons for exclusions from the Bristol valuation exercise
Number	 %	 Reason for exclusion
19	 66	 Date of out-patient appointment too close
2	 7	 Decided to use private health care
1	 3	 No telephone, so not possible to arrange appointment
1	 3	 Lived too far away
1	 3	 Convenient interview-time could not be identified
1	 3	 Unable to read
1	 3	 Too ill to be interviewed
1	 3	 Not experiencing menorrhagia
1	 3	 Had undergone a previous endometrial resection
1	 3	 Interview abandoned due to unsuitable interview
conditions
49 years age group (assumed life expectancy 40 years); and 4 (7%) women were in the
50 to 59 years age group (assumed life expectancy 30 years).
Interviews took place between 1st March and 4th November 1994. All women were
asked if they were happy for the interview to be taped, and all but 9 (15%) said they
were. The mean (SE) duration of interviews was 34.6 (1.69) minutes.
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Table 5.5	 Socio-demographic and clinical details of the sample of women interviewed in the
valuation exercise
Characteristic
Socio-demographic variables
Mean (SE) age (years) 41.09 (0.77)
Number (%) who have experienced serious illness:
Themselves 18 (33)
In their family 33 (64)
In caring for others 14 (30)
Number (%) currently smoking 19 (32)
Number (%) who have worked in health or social services 22 (37)
Number (%) in employment 33 (55)
Number (%) leaving school at minimum leaving age 39 (65)
Number (%) with degree or equivalent professional qualification 10 (17)
Clinical variables
Median (range) duration of menorrhagia (months) 24 (3-360)
Median (range) days per month bleeding 8 (4-20)
Median (range) days per month with heavy flow 4 (2-14)
Number (%) passing clots 51 (86)
Number (%) with flooding episodes 58 (97)
Maximum number of pads/tampons on heaviest day of period (numbers (%)):
1-9 18 (31)
More than 9 40 (69)
Median (range) days lost from work due to menstrual problems over last
last year for those in work (n=37) 2 (0-48)
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Table 5.6
	
Values given by women to chronic and temporary health state scenarios
and to their own health state (n=60)
Health state Mean (SE) Median (Range)
Chronic states
Menorrhagia 0.50 (0.04) 0.55 (0-0.95)
Pre-menopausal following recovery from successful TCRE 0.73 (0.04) 0.90 (0-1)
Pre-menopausal following recovery from AH 0.86 (0.03) 0.95 (0.05-1)
Own health state 0.65 (0.04) 0.75 (0-1)
Temporary health states.
Convalescence following TCRE
Approach I 0.76 (0.04) 0.85 (0-1)
Approach II 0.75 (0.04) 0.85 (0-1)
Convalescence following AH
Approach I 0.74 (0.05) 0.95 (0-1)
Approach ll 0.79 (0.04) 0.95 (0-1)
Approach I is where the temporary health state ranked second out the two is valued as a
short duration chronic health state lasting 10 weeks. For Approach II the state lasts 10
years.
Table 5.6 shows the values women provided for the three chronic health state
scenarios, their own health state valued as a chronic state and the two
temporary health state scenarios. The results show that the ordering for the
chronic health states is the same on the basis of mean and median values, and
generally as expected. The chronic health state scenario valued lowest by
women was menorrhagia which, in terms of mean values, women were prepared
to trade 50% of their future life expectancy to avoid. The mean and median
values women attached to their own health state were higher than those for the
described state of menorrhagia, probably because many women would not, at
the time of the interview, have been experiencing their period. The chronic
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Table 5.7
	 Base-case results: expected costs and QALYs over a two year period.
All costs and benefits are discounted
TCRE AH
Expected costs
Initial Surgery
Theatre £234 £292
In-patient £250 £761
Complications £5 £32
Other' £34 £45
Later costs
Re-treatment costs £264 £0
Cervical cytology £2 £0
Hormone replacement therapy £5 £9
Total expected cost £794 £1,139
Expected QALYs 1.363 1.593
Difference in costs £345
Difference in GALYs 0.23
Incremental cost per additional QALY £1,500
*	 Includes pre-operative, post-operative and general practice costs in first four months after
initial surgery and other related costs over a two year period.
health state scenario describing health after an AH, but prior to the menopause,
was valued most highly.
As regards the values women provided for the temporary health states, Table
5.6 shows the results on the basis of the two approaches to standardising
values on the conventional 0 to 1 scale. Approach I gives the values generated
for a given temporary health state valued against the worst temporary health
state, where the worst state has been valued as a short duration chronic state
lasting as long as the temporary state (10 weeks). Approach ll relates to the
values calculated when the worst temporary health state is valued as a short
duration chronic state lasting 10 years. The table indicates that the mean and
median values calculated from the women's responses are similar, whatever the
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method used for standardising the values. Furthermore, the values are broadly
similar for both health states. Hence the values based on the valuation of the
worst temporary health state as a short duration chronic state lasting 10 weeks
is employed to estimate QALYs.
5.5.2 Estimates of costs and benefits
Table 5.7 presents the base-case results of the CUA. The present value of
expected costs over two years is £794 for women initially undergoing TCRE,
compared to £1,139 for women having an AH. Although AH costs, on average,
£345 more per patient than TCRE over two years, the base-case results of the
model indicate that it also generates an additional 0.23 of a QALY. Hence, each
additional QALY generated by AH has an incremental cost of £1,500. This ratio
lies below the lower illustrative threshold ratio of £6,500 introduced above,
which would imply that the incremental cost of AH is worth incurring for the
additional benefit generated over a two year period. In other words, if the
illustrative threshold ratios used are generally accepted on the part of
purchasers, the base-case results suggest AH is more cost-effective than TCRE.
5.5.3 Dealing with uncertainty
Data inputs. But how robust is this conclusion to the uncertainty that
surrounds the data inputs in the model? Table 5.8 presents the results of a
series of one-way sensitivity analyses focusing on the uncertainty in the analysis
related to data inputs. The table shows, for each uncertain parameter, the base-
case value and the alternative (higher and lower) values used, together with the
incremental cost per QALY ratios for each of these values. The table shows that
plausible variation in each parameter individually is not sufficient to alter the
base-case finding that, over a period of two years after initial surgery, AH is both
more costly and more effective than TCRE.
To give a better sense of the variables to which the results are most sensitive,
Figure 5.7 plots each of the alternative differential cost and benefit estimates
from the one-way sensitivity analyses onto the cost-effectiveness plane. The
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Chapter 5	 The standard QAL Y model
origin runs to the base-case result, the gradient of this line being the base-case
incremental cost per QALY ratio (£1,500). Hence points below this line
represent a lower incremental cost per QALY estimate for AH than in the base-
case, and points above the line represent higher estimates.
The ward cost per in-patient day is subject to considerable uncertainty, due
partly to genuine cost differences between hospitals, but also to the
inconsistency in hospitals' costing methods. Chapter 6 considers the impact on
the conclusions of the study of variation in key unit costs between hospitals in
more detail. However, Table 5.8 and Figure 5.7 emphasise how sensitive the
incremental cost per QALY ratio is to ward cost. For indicative purposes, when
a particularly large range for this unit cost is used (£52 to £249) based on
hospital cost returns [Chartered Institute of Public Finance and Accountancy
(CIPFA), 1990], the incremental cost per additional QALY of AH varies between
£619 and £3174.
The one-way sensitivity analyses also show that the incremental cost per QALY
of AH is particularly sensitive to the health state values of the post-
convalescence /pre-menopausal states (Post-AH and Post-TCRE in Figures 5.2
and 5.3). Table 5.6 shows that the mean and median values of these health
states are different, in favour of AH. Furthermore, this difference is statistically
significant (Wilcoxon rank sum test, p =0.008), which explains why AH remains
more effective than TCRE in the one-way sensitivity analyses. However, the
incremental ratio is sensitive to the difference between these values: the mean
difference of 0.13 used in the base-case has 95% confidence intervals ranging
from 0.03 to 0.23.
Figure 5.8 looks at the sensitivity of the incremental cost per QALY to variation
in the difference in these two health state values, by keeping the Post-AH value
in the model fixed at 0.86, and varying the Post-TCRE value according to the
95% confidence intervals. The figure shows that, although the incremental ratio
is sensitive to this variation, the smallest difference between these values (0.03)
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Figure 5.8
	
A graphical representation of the variation in the incremental cost of AH per
additional QALY as the value of the Post-TCRE health state varies. The value of the
Post-AH health state remains at its base-case value (0.86).
is sufficient to keep the ratio below the lower illustrative threshold ratio of
£6,500.
An implicit assumption of one-way sensitivity analysis is that variability in a
parameter is independent of variability in one or more other parameters. This is
unlikely to be the case in practice, so, in the absence of stochastic data for all
variables, one way to explore the robustness of the conclusions of an analysis to
co-variance in parameters is an analysis of extremes [Briggs et al, 1994]. This
form of sensitivity analysis compares the base-case incremental cost per QALY
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with the ratio generated under two alternative cases: one where all the
parameters in the model are simultaneously altered to the extremes of their
plausible range in a way that favours AH (the 'optimistic for AH' scenario); and
the second where all the parameters are simultaneously altered to the extremes
of their plausible range in a way that favours TCRE (the 'pessimistic for AH'
scenario). Using the 'optimistic for AH' scenario, AH would remain more
effective, but also less costly; that is, AH would dominate TCRE. Using the
'pessimistic for AH' scenario, the incremental cost of AH per additional QALY
would be over £255,000, which is significantly higher than the upper illustrative
threshold ratio and very unlikely to be considered cost-effective. Even if the
rather wide plausible range for ward cost per in-patient day were narrowed
somewhat so that the upper value were £180, the 'pessimistic for AH' scenario
would still generate an incremental cost for AH per additional QALY of nearly
£190,000.
Extrapolation. In order to provide an indication of how robust the
conclusions of the base-case analysis are to taking a longer time horizon for
costs and benefits, Table 5.9 shows the extrapolated costs and QALYs until the
menopause and until death. Although, as described above, these extrapolations
have been based on simple assumptions, they do indicate that AH looks
increasingly cost-effective over a longer time horizon. This is because the Post-
AH health state is valued higher than the Post TCRE health state and is allowed
to have an effect for longer in these extrapolations. Given that women
undergoing both procedures are assumed to experience equally valued health
states after the menopause, it is not surprising that the incremental cost per
QALY ratio alters little for the extrapolation until death. The small difference
between the menopause and death only reflects the fact that women having
TCRE can expect to undergo, on average, more surgical procedures and,
therefore, experience a greater overall risk of operative mortality.
The implications for the conclusions of the analysis of uncertainty relating to
generalisability is considered in detail in Chapter 6. The main source of
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uncertainty in analytical method - the methods used to estimate the benefits of the
two procedures - is explored in detail in Chapter 7. Another source of uncertainty in
analytical method is the rate used to discount benefits in the model. If this is
reduced from the 6% used in the base-case analysis (the same as for costs) to 0%,
the estimates of expected benefit increase sharply, particularly when extrapolated to
the menopause and to death. However, the incremental cost per C1ALY ratios
change very little: £1463 in the two year analysis, £349 in the extrapolation to the
menopause and £346 in the extrapolation to death. This modest change in ratio is
because the temporal distribution of benefits is very similar for the two interventions.
5.6 Discussion
5.6. 1 Cost and benefit estimates
Given the uncertainty surrounding aspects of the CEA presented in Chapter 3, this
chapter builds on that analysis, presenting the results of a CUA using the standard
QALY model. The purpose of the CUA is to estimate the relative cost-effectiveness
of AH and TCRE when benefits are expressed in terms of QALYs. Although the mal7
source of data for the CUA is the Bristol RCT, the analysis develops a decision
analytic framework to provide increased flexibility to explore uncertainty in the cost-
effectiveness estimates, both in this and subsequent chapters. The data from the
Bristol RCT have been augmented by a specific health state valuation study, which
elicits values for health states associated with menorrhagia and its treatment from a
sample of women with the condition.
The results of the analysis of costs reported here confirm that, despite a 23% re-
treatment rate over two years in women initially undergoing TCRE, AH remains more
costly, from a health service perspective, over that period. However, given the
failure rates with TCRE observed in the Bristol RCT and the health state values
elicited in the valuation study, AH is also more effective in terms of QALYs.
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Table 5.9	 Results of the extrapolation exercise. All costs and benefits are discounted
TCRE AH
Extrapolation until menopause
Expected costs (£) 816 1162
Expected QALYs 5.179 5.958
Differential cost (£) 346
Differential QALYs 0.779
Incremental cost per additional QALY (£) - 444
Extrapolation until death
Expected costs (£) 816 1162
Expected QALYs 14.413 15.195
Differential cost (£) 346
Differential QALYs 0.782
Incremental cost per additonal QALY (£) - 442
5.6.2 Cost-effectiveness
The base-case analysis indicates that each additional QALY generated by AH has an
incremental cost of £1,500. These results would suggest that the decision facing
health care purchasers currently purchasing AHs for women with menorrhagia is
whether to continue with AHs, or to switch to purchasing TCREs. By devoting the
additional resources to AH, purchasers may be forgoing greater benefits elsewhere
that could be realised if less costly TCREs were purchased. Similarly, those
currently purchasing TCREs for their population with menorrhagia will need to decide
whether to use any increase in revenues to facilitate a switch to AH, and/or to make
purchasing changes elsewhere to release resources to permit a change to AH.
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Those QALY league tables that have been Published certainly suggest that the health
service is funding interventions and programmes with incremental cost per QALY
ratios in excess of the base-case result here. For example, the league table
presented by Maynard [1991] from a review of the literature suggested that kidney
transplantation, breast cancer screening and heart transplantation each has
incremental ratios appreciably higher than £1,500. It is clear that rigid adherence to
league tables would be to ignore their methodological limitations [Drummond et al,
1993B; Mason et al, 1993; Mooney and Gerard, 19931. However, if purchasers
accept the findings of CUAs, they will need to decide on a threshold cost per QALY
above or below which a serious reappraisal of purchasing policy will be triggered.
The illustrative incremental cost per QALY thresholds used here are based on some
tentative proposals made in Canada, which have been adjusted for the UK [Laupacis
et al, 1992]. If purchasers think these threshold ratios are acceptable, then, on the
basis of base-case data, AH would be considered more cost-effective than TCRE.
It is interesting to note that Laupacis et al make a distinction between cost per CIALY
thresholds relating to the acceptance or rejection of new technologies, and those
relating to existing programmes. They suggest that an existing technology that is
more effective and expensive than a new comparator might have a higher threshold
incremental cost per CtALY than a new technology which is more costly and effective
than an existing comparator. There would seem to be a case for imposing a stronger
'burden of proof' on new technologies. However, in relation to the treatment of
menorrhagia, TCRE has now diffused widely in the UK and centres will differ
according the whether it is the new or the existing intervention for the condition.
5.6.3 Uncertainty
All economic evaluations are subject to sources of uncertainty. This chapter has
looked in detail at the robustness of the base-case conclusion to uncertainty in data
inputs into the model. The sensitivity analyses show that the incremental ratio is
particularly sensitive to variation in the unit cost of a day on a ward and to the health
state values of the Post-AH and Post-TCRE health states. Varying these parameters
individually across a plausible range, however, does not reverse the base-case
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conclusion that AH is more cost-effective than TCRE, if the lower illustrative
incremental ratio (£6,500) is considered acceptable. However, an analysis of
extremes, using a particularly pessimistic scenario regarding data inputs from the
perspective of AH, indicates that the combined uncertainty of all data inputs could be
sufficient to alter the conclusion that AH is the more cost-effective.
An important area of uncertainty regarding the relative cost-effectiveness of AH and
TCRE is the costs and benefits that will accrue in the future. The base-case results
presented here are based on the firm evidential basis of a RCT, and a reasonable level
of confidence can be attached to these results over the period of follow-up in the
Bristol trial of two years. However, women's prognoses over subsequent years may
alter the economic balance between the interventions significantly. For example, AH
offers a prophylactic effect against some gynaecological cancers, but it may be
associated with premature ovarian failure and early menopausal symptoms [Biddle et
al, 1987]. This emphasises the importance of continued follow-up of women in the
RCTs comparing AH and TCRE, and the particular value of the large long-term cohort
study currently underway in the UK. However, purchasers need to make decisions
about the relative cost-effectiveness of the tvvo interv en'fions prior to the \ongei-tern
data becoming available. To assist in this process, two simple extrapolations are
presented here: one until the menopause and one until death. These extrapolations
show that AH is likely to remain the more cost-effective option if judged against the
illustratice threshold ratios. However, this conclusion must be a cautious one, and
the model presented here should be updated when longer-term follow-up data
become available.
A third area of uncertainty concerns the methods used within the CUA. The choice
of how to value the health states used within the model is likely to be crucial to the
final results. The sensitivity analysis shows that the benefit (and hence the
incremental cost per QALY) estimates are sensitive to sampling variation in some of
the health state values (for example, see points 3 and 4 in Figure 5.7). For this
study, a valuation strategy of presenting a sample of women experiencing
menorrhagia with descriptive scenarios for key health states and eliciting values
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using the TTO method was selected. Alternative approaches - for example using
generic descriptions from a valuation system such as the EuroQol or adopting the
standard gamble valuation instrument - may have generated different health state
values and, consequently, estimates of incremental cost per QALY. However, no
'gold standard' approach exists to the choice and valuation of health states, making
the validation of the methods used here difficult.
The additional data source introduced into the economic analysis in this chapter
relates to the health state values. The relative magnitude of the health state values
is broadly as expected. However, the fact that the mean value women provided for
the untreated menorrhagia scenario (0.50) was markedly less than that for their own
current health state (0.65) was surprising. As discussed in Section 5.5.1, this
difference was probably due to the fact that only a proportion of women would have
been having their period at the time of the interview, and that women were valuing
the health state of menorrhagia imagining it as a state of 'continual menstruation' (ie.
a period lasting over their life expectancy), rather than a state where the worst
effects would be experienced for approximately one week out of four, but some
effects of which would extend over the full month. There are problems in eliciting
values for health states relating to essentially chronic conditions which affect HRQL
on a daily basis, but the worst effects of which are episodic. Some uncertainty,
therefore, exists in the value to attach to the menorrhagia health state within the
CUA, in addition to the sampling variation. In Table 5.8 and Figure 5.7 (point number
1), the sensitivity analysis substitutes the mean value elicited from women for their
own current health state for the mean value women attached to the described state
of menorrhagia, and this has only a modest effect on the incremental ratio.
Table 5.8 and Figure 5.7 show that the key values are those for the Post-AH and
Post- TCRE health states. Although these values are statistically significantly
different, the absolute difference between them is subject to uncertainty. When
looked at in isolation, the conclusions of the base-case analysis are robust to this
source of uncertainty (Figure 5.8). However, the uncertainty in the difference
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between these values makes a major contribution to the absence of robustness in the
analysis of extremes.
5.6.4 Methodological issues
The focus of this chapter has been an empirical contribution to understanding the
relative cost-effectiveness of AH and TCRE, in particular estimating benefits in terms
of a generic measure reflecting patients' preferences. In addition, some 'incremental'
contributions to how uncertainty in the results of economic analysis is handled and
presented have been made. For example, the 'scatter-plot' in Figure 5.7 used to
illustrate the one-way sensitivity analyses provide a valuable visual indication of the
importance of individual variation in parameters.
In addition, the chapter does raise some important methodological issues. Firstly, a
fundamental source of uncertainty regarding analytical method is the validity of the
standard QALY model used in the analysis. A major motivation for undertaking a
CUA of AH and TCRE is the need to incorporate women's preferences about the
different outcomes of treatment into the economic evaluation framework. The
standard QALY model here seeks to achieve this by using women's preferences to
value the individual health states in the model. However, the assumptions necessary
to link the QALY to individual preferences are strong. Chapter 7 considers this
source of uncertainty, and alternative measures of benefit for CUA, in more detail.
The second methodological issue raised by the chapter relates to generalisability.
Although the CUA presented here broadens the evaluation by expressing benefits in
generic terms which may more adequately reflect patients' preferences, the analysis
still relies largely on resource and effect data from the Bristol RCT, calling into doubt
the generalisability of the estimates of cost and benefit. The decision analytic model
developed in the chapter provides a framework for incorporating data inputs from
other sources and, therefore, offers a bridge to the analysis of generalisability
detailed in Chapter 6.
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5.7 Conclusions
The base-case CUA results presented here suggest that, for an intervention which is
more effective and more costly than its comparator, if a threshold incremental cost
per 0.ALY of £6,500 is acceptable to purchasers, then AH is more cost-effective
than TCRE. However, on the basis of existing data, there are important uncertainties
associated with this conclusion. This chapter has shown that the conclusion is
robust to variation in individual data inputs, but not to extreme co-variation in these
inputs. Furthermore, methodological issues are raised in relation to benefit
estimation and generalisability. The next three chapters of the thesis consider these
methodological issues further.
165
Chapter 6
The Generalisability of the Costs and Benefits of
AH Versus TCRE
6.1	 Introduction
The use of MAS is likely to be characterised by variation between centres in the process
and outcomes of care. Related to this is the fact that MAS applications are developing
quickly over time. Therefore, in order for health service decision makers to use the data
presented in Chapter 5 to assist in the resource allocation process, they need to know
whether the conclusions of the analysis are consistent with those that would be
expected generally in routine practice.
This chapter considers the issues of method that are raised in relation to the
generalisability of economic evaluations. In particular, the chapter focuses on the
reasons why economic studies might lack generalisability, and the available approaches
to assess levels of generalisability within an evaluation. Using the general tool of
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sensitivity analysis, the chapter provides an assessment of the robustness of the base-
case conclusions in Chapter 5 to alternative data inputs drawn from sources that reflect
the variation in the costs, process and outcomes of health care delivery in this clinical
area.
The chapter is structured in the following way. Section 6.2 considers the
methodological issues related to generalisability in economic evaluation. Sections 6.3 to
6.8 detail five separate analyses of the generalisability of the base-case CUA, which re-
estimate the costs and benefits of TCRE and AH by using alternative sources for the
data inputs used in the model. Section 6.9 provides a discussion of the results, and
Section 6.10 offers some conclusions.
6.2 Generalisability in economic evaluation
Generalisability (or external validity) is concerned with the extent to which the
conclusions of an analysis, as they apply to a specc pooulatioc\, LOC.B.tknaCt (lc coRtext,
hold true in relation to a different population, location or context [Briggs eta!, 1994].
Much has been written about issues of generalisability in clinical evaluation 1BaVey,
1994; Davis, 1994]; particularly about its trade-off with internal validity when choosing
a study design [Schwartz and Lellouch, 1967]. However, with the exception of a small
number of studies looking at international generalisability [Drummond et al, 1992; Leese
et al, 1992], there has been relatively little consideration, at a methodological or
empirical level, of the external validity of economic evaluations. This is the case despite
the fact that generalisability is probably more difficult to achieve in economic than
clinical evaluation because, in addition to data inputs relating to clinical effectiveness,
economic analysis incorporates other categories of data which tend to be particularly
influenced by location and context.
The need to consider the concept of generalisability springs from the variation that
exists in clinical practice that cannot easily be handled using standard statistical
methods within a specific study. The variation likely to be exhibited in relation to MAS
technologies relates, in particular, to the effect of the learning curve on resource and
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non-resource consequences of treatment, the differences between centres in the
detailed process of treatment and changes in practice over time. The impact of
variation on an economic evaluation can be considered using the four basic categories
of data input: effectiveness, resource use data, unit costs and health state valuation,
each of which is discussed below.
6.2.1 Effectiveness data
The effectiveness data used in economic evaluations may be taken from various
sources, and the type of data source will have a major impact on the generalisability of
results. Data sources can sensibly be grouped under randomised controlled trial (RCTs)
and observational studies.
Randomised controlled trials. It is widely considered that the gold standard of
clinical evaluation is the RCT [Pocock, 1983], and this is a key design for evaluation
funded as part of the NHS programme of health technology assessment [Advisory
Group on Health Technology Assessment, 1992]. These studies are also now seen as
an important source of effectiveness data for economic evaluation [Drummond and
Davies, 1991; Drummond, 1995]. However, as discussed in Chapter 2, it has long
been recognised that such studies may exhibit a lack of external validity. This
realisation led Schwartz and Lellouch [1967] to distinguish between explanatory and
pragmatic trials. Explanatory trials seek to test specific hypotheses in 'ideal' clinical
conditions. By keeping 'extraneous variation' in the process of care to a minimum, it is
hoped that the treatment differences identified in these studies reflect true differences
in efficacy. Pragmatic trials on the other hand explicitly recognise that the
effectiveness (as distinct from efficacy) of interventions will partly reflect a range of
factors associated with the process of care which interact with the specific
interventions under consideration. These factors include the skill of the clinician, the
willingness of the patient to comply with treatment and the availability of other
therapeutic and diagnostic technologies.
In reality, it is unlikely that any RCT is a perfect example of either an explanatory or a
pragmatic trial. The result of this is that RCTs invariably have some limitation to their
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generalisability. These limitations have been described elsewhere [Simon et al, 1995],
and include the following.
(a) RCTs tend to focus on atypical populations. This can occur for a range of
reasons including the fact that they are often undertaken in tertiary referral
centres where 'unusual' cases are sent, because trials may use careful screening
procedures to achieve as homogenous a study sample as possible and because
the need for informed consent may result in the inclusion of patients who have
atypical attitudes to health care delivery.
(b) The centres taking part in RCTs may also be atypical. As RCTs are often
undertaken within specialist centres, the care a patient receives is likely to differ
from the routine in more ways than just the technologies being evaluated. For
example, it is likely that clinical staff will be more skilled and experienced than in
non-specialist centres.
(c) Even outside specialist centres, the process of care in RCTs may be quite
atypical. For example, monitoring may be necessary for safety purposes which
in themselves alter the management a patient receives; the use of questionnaires
and interviews to measure the impact of a technology on patients' HRQL may, in
itself, affect outcome through a 'Hawthorne effect'. Indeed, the whale gracess
of standardising care may impact on outcomes and is quite different to the
routine, where significant variation in medical practice is evident [Cleary et al,
1991].
(d) When a patient enters a RCT, the nature of the doctor-patient relationship may
alter. For example, in a trial, the need for long-term follow-up can result in the
hospital doctor retaining an interest in a patient for a longer period than would
routinely be the case. This may have a range of consequences, such as a
tendency for greater use of diagnostic and therapeutic interventions.
(e) Some trials seek to blind patients and doctors to the treatment allocation.
However, in routine practice, knowing which intervention is being used may
influence patients' and doctors' attitudes to and compliance with treatment, thus
impacting on overall effectiveness.
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Observational studies. In the absence of trial data, observational studies are
often used to provide data for economic evaluation. Indeed, in analyses based on
models, a mixture of RCT and observational data may be used. Although the
observational study may exhibit biases because of the strong possibility of confounding
variables influencing results, they can have the advantage of greater generalisability, as
they are less likely to involve major interference with routine practice. Furthermore,
because of the absence of a formal trial infrastructure, observational studies tend to be
less costly to undertake and are, therefore, more likely to cover the wide variation in
patient characteristics and clinical practice. However, as with all forms of clinical
evaluation, the results can only be generalised to the patient sub-groups and clinical
contexts covered, and no single study is likely to be able to cover all variations within
these.
6.2.2 Resource use data
As well as generating effectiveness data for economic evaluations of health care
technologies, RCTs are increasingly used to provide resource use data for those studies.
As a result, this category of data input may also be characterised by limitations in
generalisability. The atypical nature of trial patients and of the process of care in RCTs
directly impacts on the resources patients consume. The most obvious way that this
can manifest itself is with the use of protocol-determined investigations and hospital
visits, which need to be allowed for in an economic evaluation seeking to reach
conclusions relevant to routine practice.
For non-trial-based evaluations or modelling studies involving the synthesis of data from
several sources, resource use data can be based on observational studies, clinical
opinion or ad hoc surveys. It remains the case, however, that these data can usually be
characterised as 'the best that can be acquired in the circumstances', and are very
unlikely to reflect routine practice. Large administrative databases, usually based on
claims data, can sometimes provide a useful source of resource use data, but they are
not usually available in publicly-funded health care systems such as the NHS, they often
fail to provide the fine detail of resource consumption that may be needed and they may
not even allow resource consumption to be distinguished from overall costs.
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6.2.3 Unit costs
The process of valuing resource use may also limit the generalisability of an economic
evaluation. In principle, an item of resource should be valued according to its
opportunity cost - the benefit forgone in using it in one way rather than in the next best
alternative. Given the speed with which health care technologies develop and the major
variation that exists in the configuration and organisation of health care facilities, the
true opportunity cost of a resource will vary with time and place. At the extreme,
therefore, the unit cost of a resource can be seen as unique to the time and facility at
which it is used. This places a major limitation on the generalisability of economic
evaluation.
In practice, a more pragmatic approach to costing has been taken in economic
evaluation, with the acceptance that market prices, or surrogates for them, represent an
adequate means of valuing resource use in health care. In the recent past, the quality
of unit cost data available in the NHS was poor. If a hospital was identified which could
provide some data, the costing methods used were invariably limited; and the quest for
data from a range of hospitals, to explore the robustness of cost estimates to variations
in unit costs, was handicapped by the lack of standard costing methods. For example,
although hospitals have usually been able to provide an estimate of the average cost of
an in-patient day, it has not been clear to what extent the significant variation between
hospitals in these costs was due to genuine underlying cost differences (eg. the market
price of land or labour), to differences in the mix of patients treated or to inconsistent
costing methods. This variation is illustrated by the fact that, in 1990, the average
stated cost per in-patient day for cardiology by district ranged between £41 and £539
[CIPFA, 1990].
In recent years, the quality of unit cost data available in the NHS has improved, at least
in some centres. In large part this is due to the need to set prices within the reformed
NHS of separate purchasers and providers. This process has been assisted by
Department of Health guidelines on costing methods [NHS Management Executive,
1993], and by the development of financial information systems tailored to these
guidelines. It is now possible to identify a group of hospitals which can provide unit
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cost data using similar costing methods, so that differences between them are likely to
reflect differences in underlying costs.
6.2.4 Health state valuation data
The process of valuing the outcomes of medical technologies in order to construct
generic measures of benefit such as QALYs has been more concerned with
methodological issues such as the choice of valuation instrument, than the
generalisability of the data. Generalisability in this category of data input is related to
the choice of whose values are to be used. If the values of the general public are to
count, generalisability would require an adequately sized and stratified sample. The
work recently undertaken by the University of York to elicit valuation data from a
sample of over 3300 members of the public in the UK represents by far the most
important move towards a generalisable set of health state values relating to the UK
population as a whole [Williams, 1995]. If patients' values are considered important, it
would again be necessary to collect data from an extensive sample reflecting diversity
of opinion, preferences and clinical characteristics.
6.3 Assessing generalisability within economic evaluation
The variation that exists in the resource and non-resource consequences of health care
gives rise to two analytical concepts, generalisability and extrapolation, and it is useful
to distinguish the two. Extrapolation is concerned with taking the results of a study
undertaken in a specific context, where context can be defined in terms of such things
as location and point in time, and attempting to translate the results to another specific
context. Generalisability, on the other hand is concerned with taking the results of a
study undertaken in a specific context and seeking to assess the extent to which the
results hold true in clinical practice as a whole; that is, across a range of different
contexts. Extrapolation analysis will be of interest to particular decision makers as long
as it is their contexts that the results are being extrapolated to - that is, as long as the
analysis relates to their mix of patients, reflects the process and resource use in their
clinical practice and incorporates their unit costs. Analyses of generalisability, however,
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will be of interest to decision makers more generally by exploring the extent to which
the conclusions of an analysis are sensitive to variation.
A number of ideas have been put forward on how to increase the external validity of
clinical evaluations. These include the use of 'naturalistic' or 'real life' RCTs which aim
to superimpose randomisation on routine practice, without the research exerting any
extraneous effect on process or outcomes [Simons et al, 1995]. The greater use of
observational studies, which might be strengthened to allow for the various sources of
bias they often exhibit, has also been suggested [Sechrest and Hannah, 1990]. To the
extent that economic evaluations are undertaken alongside these clinical studies, they
may benefit from the success of these methods in increasing generalisability. However,
as noted above, no single study is likely to be able adequately to cover or reflect the
large variation that exists in patient characteristics and clinical contexts. Whatever the
source of the effectiveness data, caution is required in generalising from a single
evaluation to a specific context [Rubins, 1994]. Furthermore, even if an economic
analysis is undertaken alongside a 'real world' RCT which provides generalisable data on
effectiveness and resource consumption, there is no guarantee that the unit cost data
used to value the resource use measured in the trial will exhibit a high level of
generalisability.
There have been attempts to generalise economic assessments across national
boundaries, by undertaking separate studies in different countries [Drummond et al,
1992; Leese et al, 1992], and this has been feasible largely because they were based
on models or observational studies. However, it is clearly quite impractical to undertake
separate economic evaluations for each location and context that might emerge in
practice within a country. In the review of published economic evaluations of MAS
detailed in Chapter 2, only 2/16 studies provided any significant assessment of
generalisability
Therefore, an important role in the assessment of the level generalisability in an
economic evaluation will be played by sensitivity analysis. This may take the form of
the generation of scenarios concerning how one or more parameters in an evaluation
might differ in routine practice from that in the base-case analysis. These scenarios are
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often not based firmly on actual data, but can relate to plausible contexts or situations.
For example, in the review in Chapter 2, Mays' [1991] economic evaluation of
extracorporeal shockwave lithotripsy undertook a base-case analysis and then
recalculated its results making different assumptions about the installation cost and
utilisation of the equipment. Sculpher [1993] undertook an exploratory economic
evaluation of the diode laser in ophthalmology, basing the analysis on a number of
alternative scenarios about the hospitals considering the purchase of a laser; for
example, whether they already had another type of laser and, if so, if it had any useful
life remaining.
A potentially more rigorous approach to the use of sensitivity analysis to assess
generalisability is the development of a base-case analysis and then the incorporation of
data from alternative sources that are considered likely to reflect different aspects of
routine practice. The objective would be to assess the robustness of the base-case
results: the extent to which the alternative parameter estimates alter the conclusions of
the base-case analysis. This is perhaps most frequently undertaken with unit costs in a
study alongside a RCT: base-case unit costs are taken from the trial centre(s), but
sensitivity analysis incorporates unit costs from other non-trial centres [Sculpher et al,
1994]. However, this process can work with 0 components ef an ecenenVc
evaluation. In the MAS review in Chapter 2, only one study [England et al, 1987]
provided this level of detail in assessing generalisability.
There is a key role for the decision analytic model in this more rigorous approach to
assessing generalisability. As an evaluative tool, the model provides a framework
within which to explore the implications of alternative data sources. This implies that,
even for RCT-based economic evaluations, the model can be used within which to
organise data. Furthermore, the approach can explicitly recognise the trade-off between
internal and external validity in selecting study methods. This could be achieved by the
base-case analysis incorporating data with high levels of internal validity, and sensitivity
analysis using other data sources as alternative parameter estimates. These alternative
sources would be expected to have greater external validity, but at the expense of
lower internal validity when used to compare interventions; for example large-scale
surveys or other observational studies undertaken in routine practice.
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One alternative source of data are other RCTs undertaken in the same clinical area.
Although these other experimental studies might also lack generalisability, incorporating
data from several RCTs rather than one will facilitate some assessment of the
generalisability of the base-case. The use of several RCTs to answer a single research
question has recently acquired a great deal of interest in the form of meta-analysis
[Eysenck, 1994]. Meta-analysis is a formal means of synthesising data from a number
of studies to provide a statistically more powerful estimate of effect size than that
offered by a single study. This method has been used widely in clinical evaluation,
including the menorrhagia field [Coulter et al, 1995]. Indeed, meta-analysis is
increasingly being used to provide estimates of effectiveness for economic evaluations.
For example, O'Brien et al [1994] used a meta-analysis of the efficacy of enoxaparin
and warfarin as prophylaxis against deep vein thrombosis in a cost-effectiveness
analysis of the two drugs.
One of the problems with meta-analysis, however, is the heterogeneity of RCTs, and
the danger that combining results will inappropriately mask the underlying differences
between trials [Thompson, 1994]. Statistical tests are available to assess the extent of
heterogeneity in a meta-analysis but, as Eddy [1990] has said:
'The test for heterogeneity is basically a significance test, with the null
hypothesis being that there is homogeneity. In fact, there is virtually never
homogeneity between studies. Differences in subjects, settings, provider skills,
techniques, and other factors make it very questionable to support the
assumption that every study is estimating the same population parameter.'
(p175)
The problem of heterogeneity is likely to be one factor explaining the observed
differences between the results of meta-analyses and subsequent large RCTs [Borzak
and Ridker, 19951.
Meta-analysis is likely to play an increasingly important role in providing estimates of
effectiveness (and perhaps resource use also) for the base-case analyses of economic
evaluations. However, in order to assess the generalisability of these studies, it will be
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necessary to incorporate the results of each trial individually, to consider the robustness
of the base-case conclusions to variability in data inputs which will partly reflect
heterogeneity in trials.
To illustrate how these methods might be used, the remainder of the chapter considers
the assessment of generalisability in economic evaluation in the context of the
comparison of AH and TCRE. Six specific analyses are presented, each of which seeks
to assess whether the base-case conclusions described in Chapter 5 are robust to
alternative parameter estimates based on data from sources reflecting different aspects
of routine practice.
6.4 Analysis of Generalisability I: alternative trial results
6.4.1 Purpose
The CUA presented in Chapter 5 is based on effectiveness and resource use data taken
from the Bristol RCT described in Chapter 3. The fact that the study was undertaken in
a specialist centre, that it took place relatively early in the diffusion of TCRE (January
1990 to May 1991) and that it was a RCT may limit its external validity and hence that
of the economic evaluation. The first analysis of generalisability, therefore, considers
the results of the other two published RCTs of TCRE and AH and incorporates their key
results into the cost-utility model to assess the robustness of the base-case results.
6.4.2 Methods
The two published RCTs used for alternative parameter estimates are Gannon et al
[1991] and Pinion et al [1994]. The two RCTs have been used to provide alternative
estimates of a given parameter if the following apply:
(a) the results of the base-case analysis were shown to be sensitive to variation in
the parameter in the sensitivity analysis of data inputs in Chapter 5, or such
sensitivity is thought likely; and
(b) the alternative trial data sources have published estimates for that parameter.
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In the base-case analysis, the availability of patient-based data from the Bristol RCT
allowed some parameters to be estimated separately for patients who experienced
complications, and for those who did not. This level of detail is not available for the
two alternative trials, so the overall mean values of those parameters are used in the
sensitivity analysis.
The proportions of women randomised to TCRE who required repeat TCRE and/or
hysterectomy are based on a two-year follow-up within the Bristol RCT in the base-case
analysis. The follow-up period in the two alternative trials is, however, only one year.
In order that the sensitivity analysis is based on the same time horizon as the base-case
(ie. two years), the one year failure rates from the Gannon et al and Pinion et al trials
are extrapolated to two years. This is done using life table analysis, where the
cumulative one-year failure rates from the two alternative trials are substituted for the
one-year rates in the Bristol trial. The monthly hazard rates from month 13 to month 24
from the Bristol trial are then assumed to apply to those women from the alternative
trials. The probability of a woman having an AH by two years given a repeat TCRE is
assumed to retain its base-case value (ie. 40%). The hysterectomies undertaken on
women randomised to TCRE are all assumed to be by the abdominal route.
The alternative parameter estimates are incorporated into the cost-utility model jointly;
that is, as a multi-way sensitivity (or scenario) analysis to get a single estimate of the
two-year expected costs and QALYs for the two treatments. The parameter estimates
provided by the alternative trials have not been pooled to provide a single set of
alternative parameters. As discussed in Section 6.3 above, the reason for this is that a
meta-analysis of this type would, in effect, hide the variability between the Pinion et al
and the Gannon et a/ trials, the importance of which this analysis is seeking to explore.
6.4.3 Results
The characteristics of the two trials in terms of their samples and of the process of care
are detailed in Table 6.1, which also compares them with the Bristol ROT [Dwyer et al,
1993]. As the table shows, the two alternative trials are broadly similar in design to the
Bristol trial. However, there are differences between them which, by contributing
alternative parameter estimates, will provide one useful assessment of the
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generalisability of the base-case analysis. These differences include that fact that the
Gannon et al trial was undertaken in a district general hospital rather than a medical
school; that the Pinion et al study was undertaken in Scotland rather than England and
somewhat later than the other two trials; and that both the Gannon et al and the Pinion
et al studies used drug therapies to prepare the uteri of women randomised to TCRE
prior to surgery. An important difference between Pinion et al and the other two
studies was that women not randomised to AH could undergo either laser ablation or
TCRE. For this analysis, only the TCRE results are used.
Although the ages of the women in the three trials are similar, it is not easy to assess
the relative severity of the condition in the three groups. The Gannon et a/ trial provides
little detail of pre-operative severity; the information published on the other two trial
cohorts would suggest that the extent of menorrhagia was worse in women in the
Pinion et al study, but that more women experienced dysmenorrhoea in the Bristol trial.
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Table 6.2 Analysis of Generalisability I: parameters for which alternative estimates
have been taken from the two other RCTs, together with their base-case
values
Parameter Alternative parameter estimates Base-Case
Gannon et al [1991] Pinion et al [1994] Dwyer et al [1993]
AH TCRE AR TCRE AH TCRE
Mean time in theatre (mins)*
Without complications 66.31 45.51 76.41 54.91 62.75 50.12
With complications 66.3 45.51 76.41 54.91 63.16 63.75
Mean hospital stay (days)
-	 Without complications 7.1' 1.41 7.3' 2.5' 6.19 1.99
With complications 7.1' 1.41 7.31 2.5' 6.64 3.25
Overall complication rate (%) 46.15 0.00 ID" ID" 38. 41 8.08
Haemhorrage (%)* ID" 0.00 5.15 0.95 3.09 1.01
Uterine perforation (%) ID" 0.00 0.00 0.95 0.00 4.04
Fluid overload (%) ID" 0.00 1.03 11.43 0.00 1.01
Wound haematoma (%) ID" 0.00 14.43 0.00 1.03 0.00
Pelvic haematoma (%) art 0.00 11.34 0.00 8.25 1.01
Late complication (prior to
discharge) (%)
ID" 0.00 4.12 2.86 4.12 1.01
One repeat TCRE (%) 16.00* 10.48* 12.06'
Hysterectomy (%) 0.00* 16.19* 12.17.
Cost of uterine pre-treatment £0.00 £5.351 £0.00 £144" £0.00 £0.00
Mean time until work (days)
-	 Without complications 67.61 14.91 70.001 21.00 1 81.41 16.24
With complications 67.6' 14.9' 70.001 21.001 74.55 32.97
As for base-case analysis, 15 minutes are added to the operation length to allow for
preparation and recovery of woman
§	 No information available on distinction between with and without complications, hence
overall mean used
t	 Requiring blood transfusion
t t	 Base-case figures used
t	 Based on one-year follow-up
**	 Based on two-year follow-up
41	 150mg Depo-Provera (Upjohn)
t t	 3.6mg (as acetate) Zoladex (Zeneca)
ID	 Insufficient detail provided
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Table 6.3	 Analysis of Generalisability I: two-year results of the CUA using
alternative parameter estimates from the two other RCTs
Results Alternative parameter estimates
	 Base-case
Gannon et al [1991]	 Pinion et al [1994]	 Dwyer et al (19931
AH TCRE AH TCRE AH TCRE
Expected costs
Initial surgery
Theatre £302 £219 £333 £244 £292 £234
In-patient £850 £168 £874 £299 £761 £250
Complications £39 £0 £49 £18 £32 £5
Uterine pre-treatment £0 £5 £0 £144 £0 £0
Other* £45 £34 £45 £34 £45 £34
Re-treatment £0 £223 £0 £414 £0 £264
Longer term other' £9 £7 £9 £8 £9 £7
Total costs £1245 £656 £1310 £1161 £1139 £794
Expected QALYs 1.597 1.359 1.596 1.363 1.593 1.363
Incremental cost of AH per
additional OALY
£2475 £639 £1500
.	 Includes pre-operative, post-operative and general practice costs (until 4 months after
initial surgery) and other related costs until 2 years after surgery
t	 Includes costs of cervical cytology and hormone replacement therapy
Using the criteria described above, the parameters within the CUA for which
alternative estimates have been taken from the two trials are detailed in Table
6.2. For purposes of comparison, the base-case value for each parameter, taken
from the Bristol RCT, are also presented.
Table 6.3 provides details of the results of the sensitivity analyses using
alternative parameter estimates from the other two trials; the two-year results
from the base-case analysis are presented again for comparison. The expected
health service costs of AH are broadly similar for the three trials. Compared to
the base-case results, taking parameters from the Gannon et a/ trial increases the
expected total cost of AH by 9%, due largely to the fact that women remained
in hospital for an average of about seven days compared to about six in the
Bristol trial. Using parameters from the Pinion et al RCT increases the expected
two-year cost of AH by 15%, again due to a longer length of stay in hospital and
a longer period of time in theatre.
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The variation between the trials in the expected two-year costs of TCRE, on the
basis of the alternative trial results, is more pronounced. Using data from the
Gannon et a/trial results in an 8% reduction in expected two-year costs relative
to the base-case, due principally to a shorter mean length of stay in hospital.
Using parameters from the Pinion et a/ trial, however, results in a 46% increase
in two-year cost compared to the base-case. This is due to a number of factors,
but most importantly to the 16% hysterectomy rate by one year in the Pinion et
al trial, which is equivalent to a 20% rate when extrapolated to two years; and
the fact that the women randomised to TCRE in the Pinion et al trial underwent
uterine preparation using an expensive drug (ie. goserelin). The differential cost
of AH over TCRE, varies between £149 (Pinion et al) and £589 (Gannon et al),
compared to the base-case of £345.
Compared to the effect on expected costs, the impact of using parameters from
the two alternative trials on expected two-year GALYs is modest (Table 6.3).
Combining the expected costs and QALYs from the alternative parameter
estimates results in a higher incremental cost per additional QALY of £2475
based on data from Gannon et al; and a lower ratio of £639 per additional QALY
using parameters taken from the Pinion et a/trial. Compared to a base-case
estimated ratio of £1500, these sensitivity analyses show some degree of
variation in costs and benefits which may partly reflect variation in routine
clinical practice. However, if the illustrative cost per QALY thresholds suggested
in Chapter 5 are considered acceptable, AH would remain the more cost-
effective therapy on the basis of the alternative trial results.
6.5	 Analysis of Generalisability II: routine clinical practice
6.5.1 Purpose
The use of two alternative trials to provide data for sensitivity analysis facilitates
some assessment of the generalisability of the base-case analysis because they
were undertaken in different hospitals, by different clinicians, using different
processes and at different times to the Bristol RCT. However, as discussed in
182
Chapter 6	 Analysis of generalisability
Section 6.3 above, the high internal validity of RCTs often comes at the expense
of limited generalisability, and it is possible that the sensitivity analysis presented
in Section 6.4 may still not reflect true routine practice.
An alternative approach is to use non-trial data to provide alternative estimates
for the key parameters in the cost-utility model. Ideally, these non-trial data
would take the form of detailed observational data about the resource and non-
resource consequences of a large number of procedures in a range of clinical
settings. Although these sorts of data are rare in relation to most health care
technologies, such data are beginning to emerge on treatments for menorrhagia.
In 1993, the Royal College of Obstetricians and Gynaecologists' (RCOG) Medical
Audit Unit began a detailed survey of the use of non-hysterectomy forms of
surgery for the treatment of menorrhagia (the Minimally Invasive Surgical
Techniques Laser, Endothermal Or Endaresectiort (11111STLETOE sucteet. Over a
period of 18 months, data were collected on an estimated 80% of all cases
undertaken, and this information related to the surgeon, procedure and post-
operative phase. Questionnaires are currently being sent directly to the women
in the survey to assess their health status and use of health service resources
one year after surgery, and data are available for a sub-group of these women.
The RCOG Medical Audit Unit has given access to MISTLETOE data which otters
a further means of assessing the generalisability of the base-case CUA results.
The purpose of this second analysis of generalisability, therefore, is to use the
MISTLETOE survey as an alternative source of parameter estimates in relation to
TCRE for the cost-utility model, to retain the base-case estimates of the costs
and effects of AH and to compare the resulting incremental cost per additional
QALY of the two technologies with that of the base-case analysis.
6.5.2 Methods
The MISTLETOE survey collected data on 10,686 women. As shown in Table
6.4, the survey collected information on women undergoing a range of
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Table 6.4	 The non-hysterectomy surgical procedures undertaken on women with
menorrhagia entered into the MISTLETOE survey
Procedure Number of cases %
TCRE with rollerball and loop diathermy 4279 40.04
TCRE with loop diathermy 3740 35.00
Laser 1785 16.70
TORE with rollerball diathermy 644 6.03
Radiofrequency 136 1.27
Other 59 0.55
Cryoablation 36 0.34
Other combinations 7 0.07
non-hysterectomy surgical treatments for menorrhagia. The survey distinguished
between two types of TCRE: that based on loop diathermy and that using
rollerball diathermy. For the current analysis, data relating to loop resection
alone are used, as this was the procedure employed in the Bristol RCT.
Although not offering the array of variables collected in a ROT, the MISTLETOE
survey provides information on the key resource and non-resource consequences
of a large number of TCREs, which is important for an economic analysis of the
technology in comparison with AH. The criteria used to select which parameters
to re-estimate using MISTLETOE data are the same as those described in Section
6.4.2 above in relation to the two alternative RCTs. As for the first analysis of
generalisability, a multi-way sensitivity analysis is undertaken using all the re-
estimated parameters.
The re-treatment data relate to one-year follow-up of all women in the survey
using a postal questionnaire. That follow-up is not complete, and currently 1751
(47%) women, who initially underwent a TCRE with loop diathermy, have
responded to the questionnaire. In order to estimate re-treatment rates at one
year on the basis of the questionnaire data and using comparable women to
those in the Bristol RCT, those women who had undergone previous uterine
surgery are excluded. The hysterectomy rate at one year used in the analysis is
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based only on those hysterectomies undertaken as the first re-treatment; that is,
it excludes hysterectomies undertaken after a repeat TCRE. The probability of a
woman having a hysterectomy given that she had previously undergone a repeat
TCRE is assumed to retain its base-case value. The rates of repeat TORE and of
hysterectomy at one year are extrapolated to two years using the same methods
as for the first analysis of generalisability. The hysterectomies undertaken on
women who initially had TCREs are all assumed to be by the abdominal route.
The MISTLETOE survey collected detailed information on the rate of operative
and early post-operative complications. For the purposes of the current analysis,
a complication is defined as having occurred if either an immediate or post-
operative complication prior to discharge was noted. In addition to the overall
complication rate, information on only three specific complications was
requested in the MISTLETOE survey: haemorrhage, perforation and post-
operative complication (prior to discharge). The probabilities of the other
possible complications retain their base-case values in the current analysis. As
for the base-case analysis using data from the Bristol RCT, mean time in theatre,
length of hospital stay and time until return to work are calculated separately
according to whether or not complications were experienced.
The survey collected information on whether a woman was prescribed
endometrial thinning medication prior to surgery, and these data are used to
calculate the expected cost of endometrial thinning. For women who were
prescribed such medication, the broad category of drug was noted: progestogen,
danazol, LHRH analogue and other. These have been costed using standard
British National Formulary dosages for the most frequently used drug in each
category, based on clinical opinion. Other drugs are assumed to have the
equivalent cost of the average of the other three categories.
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Figure 6.1 Distribution of cases reported by hospitals in the MISTLETOE survey
6.5.3 Results
The distribution of the number of cases of TCRE reported by hospitals in the
survey is shown in Figure 6.1. The figure indicates that the majority of hospitals
doing TCRE (64%) reported fewer than 10 cases in total over the period of the
survey. Given the large number of women being referred to hospital for
menorrhagia (see Chapter 1), this figure seems to suggest either that these
referrals are unevenly spread across units, that there was significant under-
reporting of cases from some centres in the MISTLETOE survey or that
hysterectomy was the first-line surgical treatment in most centres.
The key pre-operative characteristics of women undergoing TCRE in the
MISTLETOE are detailed in Table 6.5. Where similar data exist, the details of the
TCRE group in the Bristol RCT underlying the base-case analysis are presented
for comparison. The table shows that the survey and trial women are broadly
similar in terms of age, use of any type of drug therapy prior to surgery and use
of danazol in particular. The clearest difference between the two TCRE samples
is that the women in the trial had experienced symptoms of menorrhagia for
longer than those women in the MISTLETOE survey. This difference may be a
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Table 6.5
	 Analysis of Generalisability II: pre-operative characteristics of the women
in the MISTLETOE survey undergoing TCRE with loop diathermy
compared to women randomised to TCRE in the Bristol RCT
Characteristic MISTLETOE Bristol RCT
Mean age (95% Cl)
Mean duration of symptoms (mths) (95%
Cl)
Previous uterine surgery (%)
Previous medical therapy (%)*
-	 None
Progestogens
Danazol
NSAID
-	 Contraceptive pill
Other
Norethisterone
42.30
35.88
(42.1
(34.6
4.72
15.57
49.67
16.38
12.23
3.14
3.01
- 42.5)
- 37.2)
40.4
61.08
(39.4 - 41.5)
(50.16 - 72.00)
0.00
14.29
17.50
30.30
11.25
21.33
80.21
In Bristol trial women may have taken more than one drug
result of the observed shifting of thresholds in referral for surgical treatment for
menorrhagia following the diffusion of minimal access methods [Coulter, 1994;
Bridgman, 1994]. In other words, since the Bristol RCT took place, women and
their clinicians may be willing to accept surgical treatment earlier than when
hysterectomy was the only surgical option available.
The key point about the comparability of the Bristol RCT and MISTLETOE
samples, however, is that the latter survey focuses on women who are currently
undergoing TCRE for menorrhagia. It is quite feasible that the type of woman
receiving TCRE has changed between 1991 and 1994, but this is the very point
of undertaking an analysis of generalisability: to assess whether the conclusions
of the base-case (RCT-based) analysis are robust to alternative parameter
estimates generated from data relating to current routine practice.
The parameters that have been re-estimated from the MISTLETOE database for
the sensitivity analysis are detailed in Table 6.6, together with their base-case
values. The table shows a shorter mean period of stay in hospital in MISTLETOE
compared to the Bristol RCT. Figure 6.2 focuses on this variable in particular by
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Table 6.6
	
Analysis of Generalisability II: parameters for which alternative estimates
have been taken from MISTLETOE survey for TCRE, together with their
base-case values
Parameter Source of Estimates
MISTLETOE Base-Case
Mean time in theatre (mins)*
Without complications 39.89 50.12
With complications 49.05 63.75
Mean hospital stay (days)'
Without complications 1.18 '1.99
With complications 2.25 3.25
Overall complication rate (%) 7.06 8.08
Haemhorrage (%) t 0.17 1.01
Uterine perforation (%) 2.27 4.04
Late complication (prior to
discharge) (%)
1.53 1.01
One repeat TCRE (%) 1.87** 12.06'
Hysterectomy (%) 1 9.00** 12.17s
Cost of uterine pre-treatment £74 £0
As for base-case analysis, 15 minutes are added to the operation length to allow for
preparation and recovery
Day-case surgery is taken as 0.5 days
Requiring blood transfusion
Only those hysterectomies undertaken as first re-treatment
Based on one-year follow-up
Based on two-year follow-up
presenting the distribution of lengths of stays in MISTLETOE compared to the
trial. The major difference between the two data sources is that TCREs are now
routinely undertaken as day-case procedures: 35% of TCRE cases in MISTLETOE
were undertaken on this basis compared to none in the Bristol RCT. The mean
stay in theatre was also shorter in the MISTLETOE survey, which may partly
reflect further development of the procedure. Another notable difference is the
lower rates of perforation and haemorrhage, but a higher rate of late
complications in MISTLETOE.
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Figure 6.2
	 Distribution of lengths of stay in hospital following TCRE in the Bristol
RCT and in the MISTLETOE survey
As regards re-treatment rates, the rate of second TCRE in the MISTLETOE survey
was 1.87% at one year which, when extrapolated to two years, is 3.29%; the
hysterectomy rate at one year is 9.00% which translates to 13.01% at two
years. This compares with 12.06% and 12.17%, respectively, at two years in
the Bristol RCT. This may suggest that a learning process has gone on since the
Bristol RCT: if the first TCRE fails, then a second one is generally not felt to be
worthwhile and a hysterectomy is, for many women, the sensible option.
The cost of uterine pre-treatment is based on the following rates of drug use:
17% of women used no thinning agent; 6% used a progestogen; 55% used
danazol; 19% used a LHRH analogue and 2% used other agents. The overall
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Table 6.7
	
Analysis of Generalisability II: two-year results of the CUA using
alternative parameter estimates from the MISTLETOE survey. Changes
relate only to TCRE with no re-estimation for AH
Results
Source of Estimates
MISTLETOE	 Base-case
Expected costs
Initial surgery
Theatre £206 £234
In-patient £150 £250
Complications £5 £5
Uterine pre-treatment £74 £0
Other* £34 £34
Re-treatment £182 £264
Longer term other' £7 £7
Total costs £658 £794
Expected QALYs
1.371 7.383
Incremental cost of AH per additional £2167 £1500
QALY I
*	 Includes pre-operative, post-operative and general practice costs (until 4 months after
initial surgery) and other related costs until 2 years after surgery
t	 Includes costs of cervical cytology and hormone replacement therapy
1	 Using base-case results for AH
expected cost of £74 is all additional to the base-case, as women in the Bristol
RCT were not prescribed these drugs.
Table 6.7 presents the revised estimates, using MISTLETOE data, of the
expected costs and QALYs associated with TCRE two years after surgery.
Expected costs clearly reflect the parameters in Table 6.6: using MISTLETOE
data, the costs of theatre and in-patient stay are lower than the base-case,
reflecting shorter mean durations in theatre and in hospital. Other costs
associated with the initial procedure are higher as a result of the fact that 93%
of women undergoing TCRE with loop diathermy in MISTLETOE were prescribed
some form of uterine thinning agent prior to surgery; and re-treatment costs are
lower because fewer women underwent repeat TCRE.
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Expected QALYs are slightly higher on the basis of MISTLETOE data, reflecting
the lower mean complication and failure rates. When the expected two-year
costs of TCRE are combined with the cost of AH estimated in the base-case, the
incremental cost of an additional GALY with AH is higher on the basis of
MISTLETOE data: £2167 compared to £1500 in the base-case. This revised
ratio remains below the lower illustrative cost per QALY threshold introduced in
Chapter 5, suggesting that AH would remain the more cost-effective option if
the threshold ratio were considered acceptable.
6.6 Analysis of Generalisability III: high and low resource use in routine
clinical practice
6.6.1 Purpose
The last sensitivity analysis, using mean values relating to TCRE with loop
diathermy from the MISTLETOE survey, does not fully reflect the variation in the
resource and non-resource consequences of treatment within routine clinical
practice. For example, although the overall hysterectomy rate following TCRE in
the survey was 9% at one year, some hospitals would have had higher rates and
some lower rates than this. This third analysis of generalisability, therefore, uses
MISTLETOE data to explore the implications, for the relative value for money of
TCRE and AH, of these variations in clinical practice.
6.6.2 Methods
The general approach is the same as for the previous two; namely, to re-estimate
key parameters in the cost-utility model using alternative data sources. As the
MISTLETOE survey is again the alternative data source, the same parameters are
re-estimated as in the second analysis of generalisability (Table 6.6). However,
instead of using mean values and overall proportions, the results at the high and
low ends of the resource use distributions are the focus. The mean values or
rates are calculated by hospital. For an analysis of resource intensive clinical
practice, the upper quartiles of the mean values or rates are incorporated into the
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model; for an analysis of resource sparing clinical practice, the lower quartile of
the mean values or rates are used'.
In general, the methods used within the analysis are the same as for the second
analysis of generalisability detailed above, apart from the following differences.
Firstly, because complications are generally rare, it is not possible to get a good
estimate, by hospital, of duration in theatre and in hospital for cases with
complications because the numbers are too few. Therefore, the upper and lower
quartile mean values of these durations by hospital do not differentiate according
to complication status.
A second difference between the methods used in the last analysis of
generalisability and this one relates to the use of endometrial thinning agents.
The second analysis of generalisability showed that, of those women who were
prescribed some form of endometrial thinning agent, 89% used either danazol or
a LHRH analogue. The more expensive of these two agents is usually the LHRH
analogue, which would normally be goserelin (typically, £144 per patient versus
£78 per patient with danazol). Therefore, the rate of LHRH analogue use is
calculated by hospital. For the resource intensive analysis, the expected cost of
the endometrial thinning agent is calculated using the cost of goserelin for the
upper quartile proportion of cases using LHRH analogues, and the average cost
of the other three categories of drug (progestogen, danazol and other) for that
proportion of cases for which LHRH analogues were not used. For the resource
sparing analysis, the lower quartile rate of uterine pre-treatment by hospital is
used, and an expected cost is calculated by multiplying that rate by the expected
cost of uterine pre-treatment estimated on the basis of all MISTLETOE TORE data
in Section 6.5.2.
1 It would be possible to estimate a more extreme scenario of high and low
resource use, by incorporating maximum and minimum mean values and rates by
hospital. However, given that these rates are incorporated individually (the values and
rates of the hospitals with, for example, high lengths of stay, times in theater and
complication rates are used simultaneously to represent a notional resource intensive
hospital), and that some hospitals reported very few cases which may have led to their
having extreme and unrepresentative mean values, the use of upper and lower quartile
values and rates are considered more appropriate.
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Table 6.8
	
Analysis of Generalisability III: parameters for which alternative estimates
have been taken from the MISTLETOE survey for the analyses of
resource intensive and resource sparing clinical practice related to TCRE,
together with their base-case values
Parameter	 Sources of Estimates
MISTLETOE Base-case
No. of
hospitals
Mean no.
of cases
Mean of
the means
Upper
quartile of
the means
Lower
quartile of
the means
Mean time in theatre (mins)*
Without complications 198 17.47 46.23 53.33 36.88 50.12
With complications 198 17.47 46.23 53.33 36.88 63.75
Mean hospital stay (days)
-	 Without complications 205 17.48 1.46 2.00 0.93 1.99
With complications 205 17.48 1.46 2.00 0.93 3.25
Overall complication rate (%) 212 17.48 9.16 12.50 0.00 8.08
Haemhorrage (%)" 212 16.65 0.15 0.00 0.00 1.01
Uterine perforation (%) 5 212 16.65 2.99 0.00 0.00 4.04
Late complication (prior to
discharge) (%)i
212 16.65 2.09 0.00 0.00 1.01
One repeat TCRE (%) 174 9.20 1.57** 0.00** 0.00** 12.06$
Hysterectomy (%) 1 174 9.20 9.83** 13.64** 0.00** 12.17s
No uterine pre-treatment (%) 214 17.48 16.07 20.00 0.00 100.00
LHRH analogue for uterine pre-
treatment (%)
212 17.48 21.09 33.33 0.00 0.00
*	 As for base-case analysis, 15 minutes are added to the operation length to allow for
preparation and recovery
a	 Day-cases have a length of stay of 0.5 days
t	 Requiring blood transfusion
i	 Only those hysterectomies undertaken as first re-treatment
§	 Only calculated for cases where data on whether or not there were any complications are
available
*.	 Based on one-year follow-up
#	 Based on two-year follow-up
It is important to note that data on the high and low resource using hospitals
only relate to TCRE procedures. Hence, comparing these extremes with the
base-case estimates of the costs and effects of AH masks the fact that there is
undoubtedly significant variation in clinical practice relating to hysterectomy.
193
rChapter 6	 Analysis of generalisability
Table 6.9
	
Analysis of Generalisability III: two-year results of the cost-utility analysis
using alternative parameter estimates from the MISTLETOE survey
relating to resource intensive and resource sparing clinical practice.
Changes relate only to TCRE with no re-estimation for AH
Results MISTLETOE Base-case
Resource sparing	 Resource Intensive
Expected costs
Initial surgery
Theatre £196 £239 £234
-	 In-patient £111 £239 £250
Complications £0 £2 £5
Uterine pre-treatment £59 £93 £0
-	 Other* £34 £34 £34
Re-treatment £51 £200 £264
Longer term other' £7 £7 £7
Total costs £458 £814 £794
Expected QALYs 1.377 1.374 1.363
Incremental cost of AH per
additional QALY 1 £3153 £1484 £1500
.	 Includes pre-operation, post-operative and general practice costs (until 4 months after
initial surgery) and other related costs until 2 years after surgery
t	 Includes costs of cervical cytology and hormone replacement therapy
i	 Using base-case results for AH
6.6.3 Results
Table 6.8 provides details of the parameters that have been re-estimated using
MISTLETOE survey data and incorporated into the cost-utility model to assess
the costs and effects of TCRE in resource intensive and resource sparing clinical
practice. The table shows, for each mean value and rate analysed by hospital,
the mean, upper and lower quartile, as well as the number of hospitals and mean
number of cases per hospital providing the estimates; the base-case estimate of
each parameter is also shown. Considerable variation between hospitals is
evident in all areas of resource use, but perhaps the most significant variation is
in the rate of complications: the proportion of cases experiencing immediate or
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post-operative (pre-discharge) complications has an inter-quartile range of 0% to
12.5%; although the incidence of costly complications is small. The table shows
that, within a year of initial surgery, most hospitals had no repeat TCREs, but
that the upper quartile rate of hysterectomy was 13.64%. This seems to
emphasise the point made in Section 6.5.3 above that clinicians and women are
increasingly eschewing repeat TCREs given initial failure, with many moving
straight to hysterectomy.
The implications for this variation in the process and results of clinical practice
for the costs and benefits of TCRE are shown in Table 6.9, together with the
base-case results. The resource sparing analysis incorporates all the lower
quartile values and rates into the cost-utility model, which results in a total two-
year expected cost of only £458, compared to £794 in the base-case. These
cost reductions come largely from a shorter length of hospital stay and less re-
treatment. If the costs and benefits of the resource sparing hospitals are
compared with the base-case estimates for AH, the incremental cost of AH per
additional QALY is £3158, compared to £1500 in the base-case.
In the case of the resource intensive hospitals, the total two-year expected cost
is £814. This is only 2.5% more than the base-case estimate, reflecting the
modest differences, relative to the base-case, in length of stay in hospital and
theatre, and the limited number of second TCREs and expensive complications.
The higher cost of this resource intensive scenario is largely generated by the
higher hysterectomy rate and the use of LHRH analogues for uterine pre-
treatment. Compared to the base-case costs and benefits of AH, the
incremental cost of each additional QALY under the resource intensive scenario
falls modestly to £1484.
If the illustrative cost per QALY thresholds introduced in Chapter 5 are
acceptable, then the revised cost and benefit results under the resource intensive
and sparing scenarios would fail to alter the conclusion that, under most
circumstances, AH is more cost-effective than TCRE.
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6.7 Analysis of Generalisability IV: variation in unit costs
6.7.1 Purpose
The three analyses of generalisability described above all focus on the
implications of variations in the resource and non-resource consequences of
TCRE and AH compared to the base-case analysis. However, as shown in
Chapter 5, a major source of uncertainty relating to the relative value for money
of TCRE and AH is the unit cost of particular resources. This analysis uses unit
cost estimates from specific hospitals and explores their impact on the relative
cost of the two interventions and, in turn, on their relative cost-effectiveness.
6.7.2 Methods
Two unit costs are the focus of this sensitivity analysis. The first of these is the
ward cost per day which, as shown in Chapter 5, has an important impact on the
differential cost of TCRE and AH and is known to vary considerably between
hospitals [CIPFA, 1990]. The second unit cost considered is the variable cost of
a minute in theatre, excluding the cost of anaesthetics and staff. Together,
these two unit costs determine the bulk of the two-year expected costs of both
procedures.
The base-case values of these two unit costs were taken from available data
sources. The ward cost per day was based on estimates by the hospital in
which the Bristol RCT was based; the theatre cost came from a national study
[Bevan 19891 (see Chapter 3). In seeking to assess the robustness of the base-
case conclusions to the value of these unit costs, it is important to be aware that
differences in unit costs between hospitals may reflect divergence in costing
methods more than genuine cost differences. When the unit costs were
estimated for the base-case analysis, the quality of unit cost data available in the
NHS was generally poor. Since then, improvements in information systems and
national guidelines [NHS Executive, 1993] have resulted in improvements in cost
data, but it is difficult to identify hospital-specific unit costs which are
comparable, in terms of costing methods, to those used in the base-case.
Therefore, the approach taken has been to acquire three sets of alternative unit
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Table 6.10 Analysis of Generalisability IV: estimates of alternative hospital-specific
unit costs for an in-patient day in hospital and a minute in theatre (June
1994 prices)
Unit cost Alternative unit costs	 Base-case
Hospital 1	 Hospital 2	 Hospital 3
In-patient day in gynaecology
ward
£83.33 £89.72 £104.00 £120.00
Minute in theatre £2.04 £1.96 £2.02 £1.08
costs from specific hospitals which use similar information systems and costing
methods, and to compare the implications of these unit costs for the expected
two-year costs of the two procedures.
The three hospitals with broadly similar costing methods were identified through
their use of the same financial information software. Out of four hospitals
contacted with a view to acquiring unit cost data from them, three were able and
willing to provide an estimate of the cost of a day on a gynaecological ward and
of a minute in theatre. These three hospitals were large teaching hospitals, one
based in London the other two in northern England. In requesting the estimates
of unit costs, a set of guidelines were given to the finance departments, and
these are shown in Appendix 6.1.
As for the other three analyses of generalisability, the sensitivity analysis
involved incorporating the alternative unit cost estimates into the model jointly.
6.7.3 Results
Table 6.10 presents the unit cost estimates from the three hospitals, together
with the values used in the base-case analysis. The table shows remarkable
consistency between the three alternative sources of hospital-specific unit costs,
with ward costs per day ranging between £83 and £104, and theatre costs per
minute ranging between £1.96 and £2.04. Compared to the base-case unit
costs, the most obvious difference is in the cost of a minute in theatre, with the
base-case value being only 54% of the mean cost of the three hospitals. This
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Table 6.11
	 Analysis of Generalisability IV: impact of alternative unit costs on
expected costs of AH and TCRE and on cost-utility ratios at two years
Results Alternative unit costs Base-case
Hospital 1 Hospital 2 Hospital 3
AH TCRE AH TCRE AH TCRE AH TCRE
Expected costs
Initial surgery
- Theatre £352 £283 £347 £279 £351 £282 £292 £234
- In-patient £530 £174 £570 £187 £661 £217 £761 £250
- Complications £32 £5 £32 £5 £32 £5 £32 £5
- Other* £45 £34 £45 £34 £45 £34 £45 £34
Re-treatment £0 £234 £0 £240 £0 £259 £0 £264
Longer term other' £9 £7 £9 £7 £9 £7 £9 £7
Total costs £968 £737 £1003 £752 £1098 £804 £1139 £794
Incremental cost of £1004 £1091 £1278 £1500
AH per additional
QALY
*	 Includes pre-operation and general practice (until 4 months after initial surgery) and other
related costs until 2 years after initial surgery
t	 Includes costs of cervical cytology and hormone replacement therapy
difference reflects the fact that the hospital-specific theatre costs have been
estimated by hospitals using the same financial information system and very
similar costing methods based on NHS Executive guidelines. The base-case
estimate came from a specific study undertaken in the late 1980s, across all
types of theatre and probably using rather different costing methods.
The implications for expected costs and cost per QALY ratios of incorporating
these alternative sets of unit costs are shown in Table 6.11. The unit costs from
Hospitals 1 and 2 generate very similar total two-year expected costs; the
somewhat higher ward cost for Hospital 3 results in higher expected costs than
for the other two hospitals. Compared to the base-case, the alternative unit
costs result in lower total expected costs for both treatments with the one
exception of TCRE using unit costs from Hospital 3, where costs increase
slightly. The general reduction in expected costs using the alternative unit costs,
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is slightly more pronounced for AH because a higher proportion of its costs
consist of ward cost, which is lower for the three hospitals. The effect of this is
to reduce the incremental cost of AH over TCRE, and the cost-utility ratios fall to
between £1004 and £1278 from the base-case ratio of £1500. Therefore, this
analysis of generalisability indicates that base-case conclusions are robust to unit
costs from specific clinical centres.
6.8 Analysis of Generalisability V: alternative surgical methods
6.8.1 Purpose
The base-case analysis compares the costs and benefits of TCRE and AH.
Although these procedures represent the main surgical treatments for
menorrhagia, other forms of surgery - both non-hysterectomy and hysterectomy
- are used in the UK. Table 6.4 shows that, on the basis of MISTLETOE survey
data, TCRE using loop diathermy was used in 35% of non-hysterectomy MAS
procedures. The table indicates that several other non-hysterectomy MAS
techniques were used, including TCRE where rollerball diathermy was used in
addition to or instead of a loop, laser ablation and radiofrequency.
Although, until recently, AH was used in about 88% of hysterectomies [Vessey
et al, 1992], vaginal hysterectomy and laparoscopic-assisted vaginal
hysterectomy are now being used in some centres [RCOG Medical Audit Unit,
personal communication]. Therefore, the case-study of surgical treatment for
menorrhagia emphasises the general point made in Chapter 2 about MAS
technologies: that the comparator against which new MAS techniques need to
be assessed will change over time and may not be conventional open surgery. In
the case of menorrhagia, TCRE is becoming the old from of MAS which should
be assessed against the new hysterectomy forms of MAS.
The focus of this thesis is the comparison of TCRE and AH, but it is of interest
to consider if the results of this evaluation can be extended to a more general
comparison of non-hysterectomy and hysterectomy forms of surgery for
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menorrhagia. In order to do this, it is necessary to consider the key differences
between TCRE and other non-hysterectomy MAS techniques, and between AH
and other forms of hysterectomy, in terms of resource and non-resource
consequences. Therefore, this final analysis of generalisability adjusts the
parameters in the base-case model in order to estimate the expected costs and
benefits of the alternative surgical treatments for menorrhagia.
It should be emphasised that the comparison of these technologies is indicative
only and the results should be interpreted with care. Unlike the TCRE and AH
comparison in the base-case, which is based on the results of a RCT, there is no
source of data that compares the use of these other surgical treatments using a
homogenous population and randomised treatment allocation. However, the
analysis provides a useful 'broad-brush' picture of the relative costs and potential
cost-effectiveness of these alternative techniques, and helps to highlight the
priorities for further research.
6.&2 Methods
In addition to the treatment options considered in the base-case analysis, the
following alternative surgical interventions are considered.
(a)	 Non-hysterectomy forms of MAS other than TCRE with loop diathermy
(i) TCRE using a combination of loop and rollerball diathermy;
(ii) TCRE using rollerball diathermy alone;
(iii) laser ablation; and
(iv) radiofrequency (RF) ablation.
(b)	 Types of hysterectomy other than AH
(I)	 vaginal hysterectomy (VH); and
(ii)	 laparoscopic-assisted vaginal hysterectomy (LAVH)1.
'A totally laparoscopic procedure is used in some centres but this is rare and is
not considered here.
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Two sets of parameters within the cost-utility model are adjusted to estimate the
costs and benefits of these alternative treatments; namely, resource and non-
resource consequences; and costs of procedures. In order to adjust the key
parameters relating to non-hysterectomy forms of MAS, the MISTLETOE survey
is used as the principal data source. Although not a RCT, the survey offers
standardised data collection on a large number of women who have undergone
treatment for menorrhagia with one of the four technologies listed above, as well
as TCRE with loop diathermy alone.
The choice of parameters to re-estimate for the model is based on the same
criteria detailed for the first analysis in Section 6.3, and the re-estimated
parameters are the same as those used in the second and third analyses of
generalisability. The non-resource consequences of these alternative treatments
are only adjusted in terms of complications and failure rates; it is likely that the
treatments will differ in terms of process and outcomes in ways that are not
allowed for in this analysis. The assumptions used to re-estimate the resource
use and non-resource use parameters are the same as those used in Analyses ll
and III above. It should be emphasised that, for women undergoing
hysterectomy because their non-hysterectomy treatment has failed, it is assumed
that an AH is performed.
No equivalent data source to the MISTLETOE survey yet exists to estimate the
resource and non-resource consequences of the alternative types of
hysterectomy in routine clinical practice for the model. Published literature and
clinical opinion has, therefore, been used in order to estimate the key parameters
- length of hospital stay and length of time in theatre - for the two alternative
types of hysterectomy. The non-resource consequences of VH and LAVH,
including complication rates, are assumed to be the same as for AH.
The costs of the alternative procedures have been estimated by adjusting the
unit cost of TCRE with loop diathermy, for the non-hysterectomy forms of MAS,
201
Chapter 6	 Analysis of generalisability
Table 6.12
	 Analysis of Generalisability V: pre-operative characteristics of women
undergoing various forms of non-hysterectomy surgery for menorrhagia
in the MISTLETOE survey. Where available, the characteristics of
women in the Bristol RCT are also detailed
Characteristic
Taken from MISTLETOE
TCRE
(L)
(n=3740)
TCRE
(L+R)
(n=4279)
TCRE
(R)
(n=644)
Laser
(n=1785)
RF
(n=136)
TCRE (L)
(Bristol RCT)
(n =99)
Mean age (95% Cl) 42.30 41.98 41.71 41.79 42.32 40.47
(42.1-42.5) (41.8-42.2) (41.2-42.2) (41.5-42.1) (41.4-43.2) (39.4-41.5)
Mean duration of 35.88 35.73 38.56 38.08 57.13 61.03
symptoms (mths) (34.6-37.2) (34.6-36.8) (35.1-42.0) (36.2-40.0) (47.9-66.4) (50.2-72.0)
(95% Cl)
Previous uterine
surgery (%)
4.72 3.89 11.99 10.17 3.64 0.00
Current smokers (%) 25.69 27.17 28.87 27.41 25.00
Previous medical
therapy (%)*
- None 15.57 13.52 14.83 13.49 4.76 14.29
- Progestogers 49.67 51.92 47.03 49.93 52.38
- Danazol 16.38 15.87 14.83 19.34 15.87 17.50
- NSAID 12.23 11.96 18.22 8.55 11.11 30.30
- Contraceptive pill 3.14 3.13 2.12 2.99 4.76 11.25
- Other 3.01 3.61 2.97 5.69 11.11 21.33
- Norethisterone - - - - 80.21
Hysteroscopy (%)
- No test 58.60 63.38 54.62 37.38 86.96
- Normal 32.02 28.93 38.46 50.31 8.69
- Polyps 3.13 3.42 3.08 4.92 1.45
- Fibroids 6.25 4.27 3.85 7.38 2.89
Normal histology 95.31 95.58 97.71 93.19 86.11
(%)
Uterine pre-
treatment (%)
82.59 86.27 89.25 97.32 98.39 0.00
One year follow-up 46.82 43.05 42.24 42.58 32.35
(%)
"
	
In Bristol trial women may have taken more than one drug
TCRE(L)	 Transcervical endometrial resection using loop diathermy
TCRE (L&R)	 Transcervical endometrial resection using loop and rollerball diathermy
TCRE (R)	 Transcervical endometrial resection using rollerball diathermy
and of AH, for the alternative forms of hysterectomy. The details of the
adjustment are shown in Appendix 6.2. The appendix indicates that, because of
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important variation in the mix of disposable consumables versus reusable
equipment as part of LAVH, two forms of the procedure are costed: 'disposable'
and 'reusable' versions.
6.8.3 Results
As the MISTLETOE survey is used as a single data source to estimate the
resource and non-resource consequences in routine practice of the non-
hysterectomy forms of MAS for menorrhagia for this analysis of generalisability,
Table 6.12 details the pre-operative characteristics of the women who
underwent the procedures considered. In addition to the laser and RF ablation
groups, three TCRE groups are shown: loop alone, loop plus rollerball and
rollerball alone. Where available, the pre-operative characteristics of the women
randomised to TCRE in the Bristol RCT are also detailed. The proportions of
women in each of the treatment groups who had been sent and returned a one-
year follow-up questionnaire are also detailed.
The table shows that the five treatment groups from the MISTLETOE survey
were broadly similar. The main differences appear to be that a higher proportion
of women in the laser and RF groups had undergone previous uterine surgery;
that women in the RF group had experienced symptoms for a longer period than
women in the other MISTLETOE groups, and were closer to women in the Bristol
RCT in this respect; that more women in the RF group had tried medical therapy
for menorrhagia prior to surgery; and that women undergoing laser and RF
ablation were more likely to have been prescribed uterine thinning agents prior to
surgery. The relatively small numbers of women in the RF group may explain its
asymmetry compared the other groups, and the difference in the use of uterine
pre-treatment is part of the process of care (ie. such preparatory therapy is
effectively mandatory for laser and RF techniques). The main difference
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between the MISTLETOE groups and the Bristol RCT is that the trial women had
experienced their condition for a longer mean time period. The possible reasons
for this were discussed in Section 6.4 above.
Table 6.13 details the parameters which have been re-estimated within the
model to assess the relative costs and benefits of the alternative non-
hysterectomy and hysterectomy forms of surgery. TCRE using loop diathermy is
the same as the technology considered in Analysis II. As regards the non-
hysterectomy surgical options, the largest adjustments to the base-case analysis
are the lower rates of complications with all treatments, but most notably with
laser and TCRE with rollerball alone; the shorter lengths of hospital stay which,
for women not experiencing complications, are day-case or one night; and the re-
treatments rates which, at one year follow-up in the MISTLETOE survey, vary
between 1.72% (TORE with rollerball) and 10.26% (RF) for repeat procedures
and between 9% (TORE with loop diathermy alone) and 23.08% (RF) for
hysterectomy. Only modest adjustments are made to the base-case parameters
of AH to estimate the costs of VH and LAVH: a reduced length of stay and a
longer period of time in theatre.
Table 6.14 details the two-year expected costs and QALYs of the various
surgical options on the basis of the adjustment made to the base-case
parameters. As regards the non-hysterectomy forms of surgery considered using
MISTLETOE survey data, the TCRE procedures and laser ablation have similar
expected costs, and they are not greatly different to the base-case estimates for
TCRE using loop diathermy; but RF has a considerably higher expected cost, due
largely to the higher repeat surgery rates shown in the survey.
As regards hysterectomy, the lower length of hospital stay that is assumed to be
associated with VH and the 'reusable' version of LAVH results in a marked
reduction in their expected total costs compared to the base-case estimates for
AH. The significant additional cost of consumables associated with 'disposable'
LAVH results in the procedure being by far the most expensive of the surgical
procedures considered.
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The two-year expected QALYs associated with the alternative non-hysterectomy
treatments differ little from the base-case estimates for TCRE. However, this is
because complications and re-treatment rates are the only parameters related to
non-resource consequences that are altered relative to the base-case. By
assumption, the expected QALYs associated with VH and the two forms of
LAVH are the same as the base-case estimates for AH.
Table 6.15 compares the expected costs and QALYs of each of the non-
hysterectomy options with those of each of the hysterectomy options. The non-
hysterectomy procedures include two estimates for TCRE with loop diathermy:
the base-case results and those based on parameters estimated from the
MISTLETOE survey. These comparisons are based on the assumption that the
non-resource consequences of each of the forms of hysterectomy are the same
as for AH (ie, the expected GALYs are identical), and that the only differences
between the non-hysterectomy options in terms of non-resource consequences is
in the incidence of complications and re-treatment.
On this basis, AH - the standard form of hysterectomy - has an incremental cost
over the non-hysterectomy forms of surgery of between £219 and £2176 per
additional QALY generated, compared to a base-case ratio of £1500 relative to
TCRE. The incremental ratios resulting from the comparison of the various non-
hysterectomy options with 'reusable' LAVH are similar to those relating to AH,
although this form of hysterectomy dominates RF. The consumable cost with
'disposable' LAVH results in appreciably higher incremental costs per QALY in
comparison with the non-hysterectomy options. However, the lower lengths of
hospital stay with VH reduces the incremental costs per additional QALY, and
the analysis indicates that VH dominates RF.
With reference to the illustrative cost per QALY thresholds suggested in Chapter
5, it would again seem that the broad conclusions of that chapter are
generalisable. The data presented here suggest that, in comparison with AH and
assuming the outcome differences are solely reflected in complication and re-
treatment rates, the use of types of TCRE other than that relying only on the
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Table 6.15	 Analysis of Generalisability V: two year expected incremental cost per
additional QALY of non-hysterectomy versus hysterectomy surgical
procedures
Non-hysterectomy
surgical procedures
Hysterectomy surgical procedures
AR (base-case) V1-1 LAV1i 1D) LA\11-1111)
TCRE (L) £2167 £896 £6167 £1856
TCRE (R&L) £2176 £900 £6195 £1864
TCRE (R) £1712 £441 £5712 £1401
Laser £1597 £350 £5527 £1292
RF £219 (VH) dom £4030 (LAVH(R))
dom
TCRE (base-case) £1500 £274 £5361 £1200
TCRE(L)	 Transcervical endometrial resection using loop diathermy
TCRE (L&R)	 Transcervical endometrial resection using loop and rollerball diathermy
TCRE (R)	 Transcervical endometrial resection using rollerball diathermy
RF	 Radiofrequency ?Nation
VH	 Vaginal hysterectomy
AH	 Abdominal hysterectomy
LAVH (D)	 Laparoscopic-assisted vaginal hysterectomy (disposable)
LAVH (R)	 Laparoscopic-assisted vaginal hysterectomy (reusable)
(*) dom	 * dominates (ie. is less costly and more effective)
loop, or the use of laser or RF ablation, is unlikely to alter the base-case
conclusion that AH is the more cost-effective treatment. If VH or 'reusable'
LAVH rather than AH were the type of hysterectomy to be used, the base-case
conclusion would be even firmer, unless these procedures are significantly less
effective (eg. in terms of complications) than AH. However, if 'disposable'
LAVH were compared to the non-hysterectomy forms of surgery, the base-case
conclusion would be less firm, although the cost per QALY ratios would remain
less than the lower illustrative threshold.
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6.9 Discussion
6.9. 1 Assessing generalisability in economic evaluation
It is rare to see a detailed consideration of the level of external validity
characterising an economic evaluation. This is surprising given that so many of
the data inputs in a typical analysis are specific to the context of their use, and
hence likely to be influenced by the known variations in clinical practice. The
dearth of formal analyses of generalisability is partly due to the widespread view
that economic evaluation is a 'once and for all' process; that a technology is
either cost-effective or not, and that the best way to test this is to attach an
economic analysis to a 'definitive' RCT.
In contrast, economic evaluation should be seen as an iterative process.
Sculpher et al (forthcoming) argued that economic evaluation should typically
consist of four stages. This would begin with Stage I analysis, when the
technology is first used on patients in experimental centres. This form of
analysis focuses largely on the costs and effectiveness of the standard
intervention that the new technology may seek to replace, assesses the
likelihood of the innovation proving cost-effective and hence worthy of further
comparative evaluation, and considers the key variables that would need to be
measured in any subsequent study. Stage II and III analyses re-visit the
economic assessment of the developing technology as it is used more widely and
as the volume and quality of patient-specific clinical data increase, to give a
firmer estimate of cost-effectiveness.
Stage IV economic analysis takes as a starting point that the value for money of
the new technology has been estimated on the basis Stage III studies, but
considers whether the conclusions of that work are generalisable. Hence
knowledge about the economic impact of health care technologies will take
shape over time, and it is inappropriate to cease economic evaluation at Stage III,
if the results of that analysis are likely to be sensitive to variation in parameters
which differ by location and context.
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Using the terminology of the four stages of economic evaluation, the analysis in
this chapter can be described as Stage IV assessment. The methods proposed
here to analyse the generalisability of a study would invariably use a decision
analytic framework to build upon the firm evidential basis and high internal
validity of a RCT, augmented with data taken from other sources which are likely
to reflect variation in clinical practice. The approach explicitly recognises the
trade-off inherent in clinical and economic evaluation between internal and
external validity. The RCT typically maximises the former, but often falls down
on the latter, and increasingly provides the pivotal evidence on effectiveness and
resource use for Stage III analysis (in the context of this study, the base-case
analysis in Chapter 5). Analysis of generalisability (or Stage IV analysis), seeks
to assess the external validity of a study, but will often use observational data to
achieve this.
A source of variability that particularly affects MAS technologies relates to the
swift development of the procedures over time. Given that new RCTs are
unlikely to be staged unless the changes to interventions are major, analysis of
generalisability must be flexible enough to be able to explore the economic
implications of technological developments shortly after they occur.
The extent of generalisability is one of four areas of uncertainty in economic
evaluation [Briggs et al, 19941, and this chapter can be viewed as a further
series of sensitivity analyses to those described in Chapter 5. The ultimate aim
of analysis of generalisability is to assess the robustness of the conclusions
coming out of the base-case analysis. In Chapter 5, two illustrative cost per
QALY thresholds were defined: the lower threshold (£6,500) was assumed to
represent the ratio below which most technologies would be considered cost-
effective; the higher threshold (£33,000) was taken as the ratio above which
few technologies would be considered cost-effective. Against these thresholds,
on the basis of base-case parameters, AH would probably be considered cost-
effective relative to TCRE. However, Chapter 5 showed that, although this
conclusion was robust to variation in individual parameters, this did not apply to
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simultaneous extreme variation. The aim of this chapter is to assess whether
the base-case conclusions are robust to uncertainty related to generalisability.
6.9.2 Alternative RCT results
The first analysis of generalisability considers the relative cost-effectiveness of
TCRE and AH based on two alternative sets of trial results. As discussed in
Section 6.3, for analysis of generalisability which explores the importance of
variation in clinical practice, there is value in keeping the data from the two trials
separate rather than undertaking a meta-analysis which risks masking the
variations between the studies.
The major source of variation between these trials and the Bristol RCT is the rate
of re-treatment of women randomised to TCRE. The alternative trials reported
between a 0% and 16% hysterectomy rate in these women at one year follow-
up, which can be extrapolated to 4% and 20%, respectively, at two years,
compared to 12% in the base-case analysis. This variation is not apparently due
to any differences in case-mix, and is more likely to reflect differences in clinical
practice and in patients' attitudes. The effect of the differences in the trial
results is to generate cost per QALY ratios which span the base-case estimate of
£1500 per additional QALY, with a range of £639 to £2475. If the two
illustrative cost per QALY thresholds are acceptable to purchasers, the
alternative trial would not seem to be sufficiently at odds with those in the base-
case to alter the conclusion that AH is the more cost-effective treatment.
6.9.3 Routine clinical practice
The second analysis of generalisability moves away from the frequently atypical
practice in clinical trials, and seeks to explore whether the process and outcomes
of routine care result in different conclusions about the relative cost-
effectiveness of TCRE and AH. The MISTLETOE survey offers a valuable source
of data on the routine use of TCRE; however, it is a limitation of the analysis of
generalisability that no comparable data are available for hysterectomy. The
Vaginal, Abdominal or Laparoscopic Uterine Excision (VALUE) survey currently
underway, will provide these data in due course.
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In comparing the resource and non-resource consequences of TCRE using loop
diathermy in the base-case analysis (the Bristol RCT) and that in the MISTLETOE
survey, two points can be made. Firstly, the use of TCRE seems to have
developed since the Bristol trial in 1990-1991. On average, length of hospital
stay, time in theatre and complication rates all appear to be lower in the
MISTLETOE survey. This may be partly due to the fact that case mix has
changed as clinicians make judgments about which women are more likely to
benefit from TCRE.
The second point to note is that the use of repeat TCRE was lower overall in
MISTLETOE than in the Bristol RCT although hysterectomy rates are similar, and
it may be the case that, given failure with an initial TCRE, clinicians are more
likely now to advise women to undergo a hysterectomy rather than a repeat
resection. Both of these findings affect the expected total cost of TCRE, with
the sensitivity analysis showing a 21% reduction compared to the base-case
estimates for TCRE. Comparing MISTLETOE-based cost estimates of TCRE with
the base-case (trial-based) cost estimates for AH results in an increase in the
incremental cost per additional QALY to £2167 from £1500 in the base-case, an
increase which is unlikely to be crucial for decision makers. It remains to be
seen how routine practice regarding AH influences the relative cost-effectiveness
of the two treatments.
6.9.4 Resource sparing and intensive clinical practice
The third analysis of generalisability deals with variation in routine practice in
relation to TCRE. Focusing on mean values and proportions tends to mask the
significant range in process and outcomes across hospitals. The coverage and
size of the MISTLETOE survey allows a by-hospital analysis which only the
largest multi-centre RCTs can offer. The analysis is again limited by the fact that
this detailed information on the routine use of TCRE is not yet mirrored by similar
data for hysterectomy.
MISTLETOE shows significant between-hospital variation in the process and
outcomes of TCRE: lengths of stay in hospital range from 0 (day-case) to 2 days
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for patients without complications; overall complication rates range from 0% to
12.5%; and, at one year, hysterectomy rates range between 0% and 13.64%.
Translated into expected costs, the analysis provides estimates at two-years
ranging between £458, in the most 'resource sparing' hospitals, and £814, in
the most 'resource intensive' hospitals. Although part of this range may reflect
variation in case-mix, requiring the exercise of caution when interpreting these
estimates, many of the women in the MISTLETOE survey would have undergone
hysterectomy if conservative surgical methods had not been available, and the
analysis suggests that, at some hospitals, TCRE is significantly less costly than
the base-case costs of AH over two-years. On the other hand, resource sparing
hospitals seem to be generating expected two year costs only sightly greater
than the base-case, again re-enforcing the importance of apparent recent
developments in the use of TORE.
It is possible that, in due course, the VALUE survey will identify similar variations
in the process and outcomes of hysterectomy. For example, VALUE might show
a large proportion of women undergoing surgery at some centres continuing to
consume health service resources for years after their hysterectomy. However,
clinical opinion suggests that this is unlikely to be the case and that, for most
women, hysterectomy is a 'once and for all' solution to menorrhagia. The ROT
results show a smaller variation in per patient costs of AH compared to those for
TORE, and it is difficult to see what would drive a similar variation in the two-
year costs of AH. Overall, the resource sparing and intensive analyses do not
generate cost per QALY ratios higher than the lower illustrative threshold. If the
illustrative thresholds are acceptable to purchasers, this would suggest that the
base-case conclusions are likely to be robust to the variation in routine resource
use associated with these procedures.
6.9.5 Unit costs
Analysis of Generalisability IV looks at how robust the base-case conclusions are
to variation in the unit costs of key resources. The sensitivity analysis in
Chapter 2 showed that the unit cost of a day in hospital had a marked influence
on total costs. Recently, the quality of cost data in the NHS has improved and it
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has been possible to compare the implications of using unit costs from three
different hospitals using similar costing methods. These hospitals showed
remarkable consistency in their costs: ward costs per day ranging from £83 to
£104 and theatre overheads per minute ranging from £1.96 to £2.04.
Compared to the base-case values, the hospital-specific ward costs per day
show between a 13% and 68% reduction; and the theatre costs per minute
show between a 81% and 89% increase. This has a larger downward impact on
the expected two-year costs of AH than of TCRE, but its effect is not sufficient
significantly to alter the cost per QALY ratios.
The three hospitals supplying the alternative unit costs may not be
representative of UK hospitals undertaking TCRE and AH: all three are teaching
hospitals based in large cities. As yet, however, reliable and similarly estimated
unit cost data are not available in a large number of hospitals. In time, an
important element of analysis of generalisability will be to study the robustness
of base-case results to variation in unit costs taken from a large and
representative sample of UK hospitals. As regards the AH versus TCRE
comparison, on the basis of the data considered here, the base-case conclusions
would seem to be robust to this source of variation.
6.9.6 Alternative types of surgical procedure
For many years, AH was the mainstay of surgical treatment for women with
menorrhagia whose condition had not improved adequately on medical therapy.
In the late 1980s, a range of conservative non-hysterectomy MAS options began
to be used in the NHS, most notably TCRE. The rationale for this economic
evaluation, as well as for the three published RCTs comparing TCRE and AH, is,
therefore, clear. However, inevitably, the scenario of AH as the conventional
surgical treatment and TCRE as 'the new technology' is over-simplistic, for
several reasons. Firstly, the speed with which TCRE diffused in the UK meant
that, by the time clinical evaluation using an RCT and economic analysis began,
TCRE had become a widely used procedure and, in many centres, the first-line
surgical treatment for menorrhagia. Secondly, TCRE was only one of several
conservative surgical options being used: TCRE itself took several forms (loop or
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rollerball diathermy, with or without uterine pre-thinning); laser and RF ablation
were also used in some centres. Thirdly, although the abdominal route is used
for the majority of hysterectomies, VH is used in some centres; recently,
laparoscopic methods, usually to complement VH, have been developed in a
limited number of hospitals.
It is an important component of analysis of generalisability to consider the
economic implications of the variation in the way technologies are used in
practice, as well as of the developments in procedures over time. The RCT upon
which the base-case CUA is based was undertaken in 1990-91. Since then,
TCRE has developed and new non-hysterectomy MAS procedures have diffused.
Analysis of Generalisability V, therefore, uses sensitivity analysis to adjust the
base-case parameters to estimate the costs and benefits of a range of surgical
treatments for menorrhagia. This analysis moves some way from the firm
evidential basis of the RCT underlying the base-case analysis.
The costs of the alternative forms of hysterectomy are estimated using
assumptions based on published results and clinical opinion, and their benefits in
terms of two-year QALYs are assumed to be equivalent to AH. The five non-
hysterectomy MAS procedures, although assessed using data taken from a large
survey collecting standardised information, were not necessarily used on
homogenous groups of patients, and the full array of process differences and
outcomes over which women may have preferences is not considered. This final
analysis of generalisability should not, therefore, be seen as a full economic
evaluation of all the important surgical treatments in menorrhagia; rather, it is a
sensitivity analysis to the AH-TCRE comparison in the base-case analysis, and
seeks to provide a broad-brush indication of whether variations in the two forms
of surgery will substantively alter the conclusions of the base-case.
A number of conclusions are possible from Analysis V. Firstly, the additional
costs of equipment and consumables with laser and RF ablation results in higher
overall procedure costs relative to TCRE. Furthermore, on the basis of the
MISTLETOE survey, there are no resource cost savings associated with these
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ablative treatments (eg. complications, re-treatment) to offset these additional
costs. Indeed, on the contrary, women treated by laser or RF in the MISTLETOE
survey had higher re-treatment costs than women undergoing TCRE, although
this finding must be tentative given possible differences in case-mix between the
alternative types of procedure. Hence laser and RF are unlikely to tip the
economic argument in favour of non-hysterectomy forms MAS; if anything, these
modalities are less likely to represent cost-effective alternatives to AH.
The second conclusion form Analysis V is that the three approaches to diathermy
delivery as part of TCRE (loop, rollerball or a combination), on the basis of
MISTLETOE data, do not differ sufficiently in terms of two-year expected costs
to affect the economic comparison markedly between TORE and AH. The range
of cost per QALY ratios between AH and the different forms of TCRE is relatively
narrow (incremental cost of AH per additional QALY £1500 to £2176).
The third conclusion prompted by Analysis V is that the type of hysterectomy
undertaken may alter the economic balance between hysterectomy and non-
hysterectomy surgical procedures. The shorter length of stay in hospital
generally associated with VH reduces the expected cost of this form of
hysterectomy relative to AH. On the basis of the data presented here, this
would suggest that VH is likely to make clearer the base-case conclusion that
hysterectomy is more cost-effective than non-hysterectomy forms of MAS if the
illustrative cost per QALY thresholds are acceptable: VH dominates RF and has
an incremental cost per QALY gained of between £350 and £900 relative to the
other non-hysterectomy forms of MAS. A similar conclusion is likely to apply if
'reusable' LAVH is used, although the expected two-year cost of the procedure
is similar to that of AH. On the other hand, 'disposable' LAVH is likely to result
in a higher cost of treatment than AH: the cost reduction due to a shorter length
of stay is more than offset by the additional cost of equipment and/or
consumables.
On the basis of data presented in Analysis V. 'disposable' LAVH is less likely
than VH, 'reusable' LAVH and AH to be considered more cost-effective than
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TCRE. However, all three forms of hysterectomy are likely to be considered
cost-effective relative to the non-hysterectomy MAS options if the illustrative
cost per QALY thresholds are acceptable. An important caveat is necessary
here. The analysis assumes that the process and outcomes of VH and of LAVH
would not be valued differently by women with menorrhagia. Although it is
likely that any differences in health state values between the forms of
hysterectomy are likely to be in the short-term (ie. period of convalescence)
which has only a modest effect on expected GALYs, firm conclusions about the
relative effectiveness of the procedures must await good comparative trials.
6.10 Conclusions
Figure 6.3 compares the differential cost and QALYs of non-hysterectomy forms
of surgery and AH, with the lower dotted line representing the base-case
estimate and the higher dotted line the lower of the two illustrative cost per
QALY thresholds suggested in Chapter 5. The figure shows considerable
variation in differential costs and benefits of the alternative estimates compared
to the base-case estimates. If the lower illustrative cost per QALY threshold is
acceptable to purchasers, the base-case conclusions can be considered robust to
this variation, and AH would remain a more cost-effective treatment than TCRE
(or the other non-hysterectomy forms of surgery).
The validity of this finding does depend crucially, however, on whether the
illustrative ratios have any meaning to purchasers. If these decision makers are
more concerned with minimising costs, their meaningful threshold will be the
point where one of the two treatments saves money relative to the other.
Against this threshold, TCRE would be the preferred intervention in the base-
case, and this would be generalisable based on the analyses in this chapter.
This chapter has addressed one major source of uncertainty relating to the
relative cost-effectiveness of AH and TCRE. The next chapter considers the
validity of the QALY as a measure of benefit.
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Figure 6.3 Graphical representation of the sensitivity analyses undertaken as part of
the analysis of generalisability using the cost-effectiveness plane. The
analyses all compare minimal access (non-hysterectomy) forms of
surgery with abdominal hysterectomy. The numbers relate to the
following comparisons: 1 = TCRE with loop (MISTLETOE) vs AH (base-
case); 2= TCRE with loop and rollerball (MISTLETOE) vs AH (base-case);
3 =TCRE with rollerball (MISTLETOE) vs AH (base-case); 4= laser
(MISTLETOE) vs AH (base-case); 5= RF (MISTLETOE) vs AH (base-case);
6 =TCRE (base-case) vs AH (base-case); 7 =TCRE vs AN (both Gannon
et al RCT); 8 =TCRE vs AH (both Pinion et al RCT); 9 = Resource sparing
TCRE (MISTLETOE) vs AH (base-case); 10= Resource intensive TCRE
(MISTLETOE) vs AH (base-case); 11 =TCRE vs AH (both with Hospital 1
unit costs); 12= TCRE vs AH (both with Hospital 2 unit costs);
13 =TCRE vs AH (both with Hospital 3 unit costs).
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Appendix 6.1
	 Costing guidelines given to the hospitals
providing alternative unit cost estimates
(a)	 Ward cost per day. The hospitals were asked to include the following in
their estimates:
(I)	 nursing costs;
(ii) ward disposables;
(iii) ward overheads (eg. heating, laundry) apportioned on a reasonable
basis;
(iv) hospital overheads (eg. chief executive costs) apportioned on a
reasonable basis; and
(v) ward-related capital cost.
Each finance department was asked to estimate the annual cost of a
gynaecological ward using these cost components and to calculate a cost
per day using the annual throughput of the ward in terms of bed days.
(b)	 Theatre cost per minute. The foffowing components of cost were to be 	 1
included in the estimation of theatre costs:
(I)	 theatre-related capital costs;
(ii) theatre overheads (eg. heating) apportioned on a reasonable
basis; and
(iii) hospital overheads apportioned on a reasonable basis.
As described in Chapter 3, the remainder of the major theatre costs - for
example, the cost of medical and nursing staff, anaesthetics,
consumables and non-standard equipment required specifically for TCRE -
were estimated separately, and are not subject to the same variation
between hospitals. Again, the hospitals were asked to estimate an annual
cost and to calculate the cost of a theatre minute by dividing the annual
cost by a measure of throughput in patient minutes.
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Appendix 6.2
Analysis of generalisability
Details of the adjustments made to the unit
costs of TCRE with the loop diathermy and AH
to estimate the unit costs of the alternative
procedures assessed as part of Analysis of
Generalisability V
The costs of the alternative procedures have been estimated by adjusting the
unit cost of TCRE with loop diathermy, for the non-hysterectomy forms of MAS,
and of AH, for the alternative forms of hysterectomy. As explained in Chapter 3,
the base-case cost analysis makes a distinction between standard equipment
that will be available in most theatres as a matter of course (eg. a diathermy
generator), and non-standard equipment which will not, because it is related
specifically to the new procedure being evaluated. In the base-case analysis, the
non-standard equipment, such as the telescope, camera and xenon light source
used as part of TCRE, were costed separately and added to the capital cost of
standard equipment which was included in the theatre overheads. For the
purposes of this analysis of generalisability, the distinction between standard and
non-standard equipment is maintained.
Table A6.1 details the assumptions that have been used to make the
adjustments to the base-case procedure unit costs. It is assumed that the fixed
cost (non-standard equipment and consumables) and the variable cost per minute
(staff, overheads and anaesthetics) of TCRE are the same whether the loop,
rollerball or a combination of diathermy methods is used. Similarly, it is assumed
that the fixed and variable costs per minute of VH are the same as for AH.
Table A6.1 shows that the main adjustments to the cost of a TCRE procedure, in
order to estimate the cost of laser and RF ablation procedures, are the changes
in equipment and consumables. The adjusted cost for a laser ablation procedure
involves the added cost of an Nd:YAG laser and laser fibres, but no cost of loops
is incurred. The adjusted cost of a RF ablation procedure requires the additional
costs of a generator, probe set and abdominal guard, but the endoscopic
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Table A6.1
	
Analysis of Generalisability V: adjustments made to the base-case unit costs of
TCRE and AH procedures in order to estimate the unit costs of alternative
surgical procedures
Cost
component
LAVH (Disposable) LAVH
(Reusable)
No changeAddition of ODA to
power laser
No change
No change
Use of saline instead of
glycine; use of re-
usable laser fibres; no
loop required
Use of Nd:YAG laser
(costing £56,400,
annual maintenance of
£4,250; an expected
useful life of 10 years
and an estimated
annual throughput of
250); no working
element or sheath
No change
No change
No change
Use of probe set
and abdominal
belt; no loop
irrigation tubing,
catheter or glycine
Use of memostat
generator and
cable set (cost
£47,000, annual
maintenance of
£4759, an
expected useful
life of 10 years
and an estimated
annual throughput
of 250); no other
specialised
equipment
No change
No change
No change
Addition of primary
trocar and canula; 2
more trocars; 5.5mm
converters x 3;
endograspers ;
endosheers; endo-GIA;
3 extra staples; suction
tubing
Use of laparoscope,
telescope; camera;
beam spitter; cable;
xenon light source;
monitor (all assumed to
last 5 years with an
estimated annual
throughput of 1500)
No change
No change
No change
Addition of
trocars and
portals x 4;
bipolar
forcepts x 2;
scissors x 2;
graspers x 2;
cannulae (all
assumed to
last 5 years
with an
estimated
annual
throughput of
250). Use of
telescope
laparoscope;
camera; beam
spitter; cable;
xenon light
source;
monitor (all
assumed to
last 5 years
with
throughput of
1500)
•	 All adjustments made are to TCRE with loop diathermy (as in base-case)
t	 All adjustments made are to AH (as in base-case)
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equipment used as part of TCRE is not required, as the procedure is undertaken
'blindly'. Apart from the cost of an ODA to power the laser, the variable costs
per minute of staff, theatre overheads and anaesthetics are assumed to be the
same for a laser and a RF ablation procedure as for a TCRE.
Adjusting the cost of AH to estimate the cost of a LAVH procedure involves the
added costs of non-standard equipment and of consumables. On the basis of
clinical advice, there appears to be considerable variation in the specific
consumables and equipment used as part of LAVH. Perhaps the most important
source of variation is in the choice of re-usable equipment rather than disposable
consumables for specific parts of the procedure. In practice, hospitals are likely
to use a mix of re-usable and disposable hardware. However, for the purposes
of the current analysis, two indicative procedure costs are estimated: a 're-
usable' LAVH and a 'disposable' LAVH. In order that these two procedure costs
reflect clinical practice in terms of assumptions about hardware, two clinicians
were interviewed to acquire details of the equipment and consunydthes
during a typical LAVH in their hospitals, one describing their hospital's policy as
're-usable', the other describing their hospital's practice as 'disposable'. Table
A6.1 describes the equipment and consumables used as part of these two forms
of LAVH, which are additional to AH. As for the base-case analysis, all
equipment and consumables have been costed using manufacturers' list prices
including VAT.
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A Cost-Utility Analysis of AH Versus TCRE
Using An Alternative Measure of Benefit
7.1	 Introduction
The existence of clear trade-offs between MAS and conventional open surgery in
the process and outcomes of care, and the fact that patients are likely to have
preferences over these trade-offs, indicates that CUA is likely to be the most
appropriate framework within which to assess these two categories of
technology. However, it is unclear whether CUA using standard QALYs can
adequately reflect patients' preferences about the process and outcomes of care.
In recent years, alternative benefit measures have been proposed for use in CUA
which may more adequately reflect patients' preferences.
The purpose of this chapter is to review the literature on the theory of benefit
measurement in CUA and to consider one of these alternative measures of
benefit in the context of AH versus TCRE. This element of the thesis can be
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viewed as a further assessment of the uncertainty associated with the base-case
analysis of the alternative surgical treatments for menorrhagia detailed in Chapter
5, this time focusing on the analytical uncertainty related to the measure of
benefit adopted.
Section 7.2 of this chapter reviews the literature which has recently developed in
this field. The remainder of the chapter reports the results of an exercise
undertaken to elicit one alternative benefit measure from a sample of women
with menorrhagia - ex ante healthy years equivalents (HYEs). The aim of the
exercise was to assess whether ex ante HYEs are consistent with individual
preferences, and whether their use alters the conclusions of the base-case
results of the CUA in Chapter 5. Section 7.3 details the methods used to elicit
these values, to assess their consistency with women's descriptive preferences
and to incorporate them into the CUA. Section 7.4 reports the results of the
analysis, Section 7.5 provides a discussion and Section 7.6 offers some
conclusions.
7.2 The theory of benefit measures in cost-utility analysis
7.2.1 The standard QAL Y model based on TTO values
An important aspect of the QALY has been its relationship to individuals'
preferences about the relative desirability of different health states [Drummond
et al, 1987], and hence of alternative technologies. To reflect individuals'
preferences it is necessary for treatments generating more QALYs to be
preferred by individuals' over those producing fewer QALYs. However, this link
between the standard QALY and preferences is based on some important
assumptions about the individual's utility function [Pliskin et al, 1980; Loomes
and McKenzie, 1989; Johannesson, 19951.
In Chapter 5, it was argued that evidence is now available indicating that, in
practical terms, the time trade-off (TTO) is preferable to the standard gamble
(SG) as a choice-based measure of the health state values necessary to estimate
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QALYs. Much of this evidence has been generated by the York Measurement
and Valuation of Health project [Williams, 1995], which is the largest health
state valuation exercise undertaken in the UK. The TTO has probably been the
most widely used of the choice-based instruments in the UK, based largely on its
perceived practical advantages. In general terms, the standard TTO-based
QALY is derived in the following way.
(a) Plausible health profiles (prognoses), following from alternative forms of
patient management, are decomposed into a series of discrete health
states.
(b) These health states are valued independently. Sometimes a distinction is
made during the valuation process between temporary and chronic health
states.
(c) The period of time in a given health state is multiplied by its value.
GALYs are calculated by summing these products over the duration of the
patient's survival (or over the time horizon of the study). This process
may involve discounting QALYs generated in future years.
(d) Uncertainty may be incorporated into this process by calculating a series
of QALY profiles and attaching a probability to each. Expected QALYs
are calculated by multiplying each QALY profile by its relevant probability
and summing across all the profiles.
The QALY estimates in Chapter 5 were derived in this way, as were the benefit
estimates of most other CUAs using the TTO instrument [Gerard, 1992; Daly,
1993; Sculpher et al, 1996B; Cook et al, 19941. For the standard QALY based
on TTO values to represent individual preferences adequately, however, the
following assumptions are necessary.
Risk neutrality with respect to life-years for all health states. The TTO
instrument measures health state values under conditions of certainty - that is,
the outcomes are known for sure. In practice, uncertainty exists in most areas
of medical practice. In the context of the treatment of menorrhagia, women face
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uncertainty in relation to such factors as the mortality associated with surgery
and the need for re-treatment following TORE. If uncertainty exists in the
decision context, the only way the standard QALY derived using the TTO can
reflect preferences is if individuals are risk neutral over life-years for all health
states [Johannesson, 1995].
Several studies in the area of health care, however, have shown that patients do
not exhibit this risk neutrality. McNeil et al [1978] interviewed 14 patients with
operable lung cancer and explored their attitudes to treatments with different life
expectancy probabilities. On the basis of a series of standard gamble exercises,
which were used to elicit patients' certainty equivalents, the authors found the
patients were generally highly risk averse.
Eraker and Sox [1981] looked at a series of hypothetical decisions individuals
made related to drug therapy. Individuals were asked to choose between two
drugs the outcomes of which were described in terms of life expectancy, one
had a certain outcome and the other an uncertain outcome. Using a series of
gambles, the investigators found that, even when the expected outcome detailed
in the scenarios was the same for both drugs, the respondents chose the therapy
with the certain outcome, indicating risk aversion. However, when the scenarios
were framed differently, in terms of loss in health status rather than gain, the
individuals were found to be risk loving, choosing the option with the uncertain
losses. Either way, the study found no evidence of risk neutrality.
Individuals' preferences regarding future survival and health status exhibit
constant proportional trade-off. This means that an individual is willing to
sacrifice a constant proportion of their remaining period of survival to acquire a
given improvement in health status, whatever the absolute number of life-years
that remain. For example, a person who is indifferent between 20 years in their
present health state and 10 years in perfect health would be assumed also to be
indifferent between 10 years in their present health state and 5 years in perfect
health.
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Little evidence exists to support this assumption. McNeil et al [1981)
investigated the attitudes of 37 healthy volunteers towards the trade-off
between quality and quantity of life associated with laryngeal cancer. They
found evidence to contradict the constant proportional trade-off assumption:
although respondents accepted some trade-offs, they refused to trade quantity
for quality when survival was down to five years.
As part of their theoretical analysis of the QALY concept, Pliskin et al [1980)
used a questionnaire to explore how 10 academics traded-off survival and quality
of life associated with angina. Various questions were asked to assess the
minimum number of years of baseline survival respondents would sacrifice for a
given improvement in quality of life. Out of 30 questions asked in the
questionnaire, only nine answers supported an assumption of constant
proportional trade-off. Furthermore, five of these nine answers indicated that the
respondent was not willing to trade-off any survival time for an improvement in
quality of life. When these respondents are removed, only four out of 25
answers were consistent with constant proportional trade-off.
Another way of conceptualising this assumption is that the value an individual
attaches to a health state is independent of the time spent in that state.
Although empirical studies have struggled to distinguish the separate effects of
time preference and duration on health state values [Dolan and Gudex, 1995],
this is again generally not supported by the evidence. On the basis of interviews
with 246 members of the general public and 29 individuals undergoing home
dialysis, Sackett and Torrance [1978] elicited TTO values for 10 health states,
each of which respondents were to imagine lasting for between one and three
time durations. They found a strong statistical relationship between value and
duration: the mean value of each health state declined as duration in that state
increased. The authors concluded that 'the duration of time that patients will
spend in a specific health state must be considered when assessing the utility, as
well as the cost, of health care programs' (p703).
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A study by Sutherland et al [1982] also casts doubt on the assumption of health
state values being independent of time. A sample of 20 physicians and
scientists was asked to rate five health state scenarios using a simple preference
statement and a certainty equivalence exercise. The authors found that, as the
duration of time in some states is increased, the values of these states change
dramatically. Their findings caused them to suggest the concept of 'maximal
endurable time'; that is, a time period within a health state beyond which
individuals radically change their attitude towards that state.
A more recent study also raises questions about the validity of this assumption.
As a sub-study within the York Measurement and Valuation of Health Study,
234 members of the public were interviewed and presented with details of 15
health states based on the EuroQol classification [Dolan, forthcoming]. The
respondents were asked to value each oi the states k.1SW1 a NAs‘sak ZSYMWIt
scale, imagining the states to last for three alternative durations: 10 years, one
year and one month. The values individuals attached to dysfunctional health
states were found to decrease as duration increased; that is, the states became
increasingly intolerable as the time spent in them increased.
A study by Hall et al [1992] contradicts this evidence, however. On the basis of
104 interviews with healthy women and women with breast cancer, the authors
used the TTO to explore the effect of life expectancy on the values women
attached to life time health profiles associated with breast cancer. They found
no association between the values and life-expectancy.
Individuals' valuations of a given health state are independent of the
health states that precede or follow it. An important characteristic of the
standard QALY model is that, to represent a given prognosis, a QALY estimate is
based on a summation of health state values over time. This additive model can
be expressed as in Equation 7.1 below:
T
Standard QALY = E u (qt)
	 (7.1)
t=1
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where T is the time horizon of the analysis and u(q t) is the value associated with
the health state q in time period t. This process of dividing a prognosis (or
lifetime health profile) into a number of independently valued units is most
obviously a key part of valuation systems such as the Quality of Well Being scale
[Kaplan and Anderson, 1990], the Rosser matrix [Kind et al, 1982)], the EuroQol
(EuroQol Group, 1990; Brooks, 1996) and the Health Utilities Index [Torrance et
al, 1982; 1996]. However, virtually all CUAs using CIALY are founded on this
assumption. In the CUA in Chapter 5, for example, the estimated QALYs for
TCRE are the sum of several health states over time.
The assumption of additive independence too must be doubted if the value an
individual attaches to their current health state is affected by the sequence of
health states they experience; that is, by what comes before and after the
current health state. Related to this, an individual may attach a different value
to a health state if they feel that their current health state will affect future
health status. For example, the value attached to a health state involving severe
pain after surgery, but which is followed by recovery, is likely to be quite
different to the value associated with the same health state followed by death.
Although additive independence may have little intuitive appeal, there is little
evidence to support or to reject it. The Sutherland et al [1982] study referred to
above does cast doubt on the assumption, as the concept of 'maximal endurable
time' means that health states cannot be valued in isolation without considering
health status in other periods [Bleichrodt, 1995].
A study by Richardson eta! (1989 and 1996) casts doubt on both the time and
sequence assumptions of the standard QALY. The authors constructed a series
of scenarios related to breast cancer that referred to a relatively short time
duration, and a health state profile which effectively linked the three and
introduced a time element into a single scenario. Using the TTO, SG and a visual
analogue scale with a sample of 63 women, the authors elicited values for each
health state and for the profile. They then tested whether the construction of a
standard (or composite) QALY, by multiplying the individual health state values
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by their relevant duration and aggregating those products, produced a similar
result to that implied by the answer to the TTO for the profile. They found that,
using some typical discount rates, the composite or standard approach to GALY
estimation produced quite different results to that for the profile (31% to 57%
discrepancy). Furthermore, it was not possible to identify a plausible discount
rate that would produce the same QALY estimates for both approaches. This
result could indicate that duration and/or sequence affects health state values.
7.2.2 Alternative approaches to CUA I: the standard QALY model based
on standard gamble values
If doubts are cast on the link between the standard TTO-based QALY employed
in Chapter 5 and patients' preferences, alternative approaches to benefit
estimation for CUA might be considered. One alternative is to use the SG
technique to elicit health state values (or utilities in the case of the SG). The
rationale for the use of the TTO in the base-case CUA was detailed in Chapter 5,
and centred on the practical advantages of the TTO identified in the York
Measurement and Valuation of Health study [Williams et al, 1995], as well as the
fact that evidence indicates that the TTO and SG seem to generate similar values
[Krabbe et al, 1996]. However, if the SG overcomes the likely difficulties of
relating QALYs with individual preferences, its use may be more appropriate than
the TTO.
The SG has been used widely in CUA, largely because it is seen as the technique
with the strongest theoretical foundation, being based on the axioms of von
Neumann-Morgenstern expected utility theory [Gafni, 1994]. Indeed, it would
seem reasonable to retain the term 'standard QALY model' if the SG is merely
substituted for the TTO.
However, there are a number of problems associated with the SG. It is true that
its use to calculate QALYs will, in theory, enable part of the assumption of risk
neutrality discussed in Section 6.2.1 to be removed from the link between that
standard QALY and individual preferences. As the SG is based on von-Neumann-
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Morgenstern axioms, which is a theory of decision making under uncertainty, it
is frequently argued that the SG health state values reflect individuals' attitude
to risk and uncertainty in a way that TTO values do not [Gafni et al, 1993].
However, although the SG, in theory, generates health state values that reflect
individuals' risk attitudes, the life-years element of the standard QALY is not
incorporated into the valuation process, and, in practice, risk and uncertainty
clearly relates to survival as well as to health-related quality of life (HRQL). So
the standard QALY based on the SG, at best, only partially reflects individuals'
risk attitude. The standard QALY is a product of a value (or a utility) function
where health status is the only argument, and an estimate of life-years is left in
natural units.
Pliskin et al [1980] referred to this version of the standard QALY model as the
risk neutral (RN) QALY. Whether the TTO or the SG is used to value health
status, the life-years (quantity) element of the QALY will not reflect individuals'
attitude to risk. Hence, the only way individual preferences can coincide with
the RN QALY is if the individual is risk neutral with respect to life years. The
evidence reviewed in Section 7.2.1 suggests risk neutrality as regards decisions
in the health area is likely to be the exception rather than the rule. Furthermore,
in order to reflect individual preferences, the SG-based QALY still requires the
same assumptions as TTO-based QALYs. In addition to risk neutrality with
respect to life-years, constant proportional trade-off must exist, and there must
be independence between health state values and the sequence of health states.
Moreover, a crucial further assumption is required; namely, that the theoretical
foundations of the standard gamble are valid. The strength of the SG is usually
considered to be its strong links with economic theory, namely the axioms of
von-Neumann-Morgenstern expected utility theory. However, this theoretical
foundation has been criticised on several levels. At a theoretical level, it has
been claimed that the SG does not, in fact, incorporate risk attitude and is
theoretically equivalent to values elicited under conditions of certainty [Bouyssou
and Vansnick, 1988]. A further criticism at a theoretical level was made by
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Richardson [1994] who argued that, although risks are used as part of the SG
technique, this is not adequate fully to elicit individuals' risk attitude. This is
because the risk of instant death in the SG is unrealistic, with the real risks faced
by patients relating to such things as surgical complications. Richardson further
criticised the key outcome of the SG, namely the value of p; that is, the
threshold probability of death which makes an individual indifferent between a
gamble involving immediate death and perfect health and a certainty of a
dysfunctional health state for the remainder of their life. Richardson argued:
'The value of p in the SG depends primarily upon the unpleasantness of
the health state, S. which is described under conditions of certainty. In
reality, S may occur in conjunction with very significant uncertainty or
with negligible uncertainty. Yet the same SG is believed to capture the
essence of both risk contexts. Clearly p cannot reflect real-world
uncertainty when information about the nature and magnitude of this is
not given to subjects' (p17I.
Much attention has been given to exploring, empirically, the performance of the
von Neumann-Morgenstern expected utility theory in explaining individuals'
observed behaviour under conditions of uncertainty. In his extensive review of
the theory and evidence relating to expected utility theory, Schoemaker [1982]
considered four areas of empirical evidence on the theory: tests of the axioms;
field studies of how individuals make decisions under conditions of uncertainty in
the real world; individuals' ability to process information to facilitate 'rational'
decision making under uncertainty; and the importance of context in decision
making. Schoemaker concluded that, in certain specific situations, expected
utility theory may predict behaviour well; for example, large corporations may
use it as a matter of policy in some contexts. However, in general, the theory
fails in three ways:
'First, people do not structure problems as holistically and
comprehensively as EU (expected utility) theory suggests. Second they
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do not process information, especially probabilities, according to the EU
rule. Finally, EU theory, as an "as if" model, poorly predicts choice
behaviour in laboratory situations. Hence, it is doubtful that the EU
theory should or could serve as a general descriptive model' (p552).
Even if the axioms of von Neumann-Morgenstern expected utility theory have a
poor predictive record in terms of individual behaviour under conditions of
uncertainty, it may have a normative role: a theory about how rational decisions
should be made. Richardson [1994] argued that, at this level too, expected
utility theory is flawed. He argued that 'if an outcome is sufficiently unpleasant,
it is not irrational to adopt a rule that avoids the outcomes or, perhaps, to adopt
a rule that maximises the value of the worst possible outcome' (p12).
It can be argued that the limitations of von Neumann-Morgenstern expected
utility theory result in the SG having no stronger a theoretical basis than the
TTO. In which case, the practical problems of using the SG discussed in Chapter
5 may support the use of the TTO as the major valuation instrument for CUA.
7.2.3 Alternative approaches to CUA II: the risk-adjusted QAL Y
A major movement away from the standard QALY is represented by the risk-
adjusted (RA) QALY, a concept introduced by Pliskin et al [1980] as part of a
theoretical framework for the QALY. The rationale for the RA QALY is to
overcome the problem with the standard QALY, as discussed in Sections 7.2.1
and 7.2.2, that it inadequately takes account of individuals' risk attitude. In the
case of QALYs based on TTO health status values, risk attitude is captured in
neither the health status nor the life-years elements of the calculation. In this
case, the RA GALY is shown in Equation 7.2:
RA QALY (TTO) = (1-1(Q) .TY	 (7.2)
In Equation 7.2 r is known as the risk aversion parameter. If the individual is risk
neutral then r =1 and equation 2 collapses to the standard QALY shown in
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Equation 5.1 in Chapter 5. If r<1 or r>1, the individual is risk averse or risk
seeking, respectively.
As health state values elicited using the SG are, theoretically at least, taken as
reflecting individuals' attitude to risk, the risk aversion parameter applies only to
life years, as shown in Equation 7.3:
RA QALY (SG) = H(Q) .Tr	(7.3)
The major assumption required to link the RA QALY with individual preferences
is that individuals need to exhibit constant proportional risk posture over life
years for all health states.
Empirically, r can be estimated using the method of certainty equivalence (McNeil
et al, 1981), where individuals are asked to state the number of years of future
life at which they would be indifferent between those years with certainty and a
gamble involving a risk of immediate death and a counter risk of full survival.
The empirical work hitherto undertaken on estimating the value of r to risk-adjust
QALYs has been largely developmental. Pliskin et al [1980] applied their model
to the evaluation of coronary artery bypass grafting. Using small numbers, they
concluded that 'on the basis of these preliminary findings it appears that the
mathematical form used to represent utilities gives internally consistent results
and is suitable for further work' (p219).
Miyamoto and Eraker (1985) further developed Pliskin et al's RA QALY model
and, on the basis of certainty equivalent exercises with 46 individuals with
coronary artery disease, the authors concluded '....that the model deserves
consideration as a medical utility model, despite some preliminary evidence that
assumptions of the model are descriptively false, because it provides a simple
representation of the utility of survival duration and health quality' (p191).
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One of the implications of the RA QALY is that TTO health state values can be
adjusted, using the risk aversion parameter, to become equivalent to SG values;
that is, SG =TTO` • Shiell et al [1995] tested this particular aspect of the model
on the basis of 119 interviews with women with early stage breast cancer.
They found a correlation coefficient between the risk-adjusted TTO and the SG
or 0.65-0.72, and concluded that it was not possible to reject the null hypothesis
of equivalence between these two measures.
The RA QALY only addresses one limitation of the standard QALY model; that is,
the failure to incorporate risk attitude into the life-years element (for SG-based
QALYs) or into either element (for TTO-based QALYs). Hence the other major
assumptions needed for QALYs to reflect individual preferences are still needed -
in particular, constant proportional trade-off and independence of health state
values with respect to time and sequence. Furthermore, the RA-0.ALY is rooted
firmly in the axioms of von Neumann-Morgenstern expected utility theory which,
as discussed in Section 7.2.2, has some major limitations.
7.2.4 Alternative approaches to CUA III: healthy-years equivalents based
on the SG
A major recent development in CUA, at a theoretical level, has been the proposal
of an alternative outcome measure: the healthy-years equivalent (HYE). The HYE
was introduced by Mehrez and Gafni [1989] as a way of tying the outcome
measure used in CUA more firmly to individual preferences. It sought to do this
by avoiding the strongest assumptions of the standard QALY model; in
particular, that of risk neutrality (per se with the TTO and with respect to future
life-years with the SG), constant proportional trade-off and the independence of
health state values from duration and from the sequence of states. The HYE
retains the QALY's purpose of incorporating the impact of a technology on both
the quantity and quality of life, and maintains the QALY's intuitive appeal for
decision makers but, its originators claim, it is more firmly tied to utility theory
[Mehrez and Gafni, 1989 and 1991].
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The HYE can be defined as in Equation 7.4:
U(QT) = U(Q* , HYEs)	 (7.4)
where U( . ) is a utility function, T is a patient's future years, Q represents a level
of health status (or HRQL) considered less desirable than full health and Q* is
perfect health status. Hence the HYE can be defined as 'the hypothetical
combination of years in a state of full health, which is equal, in terms of the
individual preferences (utility), to the patient's current projected lifetime health
profile' [Mehrez and Gafni, 1989, p143].
Mehrez and Gafni suggest that the HYE should be measured using a two-stage
lottery based on the SG. They offer an algorithm for the measurement of a
chronic health state, and for the case of many possible lifetime health profiles
[Mehrez and Gafni, 1991]. In brief, the first part of the two-stage lottery is
similar to a conventional SG and asks the respondent to select the probability
(p*) that makes them indifferent between a gamble involving perfect health for
the rest of their life and immediate death, versus the certainty of a less than
perfect health state over a period of time. In the second stage of the lottery, the
gamble is similar to that in the first stage, but p* is taken as a fixed probability
of perfect health for a lifetime ((1-p*) being the risk of immediate death). The
respondent is asked to indicate the number of years in perfect health with
certainty with which they would be indifferent to the gamble.
Mehrez and Gafni argue that the HYE offers a means of avoiding the restrictive
assumptions of the QALY. Furthermore, they argue that, because HYEs are
elicited under conditions of uncertainty using the two-stage lottery process,
HYEs will reflect individuals' attitudes to risk. An important further theoretical
advantage of the HYE is that it makes unnecessary the rather arbitrary process
of discounting benefits in economic evaluation using a small constant discount
rate. Discounting of benefits is well established in economic evaluation despite
evidence that the conventional exponential discount model does not adequately
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describe individuals' behaviour [Loewenstein and Prelec, 1993; Redelmeier and
Heller, 1993; Dolan and Gudex, 1995]. Indeed, it has been argued that it is
simply not possible to measure empirically individuals' pure time preference,
because it is not possible to divorce it from other preferences, such as that over
sequences of events [Gafni, 1995].
In eliciting HYE responses, individuals are presented with time profile
information, so their intertemporal preferences are incorporated into their values.
Hence, there is no need separately to adjust benefit measures using a discount
rate. Not only does this avoid the need to estimate pure time preference rates
by isolating this form of preference from others, but variation between
individuals in their intertemporal preferences can be registered directly in the
economic evaluation.
The HYE offers, at the theoretical level at least, an extra degree of flexibility over
the standard QALY. However, the HYE has been associated with considerable
controversy, focusing in particular on the two-stage lottery measurement
technique. Several commentators have argued that, in using the two-stage
lottery, the HYE is effectively no different to the TTO [Buckingham, 1993;
Johannesson et al, 1993; Johannesson, 1994; Culyer and Wagstaff, 1993 and
1995; Loomes, 1995]. In brief, this argument is based on the fact that the
gamble elements of both stages of the lottery are identical and cancel each other
out. What is left is the result of a TTO question: indifference between a period
of time in less than perfect health and a shorter period of time in full health.
Related to this point, it has also been suggested that the HYE does not reflect
individuals' attitude to risk. Johannesson et al [1993] argued that the equal and
opposite effects in the two-stage lottery result in risk attitude being eliminated
from HYE values. They argue: 'the net result, combining the two stages, would
be the same for both the risk-averse and risk-neutral individual, because the final
comparison is made under certainty in the form of a time trade-off' (p284).
Mehrez and Gafni [1993] refute the claim that the HYE elicited using the two-
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stage lottery is merely a TTO. They argue that the SG generates utilities and the
TTO produces values and that these need not necessarily be equal. Shiell et al
[1995] set out to assess empirically whether HYEs are equal to the values
implied by the results of TTO exercises. On the basis of interviews with 119
women, the authors concluded that the two measures did not produce equivalent
results.
Although it can be argued that the HYE offers a theoretical advance over the
standard QALY, it does so at the cost of increasing the burden of the valuation
tasks appreciably. The increased use of CUA as a tool of economic evaluation
has been facilitated partly by the development of health state valuation systems.
The advantage of this has been that patients' lifetime prognoses can be divided
into a series of health states each of which is, as closely as possible, related to a
set health state in a valuation system. A standard QALY is, therefore, calculated
by weighting a patients' time in each health state by the appropriate value, and
aggregating across their lifetime (or the relevant time horizon of the evaluation).
This process is ideal for CUA based on decision analytic models like the decision
tree or the Markov model, of which the 'segmentation' of prognoses into
separate health states is a fundamental part [Weinstein et al, 1980; Sonnenberg
and Beck, 1993].
Of course, this approach to CUA produces the standard QALY that the HYE is
trying to improve upon, and rests crucially on the assumptions of constant
proportional trade-off and the independence of value from duration and
sequence. By avoiding these assumptions, the HYE looses the flexibility of the
standard QALY, particularly in decision analytic models. In order to use the HYE
within a CUA of a technology which involves a large number of possible lifetime
pathways (or profiles), in principle, each pathway needs to be translated into a
HYE using the two-stage lottery. How the HYE approach could be incorporated
into a CUA Markov model is not clear, as the model itself determines the lifetime
profiles.
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QiT
Treatment A
Treatment B
(1-P2)
Figure 7.1	 A hypothetical decision tree illustrating the choice between two
treatments (source: Gafni eta!, [1995])
Gafni eta! (1995) have responded to the suggested valuation burden and
inflexibility of the HYE, and to the argument that it fails to reflect individuals' risk
attitude. They have developed a two-stage lottery for use with decision trees,
and extended the HYE concept by developing, what Johannesson [1995] has
termed, the ex ante HYE. Figure 7.1 shows a hypothetical decision tree
illustrating a choice between two treatments, A and B. Each pathway has a
probability (Pi) and a lifetime health profile 'T- The ex ante HYE is estimated as
follows. Firstly, a conventional SG is used to find the utility [U(Qi-r)] of each
pathway in the tree. Secondly, the expected utility of the two treatments is
calculated by, for each treatment, multiplying the utility of each arm with its
probability and summing the two arms. The expected utility of each treatment
will be a number between 0 and 1. Finally, the expected utility (EU) is used as a
probability in a lottery. Taking treatment A as an example, the respondent is
asked to compare a gamble involving a chance of a lifetime in perfect health with
a probability of EUA and a chance of immediate death with probability (1-EUA).
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The individual is asked to select a period of time in perfect health with certainty
that would make them indifferent between that and the gamble. The outcome of
this is an ex ante HYE for the two treatments.
As well as indicating how HYEs could be used with a decision tree model, Gafni
et al [1995] were responding to Johannesson et ars [1993] charge that HYEs
fail to incorporate individuals' attitude to risk. This is because the final part of
the above estimation procedure involves asking respondents to select a certainty
equivalent period of time they consider equivalent to a risky prospect. Of
course, the link between ex ante HYEs and individuals' risk attitude depends
crucially on the validity of the axioms of expected utility theory.
In order to use HYEs with decision trees, however, the valuation burden is a
major consideration. It remains the case that each feasible outcome profile
needs to be valued separately. Gafni et al [1995] argue that the use of HYEs
reduces the number of valuation tasks required because, by using profiles rather
than a series of separate health states, fewer values are required. The
disadvantage of this, though, is that the health profile descriptions are likely to
be quite complex. Furthermore, HYE values have to be estimated for each study
undertaken, and there is no apparent role for standardised and previously-valued
health states as provided by the valuation systems for estimating standard
QALYs.
7.2.5 Alternative approaches to CUA IV: healthy years equivalents based
on the TTO
The concept of the HYE is clearly very close to that of the TTO; that is, a period
of time in perfect health considered equivalent to a longer period of time in a
dysfunctional health state. Although the SG has been the focus for discussion
about the measurement of HYEs, the TTO can be used directly for this purpose.
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A hypothetical probability tree showing four health state profiles
involving a series of transitory health states
The conventional way to use the TTO as part of CUA is, as described in the
context of AH and TORE in Chapter 5, to estimate a value on a 0-1 scale for
each relevant health state, and then to use those health states in the standard
QALY model (ie. multiplying the value of a health state by a patient's duration in
that state). However, the TTO can be used to value health state profiles in
terms of HYEs. As for SG-based HYEs, TTO-based HYEs can be developed in an
ex post or ex ante form.
To describe the ex post HYE, consider Figure 7.2. The figure shows a
hypothetical probability tree relating to some form of surgery. The patient can
pass through one of four pathways (or profiles) with a given probability, where
each profile is made up of a number of transitory health states relating to such
things as complications and treatment failure. To represent the probability tree
in terms of the standard QALY model, each of the transitory health states would
be valued so that, for example, the post-operative health state received the same
value regardless of its duration or its position in the sequence. Each profile
241
Chapter 7	 Alternative benefit measures in CUA
would then be given a QALY score by multiplying the value of a health state by
its duration, and then summing across the profile. With ex post HYEs, however,
raters would be presented with four descriptive scenarios, one for each profile.
These scenarios would detail each transitory health state and their respective
durations, and the rater would be asked to state a period in full health that they
would consider equivalent for each of the four profiles (ie. they would provide
four HYE estimates).
The only published CUA based on the TTO-based ex post HYE that has been
identified in the literature was undertaken by Hall et al [1992]. As part of an
economic evaluation of mammography screening, 104 women were presented
with a range of breast cancer-related scenarios. The scenarios described health
state profiles which differed according to type of surgery, physical health and
mental health. Ex post HYEs were derived for each profile using the TTO. As
the 95% confidence intervals around the mean values overlapped for some of
the profiles, the six profiles were divided into two broadly similar groups which
were termed 'good health' and 'poor health', and mean values were allocated to
each. These two general profiles were then used in a CUA model. The expected
HYEs resulting from screening and no screening were calculated by multiplying
the HYEs for each profile by the probability of a given woman following that
profile. Expected HYEs were then related to expected costs in the form of a
cost-utility ratio.
The ex post HYE based on the TTO exercise has the strength that it avoids the
strong assumptions of constant proportional trade-off and of values being
independent of time and sequence, which are necessary with the standard
QALY. However, the HYE values will not incorporate the risk attitude of raters.
The TTO exercise follows the usual approach of being undertaken under
conditions of certainty. The incorporation of risk, in terms of an expected HYE,
is undertaken outside the valuation exercise and, unless individuals are risk
neutral with respect to life-years, the ex post HYE is unlikely to equate with the
HYE chosen if the raters were aware of the risks involved.
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To overcome this problem, the TTO can be used to elicit ex ante HYEs which
reflect individuals' attitude to risk. This involves presenting raters with
descriptions, not only of all the possible lifetime profiles associated with an
intervention, but also of the probabilities associated with those profiles. With
reference to Figure 7.2, the TTO-based ex post HYE would require four separate
TTO exercises, one for each profile, with information on probabilities not
provided. The TTO-based ex ante HYE, however, would require each of the four
profiles to be detailed in one scenario, together with their respective
probabilities. This process is similar to the conventional certainty equivalent
exercise used in earlier studies [Riskin eta!, 1980; McNeil eta!, 1981], except
the range of possible outcomes presented to the rater could, in principle, be very
large.
The advantage of the TTO-based ex ante HYE is that it requires few of the
assumptions associated with the standard QALY and the other alternative
outcome measures. Like other forms of the HYE, it avoids assumptions about
constant proportional trade-off, and sequence and duration independence.
Because risks are incorporated directly into the descriptive scenarios, raters'
responses should reflect their attitude to risk and, unlike the SG, in a way that
relates directly to the intervention in question. Furthermore, the TTO-based ex
ante HYE does not require that the axioms of expected utility theory are
theoretically, descriptively or normatively valid, as do HYEs based on the SG.
Another advantage of the TTO-based ex ante HYE is that is asks directly the
question which is at the heart of the QALY and of the HYE: what period in good
health is considered equivalent to a longer period in dysfunctional health. Hence
it is possible to get at this measure directly without a series of intervening
gambles. The evidence reviewed in Chapter 5, that suggests raters find the TTO
an easier instrument to use than the SG, is another advantage of the TTO-based
ex ante HYE.
The major disadvantage of the HYEs is that the descriptive scenarios used to
generate them have to include a large amount of information on alternative levels
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of health status over time. The trade-off that exists between the number of
scenarios (and hence valuation exercises) and the detail in those scenarios is at
its most stark with TTO-based ex ante HYEs which also need to include a range
of probability data. As Johannesson [1995] and Gafni et al [1995] comment, it
is an empirical issue whether individuals can process the sort of information
contained in these scenarios. It is worth noting, however, that the descriptions
necessary for TTO-based ex ante HYEs would have a high level of informational
content for patients and are what many patients would expect their clinician to
provide them with anyway - that is, a reasonably detailed, but comprehensible,
list of the risks, benefits and long-term prognosis of a given intervention. Indeed,
in undertaking the TTO exercise, it may be possible to draw on existing
information sources for patients such as leaflets and possibly videos. This
characteristic of TTO-based ex ante HYE scenarios is not shared by any of the
other benefit measures suitable for CUA, which divide up a patients possible
prognosis in some way. Furthermore, the information content of TTO-based ex
ante HYE scenarios could mean that they make more sense to raters, especially
if they are patients who would have thought about many of the risks and
benefits prior to the exercise [Wakker, 1996]. It may be the case, therefore,
that this type of ex ante HYE may actually be easier to elicit.
The closest thing to a CUA that has used a TTO-based ex ante HYE is that
undertaken by Cook et al [1993, '1994]. The context was an economic
evaluation of three alternative treatments for gallstone disease: open and
laparoscopic cholecystectomy and extracorporeal shockwave lithotripsy (ESWL).
Using information from interviews with patients and patient questionnaires, a
series of health state scenarios was developed. These scenarios took a 'partial
ex ante' (p158) perspective in that the treatment-related scenarios included
information on the risk of operative mortality. On the basis of interviews with
96 members of the general public, TTO exercises were undertaken to value each
scenario. The authors then compared the loss of QALYs per 100 patients
associated with the alternative treatments and their aftermaths using an ex post
and partial ex ante approach. The ex post approach involved adding the QALY
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	 Alternative benefit measures in CUA
loss associated with the procedure, the risk of complication, the risk of death
and HRQL over 18 months. The partial ex ante approach involved adding each
of these except the QALY loss associated with operative death, which was
incorporated into the scenario. The authors found large differences between the
two perspectives with the two treatments. The authors justified their partial ex
ante perspective rather than a complete one because 'the inability of an
individual to process large amounts of information in a reliable and valid way
makes such an analysis (full ex ante) difficult' (p158).
7.2.6 Summarising alternative approaches to CUA
A range of alternative benefit measures has, therefore, been developed in recent
years for use in CUA. Table 7.1 summaries each alternative measure of benefit,
indicating the restrictive assumptions necessary to link it to individual
preferences, whether the measure is based on the von Neumann-Morgenstern
axioms and the valuation burden imposed. The table clearly shows that a trade-
off appears to present itself in selecting outcome measures for CUA. The
standard QALY, whether based on SG or TTO values, requires some strong
assumptions if individual preferences are to be reflected in the analysis. As
alternative approaches have developed in an attempt to avoid some or all of
these assumptions, a progressively greater measurement and valuation burden
has apparently been imposed.
7.3 Methods
7.3.1 Introduction
The availability of a range of alternative benefit measures for use in CUA
introduces another area of analytical uncertainty into studies: which measure is
the most appropriate in a given context. This uncertainty is particularly
pronounced in the assessment of MAS interventions, where patients'
preferences about outcome trade-offs are likely to be considered important in
decisions about resource allocation.
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The remainder of this chapter considers the importance of this analytical
uncertainty in the context of the economic evaluation of AH versus TCRE, by
focusing on one of the alternative benefit measures reviewed above, the ex ante
HYE. The starting point of this empirical work is that, in principle based on the
foregoing review, the ex ante HYE based on the TTO is most likely to be able to
reflect women's attitudes to the risks and trade-offs associated with the process
and outcomes of surgical treatment for menorrhagia. This is based on the
argument that this approach to the measurement of HYEs is more direct and
intuitive than the two-stage lottery, benefits from the practical advantages of the
TTO over the SG discussed in Chapter 5 and can reflect patients' attitudes to
risks without requiring the axioms of von Neumann-Morgenstern to be valid.
The following specific questions are addressed: Is it practical to use ex ante
HYEs to estimate the benefits of the two surgical treatments? How consistent
are ex ante HYEs with individuals' descriptive preferences? Are the conclusions
of the base-case analysis in Chapter 5 robust to the use of ex ante HYEs as the
measure of benefit?
7.3.2 Valuation exercise
Given the importance of not overburdening women with too many valuation
tasks, it was not considered appropriate to use the same sample of women to
obtain ex ante HYEs as was used to elicit health state values for the standard
QALY. Therefore, a further sample of women was identified in a second centre.
In order to identify a sample of women with very similar characteristics to the
Bristol sample used for the standard QALY valuation exercise, the same process
was used to recruit women into the study. All women who had recently been
referred by their GP to the Princess Margaret Hospital in Swindon, for apparently
uncomplicated menorrhagia, were the population from which the HYE valuation
sample was drawn.
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Potentially eligible women were identified from GP referral letters received by the
hospital between August 1994 and March 1995. These women were sent a
letter explaining the study and asking if they were willing to be interviewed by a
trained female interviewer prior to their visit to the out-patient clinic. Women
were also asked to complete the same questionnaire as the Bristol sample,
focusing on their health status and preferences for treatments and the
characteristics of treatment, full details of which are provided in Chapter 4. If
women responded positively to the invitation, they were contacted by telephone
to arrange a convenient date and time to be interviewed, which would take place
in their homes unless they preferred to come to the hospital. Women were
excluded from the valuation exercise if, on the information they provided in the
questionnaire, they had significant concomitant illness; if they lived too great a
distance from the Princess Margaret Hospital to make an interview practicable;
or if interview prior to their hospital appointment was not feasible.
As for the Bristol valuation exercise, a target sample of 60 women was
established. Interviews were undertaken by a trained female researcher. The
interview schedule used in the valuation exercise consisted of two elements.
Introduction. During the introduction section of the interview, the
researcher introduced herself and the nature of the exercise; she also asked for
permission to tape the interview. Finally, a short additional questionnaire was
given to the woman to complete, asking a series of socio-demographic
questions.
Valuation. The second stage of the interview involved eliciting from
women values for health profiles in terms of ex ante HYEs. Two ex ante profiles
were presented to women, and included a clear time dimension running from
initial surgery until the menopause, and then until death. These profiles included
estimates of the risks associated with therapy: the risk of operative death (for
both treatments) based on estimates for AH which were assumed to apply to
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both treatments [Dicker et al, 1982], and of re-treatment (for TCRE) based on
the results of the Bristol trial (see Chapter 3). The two scenarios were based
partly on the synthesis of the health state descriptions used in the Bristol
valuation exercise, and partly on additional information from the same sources
used to develop the original descriptions. Appendix 7.1 reproduces the two
profiles used to elicit ex ante HYEs.
As the profiles had a time dimension lasting until death, they had to be
'customised' for each woman's life expectancy. As for the Bristol valuation
exercise, life expectancy was assumed to be 60 years (for women aged between
20 and 29 years); 50 years (for those aged between 30 and 39 years); 40 years
for those aged between 40 and 49 years; and 30 years (for those aged between
50 and 59 years). The profiles assumed the menopause would occur with
approximately 35 years of life remaining.
On being presented with the profiles, the women were asked to rank them. The
ex ante HYEs for the two profiles were then elicited using the TTO. As in the
Bristol study, the 'converging ping-pong' method was used to avoid anchoring
bias [Mohide et al, 1988]. The process of eliciting ex ante HYEs using the TTO
is the same as that used to elicit health state values to estimate QALYs, the only
difference being that the period of time in imperfect health considered
comparable to a lifetime profile is itself the HYE estimate, and is not then
transformed to a value on a 0 to 1 scale.
7.3.3 Assessing the consistency of ex ante HYEs with women's stated
preferences
One of the characteristics of the ex ante HYE is that it can be associated with a
specific treatment without first having to be combined with other health state
values and probability data. In other words, the ex ante HYE is a single and all-
embracing treatment-related preference measure. As a result of this, ex ante
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HYEs can be compared with other indications of treatment preference provided
by individuals (in this case patients), as an assessment of consistency.
As described in Chapter 4, the first part of Section 4 of the questionnaire
completed by women in the interview samples listed a series of 10
characteristics of surgical treatment for menorrhagia, and women were asked to
rate the importance of these characteristics on a 4-point scale from 'very
important' to 'not important'. The second part of Section 4 described two
options for treatment, one representing AH and one TCRE. Women were asked
to indicate which, if any, they would prefer, and to rate each of them on a visual
analogue scale. In Section 5 of the questionnaire women were asked to indicate
whether they had strong preferences for or against treatments and, if so, to
name them.
Women's responses to Sections 4 and 5 of the questionnaire have been used to
assess the consistency of the ex ante HYE estimates with the more descriptive
treatment preferences, at both the level of the individual and of the group. The
following analyses have been undertaken.
Ex ante HYEs and characteristic groups. Based on women's responses to
the questions about the importance of the various characteristics of treatment
for menorrhagia, two 'characteristic groups' are defined. If women considered
the characteristics typical of TCRE as important, they are placed in the TCRE
characteristic group; if they felt the characteristics typical of hysterectomy were
important, they are put into the hysterectomy characteristic group.
Women are put into the TCRE group if they indicated that all of the following
characteristics of treatment were 'very important' or 'of some importance':
treatment that will not remove the womb; treatment causing the least pain and
discomfort during convalescence; treatment that will reduce periods but not stop
them for good; treatment that will result in getting back to usual activities as
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soon as possible after the operation. Women are placed in the hysterectomy
characteristic group if they felt that both of the following were 'very important'
or 'of some importance': treatment that will remove the womb; and treatment
that will stop periods for good. It would be reasonable to expect that women's
ex ante HYEs would be greater for a treatment if they are allocated to its
characteristic group.
Ex ante HYEs and choices about treatment options. Women's responses
to the choice between the two treatment options described in the questionnaire
are compared to their ex ante HYEs. Consistency would require that ex ante
HYEs for a given treatment would be higher for women who indicated that they
would select the option describing that treatment in the questionnaire.
Ex ante HYEs and visual analogue scores for treatment options. The
visual analogue scores women provided for the treatment options described in
the questionnaire are compared to their ex ante HYEs. It would be expected that
the higher the visual analogue score for a treatment, the higher would be the ex
ante HYE elicited in the interview.
Ex ante HYEs and stated treatment preferences. Women's responses to
questions about positive and negative preferences for actual treatments are also
compared to ex ante HYE values. Due to small numbers, both positive and
negative preferences are grouped as being for hysterectomy or for other
treatments. Although much depends on women's prior information about the
characteristics of treatments, it would be reasonable to expect ex ante HYEs to
be higher (lower) when a woman stated a strong positive (negative) preference
for that treatment.
7.3.4 CUA of AH versus TCRE using ex ante HYEs
In order to assess whether a CUA using ex ante HYEs produces different
conclusions to that using the standard QALY, much of the original CUA detailed
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in Chapter 5 is retained here. In particular, the cost side of the original CUA is
unaltered, so the focus is on substituting the estimates of ex ante HYEs for
TCRE and AH for the QALYs in the original model. The ex ante HYE descriptive
profiles which were presented to the women were made consistent with the
parameters used in the original CUA. For example, the probabilities of death and
of re-treatment were the same in the profiles as in the standard CUA model.
The fact that ex ante HYEs relate to lifetime profiles with risks has two
implications for CUA. Firstly, the base-case results of the standard QALY-based
CUA in Chapter 5 are taken over a time horizon of two years and hence are not
the appropriate ones against which to compare the lifetime ex ante HYE-based
CUA. The sensitivity analysis reported in Chapter 5 extrapolated the base-case
results over women's lifetimes using some assumptions, and it is these lifetime
results against which the ex ante HYE-based CUA results are compared.
The second implication of the fact that ex ante HYEs relate to lifetime health
profiles is that, because the time dimension is fixed, the ex ante HYEs will reflect
women's rate of time preference. Therefore, no allowance for time preference,
using the conventional discounting formula, is necessary with this benefit
measure.
7.4 Results
7.4.1 The sample of women interviewed
As part of the valuation exercise, 202 women were identified from referral
letters sent to the Princess Margaret Hospital in Swindon, of whom 121 returned
completed interview consent forms. Of these women, 107 agreed to be
interviewed. A total of 63 women were eventually interviewed, thus just
exceeding the target sample of 60 women. In reaching this number, 44 women
were excluded for reasons detailed in Table 7.2. The fact that 27 (62%)
exclusions were because either the woman's out-patient appointment was too
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Table 7.2	 Details of reasons for exclusions from the HYE valuation exercise
Number	 %	 Reason for exclusion
14	 32	 Unable to find acceptable date and time for interview
13	 30	 Date of out-patient appointment too close or passed
6	 14	 Concomitant illness
5	 11	 Unable to make contact with woman
3	 7	 Failed to attend interview
1	 2	 Interviewee unwell on day of interview, unable to
arrange alternative date
1	 2	 Previous uterine surgery
1	 2	 Inter-menstrual bleeding
close or had passed, or a convenient time and date could not be found before
that appointment, was largely due to the fact that a waiting list initiative was
underway at the Princess Margaret during this period. This resulted in a shorter
than usual period between referral and the out-patient appointment for most
women.
Table 7.3 presents the socio-demographic and clinical characteristics of the
sample of women interviewed. The table compares the characteristics of the
Swindon sample with those of the women in the Bristol valuation study which
provided the health state values for the standard GALY analysis. The table
shows that, for most characteristics, the two interview groups were very gimilar,
with no statistically significant differences between them. The one exception to
this is the duration of menorrhagia. As detailed in Chapter 4 in relation to the
larger sample of women with menorrhagia who returned questionnaires in the
two centres, women in the Bristol sample reported that they had suffered their
menstrual problems for a longer duration than women in the Swindon sample
(median 24 versus 12 months, p =0.03).
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Table 7.5	 Ex ante HYEs elicited from women in the Swindon study*
Treatment Mean (SE) Median (Range)
AH
TCRE
34.84
32.62
(1.44)
(1.55)
37.5
(34.0
(0-60)
(0-60)
*	 Mean years of future life used in TTO exercise was 44.76
compared. If the classification data are assumed to be ordinal, differences
between the two samples in each of the groups, on both the day the
questionnaire was completed (Mann-Whitney U test, p =0.14-0.92) and the
'heaviest' day (p =0.18-0.4-9), all failed to reach conventional levels of statistical
significance. Differences between the two samples in the visual analogue scores
too are not statistically significant (Wilcoxon rank sum test, p =0.59 for day of
questionnaire; p =0.95 for 'heaviest' day).
7.4.2 The valuation exercise
The age of the Swindon sample of interviewees detailed in Table 7.3 translates
into the following assumptions about life expectancy for the TTO exercise: six
(9.5%) women were in the 20 to 29 years age group (assumed life expectancy
60 years); 22 (34.9%) were in the 30 to 39 years age group (assumed life
expectancy 50 years); 31 (49.2%) women were in the 40 to 49 years age group
(assumed life expectancy 40 years); and 4 (6.3%) women were in the 50 to 59
years age group (assumed life expectancy 30 years).
Women were asked if they were happy for the interview to be taped, and all but
one (1.6%) agreed to this. Interviews lasted for a mean duration of 52.5
minutes (SE 1.2 minutes). Table 7.5 details the ex ante HYE values elicited from
women in the study.
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Distribution of ex ante HYE values for TCRE and AH among women in
the Swindon study
The ex ante HYEs show that women considered a mean of 32 . 62 years (median
34) and 34.84 years (median 37.5) in perfect health to be equivalent to their full
life expectancy (on average 44 years) following TCRE and AH, respectively. This
difference did not reach statistical significance (mean difference 2.22 (95% Cl -
1.98 to 6.42)), probably due to the relatively small sample size, but the results
indicate that, on average, women valued the health profile following AH more
highly than that following TCRE. The distribution of ex ante HYEs amongst
women in the sample is shown in Figure 7.3. At the level of the individual
woman interviewed, 27 (43%) women valued AH more highly than TCRE, 21
(33%) valued the two interventions equally and 15 (24%) valued TCRE more
highly than AH.
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Figure 7.4
	 Analysis of consistency at the individual level. Comparison of women's
relative ex ante HYE values for AH and TCRE and their characteristic
group implied by their repsonses to the questionnaire
74.3 The consistency of ex ante HYEs
Four comparisons are undertaken between women's ex ante HYEs for AH and
TCRE, and their stated descriptive preferences regarding treatment and the
characteristics of treatment provided in the questionnaire.
Ex ante HYEs and characteristic groups. The first of these compares ex
ante HYEs elicited from women allocated to the two characteristic groups. The
consistency of responses at the level of the individual is illustrated in Figure 7.4.
The majority of women allocated to the hysterectomy characteristic group
(12/19) had a higher ex ante HYE for AH than for TCRE. Amongst those women
who were allocated to the TCRE characteristic group, the majority (9/15) valued
the two treatments the same, with equal numbers valuing AH higher than TCRE
and vice versa. Amongst those women who could not be clearly allocated to
either characteristic group, 11/25 valued AH more highly than TCRE. Therefore,
although 8 of the 59 women who completed a questionnaire (and 8 out of 34
258
Ul
,t•-•	 r-
O)
	 4-, 0
.0	 CO
8 
C.
4-,7- „ 0
a CC
-0 a) 4-,
2o2
_o
*C
	
a)	 00 a 2 -a
o0 a .-
•a 0 eu
,co	 : • 0.
_ 0
6.)
M
,
CO 8 -02
_c
, a —
< 4.4 E- -§-
c-
.c a) 0 4_,
-0 E 2
0	 ° 4,L •IL C
-
E
o
E
o c
	
_o	 ru
E ,r5
u; 0 a 0
a E cc.-
2 .c >
CD 44' 0 a)
° >
	
c?,	 >
E o8 a)
4, L
C
(12 =
C° 	 0
.0 4•
a)0
w -C	 4-'
CC 4" a) 8
UI-	 -a o
-o E	 0C
co as a) .—2
I 4-, c7) -0
< co C c0 co
c
48 	 4),4 • ciS
_0 C
C	 4-, 4-,
E a0	 a,3
o
_c
-o	 C1)
	E 	 a)
oco 0 •c-,
.E2 co
co 0
Cl)	 0 =
C
0 ••	 CO 4.
a _c co
c a
2 1.1.1
,••• 0 CC c
• a c.) co
E
_
a) >. _c
c
co > c
cou	
-0
.0 co 0).0
1:1 10) E
o
g 2 0
X 7, "D -c
a) .4_ 3 44.
° C >
c -C CD 0
E E
o0 a)
a
	
a)	 4-,
8 :2 -6 c
ou_ c o =
o o
• 0C) 3
TCRE	 Neither
Options chosen in the questionnaire
All
_ - -
- _ -
- _ -
--
-
-
-
_
-
-
-
-
1
	
TCRE>AH III TCRE.AH
	
TCRE<AH
Chapter 7
25
Alternative benefit measures in CUA
20
5
E
o 15
13
T2 10
E
zz 5
0
Figure 7.5	 Analysis of consistency at the individual level. Comparison of women's
relative ex ante values for AH and TCRE and the treatment option they
chose in the questionnaire
who could be allocated to a characteristic group) gave values which were clearly
inconsistent with the characteristic group to which they have been allocated, the
majority of women provided ex ante HYEs which were not inconsistent with their
group.
Some measure of consistency is also shown at the level of the group, as detailed
in Table 7.6. The mean ex ante HYE for AH is higher than that for TCRE
amongst women allocated to the hysterectomy characteristic group, and it is
higher for TCRE than for AH amongst women in the TCRE characteristic group.
However, although the median ex ante HYEs amongst women in the
hysterectomy characteristic group are higher for AH than TCRE, they are equal
amongst women in the TORE characteristic group. Although there is no clear
indication of inconsistency at the group level, it should be emphasised that the
differences in mean ex ante HYEs are not significant (ie. the 95% confidence
intervals around the mean differences cross 0).
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Figure 7.6 Correlation plot between the visual analogue scores women gave to the
description of AH in the questionnaire and the ex ante HYEs for AH that
were elicited from them at interview
Ex ante HYEs and choices about treatment options. The second 'test dr
consistency involves comparing women's descriptive preferences for the two
treatment options (AH and TCRE) described in the questionnaire with their ex
ante HYEs for those treatments as elicited in the interview. The results of this
analysis at the individual level are shown in Figure 7.5. For this analysis, slightly
more women provided unequivocally inconsistent ex ante HYE values given their
treatment choice in the questionnaire: 11 out of 58 women who completed the
questionnaire, and 11 out of 48 who made a treatment choice. However, the
majority of women gave ex ante HYEs which were not inconsistent with their
treatment choice.
The analysis of consistency at the group level between ex ante HYEs and
treatment choices is shown in Table 7.7. Both the mean and median ex ante
HYEs elicited from those women who preferred AH as described in the
questionnaire are higher for AH than for TCRE. Similarly, although the
differences are smaller, the mean and median values for TCRE are higher than
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Figure 7.7	 Correlation plot between the visual analogue scores women gave to the
description of TCRE in the questionnaire and the ex ante HYEs for
TCRE that were elicited from them at interview
those for AH amongst women who preferred TCRE in the questionnaire. Again,
however, these difference do not reach statistical significance.
Ex ante HYEs and visual analogue scores for treatment options. The third
test of consistency examines the correlation between the visual analogue scores
women provided for the TCRE and AH treatment options, as described in the
questionnaire, and the ex ante HYEs elicited from them in the interview.
Although the valuation instrument was different (the TTO instead of the visual
analogue scale) and the descriptions were in a different format and included
slightly different information, some degree of correlation would be expected.
The results, however, do not support this expectation. Figure 7.6 plots the ex
ante HYEs and visual analogue scores for AH, and Figure 7.7 does the same for
TCRE. No clear correlation can be discerned from these plots, and this is
confirmed by the statistics: Spearman's rank correlation between the VAS score
for AH in the questionnaire and the ex ante HYE for AH was 0 . 149, and was not
statistically significantly different from 0 (p =0.32); Spearman's rank correlation
between the VAS score for TCRE in the questionnaire and the ex ante HYE for
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	 Analysis of consistency at the individual level. Comparison of women's
relative ex ante HYE values for AH and TCRE and their stated positive
treatment preferences in the questionnaire
TCRE was -0.273, which was also not statistically significantly different from 0
(p =0.07). Although the absence of statistical significance is partly related to
the relatively small sample size, the size of the coefficients and, in the case of
TCRE, the sign, are surprising.
Ex ante HYEs and stated treatment preferences. The final consistency
test focused on stated (positive and negative) preferences for actual treatments.
Given the small numbers, only two 'treatment groups' are defined: for
hysterectomy and for other treatments. The ex ante HYEs provided by those
women who stated that they wanted a hysterectomy are compared with the ex
ante HYEs elicited from women who said they wanted some other form of
treatment and with those who had no positive preference. Similarly, the ex ante
HYEs of women who said they did not want a hysterectomy are compared to
those of women who said they did not want some other treatment and to those
of women who said they had no negative preference.
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Figure 7.9	 Analysis of consistency at the individual level. Comparison of women's
relative ex ante HYE values for AH and TCRE compared to their stated
negative treatment preferences in the questionnaire
The results of the analysis at the level of the individual are shown in Figures 7.8
and 7.9. Figure 7.8 shows that, of the nine women indicating a strong positive
preference for hysterectomy, seven (78%) provided higher ex ante HYE values
for AH than for TCRE. Of the six women who indicated a strong preference for
another form of treatment, only one (17%) gave a higher ex ante HYE to AH
than to TCRE, and two (34%) gave a higher value to TCRE than to AH.
Amongst the 34 women who indicated no strong positive preference, roughly
equal proportions had higher ex ante HYE values for TCRE than AH, higher
values for AH than TCRE and equal values
Figure 7.9 shows that, of the nine women who indicated a strong negative
preference for hysterectomy, only one (11%) gave a higher ex ante HYE to AH
than to TCRE, two (22%) gave a higher value to TCRE than AH and the
remainder valued the two equally in terms of ex ante HYEs. Of the six women
who had a strong negative preference for some other treatment, three (50%) had
a higher value for AH than TCRE. The majority of the 33 women who had no
strong negative preference valued AH more highly than TCRE.
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Table 7.9
	
Results of the alternative CUA using ex ante HYEs, compared to the
lifetime results from the standard QALY model (1994 prices)
AH	 TCRE	 Incremental cost per
additional unit of benefit
(E)
Standard QALY model'
Expected lifetime cost fa t 1162 816 442
Expected lifetime benefit (0.ALYs) 15.195 14.413
Alternative ex ante HYE model
Expected lifetime cost (£)• t 1162 816 156
Mean lifetime benefit (HYEs) 34.84 32.62
*	 See Chapter 5 for full details
t	 Discounted at 6% per annum
The results of this analysis of consistency at the group level are shown in Table
7.8. Although the numbers are small, and hence differences do not reach
statistical significance, the mean and median ex ante HYEs are consistent with
expectations. The mean and median ex ante HYEs for AH are higher than those
for TCRE for women who stated in the questionnaire that they had a positive
preference for hysterectomy, and lower for women who stated that they had a
positive preference for some other treatment. For those women who expressed
no positive treatment preference, the mean ex ante HYEs are very similar and the
median values are higher for AH. As regards negative preferences, the mean ex
ante HYEs for AH are lower than those for TCRE for women who had a negative
preference for AH and the median values are the same. The median and mean
values are higher for AH than for TCRE amongst women who had a strong
negative preference for some other treatment.
7.4.4 An alternative CUA of AH versus TCRE using ex ante HYEs
The results of the alternative ex ante HYE-based CUA are shown in Table 7.9,
alongside the lifetime results from the standard QALY-based CUA. On the basis
of both mean health state values (for the lifetime GALY analysis) and mean ex
ante HYEs, AH would be considered the more effective treatment. Furthermore,
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when expected lifetime costs are combined with the alternative benefit measure,
the incremental cost of an additional unit of benefit appears modest (£442 per
additional QALY and £156 per additional ex ante HYE). This suggests that the
base-case conclusion of Chapter 5 - that, under most circumstances other than
extreme simultaneous variation of all parameters and assuming that the
suggested illustrative threshold cost per QALY ratios are accepted, AH would be
considered a more cost-effective treatment than TCRE - is robust to the use of
an alternative means of expressing benefit.
However, the variability around the ex ante HYE values is, in terms of the overall
results, more important than that around the health state values used to
construct QALYs. Indeed, the fact that the mean ex ante HYEs are not
statistically significantly different (Table 7.5), indicates that conclusions about
the relative cost-effectiveness of the two treatments on the basis of ex ante
HYEs have to be tentative.
An important point illustrated in the comparison of QALYs and HYEs in this
context is that the absolute value of these benefit measures, for both
treatments, over women's full life expectancy is quite different, although this has
little effect on the overall relative value for money of the two treatments. The
difference is due predominantly to the effect of discounting at a constant
positive rate in the standard QALY-based CUA. The long time horizon of the
analysis (44 years average life expectancy) means that, in the QALY-based CUA,
a QALY occurring four years from death is, in present value terms, worth only
0.10 of a QALY on the basis of a 6% discount rate. The ex ante HYEs contain
within them women's time preference rates, so no subsequent adjustment using
the constant exponential discount rate approach is necessary.
The ex ante HYEs elicited from women in this study would seem to indicate that
discounting benefits at a constant exponential rate of 6% may not reflect
individual preferences. If a 0% discount rate is substituted into the standard
QALY model, the absolute estimates of QALYs become much closer to that of
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HYEs, for both treatments. This result is consistent with growing evidence to
indicate that individuals do not exhibit a positive time preference [Loewenstein
and Prelec, 1993; Redelmeier and Heller, 1993; Dolan and Gudex, 1995]. In
certain contexts, this apparent failure to reflect accurately individuals' time
preferences using discounting would cause more significant differences between
the results and conclusions of a DALY-based and a ex ante HYE-based CUA,
than appear to exist in relation to TCRE versus AH. For example, if the time
distributions of benefits differ markedly between the treatment options under
consideration, results could be very sensitive to the choice of discount rate
[Petrou et al, 1993].
7.5 Discussion
7.5.1 Theory of benefit measurement in CUA
The QALY has become a widely used tool in the economic evaluation of health
care programmes and interventions [Gerard, 1992]. However, the feeling that it
can facilitate the incorporation of patients' preferences into the calculus of
economic evaluation is not supported by strong evidence. For the economic
evaluation of MAS technologies, where patients preferences may be considered
important to factor into the analysis, this may be a major shortcoming of QALYs.
Two questions must, then, be asked about QALYs in the economic evaluation of
MAS. The first question is whether the use of the QALY as a benefit measure
within CUA is preferable to reverting to simple CEA or moving to cost-benefit
analysis (CBA). When considering the role of CEA, MAS invariably generates
multi-dimensional outcomes, as emphasised in Chapter 4 in relation to the AH
versus TCRE comparison. These outcomes might be mortality and HRQL; more
frequently there is a series of effects on different dimensions of HRQL.
Furthermore, MAS often has an important effect on the process of care over
which individuals are likely to have preferences; for example, location of
treatment. Multi-dimensional outcomes and the importance of process result in
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CEA having limited value in helping decision makers reach conclusions about
relative cost-effectiveness. Invariably, the use of CEA shifts the task of
synthesising the multi-dimensional effects of MAS, and the burden of making
judgements about the value of the outcomes of those technologies relative to
those generated by other interventions in different programmes and disease
areas, on to decision makers. This process is usually hidden from scrutiny and is
often implicit.
The strength of CUA is that the value judgements necessary to synthesise multi-
dimensional measures of outcome into a single benefit measure - namely the
health state values and the assumptions underlying the construction of QALYs -
are (or should be) made explicit. When presented with the results of a QALY-
based economic evaluation, a decision maker can accept or reject its
conclusions; but in rejecting them, alternative value judgements will have to be
discussed and presented. The QALY, therefore, can serve a valuable role within
resource allocation: as one tool in the decision maker's armamentarium for
purposes of resource allocation; as a means of making judgements about the
synthesis of multi-dimensional outcomes explicit; as a broad-brush means of
comparing outcomes, as well as costs, across programmes and disease areas;
and as a way of initiating a consideration of the economic characteristics of
health care technologies. However, this 'decision making perspective' on the
value of QALYs and CUA is quite different to the view that QALYs are a means
of incorporating individuals' preferences into resource allocation.
In order for CBA to be used as a framework within which to assess the relative
value for money of MAS interventions, some way of valuing the outcomes and
process of health care in monetary terms is required. In recent years the
methods of willingness to pay have been used more widely in economic
evaluation of health care [O'Brien and Viramontes, 1994; O'Brien eta!, 1995;
Donaldson et al, 1995; Chestnut et al, 19961. An advantage of CBA is its focus
on allocative efficiency, supporting decisions about the most appropriate level of
funding for the health service as a whole, as well as about allocation within it.
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However, the focus of this thesis is the most appropriate means of measuring
benefits from interventions with a range of process characteristics and
outcomes, to inform decisions about resource allocation within the health
service. In that context, willingness to pay methods would seem to offer no
methodological advantages over other forms of valuation, and may introduce
some practical difficulties, especially in the UK where individuals may find it
unacceptable to consider payment for health-related outcomes even at the
hypothetical level [Propper, 1988; Donaldson et al, 1995].
Indeed, as Johannesson [1995] comments, there are similarities between a TTO
exercise to generate ex ante HYEs and a conventional willingness to pay exercise
where individuals are presented with descriptions of outcomes in terms of
uncertainty and asked how much they would be willing to pay (accept) to avoid
(experience) those risks [Gafni, 1991]. With the TTO exercise, though, the
numeraire is years of life rather than money. If economic evaluation is to move
away from the flexible standard QALY towards a measure of value that may be
able to reflect individuals' utility functions more adequately, it is an important
question for further research whether willingness to pay or ex ante HYE methods
are the preferred advancement.
The second question that should be asked about the use of QALYs to evaluate
MAS is whether there are any ways of strengthening the theoretical basis of the
benefit measure used in CUA, to adhere more firmly to individuals' preferences.
Section 7.2.2 argues that the ex ante HYE requires fewer assumptions to link it
to individuals' preferences and, in this sense, may be considered theoretically
stronger than the QALY. However, HYEs may impose a greater measurement
burden on the analyst in the form of a need for more detailed descriptive
scenarios. Furthermore, HYEs are inherently less flexible than QALYs. The
decision analytic model is a popular framework for QALY-based CUA, where
parameters such as probabilities and durations in health states can be varied, and
the implications for cost and benefit results assessed, without altering the health
state values. Because scenarios for HYEs include more information, the HYE
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estimates have analytical parameters locked within them, and an assessment of
the robustness of an analysis to changes in these parameters is impossible
unless revised HYEs are elicited.
A clear trade-off, therefore, exists in selecting benefit measures for CUA of
MAS. QALYs are relatively easy to estimate, can be based on 'off the shelf'
health state values from valuation systems like EuroQol and are flexible when
incorporated into decision analytic models. However, there are clear doubts
about the consistency of QALYs with individuals' preferences. Ex ante HYEs
require fewer assumptions to link them with individuals' preferences, but are less
flexible for use in economic evaluation and probably impose a greater valuation
burden.
Quite what direction economic evaluation should take, given this trade-off, is as
yet unclear. A number of issues need to be considered. Firstly, further research
may be able to make the trade-off less pronounced. For example, it may be
possible to identify valid and efficient means of eliciting ex ante HYEs from large
numbers of valuers, using computer and video technology, such that the
valuation burden is reduced. Alternatively, new QALY models could be
developed which link the benefit measure more closely to preferences.
The second point to note is that the choice between QALYs and HYEs will
depend on whether they lead to radically different conclusions when they are
used in practice; if they do not, then the choice is less crucial. To date,
experience with HYEs in applied studies has been limited. It is important for
further research to be undertaken, in the context of applied evaluations, to
compare the two benefit measures. It is likely that the choice of measure will be
crucial in specific contexts: for example, where there is a range of different risks
associated with the technologies under comparison, where the process and likely
outcomes of care differ markedly between the comparators or where the timing
and/or sequence of outcomes differ between comparators. Further research is
needed to identify such contexts.
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A third point to note about the choice between HYEs and QALYs is that, if HYEs
were to be used widely in economic evaluation of health care interventions, it
would require a rather different approach to the timing of benefit valuation work
within the overall study. If a RCT is the major source of outcome information for
an economic assessment, the valuation data necessary to facilitate a QALY-
based CUA would usually be collected within the trial using an instrument such
as the EuroQol. If HYEs are to be estimated, the valuation exercise would have
to await the results of the trial, so that descriptive profiles could be developed to
include all relevant information. If effectiveness data are being generated using
modelling techniques rather than as part of a trial, the estimation of QALYs
would require the valuation data to be incorporated into the model, with QALYs
being a major outcome of the exercise. With HYEs, however, the model would
have to be used to generate the information to go into the descriptive scenarios,
which would then be used to elicit HYEs.
7.5.2 The consistency of HYEs and women's preferences
The validation of health state values is notoriously difficult, as there is no gold
standard for health state preferences apart from actual behaviour, which is
difficult to observe. Hence the rigour in assessing validity and reliability, which
is such an important part of developing descriptive HRQL instruments [McDowell
and Newell, 1987], cannot easily be replicated with valuation exercises. Within
the Swindon HYE exercise of AH and TCRE, women's completion of a
questionnaire exploring their attitudes to the treatment of menorrhagia afforded
some opportunity to explore the consistency between ex ante HYEs and stated
preferences about treatment and the characteristics of treatment. The relatively
small sample size limited the statistical power of this exercise and, as with any
analysis of this kind, judgements have to be made about what is sufficient
evidence to indicate consistency, but it is possible tentatively to identify some
indication of consistency.
Evidence of consistency seems stronger at the level of the group than that of the
individual. This observation has also been made in relation to the consistency of
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the ranking of health state values with a 'logical' order [Measurement and
Valuation of Health Group, 1994]. At the individual level, the majority of women
did not unequivocally contradict with their ex ante HYE values their various
descriptive preferences in the questionnaire. However, between 7% and 19%
did provide inconsistent ex ante HYEs and only between 25% and 47% gave
values which were unequivocally consistent with their descriptive preferences.
Despite not reaching statistical significance, at the group level, the mean and
median ex ante HYEs for AH were always higher than for TCRE amongst women
whose descriptive preference was for AH, and lower or the same as TCRE
amongst women whose descriptive preference was for TCRE. If one makes the
assumption that women's responses to a series of short questions in a postal
questionnaire are likely to be a reliable descriptive gauge of their preferences,
then consistency between these responses and ex ante HYEs, elicited at
interview using a choice-based valuation instrument, is important to
demonstrate.
7,5.3 The alternative CUA of AH versus TCRE
As an element of the overall economic evaluation of TCRE versus AH, the
alternative CUA using ex ante HYEs is a form of sensitivity analysis focusing on
uncertainty in analytical method [Briggs et al, 1994]. In other words, given the
controversy that surrounds the relationship between QALYs and individuals'
preferences and the likely importance of women's preferences in the
management of menorrhagia, the alternative CUA assesses how robust the
conclusions of the CUA model described in Chapter 5 are to an alternative
approach to benefit measurement.
The characteristics of these two surgical treatments for menorrhagia are such
that the assumptions of standard QALYs might be considered overly simplistic.
In particular, the trade-offs that face women and clinicians in selecting between
the treatments are unlikely to be adequately represented, in terms of
preferences, by a standard QALY model. The ex ante HYE approach presents
women with a simplified picture of the risks and benefits of TCRE and AH, with
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a clear time dimension extending until the menopause and then until death. The
descriptive scenarios used to elicit the ex ante HYEs are similar to the
information a woman might expect her clinician to provide in order to help her to
choose an appropriate therapy. Using these scenarios as a basis to elicit ex ante
HYEs provides an all-embracing treatment-related measure of benefit for use in
CUA which, in principle, reflects women's attitudes to the risks, processes and
outcomes involved.
Given that HYEs are relatively underdeveloped methodologically and have been
used in very few empirical studies, it is reasonable that the HYE-based CUA is
the 'alternative analysis' to the 'base-case' of the standard QALY model. The
results suggest that the broad conclusions of the QALY model - that the
additional benefits generated by AH compared to TCRE come at a relatively
modest incremental cost- hold true for the HYE-based analysis.
A number of caveats should be born in mind in reaching this conclusion,
however. The first of these is that the conclusions of both CUAs are sensitive to
the variability in the benefit data elicited from the sample of women valuers. In
the QALY-based CUA, the key health state values are those for the pre-
menopausal (post-convalescence) periods after TCRE and AH. The variability
around the ex ante HYE estimates was even greater than for the health state
values to the extent that there was no statistically significant difference between
TCRE and AH. If interpreted strictly, therefore, the 95% confidence intervals
around the mean difference in ex ante HYE values could imply, at one extreme,
that TCRE dominates AH (less costly and more effective) or, at the other
extreme, that AH is probably better value for money with a very low incremental
cost per additional unit of benefit.
The second caveat regarding the comparative results of QALY- and HYE-based
CUA relates to the scope of the benefits considered. Given that the follow-up
period of the firm evidential basis of the CUA - the Bristol trial - is only two
years, a number of the trade-offs that are likely to exist in the longer-term
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between TORE and AH are not explicitly considered. Hence, although the time
horizon of the comparison between the two CUAs was the average life
expectancy of a woman with menorrhagia, some of the risks from one treatment
relative to the other after the menopause are not reflected in the model. For
example, AH provides prophylaxis against endometrial and, usually, cervical
cancer, which gives it a differential risk profile relative to TCRE. However, some
evidence links AH to premature ovarian failure and, hence, possible early
menopausal symptoms, for women not taking hormone replacement therapy.
The standard QALY analysis in Chapter 5 does not build in these differential risks
into the model because, given that TORE has been used for a relatively short
period of time, no estimates of their magnitude exist; furthermore, the long-term
effects of hysterectomy, as well as TCRE, are not well understood. Similarly,
the descriptive scenarios upon which the ex ante HYEs were estimated
contained no information about these risks, although it is possible that women in
the valuation exercise augmented the information in the scenarios with their own
from other sources. As discussed in Chapter 5 in the context of the QALY-
based CUA, the effect of including these longer-term differential risks in the CUA
would almost certainty confirm the base-case conclusions of the analysis, that
AH offers additional benefits over TCRE at modest incremental cost, because the
risks on balance favour AH.
A third caveat concerning the results of the two CUAs is that both analyses are
based on the premise that one of the two therapies should be preferred, in terms
of relative value for money. An implication of this is that purchasers will select
one therapy, based on relative cost-effectiveness, for those women for whom
either is clinically feasible. However, given the fact that relative cost-
effectiveness is so sensitive to women's preferences concerning outcomes, this
policy would be based on the view that mean benefits are of primary importance.
Based on the results described in this chapter and in Chapter 5 and assuming the
illustrative cost per QALY thresholds are acceptable, this 'all or nothing'
approach would probably select AH as the more cost-effective treatment option
for all women, despite the fact that a sub-group of women have preferences
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which would suggest that TCRE is the better treatment for them. Contrary to
the way most economic evaluations are structured and undertaken, it makes
sense to explore the costs and benefits of determining a woman's treatment
based on her preferences. A full economic evaluation of this preference-based
strategy would rest heavily on the type of valuation data used in the CUAs
reported in Chapters 5 and 7.
7.6 Conclusions
Given the absence of evidence confirming a clear link between QALYs and
patients' preferences, this chapter has considered how an alternative benefit
measure to the TTO-based standard QALY might be used in a CUA of MAS. The
use of the TTO-based ex ante HYE has been shown to be feasible in the context
of the evaluation of AH and TCRE, and the chapter has described some results
showing that women's ex ante HYEs are consistent with their descriptive
treatment preferences. The alternative CUA using ex ante HYEs generates an
incremental cost per additional unit of benefit which is relatively modest
suggesting, as did the base-case analysis, that AH is likely to be the more cost-
effective treatment. However, the variability around the ex ante HYE estimates
generates substantial uncertainty about this conclusion. Although AH may be
considered the more cost-effective of the two surgical therapies, the ex ante
HYE values suggest that TCRE would be the preferred therapy from the
viewpoint of a proportion of women. Chapter 8 considers the costs and benefits
of allocating treatment on the basis of women's preferences.
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Appendix 7.1
	
	
Descriptive scenarios used in the Swindon ex ante HYE
valuation study
TCRE
She suffers from heavy and painful periods in the same way as the person in the first
description that you read, and is about to have surgery for the condition. This will involve:
• a small risk of death of 1 in 1000;
• a stay in hospital of 1 day;
• an interval of about 1 week before she resumes her daily activities, during which
she will experience some discomfort and sometimes feel tired;
• an interval of about 2 weeks before she can return to work;
• an interval of about 3 weeks before she can resume her sex life;
• the operation does not leave a scar.
Once she has recovered from the operation, she experiences the following results from surgery
after about 4 months:
• she still has periods but they are much lighter since her operation;
• she still has some pain with her periods;
• she has no limitation on her social activities or daily activities such as work;
• she occasionally feels moody, irritable or depressed;
• she still has her womb, but it is unlikely that she will become pregnant.
• she is able to enjoy her sex life.
Two years after surgery she is likely to be happy with the results of her treatment and be in
good health. However, during this time she would have faced the following risks:
• a 12% chance that she would have had the same operation again because of
her menstrual problems returning;
• a 16% chance that she would have had another type of surgery because of her
menstrual problems returning, involving 6 days in hospital and 4 weeks away
from her usual activities.
Within 5 years after surgery any bleeding she still has ceases due to the start of her
menopause.
She lives in good health for the remaining 35 years of her life.
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AH
She suffers from heavy and painful periods in the same way as the person in the first
description that you read, and is about to have surgery for the condition. This will involve:
• a small risk of death of 1 in 1000;
• a stay in hospital of about 6 days;
• an interval of about 4 weeks before she resumes her daily activities during which
she will feel tired, need occasional pain killers and be unable to lift objects or
walk very far;
• an interval of about 11 weeks before she can return to work;
• an interval of about 6 weeks before she can resume her sex life;
• she no longer has a womb, so she is unable to bear children;
• she will be left with a faint scar on her abdomen.
Once she has recovered from the operation, she experiences the following results from surgery
after about 4 months:
• she no longer has periods or experiences pain;
• she has no limitation on her social activities or daily activities such as work;
• she occasionally feels moody, irritable or depressed;
• she is able to enjoy her sex life.
Two years after surgery she is happy with the results of her treatment and in good health.
Her menopause starts within 5 years after surgery and she lives in good health for the remaining
35 years of her life.
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Incorporating Women's Preferences into the
Economic Evaluation of Surgical Treatments
for Menorrhagia
8.1	 Introduction
The conventional approach to economic evaluation in health care is to compare
the costs and benefits of two oT MOTS inteTvesItions with the aim cyf estabCd\ic‘s
which one is the more cost-effective. This is invariably conducted by
representing the distributions of costs and benefits of the options under
comparison in terms of their means, undertaking incremental analysis using these
measures of central tendency and employing sensitivity analysis to explore the
importance of variability. This can be termed an 'all or nothing' approach to
economic evaluation, because it is usually expected that purchasers would
allocate resources towards the single economically superior option. There are
circumstances where it is accepted that the all or nothing approach may be
inappropriate; these relate to situations when there are clear and important
sources of heterogeneity between patients in terms of their clinical
characteristics. Here, it may be the case that an intervention is cost-effective
for one sub-group of patients but not for others.
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It may also be inappropriate to use the all or nothing approach when there is
marked variation in patients' preference characteristics. However, it is very rare
in economic (and clinical) evaluation for sub-groups to be defined in terms of
patients' preferences, and for the costs and benefits of preference-based
management strategies to be assessed. This remains the case despite research
showing that patients have preferences about treatments and outcomes [McNeil
et al, 1978], and that many want to participate in decision making [Strull et al,
1984].
MAS interventions, in particular, are characterised by a range of treatment
processes and outcomes over which patients are likely to have preferences.
Using the case-study of TCRE and AH, it is the aim of this chapter to consider
ways in which the economic evaluation of MAS can be extended to assess
management strategies which allocate patients to treatment on the basis of their
preferences. In Section 8.2, alternatives to the all or nothing approach to
economic evaluation are considered in more detail. In Section 8.3, various ways
of modelling the costs and benefits of preference-based management strategies
are discussed. The potential cost-effectiveness of preference-based
management strategies are then compared with standard management (TCRE
only or AH only). Three preference-based management strategies are modelled
and evaluated: treatment allocation on the basis of patient choice (Section 8.4);
treatment allocation on the basis of patient values (Section 8.5); and treatment
allocation on the basis of patient-specific cost-effectiveness analysis (Section
8.6). Section 8.7 discusses the analysis and Section 8.8 offers some
conclusions.
8.2 Sub-group analysis in economic evaluation
8.2.1 Clinical sub-groups
The focus of economic evaluation in health care is the comparison of alternative
interventions to identify which single option is the more cost-effective based on
mean costs and benefits. It would then be hoped that purchasers would adopt
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this single economically superior intervention or programme. This all or nothing
approach has weaknesses at a number of levels [Asch and Hershey, 1995].
Reflecting one of these weaknesses, the all or nothing focus may be considered
inappropriate if sub-groups of patients can be defined in terms of clinical and
demographic characteristics which are felt to influence outcome. In this
situation, an assessment can be made of whether a given form of management
might be cost-effective for one sub-group, whilst not being so for others or for
the population of patients as a whole.
For example, in an economic evaluation of antihyperlipemic therapy in the
prevention of heart disease, it was found that the cost-effectiveness of therapy
varied considerably by sub-group of patient, with incremental costs per life year
saved ranging from $36,000 to $1 million [Oster and Epstein, 19871. The
authors reported that therapy was more likely to be considered cost-effective for
younger patients with multiple coronary risk factors and severe elevation of
cholesterol levels. This form of sub-group analysis has the potential to improve
the cost-effectiveness of health care delivery markedly, but its use WA% aWrays
be constrained by the limited data on baseline clinical characteristics which
influence outcomes. For example, the cost-effectiveness of TCRE could be
increased relative to AH if more was known about the clinical factors likely to
determine which women fail on the treatment.
8.2.2 Preference sub-groups
If efficient health care delivery is concerned with how patients value the process
and outcomes of interventions, in some situations the cost-effectiveness of
alternative interventions may be sensitive to patients' preferences. A major
implication of an all or nothing approach in such a context is that an optimal
treatment for a population of patients, based on mean costs and benefits, may
be sub-optimal from the perspective of a single patient. This point is illustrated
in Figure 8.1 which relates to a population of women requiring surgical treatment
for menorrhagia. The figure shows a hypothetical probability distribution of net
QALYs of AH relative to TCRE; that is, the QALYs that each woman would
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0
QALYS
No net benefit
Figure 8.1	 Hypothetical probability distribution of net OALYs associated with AH
relative to TCRE. Adapted from Heald and Owens 11994i.
expect if she were to undergo AH, minus the QALYs each woman would expect
if she were to have a TCRE. The example assumes that the differences between
women in terms of their individual net QALYs are driven solely by differences in
preferences (ie. they are clinically homogenous but heterogenous in terms of
values they would attach to health states).
The mid-point of the distribution shows the mean (expected) net QALYs with AH
which, together with expected incremental costs, is the basis of all or nothing
economic evaluation. The majority of women in this notional population would
experience positive net QALYs with AH. So, confining the comparison to these
two treatments alone, an all or nothing decision to purchase AHs for the entire
group would be individually optimal for most women. However, because of the
nature of their values, the all or nothing policy would be individually sub-optimal
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for a minority of women in this population, because they would experience
negative net QALYs from AH (equivalent to the area marked 'A' in Figure 8.1)1
In the context illustrated in Figure 8.1, it may be appropriate to undertake sub-
group analysis where the sub-groups would be defined in terms of patients'
preferences. Hence, if treatment were allocated to patients on the basis of their
preferences, this may prove more cost-effective than reliance on one intervention
alone. Furthermore, it is possible that patients value the process of choice in
itself [Ryan and Shackley, 1995], which may further increase the potential cost-
effectiveness of this strategy2.
The term 'patient preference' is often used in relation to two distinct concepts.
The first of these is patient choice, where patients select a treatment that they
consider better from their perspective using any information they have access to.
The second concept is patient values, where patients show the strength of their
attitude to a health state or a prognosis following treatment on a cardinal scale.
Both of these concepts could be used to define patient sub-groups and treatment
allocation strategies.
Patient choice. In some disease areas, many patients have clear ideas
about the characteristics of treatment that are important to them and are keen to
be able to choose the treatment they undergo based on relevant information
[McNeil et al, 1978]. The surgical treatment of menorrhagia appears to be one
such area. Chapter 4 of this thesis indicated that, when information on AH and
'The conflict between the group and the individual optimum might be even more
extreme than shown in Figure 8.1. In principle, net QALYs might be positive with AH
on a group basis, but the treatment might result in negative net QALYs for the majority
of women. This could happen if the positive net QALYs for the minority of women for
whom AH is the personal optimal choice are very large, but the negative net QALYs
associated with AH in the majority of women for whom TCRE is the personal optimal
choice are small
2Evidence does exist, moreover, to indicate that allowing patients' preferences to
determine choice of therapy can have a direct influence on outcomes [Greenfield et al,
1985; Brody et al, 1989].
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TCRE was presented to women with menorrhagia, over 80% were willing to
choose one of these therapies. The chapter also showed that different
characteristics of treatment were more important to some women than to others,
and this may explain the fairly even split between women who would choose
TCRE, based on the information provided, and those who would choose AH.
Patient values. In many economic evaluations, the cost-effectiveness of
an intervention will be sensitive to the values attached to health states. This
situation has been shown clearly to exist in relation to the comparison of AH and
TCRE in the cost-utility analyses reported in Chapters 5 and 7 of this thesis. In
this context, patients' values could be elicited prior to their knowing the outcome
of treatment for them (ie. ex ante values), which could then be used to predict
which therapy would be optimal from their individual viewpoint.
Studies have explored how values could be used as a basis of individual decision
making. For example, a recent study of how women value the information
generated by antenatal screening explored the concept of individual decision
making based on the individual values elicited from a sample of women [Cairns
et al, 1996]. The study found that expected benefit would be maximised for the
majority of women if screening was used, but the type of screening strategy that
would generate greatest benefit was finely balanced, using analysis at the level
of both the individual and the group. Few studies have looked at the cost-
effectiveness of management strategies using treatment allocation based on
patients' individual values.
To an extent, patients' treatment choices would be expected to reflect their
health state values. However, there may be inconsistency between these two
concepts. As reviewed in Chapter 7, there is evidence to indicate that when
health state values are used to estimate QALYs, this measure of benefit may not
be consistent with individual choices. Given a possible inconsistency between
choices and values, management strategies could be designed which allocate
patients to treatments using either concept.
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8.3 Building patients' preferences into economic evaluation
An all or nothing approach to the economic evaluation of TCRE and AH would
almost certainly result in some women receiving a treatment which is sub-
optimal from their individual perspective when their individual preferences are
considered. It is important to assess, therefore, whether a different approach to
economic evaluation is feasible; one which explicitly considers the costs and
benefits of allowing patients' preferences (either choice or values) to determine
treatment allocation. This is quite distinct from the general methods of CUA
which only provide a role for patients' values within the evaluation calculus at
the group level, which is where decision rules about treatment allocation are
conventionally set.
This extension to the methods of economic evaluation involves adding one or
more comparators to the interventions under consideration, where these
comparators are management strategies which allocate an intervention to a
patient on the basis of their choice or values. This new comparison may not,
however, require an entirely new study design. Using sub-groups, the costs and
benefits of the new comparators can be modelled if data are available on the
values and/or treatment choices of a cohort of patients. Below, three specific
approaches are discussed, each in the context of the economic evaluation of AH
versus TCRE. These are treatment allocation on the basis of patient choice, on
the basis of patient values and on the basis of patient-specific cost-effectiveness
analysis (CEA).
8.3.1 Treatment allocation on the basis of patients' choices
The first approach is to undertake an economic evaluation comparing three forms
of management for menorrhagia: TCRE only, AH only and a strategy where the
woman chooses which of these two treatments she would like after being given
relevant information. A modelling approach to the evaluation of a choice-based
management strategy would require some specific data collection, but could take
the following form, in relation to the treatment of menorrhagia.
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A cost-utility model would be developed to compare the costs and benefits of
TORE and AH, where benefits would be expressed in terms of expected QALYs.
A group of women with menorrhagia would then be interviewed, given
appropriate information about TORE and AH and asked which treatment they
would prefer, if any. The cohort would then be asked to value a series of health
states associated with the outcomes of TORE and AH, which would be the
building blocks of the cost-utility model. The model would then be used to
assess the aggregate expected costs and benefits of a TORE only and an AH
only treatment policy, where benefits would be calculated using expected QALYs
based on the mean values the group attach to each health state.
To assess the costs and benefits of the choice-based approach to management,
each woman in the sample would be considered separately: the expected cost
and benefit would be calculated based on the cost of the treatment each woman
chooses; and the expected benefit would take into consideration the QALYs for
each woman's choice of treatment based on her own health state values relating
to the chosen treatment. For example, if the first woman in the sample chose
TORE, her cost would be the expected cost of TORE calculated for the TORE
only option; the QALYs associated with her management would be calculated by
'plugging' into the model her own health state values related to TORE and
identifying the expected QALYs for TORE. If the second woman in the sample
preferred AH, the cost of her management would be the expected cost of AH
based on the AH only option, and her GALYs would be calculated using her own
health state values relating to AH, incorporating them into the model and using
the expected QALY estimate for AH.
Decision rules would be needed regarding the treatment allocation for patients
who are indifferent between therapies, or who want the doctor to make the
decision for them. In the case of indifference, allocation to the cheapest
treatment option may be justified. The flexibility of the modelling approach to
evaluating this strategy would be an advantage in this respect, as alternative
rules could be explored to assess the robustness of the results. It is important to
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note that this approach to the evaluation of choice-based management would be
from an ex ante perspective: women's choices and values would be elicited prior
to their actually undergoing any treatment.
Therefore, each woman in the sample would have a cost and QALY estimate
allocated to her on the basis of her choice of treatment. The mean cost and
QALYs of the sample would then be used as an estimate of the cost and benefit
of the choice-based strategy, and compared with TCRE only and AH only
options. The decision rule to select between the three options would be the
same as normal in CUA at the group level. An economic evaluation of choice-
based management would obviously need to consider the resource cost of
providing women with sufficient information to make a treatment choice and of
eliciting that choice.
As discussed in Chapter 7, the calculation of QALYs is based on strong
assumptions about how individuals make choices, and the chapter referred to
evidence that would suggest that treatment-specific GALY estimates, based on
an individual's own health state values, may not accurately predict the treatment
which the individual would choose to have. If the assumptions that link QALYs
with individuals' preferences are unsound, it may be unwise to use health state
values and patient-specific QALYs as a way of evaluating choice-based forms of
patient management. An alternative way of measuring values would be in terms
of ex ante HYEs which, as discussed in Chapter 7, require fewer assumptions in
principle to link them to actual treatment preferences.
8.3.2 Treatment allocation on the basis of patients' values
Section 8.2 makes the distinction between the choices patients make about
treatment options, and the values they have for particular health states or
prognoses. An alternative to a management strategy where patients would be
directly asked to choose which treatment they would wish to have, is one which
focuses solely on their values. This strategy would have the advantage of not
obliging the patient to make a direct choice: in the case of a QALY-based
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approach, patients could indicate a preference for a series of health states rather
than come to an overall decision about a treatment. On the other hand, the
choice-based approach is less constraining for the patient as they can take into
consideration what they wish when selecting a preferred therapy.
For the patient values-based management strategy, a decision analytic model
would be developed into which each woman's health state values would be
incorporated individually to identify the treatment with the highest patient-
specific expected benefit, to which the woman would then be allocated as her
personal optimal treatment. As before, the expected QALYs and cost of each
woman in the sample would be estimated, based on her receiving her individually
optimum treatment, which would be compared with the expected costs and
benefits of TCRE only and AH only, and the normal decision rule for group-level
CUA would apply.
An economic evaluation of a management strategy which allocates treatment on
the basis of women's values would need to consider the resource cost of
eliciting values as part of routine clinical practice. Unlike the form of
management where women are allocated to a treatment based on their choices,
eliciting values would probably require each woman to be interviewed, incurring
opportunity costs in terms of the time of health service staff and the women
themselves.
In order for values (and hence treatment allocation) to reflect patients' underlying
utility functions more accurately, it would be possible to express individual
values in terms of ex ante HYEs rather than health state values and expected
QALYs. The difference between the choice-based and the values-based
allocation of treatment is clear when the values relate to health states. For a
woman's direct choice between AH and TCRE to be identical to that implied by
incorporating her health state values into a decision analytic model, not only
would she have to make decisions by maximising her expected utility, also the
'model' she forms in her mind when selecting a treatment would have to be
289
Chapter 8	 Preference-based economic evaluation
identical, in terms of health states, probabilities etc., to the formal model.
Clearly, this is very unlikely to occur in practice. However, if ex ante HYEs were
the means of measuring values, it would be expected that a woman's choice of
actual treatment would be reflected in her HYE values, because she would be
valuing a prognosis directly related to a specific treatment, rather than a series of
health states which only subsequently are related to a treatment using an
external model.
8.3.3 Treatment allocation based on individual cost-effectiveness
The two management strategies described above would allocate women to their
individual optimal treatment on the basis of either their direct choice or their
values. As a basis for allocating limited resources at a group or societal level this
strategy would be inappropriate, because, at the level of the individual, it ignores
the cost implications of treatment selection. The logic appWzd at z gyzmp kevel csE
asking whether the expected incremental benefits generated by an intervention
justify its additional costs can also be applied at the level of the individual patient
and incorporated into management strategies based on patients' choice or
values.
A strategy of allocating treatments on the basis of patient-specific CEA was
discussed by Nease and Owens [1994]. The authors related the concept to the
development of clinical guidelines, and distinguished a 'preference-fixed'
approach, where treatment allocation is determined solely by a patient's clinical
characteristics, from a 'preference-flexible' approach, where their values are
used to determine whether the benefit they would derive from a treatment is
sufficient to justify its cost. As noted above, the preference-flexible
management strategy would have to be compared with a preference-fixed form
of management (TCRE only or AH only are the terms used here) in terms of costs
and benefits.
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Nease and Owens explained their methods using a four-step process. Their
illustrative clinical area was the management of mild hypertension, but the steps
can also be explained using the example of surgical management of menorrhagia.
Step 1 involves the identification of a cohort of menorrhagia patients, and the
elicitation of their health state values. Step 2 is the calculation of the expected
QALYs and costs of the alternative preference-fixed treatment allocations (All
only and TCRE only). These preference-fixed options are assessed by
incorporating the health state values of all individuals into a decision analytic
model for each therapy and aggregating the total QALYs and cost assuming
everyone in the cohort receives that therapy'.
Step 3 is the estimation of the expected costs and benefits of the preference-
flexible management strategy. This involves calculating the expected QALYs of
the treatment options using the health state values of each patient in the cohort.
Each patient would be allocated to a given treatment if one of the following
applied: (a) their expected QALYs for that therapy, implied by their health state
values, are higher than for the other comparators, and the cost of that treatment
is no higher than that of the others under consideration; (b) if the cost of a
patient having the intervention from which they would enjoy the highest
expected benefit is higher than for one of the comparators, but their
individualised cost-utility ratio is less than $50,000 per additional QALY.
The expected costs and QALYs associated with the preference-flexible approach
are then calculated by adding up the expected costs and QALYs of each patient
in the cohort according to the treatment to which they were allocated. In Nease
and Owen's work, this calculation included the cost of eliciting the health state
values from patients, which was assumed to be $100 per patient. Finally, in
Step 4, the expected costs and QALYs of the preference-fixed (AH only or TCRE
'This is an unusual approach to estimating the costs and benefits of an all or nothing
strategy for two or more treatments using a model. Usually the mean values provided
by the sample of patients for each health state would be incorporated into the model.
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only) and preference-flexible strategies are compared to establish relative cost-effectiveness
This approach to incorporating patients' preferences into an economic evaluation
would also need to decide upon the incremental cost per QALY threshold, for a
given intervention, above which the individual patient would not be allocated to a
therapy, but instead would undergo the cheaper alternative which their health
state values suggest will generate fewer benefits. Also, as for the other two
approaches, the individual cost-effectiveness approach could employ ex ante
HYEs as a measure of value. This would again have the advantage of requiring
fewer assumptions to link the values to individuals' treatment-related choices.
This section has outlined how three possible preference-driven management
strategies might be evaluated using modelling techniques: treatment allocation
based on choice, patients' values and patient-specific CEA. The next three
sections of the chapter apply these three alternative methods to the assessment
of AH versus TCRE. Using the data presented in Chapters 5 and 7, these
sections consider a series of alternative additional comparators to TCRE and AH
alone, where treatment allocation is decided at the level of the individual patient
based on their preferences. The objective of this empirical analysis is to assess
the potential cost-effectiveness of moving towards ways of managing
menorrhagia that explicitly take account of women's preferences.
8.4 Surgical management of menorrhagia: treatment allocation by
patient choice
This first empirical section compares the costs and benefits of TCRE only, AH
only and a management strategy where women choose which therapy they
would like.
8.4.1 Methods
The methods employed are similar to those described in general terms in Section
8.3.1. Two alternative measures of benefit are used: expected QALYs and ex
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ante HYEs. The expected costs are based on those reported in Chapter 5, and
expected benefits of TCRE only and of AH only are taken directly from Chapter
5 (for the 'DALY analysis) and from Chapter 7 (for the ex ante HYE analysis), and
are based on extrapolation over a woman's expected lifetime. The expected
cost and benefit of the strategy of treatment allocation by choice are modelled
based on the patient-specific valuation data and treatment choice information
collected from the cohorts of women with menorrhagia recruited in Bristol (for
health state values) and Swindon (for ex ante HYEs), and which were also
detailed in Chapters 5 and 7, respectively. The various steps used in this
analysis are detailed below.
(a) As detailed in Chapter 4, each woman in both the Bristol and the Swindon
cohorts was asked to complete a questionnaire which sought information
on their attitudes to treatments and to treatment characteristics. In
Section 4 of the questionnaire, women were presented with two
descriptions, one of TCRE and the other of AH. These details included
information on some aspects of the process of care as well as the
outcomes, and included available prognostic information throughout the
woman's remaining lifetime. Women were asked to indicate which of
these two treatments they would choose to undergo, but were given the
opportunity to respond that they were unsure which treatment to choose
or that they would not choose either of the treatments. For the current
analysis, a woman is assumed to have chosen between TCRE and AH on
the basis on her answer to this question. Women who answered that
they would not undergo either therapy are excluded from the analysis.
Two alternative analyses are undertaken to deal with women who said
they were unsure which treatment to choose: in one they are assumed to
have a TCRE and in the other they are assumed to undergo AH.
(b) Depending on her treatment allocation, the cost of a woman's therapy is
taken as the expected lifetime cost of TCRE or of AH as detailed in
Chapter 5.
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(c) For the QALY analysis, the expected lifetime benefit following the therapy
is calculated by incorporating the health state values of each woman in
the Bristol cohort into the cost-utility model described in Chapter 5.
Depending on the treatment she chooses, the benefit for each woman is
taken as the expected QALYs associated with TCRE or AH, based on her
own health state values.
(d) For the ex ante HYE analysis, the estimate of lifetime benefit is based on
the ex ante HYEs elicited from women in the Swindon cohort. Depending
on which treatment a woman chooses, her ex ante HYE is that of AH or
TCRE, again based on her own values.
(e) The cost of the treatment allocation by choice strategy is taken as the
average of the cost of treating the women according to the her chosen
therapy. In the base-case analysis, it is assumed that the process of
informing women and of eliciting their choice of treatment imposes no
additional cost.
(f) Similarly, the expected benefit of the choice-based strategy is estimated
by averaging the individual expected QALYs for the Bristol cohort and the
individual ex ante HYEs for the Swindon cohort, according to each
woman's treatment choice.
8.4.2 Results
Consistency between patient-specific benefits and their treatment choices
in the questionnaire. Of the 60 women interviewed in Bristol to elicit health
state values, 59 responded to the item in the questionnaire which asked them to
choose between AH and TCRE on the basis of the information provided. Of
these, 29 (49%) chose AH, 21(36%) chose TCRE, 2 (3%) indicated that they
would choose neither and 7 (12%) said they were unsure which one to choose.
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The consistency between women's treatment choices in the
questionnaire and the treatment with the higher expected QALYs based
on incorporating women's individual health state values into the cost-
utility model
When the health state values elicited from these women are incorporated into
the model, it is possible to assess the consistency between women's choice of
treatment in the questionnaire and the therapy with the highest expected QALYs
on the basis of their particular health state values. Figure 8.2 shows this
assessment of consistency. The majority of women (26/29) who chose AH in
the questionnaire also have higher patient-specific QALYs for AH than for TCRE.
However, this level of consistency is not maintained for women who chose TCRE
in the questionnaire, as 1 2/1 9 of these women had higher patient-specific
QALYs for AH than for TCRE. This finding is probably due to the fact that, as
reviewed in Chapter 7, QALYs do not predict accurately individual choice; in
other words, women do not make decisions using the same 'model' as is being
employed for the CUA. For example, if a women chose TCRE in the
questionnaire because the duration and severity of convalescence were very
important to her, this is unlikely to be reflected in her QALYs because
convalescence gets 'drowned out' in the QALY model as it is only a very small
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part of the 44 year time horizon. Overall, there was clear inconsistency between
women's choice in the questionnaire and the treatment with the higher patient-
specific QALYs in 15/59 women.
Of the cohort of 63 women from whom ex ante HYEs were elicited in Swindon,
58 responded to the item in the questionnaire about choosing between AH and
TCRE on the basis of the descriptions provided. Of these, 24 (41%) chose AH,
24 (41%) chose TCRE, 2 (4%) said that they would choose neither and 8 (14%)
said they were unable to choose. Figure 8.3 shows the consistency between
these treatment choices and the treatment with the highest individual ex ante
HYEs. Of those women choosing AH in the questionnaire, 17/24 provided a
higher ex ante HYE for that therapy than for TCRE. Of the women choosing
TCRE, however, 11/24 provided ex ante HYEs that were equal for TCRE and AH,
and 7/24 gave higher ex ante HYEs for AH than for TORE.
The equality of HYEs in women choosing TCRE could be explained by that fact
that, although women might choose TORE before AH, their strength of
preference is not sufficient to register in terms of HYEs. However, the 29% of
women who 'chose' TORE but registered a higher HYE value for AH is a source
of inconsistency that is less easily explained. One possibility is that the
descriptors used to elicit HYEs were slightly different to those used in the
questionnaire; another explanation could be that women's views altered between
completing the questionnaire and being interviewed. Overall, there was clear
inconsistency between women's choice in the questionnaire and the treatment
with the higher patient-specific ex ante HYEs in 12/58 women, a slightly lower
rate than for the QALY-based analysis.
The cost and benefit of choice-based treatment allocation. Table 8.1
shows the costs and benefits of the management strategy of treatment
allocation by choice, compared to TORE only and AH only. Analyses using
expected QALYs and ex ante HYEs are presented and, in both cases, the
implications are considered of alternative assumptions about the treatment
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The consistency between women's treatment choices in the
questionnaire and the treatment with the higher benefit based on their
individual ex ante HYE values
allocated to women who are unable to choose between AH and TCRE. The
choice-based strategy obviously has a mean expected cost per patient lying
somewhere between the expected cost of TCRE only and that of AH only,
because there will be a mix of the two treatments chosen.
When benefits are measured in terms of expected QALYs using the cohort of
women from Bristol, the mean benefit per patient is less than that of AH only,
whatever the treatment allocation for women who are unable to choose between
the two therapies. In Chapter 5 two illustrative incremental cost per QALY
thresholds were suggested to guide decision making using CUA. If these
threshold ratios are considered acceptable, the incremental costs per QALY in
Table 8.1 suggest that a patient choice strategy, with women who are unable to
choose being allocated to AH, would probably be considered better value for
money than TCRE only or patient choice with TCRE given to women who are
unable to choose. However, with an incremental cost per additional GALY of
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Table 8.1
	
Lifetime expected costs and benefits of TCRE only, AH only and a
management strategy where women are allocated to treatment on the basis
of their choice
Management Strategy	 Expected cost
	 Benefit per	 Incremental cost pe
per patient (£)
	
patient	 additional unit of
benefit (£)
Using expected (standard) QALYs
TCRE only
Allocation by choice:
n Given TCRE if unable to
choose
992	 15.038
	 282
Given AH if unable to
choose
AH only
Using ex ante HYEs
TCRE only
Allocation by choice:
1035	 15.142	 413
1162	 15.195	 2396
816	 32.62
.n
	 Given TCRE if unable to
choose	 964	 35.06	 146
- Given AH if unable to
choose	 1014	 35.24	 278
AH only	 1162	 34.84	 Dominated
£2396 over patient choice, AH only is likely to be viewed as the most cost-
effective of the comparators if the illustrative thresholds are acceptable.
This conclusion is not replicated when benefits are considered in terms of ex
ante HYEs, as both choice-based strategies have a higher mean benefit than AH
only, and a lower expected cost; in other words, the choice-based strategies
dominate AH only. On the basis of the incremental costs per additional HYE
shown in Table 8.2, the use of choice, with AH given to those women unable to
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choose, would probably be considered the most cost-effective form of
management.
This analysis has not included the cost of presenting women with information
and eliciting their choice of therapy. If the information element of this process
took the form of a video and/or booklet, the resource cost would mainly be fixed
and, once spread out across thousands of women, would be quite modest. If a
Grade F nurse were used to undertake a semi-structured interview lasting about
15 minutes, the cost would be about £2.50 per patient. Even allowing for
hospital overheads, the cost of information and choice elicitation is unlikely to
alter the conclusions reached above.
8.5 Surgical management of menorrhagia: treatment allocation by
patients' values
This second empirical section compares the costs and benefits TCRE only, AH
only and a management strategy where women are allocated to one of these two
treatments according to which has the higher patient-specific benefit, where
benefit is measured in terms of expected QALYs or ex ante HYEs. This differs
from the first analysis in that women's treatment-related choices play no part in
treatment selection, which is based only their values. The premise of this
management strategy is that women's values will be a reasonable, albeit
imperfect, predictor of their preferred treatment.
8.5.1 Methods
The methods used for this analysis are very similar to those used in the choice
analysis, and these are detailed below.
(a)	 Again, two analyses are presented: one using expected lifetime QALYs as
the means of treatment allocation and of benefit measurement, and the
other using lifetime ex ante HYEs.
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(b) For the values based strategy, women are allocated to AH or TCRE using
the following decision rules. For the expected QALYs analysis, the health
state values of each woman in the Bristol interview cohort are
independently entered into the cost-utility model. Treatment allocation for
a given woman depends on which treatment provides the higher number
of expected QALYs. For the ex ante HYE analysis, the same principle
applies: a given woman in the Swindon interview cohort is allocated
between AH and TCRE on the basis of which treatment she valued more
highly in terms of ex ante HYEs. Women who valued AH and TCRE
equally in terms of ex ante HYEs are assumed to be allocated to TCRE
which would dominate AH for these women (ie. TCRE is valued equally
with AH, but AH is more costly).
(c) The estimated benefit of the values-based treatment allocation strategy is
the mean expected lifetime GALYs or ex ante HYEs for the group as a
whole, where each woman has been allocated to AH or TCRE as
described in (b).
(d) The expected lifetime cost of the values-based strategy is calculated in
the same way as for the choice-based allocation strategy. In the base-
case analysis, the process of eliciting values is assumed to impose no
additional cost.
8.5.2 Results
Figure 8.4 shows the distributions of expected lifetime QALYs for AH and TCRE
resulting from incorporating the health state values of each woman in the Bristol
cohort separately. The figure shows the greater concentration of expected
QALYs at the top of the range for AH compared to TCRE which, of course,
explains the higher mean expected QALYs with AH detailed in Chapter 5. Also
reflecting this, if women are allocated to one of the two treatments depending
on which one generates the higher number of QALYs using women's individual
health state values, 77% would be allocated to AH and 23% to TCRE.
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Figure 8.4
	
Distribution of expected lifetime QALYs based on the individual health
state values of women in the Bristol interview cohort
Figure 7.3 in the previous chapter showed the distribution of ex ante HYEs
elicited from women in the Swindon interview cohort. If treatment allocation is
on the basis of the higher ex ante HYE value, only 43% would be allocated to
AH and 57% to TCRE. However, these figures are partly a product of the
assumption that the 29% of women who valued AH and TCRE equally in terms
of ex ante HYEs are allocated to TCRE because it is the cheaper option.
Table 8.2 shows that, if the values elicited from the Bristol and Swindon cohorts
are considered representative of women with menorrhagia generally, a
management strategy of treatment allocation on the basis of women's values
would almost certainly be considered cost-effective relative to AH only or to
TCRE only. On the basis of both expected QALYs and ex ante HYEs, the values-
based management strategy would dominate AH only, generating greater benefit
and costing less per patient. Compared to TCRE, treatment allocation on the
basis of values would cost more per patient but generate more benefit, with each
extra unit of benefit costing a relatively modest amount - if illustrative cost per
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Table 8.2
	
Expected costs and benefits of TCRE only, AH only and a management
strategy where women are allocated to a treatment on the basis of their
health state values or ex ante HYEs
Management Strategy Expected cost
per patient (£)
Benefit per
patient
Incremental cost per
additional unit of
benefit (£)
Using expected (standard)
QALYs
TCRE only 816 14.413
Allocation by values 1,081 15.275 307
AH only 1162 15.195 Dominated
Using ex ante HYEs
816 32.62
TCRE only
964 36.63 37
Allocation by va(ues
1162 34.84 Dominated
AH only
QALY thresholds suggested in Chapter 5 are accepted, a values-based treatment
allocation strategy would be considered more cost-effective than TCRE only.
This analysis does not include the cost of eliciting women's values. If a Grade F
nurse were used to undertake a semi-structured interview lasting about 45
minutes, the cost would be about £7.50 per patient - more than for the choice-
based strategy as values are likely to take longer to elicit that choices. Even
allowing for hospital overheads, the cost of eliciting values is unlikely to alter the
conclusions of the analysis.
8.6 Surgical management of menorrhagia: treatment allocation using
patient-specific CEA
This third empirical section compares the costs and benefits TCRE only, AH only
and a management strategy where women are allocated to one of these
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treatments according to patient-specific CEA. This analysis differs from the last
one due to the fact that cost as well as benefit are considered when allocating
an individual woman to a treatment. Hence, it is not enough for a woman to
benefit (on the basis of her health state values or ex ante HYEs) more with one
therapy than the other; the additional benefits have to be sufficient to justify any
additional cost at an individual level.
8.6.1 Methods
The methods used for this analysis are similar to the last, with two analyses
being undertaken, one using expected lifetime QALYs and the other lifetime ex
ante HYEs. The only difference is the way in which women are allocated to AH
or TCRE. Taking the expected QALYs approach first, as before, the health state
values of each woman in the Bristol cohort are incorporated individually into the
cost-utility model. The expected GALYs generated for AH and TCRE are
compared with the average cost of delivering those two therapies, and a woman
is allocated to one of them based on the following decision rules.
(a) If a woman's expected lifetime QALYs (based on her specific health state
values) are greater for TCRE than for AH, she is allocated to TCRE
because, in terms of her personal analysis, TCRE dominates AH, being
less costly and generating more benefit.
(b) If a woman's expected lifetime QALYs are higher for AH than for TCRE,
she will be allocated to AH as long as her personal cost-utility ratio
(additional expected cost of AH divided by the additional personal
expected QALYs with AH) is lower than the threshold ratio. Alternative
analyses are undertaken using the upper (£33,000 per additional QALY)
and lower (£6,500 per additional QALY) illustrative thresholds adopted in
Chapter 5.
303
Chapter 8
	 Preference-based economic evaluation
Table 8.3
	
	
Proportions of women allocated to TCRE and AH at different critical ratio
threshold ratios using patient-specific cost-effectiveness analysis
Threshold ratio (£)
% of women allocated to:
AH TCRE
Using expected (standard) QALYs
£6,500 58 42
£33,000 75 25
Using ex ante HYEs
100 36 64
80 25 75
60 22 78
40 16 84
20 6 94
The methods for the ex ante HYE analysis are similar. Each woman's personal
ex ante HYEs for AH and TCRE are considered, and she is allocated to AH or
TCRE using the following decision rules.
(a) If a woman's ex ante HYEs for TCRE are greater than or equal to those
for AH, she is allocated to TCRE because, in terms of her personal
analysis, TCRE dominates AH.
(b) If a woman's ex ante HYEs are higher for AH than for TCRE, she will be
allocated to AH as long as her personal cost-utility ratio is lower than a
threshold ratio. Given that ex ante HYEs have yet to be used widely in
applied economic evaluation, it is not clear what values would be
attached to cost per unit of benefit thresholds above which treatment
would not be considered cost-effective. However, for the purposes of
this analysis, alternative analyses are reported using five illustrative
thresholds.
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8.6.2 Results
Table 8.3 shows the proportions of women, under alternative threshold ratios,
who would be allocated to TCRE and AH using a management strategy based on
patient-specific CEA. Clearly, as the threshold ratio increases, more women
would be allocated to AH.
Table 8.4 shows the expected costs and benefits of a management strategy
based on patient-specific CEA, in comparison with TCRE only and AH only. As
with the management strategy based on women's health state values, a policy
of AH only is dominated on the basis of expected QALYs and of ex ante HYEs.
Furthermore, using expected QALYs, patient-specific CEA would be considered
better value for money than TCRE only if the lower illustrative threshold ratio of
£6,500 is accepted, with an incremental cost per additional QALY of only £236.
If the upper threshold of £33,000 were accepted as the threshold above which
women would be allocated to TCRE, this would be more costly and generate
more expected QALYs, which each additional GALY costing an additional
£9,667 over patient-specific CEA with the lower threshold. A similar position
prevails when ex ante HYEs are used as the benefit measure. Although it is
difficult to suggest what might be a generally acceptable cost per HYE threshold,
the incremental cost per additional HYE of moving from a TCRE only to a patient-
specific CEA (with a £20 threshold ratio) would only be £13. As with the other
strategies analysed above, the cost of eliciting the values from women is unlikely
to alter the position shown in Table 8.4 markedly.
8.7 Discussion
8.7. 1 The concept of preference-based treatment allocation
To date, economic evaluation has concentrated on identifying a single cost-
effective intervention from amongst those under comparison. In those clinical
areas where there are clear trade-offs between aspects of the process and
outcomes of treatment, strict adherence to an all or nothing approach by
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Table 8.4
	 Lifetime expected costs and benefits of TCRE only, AH only and a
management strategy where women are allocated to treatment on the
basis of patient-specific cost-effectiveness analysis
Management Strategy Expected cost
per patient (f)
Benefit per patient Incremental cost per
additional unit of benefit
(El
Using expected
(standard)
GALYs
TCRE only 816 14.413 -
Allocation by patient-
specific CEA with
threshold ratios of:
£6,500 1018 15.269 236
£33,000 1076 15.275 9,667
AH only 1162 15.195 Dominated
Using ex ante HYEs
TCRE only 816 32.62
Allocation by patient-
specific CEA with
threshold ratios of:
£20 838 34.28 13
£40 871 35.39 30
£60 893 35.87 46
£80 904 36.02 73
£100 942 36.47 84
AH only 1162 34.84 Dominated
purchasers will lead to a proportion of patients receiving interventions that are
inconsistent with their preferences. Just as it is an established part of clinical
(and economic evaluation) to explore management strategies which allocate
patients to therapies on the basis of clinical characteristics which may influence
outcomes, there is surely a need to consider ways in which the impact of
patients' preferences on the benefits they derive from treatment can be reflected
in treatment allocation. Whatever the form of preference-based treatment
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allocation, the principal aim is to maximise benefits just like any other economic
evaluation. However, this approach to patient management explicitly accepts
that, given appropriate information, patients may be the best judges, on an ex
ante basis, of the benefits they are likely to experience from treatment. This
judgement could be direct, through choice-based allocation, or indirect, through a
values-based approach.
MAS is a prime example of a group of technologies where there is likely to be a
trade-off in the process and outcomes of care relative to conventional surgery,
where patients are likely to have clear attitudes to these trade-offs if made
aware of them and, therefore, where the role of preferences in patient
management should be carefully assessed. Surgical treatment for menorrhagia is
a good, but by no means the only, example of where these methods could be
used. For example, the trade-offs between the process and outcomes of
percutaneous transluminal coronary angioplasty (PTCA) and coronary artery
bypass surgery (CABG) are perhaps even more stark, and suggest a possible role
for preference-based treatment allocation in that clinical area [1-1Iatky 1995].
In the specific context of surgical treatment for menorrhagia, the foregoing
analysis has indicated that a greater use of patients' preferences in making
treatment decisions may prove a cost-effective alternative to reliance on one
therapy for all patients. If such strategies are to be used in practice, decisions
will be required about which of the three approaches considered here is likely to
be the most cost-effective. Table 8.5 compares the costs and benefits of all
three preference-based forms of management and of AH only and TCRE only.
Given that the pattern of relative costs and benefits is broadly similar whether
expected Q.ALYs or ex ante HYEs are used as the benefit measure, the table
presents data relating to expected QALYs only, where it is easier to judge what
incremental costs might be considered worth paying to generate additional
benefits.
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Table 8.5
	
	
Lifetime expected costs and QALYs of TCRE only, AH only and the three
alternative preference-based management strategies
Management Strategy	 Expected costper	 Benefit per patient Incremental cost
patient (£)	 additional unit of
benefit (£)*
TCRE only	 816	 14.413
Preference-based
allocation by:
choice (given TCRE if
	 992	 15.038	 ED
unable to choose)
personal CEA (threshold
	
1018	 15.269	 236
ratio = £6,500)
choice (given AH if unable	 1035	 15.142	 D
to choose)
personal CEA (threshold	 1076	 15.275	 9667
ratio = £33,000)
Values	 1081	 15.275	 D
AH only	 1162	 15.195	 D
D	 =	 Subject to domination (more costly, no more effective than next least costly option)
ED	 =	 Subject to extended dominance (higher incremental ratio than that relating to a more
costly and more effective option).
*	 =	 Relative to the next least costly option not subject to dominance or extended
dominance
The table ranks all options under consideration in ascending order of expected
cost. An incremental cost per additional QALY is then calculated relative to the
next least costly non-dominated option. Coming down the table, options that are
more costly and no more effective than earlier ones are subject to dominance
(they are unequivocally inferior in economic terms). If an option has a higher
incremental ratio than a more costly and more effective option, it is subject to
extended dominance and can also be rejected [Cantor, 1994]. On that basis,
patient-specific CEA would seem to be the most cost-effective preference-based
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strategy: it dominates the choice-based and values-based strategies and AH only,
and has only a modest incremental cost per additional QALY over TCRE only.
This conclusion is not surprising as the strategy goes furthest towards 'fine-
tuning' treatment allocation to patient benefit but with a consideration of cost at
the level of the individual.
There are some important caveats, however, associated with this conclusion.
Firstly, Chapters 5 and 7 of this report detailed the uncertainty which exists in
key parameters of the CUA of TCRE versus AH. In particular, the health state
values elicited from the Bristol cohort of women and the ex ante HYEs provided
by the women interviewed in Swindon showed considerable variability. Although
the conclusions of the QALY-based analysis in Chapter 5 were found to be
robust to individual variation in these parameters, the variability in the ex ante
HYE values limited the firmness of the conclusions of the alternative CUA in
Chapter 7. Indeed, the sensitivity of the relative cost-effectiveness of the two
surgical options to women's values was a major reason for assessing the costs
and benefits of preference-based management strategies. A key source of
uncertainty associated with cost and benefit estimates presented in this chapter
is the relatively small size of sample of women from whom values and choices
were elicited. For this reason, the absolute value of the incremental cost and
benefit estimates related to preference-based management should be considered
tentative. However, the general finding that expected benefits can be increased
by tailoring treatments to women's preferences, and that this has the potential
also to be cost-effective, is important and, although in need of confirmation with
further research, is likely to be robust to the various sources of uncertainty.
A second and related caveat is that the generalisability of the values and
treatment choices elicited from the women in Bristol and Swindon needs to be
considered. The fact that the cohorts were drawn from just two centres would
suggest that these samples may not be representative of women with
menorrhagia in the country as a whole. Again, although the broad conclusion
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remains valid, definitive estimates of cost-effectiveness should await further
research.
A third caveat associated with the conclusions of the analysis is that women's
choices in the study were based on restricted information. A management
strategy which allows women to select their therapy would only be feasible if
sufficient detailed and comprehensible information on the alternative therapies
were provided to women in an accessible form. In the analysis presented here,
women's choices were based on their responses to an item in the questionnaire
sent to them shortly after referral which provided limited information on the two
forms of surgery.
A fourth caveat concerns the scope of the benefits considered in the model. A
preference-based approach to the management of menorrhagia could include two
important benefits which are not typical outcomes from care: information
provision and choice. These can be viewed as process-related benefits [Ryan
and Shackley, 1995], or as specific forms of outcome [Dowie, 19931. Either
way, although the use of ex ante HYEs in Chapter 7 allowed patients' values in
relation to the process of treatment to be reflected in the measure of benefit, the
combination of a modelling approach and the type of descriptive scenarios
chosen for the valuation exercise has effectively excluded patients' values
regarding information and choice. Indeed, it is not clear whether these
consequences of preference-based management would be benefits or disbenef its:
evidence indicates that, whilst most patients value information, many prefer not
be to involved with decision making and may derive disbenef its from being
obliged to make choices [Cassileth et al, 1980; Beisecker et al, 1990].
A final caveat relates to the cost of preference-based treatment allocation. If a
health care provider has to be able to provide two or more treatments when, on
the basis of all or nothing economic evaluation, they would have offered only
one, there may be cost implications not allowed for in the analysis here. For
example, if the procedures involve the use of expensive equipment, the use of
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preference-based strategies would probably result in fewer patients undergoing
any given treatment, resulting in higher equipment costs per patient as these
fixed costs are spread over fewer procedures.
8.7.2 The practicalities of preference-based management
If the realities of using the three preference-based strategies in routine practice
are considered, the patient-specific CEA may be considered the least practical of
the strategies, although the analysis presented here suggests it is likely to be the
most cost-effective. There may be logistical difficulties in eliciting values for
each woman presenting for surgical treatment for menorrhagia (a problem shared
by the treatment allocation by values strategy), but the development of valuation
tools such as interactive videos and computers could address some of these
difficulties [Neese et al, 1996]. It is possible that patients will understand that
the higher the values they give for a specific treatment or health state, the more
likely they are to receive the treatment they desire, so a problem of 'gaming'
may exist. Perhaps a more fundamental problem for some would be the equity
implications of patient-specific CEA, in that some patients would not receive an
intervention despite being clinically identical to other patients who would
undergo the treatment: in this context tile hea(th care system would be saying
that a woman would derive clinical improvement from a procedure but they
would not value that improvement sufficiently to justify the cost. However, if it
is accepted that patients' benefits from a given intervention are related to their
values as well as to expected clinical outcomes, and that resource allocation
should consider patients' capacity to benefit, it follows that values and clinical
characteristics should be assessed at the individual level, as well as the level of
the group as with standard CUA.
Given that the use of choice-based management avoids the need to elicit values
from patients and is probably less controversial from the viewpoint of its equity
implications, it might be considered more feasible for routine practice. Although
the analysis here suggests it may not be as cost-effective as AH alone in terms
of QALYs, it is also found to dominate AH in terms of ex ante HYEs.
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Furthermore, this balance might change once 'process-related' benefits are
incorporated, such as the value patients attach to information and choice per se.
The major challenge for all forms of preference-based treatment allocation is the
need to provide accurate, comprehensive and accessible information to women.
Whereas a strategy based on women's values to estimate individualised QALYs
relates information to a limited number of health states and allows the model to
indicate the treatment with the highest expected benefit, choice-based
management requires that the patient is able to come to a decision themselves
about their preferred therapy on the basis of any information they care to use.
For this sort of approach to work, there needs to be more research into the use
of novel information tools such as interactive videos and computers [Barry et al,
1995; Shepperd eta!, 19951.
It is important to consider the potential conflicts which may arise between
clinical judgements about specific patients and preference-based treatment
allocation. The assumption that underlies the analysis in this chapter is that the
women in the Bristol and Swindon cohorts are clinically homogenous and differ
solely in terms of their preferences. Clearly, however, clinicians will form
opinions about the clinical appropriateness of treatments for specific women
which may or may not be based on good evidence. The use of preference-based
treatment allocation is likely to work best when the clinician is satisfied that AH
and TCRE are both clinically feasible and acceptable. Clearly, it will not be
possible to use the strategy when a woman has an absolute clinical contra-
indication for one of the treatments. However, conflicts may arise when a
woman is considered to have a relative clinical contra-indication for a particular
therapy. Generally, a clinician would probably rule out the therapy in those
circumstances. However, under preference-based management strategies, the
woman should ideally be made aware of the contra-indications of therapy and
their implications for her prognosis, and be allowed to make her choices or
provide her values accordingly.
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8.8 Conclusions
This chapter has modelled the costs and benefits of three preference-based
forms of management, and has shown, in the context of AH versus TCRE, that
each of them has the potential to be more cost-effective than TCRE alone, and
that values-based and patient-specific CEA-based approaches could be more
cost-effective than both TCRE and AH alone. Although the empirical estimates
presented in this chapter should be interpreted with caution, the conclusion that
preference-based management has the potential to be more cost-effective than
the conventional all or nothing strategy is an important one for the economic
analysis of MAS. Given the trade-offs in the outcomes between many forms of
MAS and open surgery, it may be the case that expecting all patients to undergo
the same therapy, whatever their choices or values, is unrealistic. It is likely,
therefore, that management based on patients' preferences will play a greater
role in these contexts.
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The starting point of this analysis was a consideration of trial-based economic
evaluation of MAS. Like all economic evaluations, this form of analysis
introduces a range of different uncertainties relating to data inputs,
generalisability, extrapolation and analysis [Briggs eta!, 1994]. The subsequent
chapters of the thesis focused on issues of method associated with illuminating
particular areas of uncertainty related to benefit measurement, generalisability
and incorporation of patients' preferences into treatment allocation.
The purpose of this final chapter is to pull together and summarise the main
methodological and empirical findings of the six main chapters, to draw some
broad conclusions about the economic evaluation of MAS and to indicate the
contribution of the thesis to the methods of economic evaluation.
9.2 Trial based evidence
9.2.1 Methodological analysis
The economic evaluation of many applications of MAS will begin at a much
earlier stage than the randomised controlled trial (RCT). Ideally, analysis should
begin when new MAS technologies are to be used in a few centres by
enthusiasts, using available data and modelling techniques - Stage I analysis in
the language of iterative economic analysis [Sculpher et al, forthcoming]. In the
case of the evaluation of TCRE relative to AH, however, no economic analysis
had been undertaken prior to the start of the Bristol trial which, therefore,
became a valuable source of data with which to begin the economic evaluation.
Chapter 3 presented the economic analysis of AH and TCRE undertaken
alongside the Bristol RCT. The analysis represents the foundation on which the
subsequent analyses in the thesis is built. The main purpose of this element of
work was to identify the limitations of trial-based economic evaluation in the
particular context of the evaluation of MAS, and hence to act as a rationale for
the methodological developments described in later chapters. Many of the
methodological issues highlighted by the analysis in Chapter 3, therefore, have
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been identified in earlier studies. However, it remains an important contribution
of the thesis to have indicated which shortcomings of economic analysis
alongside trials are particularly problematic for the evaluation of MAS
applications, and these are detailed below.
• A trial set up to evaluate a new MAS application from a clinical
perspective is likely to exhibit weaknesses in terms of its usefulness in
facilitating economic conclusions. These may include a failure to collect
all the items of data which are important for economic analysis; and too
small a sample size to generate reliable estimates of those parameters
central to the economic comparison, a problem often compounded by the
difficulty in recruiting patients into trials involving MAS techniques.
However, the value of RCT data for economic analysis is its high level of
internal validity. This can provide a valuable empirical platform upon
which to assess relative cost-effectiveness, but this form of analysis
cannot be seen as the final word in the economic evaluation of a new
form of MAS.
• A major limitation of data from an ROT is the limited external validity they
often exhibit. Most of the RCTs undertaken to compare MAS with
conventional surgery have been undertaken within a small number of
specialist centres using clinical practice which is atypical of that routinely
used in the majority of centres. The trial used as a starting point for the
economic analysis of AH versus TCRE was an extreme example of this,
taking place in a single medical school, with both forms of surgery
undertaken by a single surgeon using specific versions of the operations.
The external validity of trials can be increased by incorporating a greater
mix of centres, clinicians and techniques, but limitations to generalisability
will remain. Furthermore, trials of MAS tend to take many months, often
years, to report their results, during which time the technologies have
moved on in the form of minor or substantive modifications. The
uncertainty in terms of generalisability that this generates needs to be
addressed using other data sources.
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• Trial-based economic analysis of MAS is often limited by the outcome
data collected. Many trials are set up principally to answer clinical
questions, and they tend to collect a range of outcome data, most of
which are not patient-based. It is frequently the case that MAS
applications have a range of different outcomes which, in comparison
with those of conventional surgery, tend to go in different directions.
This situation is made more complex by differences in process
characteristics. Even when trials have been set up with an explicit aim of
informing economic analysis of MAS, it is usually difficult to identify a
single, all-embracing and uni-dimensional measure of outcome suitable for
cost-effectiveness analysis (CEA) of this group of technologies. The
patient-based measures of outcome have usually been descriptive health-
related quality of life (HRGLI profRes which do not provide a single score.
A number of RCTs of MAS procedures have been powered on patient
satisfaction rates. In relation to AH and TCRE, Chapter 3 showed that
dichotomising satisfaction offers a means of undertaking CEA in this area.
However, differences in measuring satisfaction between studies and
uncertainties about measurement techniques make this an imperfect
measure of outcome upon which to base CEA.
• Even if 'natural' measures of outcome suitable for CEA can be identified
in RCTs, at best they will be able to inform resource allocation within
programmes and disease areas. Furthermore, CEA does not provide a
clear means of factoring individuals' (patients' or others') preferences into
the economic analysis. If, from the outset, a trial has been set up to
explore economic issues, there is now scope to collect data necessary to
develop a cost-utility analysis (CUA) and to inform system-wide resource
allocation. Valuation systems such as the EuroQol instrument allow
patients to be 'described' over time using a generic classification linked to
a tariff of health state values. In the economic analysis of AH versus
TCRE, the trial was planned from the perspective of clinical evaluation,
and no such data were collected. In certain contexts, the usefulness of
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the valuation system approach may be limited by too few data collection
time points being feasible within a trial and by the limited sensitivity of
the instruments. It will, therefore, frequently be necessary to collect data
for CUA subsequent to a RCT.
9.2.2 Empirical analysis
From this trial-based empirical work, it is possible to reach a number of
conclusions about the economic comparison of AH and TCRE as an example of
MAS compared to conventional surgery.
• On the basis of the outcome data collected in the trial, it is not possible to
select either therapy as unequivocally more effective. On the side of
hysterectomy is the once-and-for-all end to heavy blood loss, a greater
improvement in other menstrual symptoms, some evidence of a greater
improvement in HRQL and higher rates of satisfaction with treatment on
the part of women. In favour of TCRE is the shorter convalescence and
the fact that menstrual symptoms and HRQL do improve, albeit not to the
extent experienced by women undergoing hysterectomy. The failure rate
of TCRE (between 23% and 25%), manifesting itself in terms of repeat
surgery, is a major shortcoming of the procedure.
• If it is assumed that women weigh up their perception of the various
aspects of the process and outcomes of the treatment they received to
come to an overall assessment in terms of their stated satisfaction with
treatment, then this measure perhaps come nearest to an all-embracing
measure of the relative effectiveness of AH and TCRE from a RCT. If this
is the case, AH would probably be considered more effective than TCRE:
96% of women were 'very satisfied' or 'quite satisfied' with AH
compared to 79% with TCRE in the Bristol trial at a mean follow-up of
2.2 years.
• The implications of the two forms of treatment for NHS costs is rather
clearer than their relative effectiveness. The initial cost of AH is
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significantly higher than that of TORE, a cost difference which is driven
largely by the higher length of stay in hospital. The key question has
been whether this cost differential will be substantially eroded, or even
removed, by the re-treatment necessary for some women after TORE? On
the basis of the data reported in Chapter 3, the answer to this question
appears to be that it will not. The longer the follow-up, the more women
will reach the menopause or be prepared to put up with any failure of
TORE until the menopause, so the failure curve shown in Figure 3.1 is
likely to flatten out. This, together with the effect of discounting of
future costs, would suggest that TORE will retain its cost advantage.
•	 A key issue, therefore, is whether the improved effectiveness of AH, in
terms of women's satisfaction with treatment, is sufficient to justify its
additional cost. The tools of CEA express this problem for purchasers in
terms of an incremental cost effectiveness ratio. On the basis of the
evidence from the two-year follow-up in the Bristol ROT, this ratio was
estimated to be f1882 per additional women satisfied with treatment. It
remains for decision makers to decide whether this is a reasonable cost to
pay.
The ROT is seen as the gold standard of clinical evidence, and is becoming an
important vehicle for the economic analysis of MAS. However, both in general
terms and in the specific context of the comparison of AH and TCRE, RCTs need
to be augmented by data from other sources to assist decisions about resource
allocation. However, methods for moving beyond standard trial-based analysis
are not refined. An important goal of this thesis has been to develop evaluative
methods in three areas: generic measures of benefit for use in CUA which
adequately reflect patients' preferences for the process and outcomes of care;
methods to assess the generalisability of RCT-based economic evaluation when
the resource and non-resource consequences of routine clinical practice are
considered; and an analysis of how choices about treatment allocation might be
shaped by the preferences of individual patients.
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9.3	 Cost-utility analysis
Chapters 5 and 7 of the thesis considered in detail the methods of CUA and their
implications for the economic comparison of AH and TCRE. The purpose of
undertaking such an analysis in this clinical context is threefold:
(a) to assess cost-effectiveness using a measure of benefit which draws
together the multi-dimensional outcomes of the two treatments more
meaningfully than the satisfaction rates collected in the trial;
(b) given the fact shown in Chapter 4 that women do have preferences about
the characteristics of treatment, to undertake this combination of
outcomes into an overall measure of benefit in a manner which reflects
patients' preferences about the relative value of those outcomes; and
(c) to provide a generic measure of benefit which has meaning outside the
area of menorrhagia and can, therefore, provide an input into decision
making across specialties and treatment areas.
9.3.1 Methodological analysis
Although CUA is now frequently used in the economic evaluation of health care
programmes [Gerard, 1992], much uncertainty exists about the appropriate
methods for such analysis. The methodological issues relating to CUA
considered in this Chapters 5 and 7 are detailed below.
•	 The methods adopted in the base-case of the CUA reported in Chapter 5
focused on standard quality-adjusted life years (QALYs). The process
involved the development of descriptive scenarios to represent key health
states experienced after the procedures; the valuation of those health
states, using the time trade-off instrument, by a sample of 60 women
recently referred to hospital with menorrhagia; and the estimation of
QALYs using this group's values. Other methods have been used in
economic evaluation and could have been adopted here. For example,
women's prognosis after surgery could have been broken up into a
different series of health states; the scenarios could have been framed
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differently; an alternative valuation instrument could have been employed;
and health state values could have been elicited from a different sample
of individuals. The evidence on framing effects is conflicting and a recent
large-scale study in the UK indicates that the time trade-off is probably
the strongest of the choice-based valuation instruments, at least in
practical terms. However, the range of methods available for CUA
inevitably emphasises the degree of analytical uncertainty which exists in
this and all other CUAs.
• The use of CUA to reach conclusions about the cost-effectiveness of
MAS compared to conventional surgery, where one intervention is more
costly and generates more benefits in terms of QALYs, is limited by the
absence of widely accepted cost per QALY thresholds. Such thresholds
are necessary, if CUA is to be used to inform cross-programme resource
allocation, as a means of systematically exploring the robustness of
conclusions to the myriad sources of uncertainty that exist within
analyses. However, these thresholds are likely to vary by location and
over time. Tentative suggestions for the value of these thresholds have
been been put forward in Canada. These have no firm methodological or
empirical basis and, although the broad range of thresholds used
throughout this thesis is based on the suggested Canadian thresholds,
they are illustrative only - local decision makers will have to decide the
extent to which they reflect policies towards resource allocation in their
areas. Based on these illustrative thresholds and following on from earlier
work undertaken by the author and colleagues [Briggs et al, 1994; Briggs
and Sculpher, 1995], the organisation and presentation of the sensitivity
analyses in Chapter 5 represent one contribution of this thesis.
• The standard QALY is characterised by splitting possible prognoses into a
series of health states which are valued and aggregated over time.
Chapter 7 shows that there is little evidence to link this approach to
benefit measurement in CUA to individual preferences. The value of the
standard QALY approach to CUA is as a management tool, as one
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element of the decision maker's resource allocation armamentarium. If
the benefit measure used in the economic evaluation of MAS is to reflect
how patients trade-off the various process and short- and long-term
outcomes of these interventions relative to open surgery, something less
crude than the standard QALY is required. A range of adaptions and
alternatives to the standard QALY have been suggested, but rarely
employed in applied studies.
• Chapter 7 used one of these measures - the ex ante healthy years
equivalent (HYE) - to assess the robustness of the standard CUA in
Chapter 5 to an alternative approach to benefit estimation. Instead of
splitting patients' possible prognoses following surgery into discrete
health states which are valued separately and in isolation, the ex ante
HYE values prognoses taken as a whole which include their inherent risks
and time-related factors. Ex ante HYEs were estimated from a sample of
63 women with menorrhagia, presenting each with a scenario describing
the lifetime profile of health-related factors that may follow the two forms
of surgery. The time trade-off was used to obtain a direct measure of the
periods of time in good health each woman considered equivalent to these
lifetime profiles. A notable outcome of the work presented in Chapter 7
showed that it is feasible to elicit ex ante HYEs from a patient population.
• Women's mean and median ex ante HYEs were found to be higher for AH
than TCRE, which is consistent with estimated benefits in terms of
expected CIALYs. However, the sampling variation around these
estimates is such that the two HYE estimates are not statistically
significantly different. As an all-embracing measure of benefit related to
particular technologies, ex ante HYEs can be directly related to other
indications of individuals' treatment-related preferences, both stated and
revealed by behaviour. Chapter 7 described a comparison of the
descriptive preferences provided by women in relation to AH and TCRE
and their ex ante HYEs. Although the sample size was small, some
indications of consistency between these two measures of preference can
322
Chapter 9	 Conclusions
be discerned, particularly at the level of the group, and this is an
important contribution of the thesis.
• The work reported in Chapters 5 and 7 emphasises that the choice
between the HYE and the standard QALY for applied economic evaluation
presents a trade-off to analysts. The GALY has value as a management
tool, but has no clear link with individual preferences; and it imposes a
reasonable measurement task, particularly when valuation systems are
used. The HYE has a clearer link to individual preferences, but it is likely
to impose a greater measurement burden; it also lacks the flexibility of
CIALYs for use in decision analytic modelling.
• Recently, a parallel area of methodological research in economic
evaluation in health, to the development of benefit measures for CUA, has
been the refinement of stated preference methods to facilitate cost-
benef it analysis (CBA). The major difficulty of valuing health-related
outcomes in monetary terms is the principal reason why CBA has not
been widely used in the field of health. However, recent work on
willingness to pay (WTP) methods has opened the possibility that CBA
can more frequently be applied in the area. Indeed, by trying to tie the
measurement of benefit used in economic evaluation more firmly to the
principles of welfare economic theory, the development of the ex ante
HYE mirrors that of WTP: typically, both methods present responders
with descriptions of interventions including information on risk, but the
basis of valuation with HYEs is healthy years whereas that for VVTP is
money. It remains an important research question whether economic
evaluation in health should move towards HYEs or WTP, or neither.
9.3.2 Empirical analysis
The CUA of AH and TCRE, using both standard GALYs and ex ante HYEs,
generated some important empirical conclusions.
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• Using the mean health state values elicited from women interviewed in
Bristol and a simple decision tree to model the clinical pathways along
which women pass, AH was found to generate more expected QALYs
than TCRE. Expected QALYs were sensitive to the values women
attached to the post-convalescence/pre-menopause health states relating
to the two forms of surgery. However, the value elicited for the post-AH
health state was statistically significantly higher than that for the post-
TCRE state, indicating that this conclusion was robust at least to the
sampling variation in the two health state values.
• When the estimates of expected QALYs were synthesised with cost
estimates based on resource use data collected within the Bristol RCT,
the base-case estimate of the increment& cost par arklitiDn& 4ALY with
AH was £1,500. As with the incremental cost-effectiveness ratio in
terms of additional women satisfied with treatment, decision makers will
have to decide whether this is a reasonable additional cost to pay for the
extra benefits offered by AH for the typical women with menorrhagia.
Here, two illustrative cost per QALY thresholds were used to guide
decision makers. If these thresholds are widely accepted, AH is likely to
be considered more cost-effective than TCRE on the basis of the base-
case estimate of costs and benefits.
• A series of sensitivity analyses has found that this conclusion is robust to
plausible one-way variation in data inputs. Although the estimate of
incremental cost per QALY was sensitive to such parameters as the cost
of a day on a ward and the value attached to the post-surgery health
states, plausible individual variation in these parameters was not
sufficient to take the ratio above the lower illustrative ratio of £6,500.
However, the conclusion that AH is more cost-effective than TCRE was
not robust to simultaneous variation in all uncertain data inputs. When all
the parameters were varied together to generate a pessimistic scenario
from the viewpoint of AH, the resulting ratio was as high as £255,000.
Although the circumstances necessary to generate such a high ratio in
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practice are unlikely to occur, the size of this theoretical ratio demands
some caution in interpreting the base-case cost per QALY estimate.
• When costs are related to the HYE-based measure of benefit, the
incremental cost per additional HYE was f'l 56, on the basis of mean
benefits. Although it is difficult to judge what would be considered an
acceptable ratio because very few CUAs using HYEs have been
undertaken, this would probably be seen as a modest additional cost per
unit of benefit. However, the fact that the HYE estimates for AH and
TCRE were not statistically significantly different generates a major
source of uncertainty in this conclusion.
9.4 Generalisability
Although trial-based evidence can provide high levels of internal validity for a
clinical and economic evaluation of MAS, it often fails to reflect the resource and
non-resource consequences of interventions as they are used in routine clinical
practice. Furthermore, the reliance only on trial data within an economic
evaluation may overlook the fact that variation in costs and outcomes within
trials may not be an accurate reflection of variation within routine practice; and
that new technologies tend to develop more quickly than trials can evaluate
them. These considerations generate a further source of uncertainty for
estimates of cost-effectiveness. Chapter 6 of this report, therefore, looked at
methods that can be used to assess the generalisability of an economic study.
9.4.1 Methodological analysis
The development of a framework within which to assess the generalisability of
economic evaluations is an important contribution of this thesis. The key
methodological issues are discussed below.
• The location and context of an economic evaluation is likely to influence
markedly the four elements of an analysis: resource use, outcomes, unit
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costs and health state valuation data. Despite this, formal assessment of
generalisability is rarely undertaken in economic evaluation, with the
limited published work focusing on comparing the results of studies
across national boundaries. The review of economic evaluations of MAS
in Chapter 2 indicated that a number of studies used sensitivity analysis
to assess the importance of variation in some parameters which may vary
by location and context. A few evaluations looked at generalisability
more explicitly, using scenario analysis to explore under which local
circumstances the conclusions of the analysis may alter.
• The analysis in Chapter 6 of this thesis went a step further by using
sensitivity analysis to incorporate alternative sources of data into an
analytical framework, where those sources are likely to be more
representative of routine practice. An important characteristic of this sort
of analysis is the use of data with high internal validity (usually
adequately powered RCTs) to provide the main data source for the base-
case analysis, and the use of alternative data sources systematically to
explore the robustness of the results. As decision makers begin to require
analyses to be more relevant to their local situation, this approach to the
assessment of generalisability is likely to be adopted more frequently.
• The advent of meta-analysis offers a valuable tool to increase the
statistical power of clinical evaluations by pooling the results of a number
of smaller studies. However, little thought has been given to the
appropriate role of meta-analysis within economic evaluation. In
combining the results of a number of RCTs, meta-analysis is a useful way
of generating more reliable estimates of the resource and non-resource
implications of interventions for the base-case analysis of economic
evaluations of MAS and other technologies (Stage III analysis). However,
the danger of meta-analysis is that the heterogeneity that exists when
any trials are compared is masked, and there will remain an important role
for the incorporation into economic analysis of disaggregated trial data, to
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explore the implications for variability between trials as an aspect of the
analysis of generalisability.
• The need for analysis of generalisability highlights the importance of the
decision analytic model as a framework for economic evaluation. Even
when the primary source of data for a study is a RCT, the use of models
can provide a platform to explore the importance of variation in
parameters and to incorporate non-trial data (Stage IV analysis).
9.4.2 Empirical analysis
The analysis of generalisability in relation to AH versus TCRE focuses on how
robust the results presented in Chapter 5 are to variation in key parameters. The
alternative estimates come from alternative RCTs and the a national survey,
where the latter represents a description of a large number of TCREs undertaken
in England, Wales and Northern Ireland over a 18 month period. The following
conclusions can be reached from this element of the study.
• These alternative sources of data indicate differences in a range of
parameters. However, if the illustrative cost per QALY thresholds
suggested in Chapter 5 are acceptable, these differences are not
important in terms of their impact on the incremental cost per additional
QALY of AH relative to TCRE. Again, the variation in parameters is not
sufficient to take the estimated ratio above the lower illustrative threshold
ratio of £6,500.
• Part of this analysis of the generalisability of the base-case results
focused on resource intensive and resource sparing clinical practice in
relation to TORE using data from the national survey, and the extent to
which parameter estimates based on these types of practice influence the
cost per QALY ratios. Resource sparing practice increases the estimated
cost per QALY of AH (to £3153 from £1,500 in the base-case).
Resource intensive practice has only a modest impact on the cost per
QALY (reducing it to £1484). Therefore, this analysis of the extremes of
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clinical practice as regards resource use has little impact on the base-case
conclusions. However, the national survey provides data only for TCREs;
a detailed picture of routine practice in relation to hysterectomy is
currently awaited.
• The analysis of generalisability also looked at the robustness of the base-
case conclusions to alternative unit costs. Three specific hospitals were
located which use similar costing software and methods, and these
centres were asked to provide estimates of two unit costs to which the
total expected cost of the two treatments is sensitive: the cost of a day
in hospital and of a minute in theatre. The variation between the three
hospitals is limited (theatre costs of between £1.96 and £2.04 per
minute; ward costs of between £83 and £104 per day), but there is
greater difference compared to the base-case unit costs (theatre £1.08
per minute; ward £120 per day) . Overall, the substitution of these
alternative values has very limited impact on the estimate of cost per
QALY.
• The final component of the analysis of generalisability was a broad-brush
analysis of the comparative costs and benefits of non-hysterectomy forms
of surgery other than TCRE with loop diathermy, and of forms of
hysterectomy other than AH. The purpose of this analysis was to explore
whether the AH versus TCRE analysis, which is the focus of the thesis,
can be generalised to one of non-hysterectomy forms of surgery versus
hysterectomy. Although the results have to be interpreted cautiously
given the absence of experimental data for each comparison, it is unlikely
that any of the alternative non-hysterectomy forms of surgery upon which
data were collected in the national survey are so markedly different to
TCRE with loop diathermy, in terms of either resource or non-resource
consequences, to affect the base-case conclusions significantly.
• The estimated cost of the various alternative forms of hysterectomy to
AH suggest that scope does exist to reduce the cost of treatment. In
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particular, if a greater use were made of vaginal hysterectomy or
laparoscopic-assisted vaginal hysterectomy (LAVH) with reusable
equipment, the cost of in-patient care would probably fall. The analysis
indicates, however, that LAVH with disposable consumables may increase
the cost of hysterectomy markedly. The exploratory analysis presented
here suggests that a change in the form of hysterectomy provided is
unlikely to take the cost per QALY ratio, relative to TCRE with loop
diathermy, over the lower illustrative threshold of £6,500.
9.5 Preference-based treatment allocation
Most applications of MAS have quite different characteristics, in terms of their
process and possible outcomes, to open surgery, and the characteristics of MAS
may not always be preferable. In the context of surgical treatment for
menorrhagia, the importance of Chapter 4 of this thesis is that it indicates that
many women have views about the characteristics of treatment they prefer and,
in some cases, about the actual treatment they wish to undergo. Furthermore,
Chapter 5 showed that the benefit estimates for TCRE and AH are sensitive to
the values women attach to health states associated with the prognoses
following these two treatments. These findings suggest that, instead of
economic evaluation being used to identify which one of these two treatments is
the more cost-effective based on mean costs and benefits, it should be possible
to explore the economic characteristics of management strategies where
women's preferences play an important role in deciding which treatment they
should receive. The methodological and empirical analysis of preference-based
forms of management in Chapter 8 represents an important contribution of the
thesis.
9.5.1 Methodological analysis
The methodological issues related to the modelling and evaluation of
management strategies where patients' preferences determine treatment
allocation are under researched. A range of issues was covered in Chapter 8.
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• The standard approach to economic evaluation is the all or nothing
analysis, where a mean costs and benefits are used to identify a single
economically preferred intervention. It would then be expected that this
would be the option to be provided to all patients unless there is a good
non-economic reason for not doing so. It is, however, recognised that
this approach may not be appropriate if there is heterogeneity between
patients in their baseline clinical and demographic characteristics, and that
these factors may influence outcomes. In this context, sub-group
analysis is well established as a means of identifying groups of patients,
defined in clinical terms, for a whom an intervention is cost-effective
while not being so for other sub-groups.
• However, heterogeneity in patients' preferences can mean that a decision
to provide a single treatment option for all patients, on the basis of mean
costs and benefits, may result in a significant proportion of women not
receiving the treatment which their preferences indicate is their personal
optimum. If the values patients attach to the process and outcomes of
care are to be used to determine resource allocation (a key premise of the
principles of economic evaluation in health), it is surely valid to assess
whether sub-groups can be defined in terms of patients' preferences,
which may then used to drive treatment allocation.
• Of the three forms of preference-based treatment allocation considered
here, the one that adheres most closely with the principles of economic
evaluation is patient-specific CEA. This approach considers a patient's
(health state or profile) values in the context of the incremental cost of
the treatment which those values indicate is optimal for that patient.
However, from a practical viewpoint, the development of systems to
allocate patients to therapies on this basis may prove hard to accomplish.
• The use of health state values as part of a values-based or patient-
specific CEA-based treatment allocation policy again raises the issue of
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the relationship between the benefit measure used in economic evaluation
and patient preferences. Given the evidence reviewed in Chapter 7
suggesting that the link between preferences and QALYs is tenuous, the
use of health state values to allocate treatment may result in patients
receiving a treatment that they would not choose. The possible role for
alternative benefit measures such as the ex ante HYE would, therefore,
have to be considered further, if these forms of management were to be
employed.
9.5.2 Empirical analysis
The analysis presented in Chapter 8 generates some important conclusions in the
context of AH and TCRE.
• If women are allocated according to their choice, it would be expected
that the mean cost of care would lie somewhere between that of AH and
TCRE. On the basis of questionnaire responses from women in Bristol
and Swindon, the cost of this form of management would be between
£964 and £1,035. However, the choice-based strategy would probably
be considered more cost-effective than a TCRE only strategy, with an
incremental cost per QALY of between £282 and £413. The extent to
which this particular preference-based strategy was found to be more
cost-effective than AH alone depends on the benefit measure used: in
terms of QALYs and using health state values from the women in Bristol,
AH was found to have a relatively modest cost per QALY (£2,396); in
terms of ex ante HYEs, however, the choice-based strategy was found to
dominate AH.
• The values-based approach was found to have an expected cost of
between £964 and £1,081. In terms both of expected QALYs and ex
ante HYEs, it would probably be considered more cost-effective than
either AH only or TCRE only, dominating AH and with an incremental cost
per GALY over TCRE of £307.
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• Management based on patient-specific CEA has the potential to be the
most cost-effective of the preference-based strategies. Compared to
TCRE only it was found to offer additional benefits at a modest
incremental cost; and the strategy was found to dominate AH. Compared
to the other preference-based forms of management, patient-specific CEA
would probably be considered the more cost-effective.
• The systematic use of women's preferences to determine treatment
allocation has, then, been shown to have the potential to be a cost-
effective form of management in the treatment of menorrhagia. In
practical terms, the use of patient-specific CEA is perhaps less feasible
than the values-based approach, and the choice-based form of
management is probably the most likely to be adopted.
9.6 Further research
The projection that, by the year 2000, 70% to 80% of surgical practice will be
based on MAS techniques highlights the importance of detailed evaluation in this
area [Cushieri, 1993]. This is likely to require the further development of the
methods of clinical and economic evaluation. This thesis has focused specifically
on developments in the methods of economic evaluation necessary to cope with
the characteristics of MAS. Some specific areas of further research are
necessary.
• If CUA is to have an important role in supporting decisions made by local
purchasers, the systematic handling of uncertainty within studies would
benefit greatly from some guidelines regarding acceptable cost per QALY
thresholds. Research would be valuable to identify whether purchasers
have such thresholds in their minds when they consider the results of
studies; and whether work can be undertaken with purchasers to
translate explicit policy objectives into threshold values.
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• A programme of further research is required to assess the extent to which
QALYs and HYEs generate different conclusions in a range of applied
evaluations; whether the measurement of HYEs can be made more
manageable, for example, by using video and group valuations; and
whether a firmer link between QALYs and individual preferences can be
established.
• A modelling approach to the economic evaluation of preference-based
management strategies is adopted in Chapter 8, which has the advantage
of flexibility. It would be useful to extend this modelling work in a
number of directions. These would include the use of larger and more
representative samples of women; the provision of improved information
on alternative treatments to these women upon which they can make
choices; and the development of a more detailed cost-utility model which
would facilitate the incorporation of patient-specific clinical information as
well as preferences. In addition or as an alternative, it is important to
subject the preference-based strategies to prospective evaluation using a
randomised trial. This would facilitate an analysis of how this sort of
management might work in practice when patients are actually in the
position to have to make treatment decisions.
9.7 Concluding comments
The characteristics of MAS highlight a number of weaknesses in the methods of
economic evaluation. An important finding of this thesis is that, despite being
considered by many to be the gold standard for clinical evaluation, the use of the
RCT as a vehicle for economic evaluation is likely, if used in isolation, to leave
unanswered a number of important issues relating to the cost-effectiveness of
MAS applications. Given the likely significant increase in the use of this group of
technologies in the near future, it essential to develop further key areas of
evaluative method. The contribution of this thesis has been to begin that
process in the important areas of benefit measures for CUA, the analysis of
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generalisability and the economic evaluation of preference-based management
strategies.
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